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1017-157 Role of Oxidative Stress in Diastolic Function in 
Patients With Hereditary Hemochromatosis
Yukitaka Shizukuda, Tammy Nguyen, Charles D. Bolan, Vandana Sachdev, Dorothy 
Tripodi, Ernst Inez, Yu Ying Yau, Susan F. Leitman, Toren Finkel, Douglan R. Rosing, 
NHLBI/NIH, Bethesda, MD
Background: Abnormal diastolic function has been reported in patients with hereditary 
hemochromatosis (HH). Little is known about the mechanisms mediating this abnormality; 
however, it is possible that an increased oxidative stress related to iron overload is involved 
in this process. Thus, we evaluated relationships between biomarkers of oxidative stress 
and diastolic function in the patients with HH.
Methods: 27 consecutive patients (aged 50±10, mean±SD), were recruited from an 
NHLBI-sponsored “Heart study of hemochromatosis” protocol. All patients had conﬁrmed 
C282Y homozygosity and a documented history of iron overload. The level of oxidative 
stress was evaluated by plasma MDA, erythrocyte SOD and glutathione (GSH) levels. 
Diastolic function was assessed with early ﬁlling (E) and atrial contraction (A) diastolic 
tissue velocities measured with pulsed tissue Doppler (PW) or strain rate imaging (SRI) in 
the apical four chamber views near the annuluses. Correlations between tissue Doppler 
velocities and oxidative stress makers were evaluated with the Spearman correlation.
Results: A signiﬁcant positive correlation was found between MDA and A velocities of 
the lateral mitral annulus (r= 0.405, p=0.039) and between SOD and E velocities of the 
tricuspid annulus at the right ventricle free wall measured with PW (r=0.453, p=0.021). 
In addition, a strong positive correlation was noted between GSH and E velocities of the 
septal mitral annulus measured with SRI (r=0.669, p=0.006). When the patients were 
dividend into 2 groups by the average value of GSH, a signiﬁcant difference of the septal 
annulus E measured with SRI (2.14±0.65 sec-1 in high group vs. 1.42±0.55 sec-1 in low 
group, p=0.005) was noted. However, the level of iron overload itself measured with ferritin 
failed to correlate with any of these measurements of diastolic function. These results 
indicate a trend that chronic exposure to oxidative stress manifesting elevated MDA and 
reduced SOD and GSH, attenuates E velocities and increases A velocities.
Conclusions: Our results suggest that oxidant stress per se, not the direct level 
of iron overload, may be affecting diastolic function in patients with hereditary 
hemochromatosis.
1017-158 Relationship of Carbohydrate Antigen 125 Levels With 
Left Ventricular Diastolic Dysfunction. Comparison With 
Doppler Echocardiography.
Andreea Catarina Popescu, Bogdan Alexandru Popescu, Francesco Antonini-Canterin, 
Daniela Rubin, Pietro Cappelletti, Rita Piazza, Carmen Ginghina, Doina Dimulescu, 
Gian Luigi Nicolosi, ARC, Ospedale Civile, Pordenone, Italy, Chimica Clinica, Ospedale 
Civile, Pordenone, Italy
Background. Carbohydrate antigen 125 (CA125) is a marker used for ovarian cancer 
diagnosis and monitoring. CA125 levels are increased in patients (pts) with heart failure 
(HF) and left ventricular (LV) systolic dysfunction, relating to HF severity and prognosis. 
The relation of CA125 with LV diastolic dysfunction (DD) has not been studied yet.
Purpose. To assess CA125 levels in patients with different degrees of LVDD.
Methods. 75 consecutive patients (53 men, 73±10 years), referred for LV function 
assessment were studied. A comprehensive Doppler echocardiography study was 
performed, measuring transmitral ﬂow: E, A, E/A ratio, Edt at baseline and during a 
standardized Valsalva maneuver; ﬂow propagation velocity Vp; PW pulmonary venous 
ﬂow Ar; M-mode derived mitral annular plane systolic excursion (MAPSE) at four sites of 
the mitral annulus; LV ejection fraction (EF). E/Vp ratio, Ar-A duration, A velocity change 
(Achange) during Valsalva, and mean MAPSE were calculated. Right atrial (RAP) and 
systolic pulmonary artery pressures (SPAP) were estimated. LV diastolic function was 
staged using an algorithm previously validated in outcome studies: normal, stage 1 DD 
(E/A<0.75, Ar-A<0, Achange<0, E/Vp<1.5), stage 2 DD (E/A 0.75-1.5, Edt>140, Ar-A>30, 
Achange>0, E/Vp≥1.5), and stage 3 DD (E/A>1.5, Edt<140, Ar-A>30, Achange>0, E/
Vp≥1.5). Blood taken immediately before echocardiography was assayed for CA125 levels.
Results. CA125 levels correlated with LVDD stage (r=0.50, p<0.001). At univariate 
regression analyses, CA125 levels correlated with NYHA class (r=0.39, p=0.001), LVEF 
(r=-0.41, p<0.001), mean MAPSE (r=-0.46, p<0.001), SPAP (r=0.49, p=0.001), and RAP 
(r=0.33, p=0.007). At stepwise multiple regression analysis LVDD emerged as the only 
independent predictor of CA125 levels (r=0.50, p=0.002).
Conclusions. CA125 levels are increased in proportion to the degree of LVDD. This 
study demonstrates the association of CA125 levels with parameters reﬂecting increased 
cardiac pressures and LV dysfunction. Properties of LV diastolic function may be an 
important determinant of CA125 levels, and measuring this inexpensive marker may be 
useful in detecting advanced stages of DD.
1017-159 Is MRI-Determined LV Mass Associated With Ventricular 
Filling and Exercise Capacity in Non-obstructive 
Hypertrophic Cardiomyopathy?
Jonathan F. Plehn, David S. Owens, Dorothea McAreavey, Steve L. Bacharach, Andrew 
E. Arai, Lameh Fananapazir, Dorothy Tripodi, Saidi A. Mohiddin, National Heart, Lung 
and Blood Institute, Bethesda, MD
Background: The correlation between left ventricular (LV) mass, diastolic function 
and exercise capacity in patients with hypertrophic cardiomyopathy (HCM) is not well 
established owing to the inherent limitations of two-dimensional echocardiographic 
evaluation of regional wall thickening, a common presentation in this disease.We, 
therefore, compared MRI-quantiﬁed LV mass indexed for body surface area (LVMI) 
with radionuclide ventriculographic (RNV) and Doppler echocardiographic LV relaxation 
parameters as well as hemodynamics and objective measures of exercise capacity in 89 
subjects (58 males, mean age=36 years) with non-obstructive HCM (mean LVMI =115 
+41, range= 44-282 gms/m2).
Methods and Results: Subjects underwent MRI, echocardiography, radionuclide 
ventriculography (RNV), cardiac catheterization and metabolic exercise testing all within 
5 days or less. LVMI was compared with: a) Doppler-determined early and late (atrial 
systolic) peak velocities, peak velocity ratio (E/A), deceleration slope, isovolumic relaxation 
time (IVRT), b) RNV peak ﬁlling rate (PFR), time to PFR, atrial volumetric contribution to 
ﬁlling (ACF) and c) pulmonary capillary wedge pressure and LV end-diastolic pressure. 
Weak correlations were observed between LVMI and IVRT (r=0.35; CI 0.15,0.52) and 
ACF (r=0.27; CI=0.06,0.45) but no other ﬁlling parameters. No relationship was observed 
between LVMI and resting hemodynamics or echocardiographic end-systolic left atrial 
area. LVMI was weakly associated with bike ergonometry-determined peak V02 (r=0.27; 
CI 0.05,0.46) but not anaerobic threshold.
Conclusion: MRI-determined LVMI in patients with non-obstructive HCM is at most 
weakly related to noninvasive measures of LV relaxation and objective measures of 
exercise capacity but is in unassociated with resting hemodynamics or left atrial area, 
a marker of chronic LV diastolic burden. These results suggest that other factors such 
as altered myocardial material properties (e.g. collagen remodeling) may play a more 
important role in LV diastolic dysfunction and associated exercise limitations found in 
this population.
1017-160 Cardiac Volumes in Diastolic Heart Failure: 
Echocardiographic Insights on the Pathophysiologic 
Debate
Craig S. Vinch, Jeffrey C. Hill, Dennis A. Tighe, Theo E. Meyer, William H. Gaasch, Gerard 
P. Aurigemma, UMASS Medical School, Worcester, MA, Lahey Clinic, Burlington, MA
Background: Abnormal LV compliance, thought to be the central hemodynamic 
derangement in diastolic heart failure (DHF), dictates that diastolic pressure will 
be elevated in the face of normal or mildly increased LV diastolic volume (vol). This 
“conventional wisdom” was challenged by an hypothesis that LV pressure-vol. relations 
are normal in DHF and that elevated diastolic pressure results from increased LV vol. 
Accordingly, we compared LV vol. and Doppler indices in pts before and after treatment 
for acute DHF and with results in age- and gender-matched controls. 
Methods: 32 pts (76±10 years, 17 male) had clinical examination and echo at 
presentation and after 48 h. 27 older healthy controls (NL-68±10 years, 13 male) 
were also studied. DHF was deﬁned as signs and symptoms of CHF and EF≥ 50%. 
Results: LV vol., dimensions, and geometry were similar in DHF and NL. LV vol. did 
not decrease after treatment (Table). DHF had Tissue Doppler evidence of higher ﬁlling 
pressures and higher PASP than NL. BNP levels were signiﬁcantly higher in DHF than NL. 
†p< 0.05 compared with Normal. Volumes calculated by biplane method of discs.
Acute DHF Treated DHF Normal Controls
LV End Diastolic Volume (ml) 70±25 81±32 65±20
LV End Systolic Volume (ml) 31±13 30±14 23±9
LV Ejection Fraction (%) 63±9 62±6 66±3
LV end diastolic dimension (LVIDd) (cm) 4.6±0.8 4.6±0.6 4.3±0.5
LV end systolic dimension (LVIDs) (cm) 2.9±0.7 3.0±0.6 2.6±0.4
Ventricular length from AP4C view (cm) 8.1±1.4 8.0±1.1 6.8±2.3
Long/short axis ratio 1.8±0.3 1.8±0.3 1.6±0.5
E:E’ Ratio 9.5±4.2† 10.3±6.0† 6.6±1.9
PASP (mmHg) 46±16† 42±17† 28±5
BNP (pg/ml) 422±546† 547±952† 24±19
 
Summary/Conclusions: LV dimensions and volume in DHF are similar to NL and do 
not change signiﬁcantly following treatment. Elevated PASP and the tendency for LV 
volume to increase following short term treatment suggest an RV/pericardial effect on LV 
compliance. These ﬁndings demonstrate that elevated LV ﬁlling pressures are not due to 
increased LV volumes. Increased ﬁlling pressure despite normal LV size is in keeping with 
abnormalities in LV compliance.
1017-161 Myocardial Perfusion Abnormalities Revealed by 
Myocardial Contrast Echocardiography in Patients with 
Left Ventricular Hypertrophy: Relation to Left Ventricular 
Diastolic Function
Akira Yamada, Akiko Noda, Hideo Izawa, Yosuke Murase, Hiroyuki Asano, Tomoko Kato, 
Toyoaki Murohara, Mitsuhiro Yokota, Nagoya University Graduate School of Medicine, 
Nagoya, Japan, Nagoya University, Nagoya, Japan
Background: Myocardial ischemia plays an important role in the pathophysiology of left 
ventricular (LV) hypertrophy (LVH), which is an important risk factor for cardiovascular 
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events. Given that intravenous myocardial contrast echocardiography (MCE) allows 
assessment of myocardial perfusion, we investigated whether this approach would detect 
myocardial perfusion abnormalities which are associated with LV diastolic dysfunction in 
individuals with LVH.
Methods: Besides conventional echocardiography, MCE was performed in 20 patients 
with nonobstructive HCM (Group HCM; 53.5 ± 7.4 years), 14 patients with hypertensive 
LVH (Group HT; 56.6 ± 10.9 years), and 16 controls (Group C; 49.9 ± 14.9 years). Images 
were obtained from the apical two- and four-chamber views at pulsing intervals of one to 
four cardiac cycles followed by a bolus infusion of Levovist (3ml, 300ng/ml). The color pixel 
intensity was determined at 8 different regions of interest (ROIs) in the LV myocardium 
(inferior base and apex, anterior base and apex, septal base and apex, lateral base and 
apex) and within the chamber adjacent to them. The intensity difference between chamber 
and myocardium was calculated in every region after 10 beats from the peak phase. LV 
pressure was measured directly in all subjects.
Results: The mean value of intensity difference (ID) for all ROIs was signiﬁcantly greater 
in Group HCM and Group HT compared with Group C. (25.8 ± 4.9 Versus 22.3 ± 3.6 
Versus 17.2 ± 5.2dB, respectively). ID in Group HCM was greater than that in Group HT 
(p<0.05). However, there was no difference in LV mass index between Group HCM and 
Group HT (194.3 ± 36.7 Versus 190.6 ± 28.5 g/m2, ns). LV fractional shortening and 
ejection fraction did not differ between the three groups. In Group HCM and Group HT, 
ID was correlated with T1/2 (r = 0.678, p < 0.005) and it did not depend on the severity of 
the increase in wall thickness.
Conclusions: ID, reﬂecting myocardial perfusion defect, was greater in LVH, especially 
in HCM patients, which suggests disturbed coronary microcirculation, contributing to 
impaired relaxation. MCE could reﬂect the difference of pathophysiology between HCM 
and hypertensive LVH.
1017-162 Renin-Angiotensin-Aldosterone System Activation in 
Diastolic Heart Failure: Comparison with Systolic Heart 
Failure and Age-Matched Normal Subjects
Kurt R. Daniel, Bridget Brosnihan, Brittney Fray, Kathryn P. Stewart, Dalane W. Kitzman, 
Wake Forest University, Winston-Salem, NC
Background: Renin-angiotensin-aldosterone system (RAAS) activation is a pivotal factor 
in the pathophysiology and treatment of systolic heart failure (SHF). However, most older 
patients with HF have a normal EF, a syndrome presumptively termed diastolic heart 
failure (DHF). Few data are available regarding RAAS activation in DHF.
Methods: Plasma renin activity, serum aldosterone, angiotensin-II, and vasopressin were 
measured in 148 subjects >60 years old in 3 groups: 60 with isolated DHF (clinical HF, EF 
>50%, and no coronary, valvular, or pulmonary disease); 60 with typical SHF (EF < 35%); 
and 28 age-matched, healthy normals.
Results: Compared to healthy normals, plasma renin activity was increased in DHF 
(1.8±1.5 ng/ml/hr vs. 1.5±1.8 ng/ml/hr; p=0.01), and in SHF (8.2±1.4 ng/ml/hr vs. 1.5±1.8 
ng/ml/hr; p<0.01). Compared to healthy normals, serum aldosterone was increased in DHF 
(11.0±1.1 mg/dl vs. 8.4±1.4 mg/dl, p=0.07 for trend) and in SHF (13.8±1.1 mg/dl vs. 8.4±1.4 
mg/dl, p<0.01). Plasma renin activity and aldosterone were more severely increased in SHF 
than in DHF (see Table). Angiotensin II and arginine vasopressin were similar in all 3 groups. 
These relationships were unchanged after adjusting for medication use.
Conclusions: The renin-aldosterone system is activated in DHF, though not as severely 
as in SHF. This may contribute to the pathophysiology of DHF. This ﬁnding has important 
prognostic and therapeutic implications.
RAAS in DHF, SHF, and Age-Matched Normals 
Mean ±SE p-value
Variable NO SHF DHF DHF vs NO
SHF vs 
NO
DHF vs 
SHF
Plasma Renin Activity 
(ng/ml/hr) 1.5±1.8 8.2±1.4 1.8±1.5 0.01 <0.01 <0.01
Aldosterone (ng/dl) 8.4±1.4 13.8±1.1 11.0±1.1 0.07 <0.01 0.07
Angiotensin II (pg/ml) 51±5 50±4 51±4 0.34 0.60 0.42
Vasopressin (pg/ml) 4.7±1.2 5.0±0.9 4.4±1.0 0.52 0.74 0.34
1017-163 Relationship of Electrocardiographic Strain Pattern 
to Left Ventricular Diastolic Function in Hypertensive 
Patients: The LIFE Study
Vittorio Palmieri, Peter M. Okin, Kristian Wacthell, Jonathan N. Bella, Eva Gerdts, Kurt 
Boman, Markku S. Nieminen, Richard B. Devereux, Weill Medical College of Cornell 
University, New York, NY
Background: Whether ECG strain pattern (ST+), associated with left ventricular 
hypertrophy (LVH) and risk of development of congestive heart failure, is independently 
associated with diastolic dysfunction is unclear.
Methods: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) 
study enrolled hypertensive patients with ECG-LVH, of whom 10% underwent Doppler 
echocardiography. ST+ was assessed in leads V5 and/or V6. LV diastolic function measures 
included the ratio of peak E and A waves velocities (E/A); E deceleration time (EDT); atrial 
ﬁlling fraction (AFF); and isovolumic relaxation time (IVRT). A combined index of systolic-
diastolic function was also computed (isovolumic time/ejection time, TEI-index).
Results: ST+ (in leads V5 and/or V6, 14% of the sample) was associated with male gender, 
African-American race, diabetes, history of coronary heart disease (CHD+), higher systolic 
blood pressure (SBP), lower heart rate, higher LV mass (all p<0.05). Age, diastolic BP, 
ejection fraction did not differ signiﬁcantly between ST+ and ST-. Diastolic parameters did 
not differ signiﬁcantly between ST+ and ST- (all p>0.1); the TEI-index was higher with ST+ 
(0.51 vs. 0.44, p<0.05). After adjustment for covariates, all diastolic parameters were similar 
between ST+ and ST- (Table showing adjusted mean (standard deviation), all p=NS).
Conclusions: In hypertensive patients with ECG-LVH, the ST+ pattern was not 
independently associated with LV diastolic abnormalities.
ST+ (n=110) ST- (n=681)
E/A 0.87 (0.42) 0.87 (0.52)
EDT, msec 210 (66) 217 (63)
AFF, % 42 (10) 42 (10)
IVRT, msec 114 (25) 115 (24)
TEI 0.49 (0.27) 0.45 (0.26)
1017-164 Contribution of Diastolic Dysfunction to Heart Failure 
Regardless of Ejection Fraction
Steffen Brucks, William C. Little, Tania Chao, Dalane W. Kitzman, Deborah Wesley-
Farrington, Sanjay Gandhi, Zakariya K. Shihabi, Wake Forest University School of 
Medicine, Winston-Salem, NC
Background: Heart failure (HF) has been classiﬁed as systolic and diastolic based on the 
left ventricular (LV) ejection fraction (EF). We hypothesized that diastolic dysfunction is an 
important element of HF regardless of EF.
Methods: Two hundred six patients with clinical HF were compared to 72 age-matched controls.
Results: Diastolic function assessed by mitral ﬁlling pattern and tissue Doppler imaging 
as normal (grade 0), impaired relaxation (grade 1), pseudonormal (grade 2), or restricted 
(grade 3). Diastolic dysfunction (> grade 1) was present in >90% of patients with HF 
regardless of EF, and was more frequent and severe than in age-matched controls (P 
<0.001). In patients with HF, B-type natriuretic peptide (BNP) correlated with the grade of 
diastolic dysfunction (r=0.62, P <0.001), but not EF or end-diastolic volume index (EDVI). 
The degree of diastolic dysfunction inﬂuenced survival (RR=1.64, P <0.05) where EF 
and EDVI did not. Systolic function measured by the systolic mitral annular velocity was 
reduced in HF patients with EF <0.40 (4.8±1.1 cm/sec) and to a lesser extent with EF 
>0.50 (6.6±1.8 cm/sec) compared to normals (8.0±2.1) (P <0.01). HF patients with EF 
>0.50 had increased mass/EDVI (2.6±1.0 vs 2.2±0.7 gm/ml, P <0.05). HF patients with 
EF <0.40 had increased LV EDVI.
Conclusion: Patients with HF have diastolic dysfunction regardless of EF. Diastolic 
dysfunction is a better predictor of BNP and mortality than EF or LV EDVI. In addition to 
diastolic dysfunction, HF with EF >0.50 is associated with mild systolic dysfunction and 
increased LV mass/EDVI. In HF with EF <0.40 have both systolic and diastolic dysfunction 
and LV dilatation.
1017-165 Marked Increases in the Prevalence of Diastolic Heart 
Failure Amongst Community and Referral Patients 
Hospitalized With Heart Failure
Theophilus E. Owan, David O. Hodge, Regina M. Herges, Véronique L. Roger, Margaret 
M. Redﬁeld, Mayo Clinic, Rochester, MN
Background: Community-based studies report normal ejection fraction (EF) in 50% of 
heart failure (HF) patients (pts). This is termed diastolic HF (DHF). Differences in the 
prevalence of DHF over time or between Community and Referral HF cohorts have not 
been examined.
Objective: In hospitalized HF pts, determine if the prevalence of DHF has changed over 
time or is different in Community-based and Referral HF cohorts.
Methods: Electronic chart review of all consecutive unique HF pts (DRG 127) discharged 
from Mayo Clinic hospitals, Olmsted County, Rochester MN from 1/1/87 to 12/31/02. Pts were 
designated as Community (Olmsted County residents) or Referral (Non-Olmsted County 
residents). EF was available in 4610 of 6440 total HF pts. Pts with EF>50% were considered 
DHF.
Results: Overall, 24% of pts were Community pts and 49% (n=2259) had DHF. The % HF 
pts with DHF increased over time (p<0.001, ﬁgure) and was higher in the Community cohort 
(p<0.001). Community DHF pts were older (78+13 yrs vs 73+14 yrs, p<0.001) and more 
likely female (65% vs 49%, p<0.001) than Referral DHF pts. In univariate analysis, 3 month 
mortality was lower in DHF (odds ratio, OR, for DHF=0.84, p=0.03). However, controlling for 
age, sex, renal function and hemoglobin, mortality was higher in DHF (OR for DHF=1.98, 
p<0.001) but not different between Community and Referral cohorts (p=0.68).
Conclusion: We speculate that increased awareness of DHF as well as increases in the 
% of the population over age 65 contribute to the increased prevalence of DHF.
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1017-166 Determinants of Late (Six-Month) Mortality in Patients 
With Heart Failure and Preserved Systolic Left 
Ventricular Function in the Real World: Results From 
the Israel 2003 National Heart Failure Survey
Basil S. Lewis, Avraham Shotan, Shmuel Gottlieb, Ehud Grossman, Avi Porat, Shlomo 
Behar, Reuven Zimlichman, Jonathan Leor, Moshe Mittelman, Manfred S. Green, 
Abraham Caspi, Moshe Garty, Israel Heart Failure National Survey Investigators, Lady 
Davis Carmel Medical Center, Haifa, Israel
Background: Left ventricular (LV) systolic function may be preserved in pts hospitalized for 
heart failure (HF) and HF is then due to predominantly diastolic dysfunction. Determinants 
of late mortality have not been well studied in these pts.
Methods: We conducted a prospective 2 mth nationwide survey of 4102 consecutive HF 
patients hospitalized in 93/98 internal medicine and 24/25 cardiology departments in all 
25 public hospitals in Israel. In 1363/2842 (48%) pts, echo LV ejection fraction (EF) was 
≥40% (preserved systolic LV function).
Results: Hospital mortality was 3.7% and late (6 mth) mortality 14.3% (vs 5.1% and 19.4% 
in pts with reduced LV function, both p<0.01). Pts who died were older (77±11 vs 72±12 
years, p<0.0001), lower admission systolic pressure (138±34 vs 149±32 mmHg, p<0.0001), 
no difference in diabetes mellitus, hypertension, echo LV dimension or EF. Relation between 
late (6 mth) mortality and drug treatment is given in Table. Mortality was independently 
related to age, treatment with ACE-inhibitors, angiotension receptor blockers (ARB’s).
Conclusions: This observational nationwide survey showed that in pts hospitalized for HF 
with preserved LV function: 1. Late (6 mth) mortality was high (14%), though less than in pts 
with reduced LV function. 2. Mortality was higher in older pts and in those treated with digoxin 
and diuretics, lower in pts receiving beta blockers, ACE-inhibitors, ARB and aspirin.
Late mortality (6 months) in relation to drug 
treatment at discharge 
Dead Odds ratio 95% CI p value
Total group (hospital survivors) 11.1% - - -
Digoxin 17.1% 1.76 1.06-2.91 0.02
Diuretic 12.8% 1.89 1.23-2.91 0.003
Beta blocker 8.9% 0.60 0.42-0.85 0.003
ACE-inhibitor 9.0% 0.61 0.43-0.87 0.005
Angiotensin receptor blocker 4.5% 0.36 0.14-0.90 0.02
Aspirin 9.3% 0.59 0.42-0.84 0.003
Calcium antagonist 12.2% 1.18 0.82-1.69 0.37
Coumadin 12.5% 1.19 0.78-1.81 0.41
1017-167 Diastolic Dysfunction in Chronic Kidney Disease: 
Association With Coronary Calciﬁcation and Arterial 
Stiffness (The Renal Research Institute-Chronic Kidney 
Disease [RRI-CKD] Study)
Theodore J. Kolias, Sanjay Rajagopalan, Xiaotong Zhang, Margaret Kiser, Alan 
Hinderliter, George Eisele, Frederick Finkelstein, Brenda Gillespie, Nathan Levin, Rajiv 
Saran, University of Michigan, Ann Arbor, MI
Background: While diastolic dysfunction (DD) is known to be prevalent in patients on 
dialysis, little is known about its prevalence in non-dialysis chronic kidney disease (CKD). 
Furthermore, the relationship between DD, coronary calciﬁcation, and arterial stiffness is 
not well characterized.
Methods: Diastolic function was evaluated by echocardiography in a sub-cohort of 
patients enrolled in the RRI-CKD study, a prospective observational multicenter study of 
non-dialysis CKD patients at 4 centers. DD was graded as: none (E/A 1-2 and absence of 
LVH), mild (E/A < 1), moderate (E/A 1-2 and presence of LVH), or severe (E/A > 2). LVH 
was deﬁned as LV mass index > 134 g/m2 for males and > 110 g/m2 for females. Coronary 
calcium (CC) scores (Agatston) were determined by computed tomography (n=75), and 
arterial stiffness was determined by measuring aortic pulse wave velocity (PWV) from 
carotid and femoral pressure wave contours (n=129). Statistical analysis was performed 
using t-test or Chi square as appropriate.
Results: DD was present in 118 out of 171 patients (69%) in whom diastolic function 
was determined (mild = 52%, moderate = 11%, and severe = 6%). The table compares 
patients with normal vs. abnormal diastolic function. DD was associated with older age, 
higher CC score, greater carotid intima-media thickness (CIMT), and higher PWV.
Conclusions: DD is highly prevalent in non-dialysis CKD patients, and is associated with 
markers of atherosclerosis and arterial stiffness.
Normal vs. Abnormal Diastolic Function 
Normal n (Normal) Abnormal n (Abnormal) p
Age (years) 51 + 15 53 61 + 17 112 0.001
% Female 47 % 25/53 46 % 52/112 0.929
Diabetes 19 % 10/53 33 % 37/112 0.059
HTN 92 % 49/53 90 % 101/112 0.624
GFR 26 + 12 27 25 + 11 40 0.738
Hemoglobin (g/dl) 12.1 + 1.5 37 11.9 + 1.5 56 0.440
CC Score 166 + 342 29 501 + 846 46 0.020
Max CIMT (mm) 1.17 + 0.69 34 1.55 + 1.08 63 0.042
PWV (m/s) 7.76 + 2.71 44 9.38 + 3.64 85 0.005
1017-168 Spironolactone Improves Diastolic Function in The 
Elderly
Chanwit Roongsritong, Piraon Sutthiwan, Jason Bradley, Jan Simoni, Gary Meyerrose, 
Texas Tech University Health Sciences Center, Lubbock, TX
Diastolic dysfunction(DD) is common in elderly. Myocardial ﬁbrosis is a major determinant 
of diastolic function. Increased scar formation in the ventricular wall has been shown 
with advancing age. Aldosterone promotes collagen deposition in the myocardium 
and spironolactone has been shown to reduce cardiac ﬁbrosis. We hypothesized that 
spironolactone can improve diastolic function in the elderly.
Methods: Thirty-eight patients, between 60-85 years of age, with DD on Doppler 
echocardiography (ECHO) were randomized to 25 mg/d of spironolactone or placebo 
for 4 months. Exclusion criteria were active myocardial ischemia, uncontrolled 
hypertension (HTN), long-term steroid use, and spironolactone allergy. Diastolic function 
was reassessed after 4 months with ECHO. Serum brain natriuretic peptide (BNP) and 
procollagen type IC peptide (PICP) were obtained at baseline and at 4 months. Serum 
potassium was checked at 2 weeks and when clinically indicated.
Results: Mean age was 71.7 +/- 6 years.74% were female. HTN and coronary artery 
disease were present in 80% and 38%. 46% were taking angiotensin II inhibitors. There 
was no signiﬁcant difference in baseline characteristics, diastolic function or BNP between 
the two groups. There was no serious adverse events or clinically signiﬁcant hyperkalemia.
Placebo
Baseline Follow-up
Spironolactone
Baseline Follow-up
Mitral E/A 0.86 +/- 0.39 0.72 +/- 0.27 0.84 +/- 0.24 0.95 +/- 0.28*
DT (msec) 275.2 +/- 58 299.1+/- 110 293.9 +/- 75.3 250 +/- 82.6**
BNP (pg/ml) 55.9 +/-48.5 93.3 +/-85.9 60.0 +/-51.1 81.3 +/- 63.6
PICP (ng/ml) 294.2 +/- 57.5 236.3 +/-79.4# 304.7 +/- 47.7 236.6+/-95.6#
* p < 0.05 vs placebo, ** p = 0.14 vs placebo, # p<0.05 vs baseline
Conclusion: Spironolactone can improve diastolic function in the elderly. Further study in 
elderly with diastolic heart failure is warranted.
1017-169 Stress-induced Left Ventricular Diastolic Impairment 
Causes Exercise Intolerance In Patients With Heart 
Failure And Preserved Left Ventricular Systolic 
Function.
Sudipta Chattopadhyay, M. F. Alamgir, N. P. Nikitin, A. L. Clark, J. GF Cleland, Academic 
Cardiology, University of Hull, Kingston-upon-Hull, United Kingdom
Impaired diastolic relaxation with stress in patients with heart failure (HF) and preserved left 
ventricular systolic function (PLVF) may increase the LV end-diastolic pressure (LVEDP) 
leading to exercise intolerance. The ratio of early LV ﬁlling (E) to early diastolic mitral 
annular velocity (Em) is a validated estimate of LVEDP. This measured at dobutamine 
stress echocardiography (DSE) could elucidate the mechanism for this intolerace.
84 subjects with PLVF [41 with HF (Group1) and 43 without (Group2)] underwent DSE 
using a standard protocol in TDI mode after a 6-minute walk (6mw). Images, in standard 
views at rest and peak stress, were analysed off-line. Mitral E and A velocities were 
measured. The Em was measured at 6 positions around the mitral annulus and averaged. 
Pearson correlation was used to test the signiﬁcance of relation between continuous 
variables. A two-tailed p value <0.05 was considered signiﬁcant.
Both groups were matched at rest. At peak stress, E and E/Em were similar but Em 
was signiﬁcantly lower in Group1. With stress, E remained unchanged in both groups. In 
group 1, Em was unchanged with signiﬁcant increase in E/Em. In Group 2, Em increased 
signiﬁcantly with no increase in the E/Em ratio. The change in Em correlated negatively 
with E/Em (r=0.63, p<0.001). The 6mw distance correlated signiﬁcantly with Em and the 
E/Em at peak stress only in Group1.
Stress-induced impairment in diastolic relaxation leads to increased LVEDP reducing 
exercise tolerance in patients with HF and PLVF.
1017-170 Unique Features of Patients Hospitalized with Heart 
Failure and Truly Normal Ejection Fraction (EF)
Nancy K. Sweitzer, Clyde W. Yancy, Margarita Lopatin, Lynne W. Stevenson, University 
of Wisconsin, Madison, WI, Brigham and Women’s Hospital, Boston, MA
Background: Studies of diastolic heart failure (DHF) utilize widely varying EF cutoffs 
(40-55%), which may result in mixing two distinct groups into one analysis and dilute 
treatment effects speciﬁc to particular etiologies. We hypothesized that patients (pts) with 
high (≥55%, highEF) vs. mildly impaired EF (40-55%, mildEF) would be more often female 
and less often have coronary artery disease (CAD). 
Methods: Data from 105,388 hospitalizations were in the ADHERE® registry as of 
January 2004. Of these, 74,863 had in- or prehospital assessment of EF; 17,022 were 
highEF and 17,045 mildEF. Characteristics and outcomes of the groups were compared 
using Chi-square and ANOVA tests. 
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Results: HighEF pts were more often female, slightly older and more often on Medicare 
than mildEF pts (Table). HighEF pts had less history of HF, CAD, diabetes, and renal 
insufﬁciency. Etiology of heart failure was more often hypertensive and less often ischemic 
for high vs. mildEF. Both groups had similar systolic BP and BUN. High EF pts had higher 
pulse pressure. No differences in length of stay or mortality were found.
Conclusions: HighEF patients are predominantly female and hypertensive with fewer 
CAD comorbidities than mildEF pts. When designing clinical trials of DHF one must 
determine EF cutoff carefully to improve understanding of the pathophysiology and 
treatment of this important condition. 
EF ≥55% EF 40-55% p-value
Age (mean, years) 74.3 73.8 0.0001
Gender (% Female) 69.4 54.3 <0.0001
Medicare (%) 76.3 74.8 0.001
Medical History
Known HF (%) 66.5 72.8 <0.0001
CAD (%) 46.9 59.7 <0.0001
Diabetes (%) 44.4 47.7 <0.0001
Renal Insufﬁciency (%) 27.1 30.9 <0.0001
Ischemic HF* (%) 29.0 47.8 <0.0001
Hypertensive HF* (%) 28.8 20.6 <0.0001
Initial evaluation
Systolic BP (mean, mm Hg) 152.4 150.3 <0.0001
Pulse Pressure (mean, mm Hg) 75.4 71.4 <0.0001
BUN (mean, mg/dL) 29.6 31.0 <0.0001
Outcomes
Mortality (%) 3.0 3.2 0.39
Total LOS (mean, days) 6.1 6.1 0.74
* based on patients with reported HF etiology
1017-171 Diastolic Dysfunction Is Accompanied With Increased 
Arterial Wave Reﬂections and Prolonged Mechanical 
Systole
Thomas Weber, Johann Auer, Michael F. O´Rourke, Christian Punzengruber, Bernd 
Eber, Klinikum Kreuzschwestern, Wels, Austria, UNSW, Sydney, Australia
Background: In patients with diastolic heart failure, exercise capacity has been 
linked to aortic distensibility. Moreover, slowed relaxation in diastole is associated 
with a prolongation of systole as well. Therefore, we hypothesized that non-invasive 
determination of Augmentation index (AIx), a measure of wave reﬂections and arterial 
stiffness, and left ventricular ejection time (LVET), would be useful to identify patients with 
diastolic dysfunction.
Methods: From a larger group of patients undergoing coronary angiography and left 
heart catheterization, we identiﬁed those with preserved systolic function, without 
signiﬁcant coronary or valvular heart disease and (1) elevated left ventricular enddiastolic 
pressures (LVEDP > 16 mm Hg) as well as elevated aminoterminal brain natriuretic 
peptide levels (nt-BNP > 125 pg/ml) (group 1: diastolic dysfunction; n = 76) and (2) normal 
LVEDP and normal nt-BNP levels (group 2: controls; n = 39). Wave reﬂections and LVET 
were assessed non-invasively, using radial applanation tonometry and a validated transfer 
function to generate the central aortic pressure curve. AIx as well as heart-rate corrected 
AIx (AIx@75) were used to quantify wave reﬂections. LVET was corrected for heart rate 
as well (LVETI). Values are mean +/- standard deviation, statistics were unpaired t-test 
and Spearman´s correlation.
Results: AIx (31.7 +/- 12.4 % vs 22.4 +/- 12.7 %, p<0.001) as well as AIx@75 (26.1 
+/- 11.5 % vs 20.6 +/- 10.2 %, p=0.01) were higher in diastolic dysfunction patients 
than in controls. LVETI was longer in the diastolic dysfunction group than in the control 
group (409.3 +/- 25.8 vs 392.4 +/- 21.9, p<0.001). AIx and LVETI correlated statistically 
signiﬁcant with the extent of diastolic dysfunction, quantiﬁed as LVEDP (Spearman-R for 
AIx or LVETI vs LVEDP both 0.29, p<0.01, respectively) or as nt-BNP (Spearman-R for 
AIx vs nt-BNP 0.22, and for LVETI vs nt-BNP 0.23, p=0.02 for both, respectively).
Conclusions: Diastolic dysfunction is related to increased arterial wave reﬂections and 
prolonged ejection duration. Both can be detected non-invasively, thus facilitating the 
diagnosis of this important condition.
1017-172 Comparison of Echocardiographic Predictors of Clinical 
Events in Patients With Predominantly Systolic or 
Diastolic Dysfunction
Richard A. Krasuski, Brad Smith, Karl C. Stajduhar, Michael D. Kwan, Robert Ellis, Kiran 
Cheruku, Autumn Dawn Galbreath, Gregory L. Freeman, Wilford Hall Medical Center, 
San Antonio, TX, University of Texas Health Science Center, San Antonio, TX
Background: Echocardiographic predictors of clinical outcome in patients with systolic 
dysfunction (SD) have been well established. Whether similar criteria are useful for risk 
stratiﬁcation in patients with diastolic dysfunction (DD) is less clear.
Methods: The echos of 1,069 patients were assessed at the time of entry into an 
18-month, community-based, randomized clinical trial of heart failure (HF) disease 
management. The 318 patients with DD (HF signs and symptoms with ejection fraction 
(EF) ≥50% and Doppler evidence of relaxation abnormalities) were compared with the 
751 patients with SD (HF signs and symptoms and EF<50%).
Results: DD patients were older, had less coronary disease, and were more likely 
female (all p≤0.002). Over 18 months, 5.6 % of DD patients died vs. 10.0% of SD patients 
(p=0.022), and hospitalization or death occurred in 30% of DD patients vs. 40% of SD 
patients (p<0.001). Signiﬁcant predictors of mortality in SD (after Bonferroni correction) 
included ≥mild mitral regurgitation (MR; hazard ratio-HR 1.78), left ventricular (LV) 
diastolic diameter (HR 1.93 per cm increase), LV mass index (HR 1.06 per 10 gm/m2 
increase), and estimated pulmonary artery (PA) pressure (1.58 per 10 mm Hg increase). 
The only signiﬁcant predictor of mortality for DD was PA pressure (1.84 per 10 mm Hg 
increase). Hospitalization or death in SD increased with ≥mild MR (HR 1.49), ≥mild 
tricuspid regurgitation (HR 1.33), diastolic dimension (HR 1.28 per cm increase), left atrial 
dimension (HR 1.36 per cm increase), fractional shortening (HR 0.96 per % increase), 
LV mass index (HR 1.30 per 10 gm/m2 increase), and PA pressure (HR 1.33 per 10 mm 
Hg increase); while for DD, LV systolic dimension (1.58 per cm increase) and PA pressure 
(1.55 per 10 mm Hg increase) were signiﬁcant.
Conclusions: In a community-based cohort of patients with HF, different echo features 
predicted survival and event-free survival in patients with SD than DD. Estimated PA pressure 
appears similarly predictive of hospitalization and mortality in both SD and DD. Attempts to 
estimate PA pressure should be a routine step in the echo assessment of patients with heart 
failure, and may identify patients at particularly high risk for clinical events.
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1018-173 Diabetes Reduces Long-Term Post-transplant Survival 
in Left Ventricular Assist Device Patients
Veli K. Topkara, Nicholas C. Dang, Timothy P. Martens, Faisal H. Cheema, Isaac 
George, Mehmet C. Oz, Yoshifumi Naka, Columbia University College of Physicians and 
Surgeons, New York, NY
Background: Diabetes mellitus (DM) is a frequent comorbidity in patients with congestive 
heart failure (CHF). Implantation of left ventricular assist devices (LVADs) is an acceptable 
option for diabetic patients with end-stage heart failure, yet no previous study has 
speciﬁcally examined the clinical outcomes of this patient population.
Methods: A retrospective analysis was performed of all patients who underwent Thoratec 
HeartMate LVAD insertion at a single institution from 6/17/96 to 4/14/04. Patients were 
divided into two groups_diabetics (DM) and non-diabetics (NDM). The two groups were 
compared in regards to demographics, etiology of heart failure, body mass index (BMI), 
and serum-based renal function. Outcome parameters included post-operative infection, 
intensive care unit (ICU) stay, early mortality (<30 days), bridge to transplantation rate, 
and post-transplant survival.
Results: Two hundred one patients were identiﬁed. Of these, 49 (24.4%) were DM. 
Compared to the NDM group, DM patients had a higher mean BMI (30.14±6.03 vs. 
26.05±4.76, p<0.001) and a higher proportion of hypertension (57.40% vs. 19.70%, 
p<0.001). Preoperative chronic renal disease prevalence and serum creatinine levels 
were comparable in both groups. There were no statistically signiﬁcant differences in 
ICU stay, early mortality, and bridge to transplantation rate between the groups. Post-
transplant survival in DM patients was signiﬁcantly lower compared to NDM patients, with 
1-, 3-, 5-, and 7-year actuarial survival rates of 86.92%, 70.96%, 56.48%, and 56.48% vs 
90.46, 88.35%, 83.02%, and 80.71% (log rank p = 0.020), respectively.
Conclusions: Our results suggest similar short-term clinical outcomes in DM and NDM 
patients; however, long-term post-transplant survival is signiﬁcantly reduced in the 
diabetic population. Patients with severe heart failure and concomitant DM should be 
carefully selected for LVAD placement as bridge to transplantation.
1018-174 Risk Factors for Poor Outcomes in Ventricular 
Assist Devices: The Pittsburgh Bridge to Transplant 
Experience
Marc A. Simon, Jeffery Teuteberg, Robert L. Kormos, Pradeep Nair, Mary Amanda 
Dew, Michael Heffernan, Dennis McNamara, Michael Mathier, Linda Cadaret, Hiroyuki 
Tsukui, Stephen Winowich, Eileen Stanford, Lisa Carozza, Srinivas Murali, University of 
Pittsburgh, Pittsburgh, PA
Background: Ventricular assist devices (VAD) for patients with severe heart failure 
(HF) are effective as a bridge to transplantation. Patient selection is critical for optimal 
outcome.
Methods: We reviewed pre-implant data for consecutive adult HF patients receiving 
VAD as a bridge to transplantation at the University of Pittsburgh 1996 - 2002. Primary 
outcome was survival to transplantation.
Results: There were a total of 134 VADs, 81 left ventricular assist devices, 53 biventricular 
assist devices. Mean age 50 ± 11 years, 78% male, LVEF 17 ± 8%, 52% ischemic. Mean 
length of VAD support was 127 days (range 2-670), 104 (78%) patients survived to 
transplant or had VAD weaned (n=2) and 30 (22%) patients died. Univariate analysis 
revealed the following signiﬁcant pre-implant risk factors for death prior to transplant: 
ischemic etiology (p < 0.01), creatinine clearance < 70 ml/min (p = 0.03), therapy with 
an antiarrhythmic other than amiodarone (p = 0.03), lack of ICD pre-VAD (p = 0.04), 
IABP for > 3 days preimplant (p = 0.04), prior sternotomy (p = 0.05), diabetes (p = 0.05), 
requiring > 1 inotrope preimplant (p = 0.09). Presence of > 3 of any of these risk factors 
was a signiﬁcant predictor of death at 3 months, 71% vs 94%, and at 6 months 57% vs 
87%, p < 0.00005.
Conclusion: Easily identiﬁable clinical variables predict survival to transplant after VAD. 
Moreover, the presence of > 3 of these variables is a powerful discriminator for who will 
do poorly with VAD as a bridge to transplant.
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1018-175 Tissue Imaging Of 111In-Oxine Labeled Human 
Endothelial Progenitor Cells in Muscle Ischemia and 
Inﬂammation
Rossella Di Stefano, Paola Erba, Tatiana Santoni, Chiara Armani, Maria Chiara Barsotti, 
Daniele Barone, Paola Collecchi, Giuliano Mariani, Alberto Balbarini, University of Pisa, 
Pisa, Italy
Background: Endothelial progenitor cells (EPCs) have been shown to selectively home 
to ischemic foci and contribute to neovascularization. Aim of this study was to evaluate 
111In-oxine labeled EPCs biodistribution in a murine model of ischemia or inﬂammation.
Methods: EPCs, obtained from in vitro culture of peripheral blood mononuclear cells, were 
characterized by UEA-1 binding and Dil-AcLDL uptake and angiogenesis capability on 
Matrigel. Radioactive labelling with 111In-oxine was performed as routinely for white blood 
cells. Radiolabeled EPCs were tested for cell viability, endothelial marker expression and 
angiogenesis capability and injected (3.7 to 4.8 MBq) via tail vein into male Balb-c mice 72 
hr after the induction of hindlimb ischemia through artery ligation (n=8), after aseptic right 
leg muscle inﬂammation induced with i.m. injection of terpentine (n=8) or in normal mice 
(n=8). EPC biodistribution was evaluated in normal mice 2, 8 and 24 hr after injection; in 
ischemic or inﬂammed animals at 8 and 96 hr. Results are expressed as % injection dose 
(ID/g). Immunohistochemical (IHC) analysis for EPC markers was performed.
Results: Early biodistribution (2 hr) of labeled EPCs showed high radioactivity 
content in the lungs, spleen, liver and bladder, followed by later increase in the 
kidneys, thyroid and stomach (possibly due to release of free radioactive label). 
Blood radioactivity peaked at 8 hr, while no radioactive accumulation was found in 
the bone marrow. A consistent pattern of overall tissue biodistribution was obtained in 
normal, ischemic and inﬂammed mice up to 8 hr (average 1.32 %ID/g in the normal 
muscle). Radioactivity was signiﬁcantly higher both in the ischemic and inﬂammed 
muscle as compared with the controlateral normal muscle (2.21 and 2.70 %ID/g, 
respectively), although there was no signiﬁcant difference between the two groups. 
IHC conﬁrmed high accumulation of EPC in both ischemic and inﬂammed muscles.
Conclusions: Radioactive labelling of EPCs provides a satisfactory noninvasive imaging 
approach able to assess in vivo biodistribution of transplanted EPCs and a possible basis 
for external imaging. Non selective recruitment of EPC needs of thinking it over.
1018-176 Post-Transplant Survival is Equivalent in Older Versus 
Younger Patients Bridged to Heart Transplant with Left 
Ventricular Assist Device Support
David B. Dyke, Scott L. Hummel, Jennifer C. Matthews, Keith D. Aaronson, Audrey H. 
Wu, Preeti Malani, Todd M. Koelling, Ragavendra Baliga, Maureen Daly-Myers, Susan 
Wright, Francis D. Pagani, University of Michigan Health System, Ann Arbor, MI
BACKGROUND: Left ventricular assist device (LVAD) support has become an accepted 
means of successful bridging to transplantation (BTT) for patients with severe end-stage 
cardiomyopathy. Although results have been encouraging, little is known about outcomes 
in older patients who undergo LVAD BTT. 
METHODS: In order to determine patient survival characteristics for older vs. younger 
patients who undergo LVAD BTT, a retrospective analysis was performed on our 
population of LVAD recipients. Older patients were deﬁned as age greater than or equal to 
60 years. Statistical analysis was performed using the Kaplan-Meier method with logrank 
test comparison of time-to-events between the two groups of patients. A Cox’s regression 
model was employed in order to adjust for covariates. 
RESULTS: Between May 1997 and May 2004, a total of 139 intra- and para-corporeal 
LVADs have been implanted at UMHS. Of these patients, 33 (24%) were 60 years or 
older. For the period of LVAD support, older patients had signiﬁcantly inferior survival 
as compared to younger patients (p=0.02). For the combined (LVAD support plus post-
transplant) time period, older patients had signiﬁcantly inferior survival as compared 
to younger patients (p=0.002). However, for LVAD supported patients who survived to 
transplant, there was no signiﬁcant difference in conditional post-transplant survival 
between older and younger patients (p=0.37). Covariates associated with decreased 
LVAD survival include male sex (p=0.002), pre-LVAD need for IABP, hemodialysis, ECMO, 
or mechanical ventilation (p=0.02), and higher pre-LVAD heart rate (p=0.02). 
CONCLUSION: LVAD implantation in older patients is associated with a statistically 
signiﬁcant reduction in survival as compared to younger patients. However, for those 
older patients who survive the period of LVAD support, post-transplant survival appears 
to be equivalent to that of younger patients. In conclusion, LVAD BTT in older patients is 
associated with excellent conditional post-transplant as well as graft survival.
1018-177 Arterial Stiffness Is Increased in End-Stage Heart 
Failure Patients on a Left Ventricular Assist Device
Richard S. Schoﬁeld, Gary L. Pierce, Wilmer W. Nichols, Juan M. Aranda, Jr., Daniel 
F. Pauly, Charles T. Klodell, James A. Hill, Randy W. Braith, Veterans Affairs Medical 
Center, Gainesville, FL, University of Florida, Gainesville, FL
Background: Chronic heart failure (HF) is associated with increased arterial stiffness 
leading to increased pulse wave velocity and an early return of reﬂected aortic pressure 
waves from the peripheral reﬂecting sites to the ascending aorta. This may contribute, in 
part, to increased left ventricular (LV) afterload and myocardial oxygen demand (MVO2) 
in HF. However, the effects of left ventricular assist device (LVAD) placement on the 
amplitude and timing of reﬂected aortic pressure waves in end-stage HF patients (pts) 
are unknown.
Methods: High-ﬁdelity radial artery pressure waveforms were recorded non-invasively by 
applanation tonometry and ascending aortic pressure waveforms were generated using 
a validated general transfer function (Sphygmocor™ device) in ﬁve end-stage HF pts on 
LVAD support (age 47 ± 9 yrs; 3 male), and in 10 HF pts on intravenous inotropes (age 58 
± 4 yrs; 7 male) awaiting cardiac transplant.
Results: Aortic augmented pressure and aortic augmentation index corrected for heart 
rate of 75 b/min, were signiﬁcantly greater in LVAD compared to inotrope pts (9.4 ± 5 vs. 
4.1 ± 3 mmHg, p<0.05; and 28.2 ± 10 vs. 7.9 ± 9%, p<0.01, respectively). There was no 
signiﬁcant difference in brachial systolic, diastolic, or pulse blood pressure between LVAD 
and inotrope pts, but there was a trend toward greater aortic systolic blood pressure in 
the LVAD group (107 ± 12 vs. 97 ± 9 mmHg, p=0.09). There was no signiﬁcant difference 
between LVAD and inotrope pts in �tp, the roundtrip travel time of the aortic reﬂected 
pressure wave to periphery and back (146.2 ± 13 vs. 149.1 ± 14 ms, p=NS), but aortic 
systolic tension time index, an index of LV MVO2, was higher in the LVAD group (2655 ± 
298 vs. 1748 ± 303 mmHg/sec/min, p<0.01).
Conclusion: Despite normalization of cardiac output and stroke volume, pts with end-
stage HF on LVAD support have increased arterial stiffness compared to patients on 
intravenous inotropic drugs. We believe that the LVAD-related improvement in aortic ﬂow 
leads to increased reﬂected wave amplitude and increased LV MVO2 in the setting of HF-
related peripheral arterial stiffness. This may have clinical relevance for antihypertensive 
management of HF pts post-LVAD placement. 
1018-178 A Novel Use of Optical Coherence Tomography to 
Distinguish Pericarditis and Its Extent from Healthy 
Atrium
Kyungmoo Ryu, Sung W. Jeon, Celeen M. Khrestian, Naomichi Matsumoto, Jayakumar 
Sahadevan, Michael W. Jenkins, David R. Van Wagoner, Andrew M. Rollins, Albert L. 
Waldo, Case Western Reserve University, Cleveland, OH, Cleveland Clinic Foundation, 
Cleveland, OH
Sterile pericarditis (SP) after open heart surgery (OHS) provides an important substrate for 
initiation and maintenance of atrial ﬁbrillation and ﬂutter (AFL). Using Optical Coherence 
Tomography (OCT), which provides high resolution and cross sectional imaging of internal 
structures, we tested the hypothesis that OCT will distinguish SP from normal atrial tissue, 
and that the measured difference will correlate with AFL occurrence. 
Methods: In 4 SP and 4 normal (NL) dogs, we tried inducing AFL using burst pacing from 
a right atrial (RA) or Bachmann’s bundle site. Tissue from the RA freewall (RAFW) was 
subjected to in vitro OCT, and image sections from 3-5 selected regions were studied. To 
differentiate NL and SP quantitatively, a light attenuation slope was calculated using linear 
ﬁtting from all sections in each dog after transversely averaging the axial scan proﬁles for 
each section. Histology was also performed to identify inﬂammation due to pericarditis. 
Results: Sustained AFL (CL 168±21ms) was only inducible in SP dogs (4/4). OCT images 
in the SP RAFW had relatively fast light attenuation and damaged tissue structures 
(ﬁgure). The mean attenuation slope was signiﬁcantly greater in SP (584±144 1/mm) 
than in NL (381±56 1/mm) (p=.02). Histology conﬁrmed inﬂammation in SP. Conclusion: 
This study demonstrates for the ﬁrst time that OCT can be used as a valuable tool to 
identify the presence and extent of pericarditis. The attenuation slope above 450 1/mm is 
associated with AFL occurrence in this study.
 
2005_4_CardiacFuncHeartFail.indd   133 12/23/04   10:03:21 AM
134A ABSTRACTS - Cardiac Function and Heart Failure JACC February 1, 2005
C
ar
di
ac
 F
un
ct
io
n 
an
d 
H
ea
rt
 F
ai
lu
re
1018-179 First Human use of a 16 F Axial Flow Pump (AMED) in 
Cardiogenic Shock and High-Risk PCI
Markus Ferrari, Gerald S. Werner, Markus Schlosser, Walid Abouldhosn, Klaus Pethig, 
Hans R. Figulla, Friedrich-Schiller-University, Jena, Germany, Amed Inc., Sacramento, CA
Background: Axial ﬂow pumps with ﬂow rates > 2 l/min. require a surgical approach to the 
femoral artery. But percutaneous implantation with sufﬁcient ﬂow rates is desirable.
Methods: The novel axial ﬂow pump (AMED) can be implanted percutaneously creating 
a ﬂow of 3.3 l/min. After advancing a 16 F sheath by Seldinger’s technique with its tip 
in the left ventricle the inner guiding pigtail catheter is replaced by the impeller pump. 
We percutaneously implanted the device in 3 patients. The left ventricular ejection 
fraction (LVEF) was measured before insertion of the pump. Free hemoglobin (FHB) and 
haptoglobin (HGB) were analyzed every 2 hours after the insertion to monitor the amount 
of hemolysis. A follow-up examination was performed 30 days after the procedure.
Results: The AMED pump was implanted within 14.6 min. in all 3 patients without any 
complication. Two patients were on inotropic support and had an IABP implanted before 
due to cardiogenic shock. The third patient had a left main stenosis and an occluded right 
coronary artery but refused cardiac surgery. All patients had severe 3 vessel disease. 
A PCI was performed on an average of 2.3 vessels without hemodynamic compromise 
during any procedure. After 1 month all patients were able to perform daily activities 
without angina pectoris.
Conclusions: The novel 16 F turbine pump provides sufﬁcient circulatory support in 
cardiogenic shock and for high-risk PCI. The amount of hemolysis is relatively low. The 
device can be implanted easily within 15 minutes.
Patient Age (years) LVEF (%) FHBmax (<3.1µmol/l)
HGBmax 
(<2.0g/l) pump time (hours)
1 75 17 67.4 1 8
2 78 30 8.7 1.4 2.5
3 49 70 11.4 1.2 2
1018-180 Salvage Ventricular Assistance for Patients Undergoing 
Cardiopulmonary Resuscitation: Long Term Results
Gil Bolotin, Jaishankar Raman, Neil Thomas, Valluvan Jeevanandam, University of 
Chicago, Chicago, IL
Background: It is possible to transfer patients undergoing cardiopulmonary resuscitation 
(CPR) with closed chest compressions or open massage to the operating room (OR), 
place them emergently on cardiopulmonary bypass and continue with ventricular assist 
device as a bridge to transplant or recovery. We retrospectively reviewed short and long 
term results of these salvage procedures.
Methods: Between March 2000 and July 2004 eighty eight patients underwent left, 
right, or biventricular assist device implantation in our institute. Thirteen of those patients 
(14.8%) had CPR at the time of the implantation. In ﬁve patients the CPR was started 
during the transfer to or while entering the OR, while in the other eight patients the CPR 
was initiated on the ﬂoor or in the ICU.
Results: Mean time of CPR was 61±31 (range: 15-120) minutes. Twelve of the 13 patients 
(92%) survived the operation and nine (69%) were neurologically intact. Five patients 
were transplanted (38%), seven patients (54%) were discharged from the ICU and four 
(31%) were discharged home. However, only three (23%) survived past 6 months. The 
common causes of death included: GI complications (31%), smoldering sepsis (31%), 
and coagulopathy with bleeding (15%).
Conclusions: A signiﬁcant number of patients undergoing salvage ventricular assist 
device implantation survive the operation without neurological compromise. However, long 
term survival was low due systemic complications, related to the GI tract and persistent 
sepsis. Better strategies are required to protect other organs during the CPR and the 
assist device implantation.
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1019-143 Comparaison of The Prognostic Value of the Peak Vo2, 
the Peak Circulatory Power and the VE/VCO2 Slope In 
Chronic Heart Failure Patients on Betablockers.
Jy Tabet, M. Metra, S. Nodari, L. Deis Cas, G. Thabut, F. Beauvais, A. Cohen Solal, AP-
HP hopital Beaujon, Clichy, France, Brescia universita, Italy
Introduction: The prognostic value of peak oxygen uptake (PVO2) in patients with chronic 
heart failure (CHF) has been recently challenged by 2 new exercise parameters, the slope 
of increase of ventilation relative to carbon dioxide production (VE/VCO2) and the peak 
circulatory power (CP) deﬁned as PVO2 times maximal systolic blood pressure. However, 
the prognostic value of these 3 parameters has never been compared in patients treated 
with betablockers, a treatment known to affect maximal exercise capacity variables.
Methods: Four hundred and two CHF patients, with 255 of them treated by betablockers, 
with ejection fraction (EF) <45% (mean 26±10%), in NYHA class II-IV underwent a 
cardiopulmonary exercise test. VE/VCO2 slope, PVO2 and CP were assessed. Death was 
the end-point considered (mean follow-up 24±21 months). The prognostic value of models 
was assessed using the D index described by Royston and Sauerbrei
Results: Mean values of VE/VCO2 slope, PVO2 and CP were 40.2±12.1, 15.5±5.1 ml/min/
kg, and 2267±1002 mm Hg.ml.min-1.kg-1 respectively. By univariate analysis, VE/VCO2 
(Chi2 28.1), CP (Chi2 23.4), NYHA class (Chi2 15.6) PVO2 (Chi2 20.8,), LVEF (Chi2 18.6) 
(all p<10-4) and age (Chi2 10.4 p=0.001) were predictive of death.
By multivariate analysis, the ﬁrst model including age, LVEF and NYHA was signiﬁcantly 
associated with outcome (D index =1.18 in the overall population and 1.38 in patients 
treated by betablockers) The inclusion of VE/VCO2 (model 2) or peakVO2 (model 3) or 
peak circulatory power (model 4) added signiﬁcant incremental predictive diagnostic 
value (D index = 1.74 and 2.03, 1.91 and 2.05, 2.08 and 2.41 in the overall population and 
in patients treated by betablockers respectively). Among the three exercise variables, the 
model including CP carries the greatest prognostic information in the overall population 
as well as in patients treated with betablockers.
Conclusion: In CHF patients, the peak circulatory power, a surrogate of peak cardiac 
power, has a greater prognostic value than the VE/VCO2 slope and than PVO2, especially 
in patients treated by betablockers.
1019-144 The Impact of Diabetes on the Prognostic Efﬁcacy of 
Duke Treadmill Score in Patients Risk Stratiﬁed for 
Coronary Artery Disease
Dhanunjaya Lakkireddy, Hema Korlakunta, Jyothi Bhakkad, Aryan Mooss, KayRyschon, 
Xuedong Shen, Syed Mohiuddin, Creighton Cardiac Center, Omaha, NE, Cleveland 
Clinic Foundation, Cleveland, OH
Background: The Duke Treadmill Score (DTS) is an established clinical tool for risk 
stratiﬁcation coronary artery disease. We sought to assess the prognostic value of DTS in 
diabetics compared to non diabetics in this study.
Methods: We studied 100 diabetics and 202 age and gender-matched non- diabetic 
controls without known coronary artery disease risk stratiﬁed by DTS and followed for 
a median duration of 6.6 years. The association between DTS and primary, secondary 
outcomes, composite events and rate of coronary angiography was tested.
Results: Survival free from cardiac death, non-fatal MI, CHF, or early and late 
revascularization was 89%, 54% and 13% respectively in the low, intermediate and 
high risk categories of diabetic group (p<0.0001); and 91%, 57% & 17% respectively in 
the low to high risk groups of non-diabetics (p<0.0001). During follow up diabetics had 
more secondary events (p=0.011) and coronary angiography (p<0.001) compared to non 
diabetics. The Duke Score was a strong independent predictor of composite events in 
both diabetics (p<0.001) and in non-diabetics (p<0.001). A signiﬁcant number of diabetics 
were classiﬁed as intermediate risk, and had a signiﬁcantly higher incidence of coronary 
angiography (87.5% vs 70.8%, p=0.032) and late revascularizations (35.4% vs 15.3%, 
p=0.011) within this risk group compared to non diabetics. Survival free from MACE 
differed signiﬁcantly across the three Duke risk groups for diabetics (p=0.002) but not for 
controls (p=0.07). Survival free from composite events differed signiﬁcantly across the 
three Duke risk groups for both diabetics and non diabetics (p<0.0001). Overall, diabetics 
had higher rates of MACE, composite events (p=0.011), and coronary angiography 
(p<0.001) than non diabetics. DTS is a strong predictor of survival free of composite 
events in both groups by multivariate analysis (p<0.001)
Conclusions: The DTS predicted survival free from MACE, and composite events equally 
well in patients with and without diabetes.
1019-145 Inﬂuence of VE/VCO2 Slope on the Prognostic Ability 
of other Clinical Variables Obtained During Routine 
Cardiopulmonary Exercise Testing in Heart Failure
Robert L. Bard, Brenda W. Gillespie, Nicholas Clarke, John M. Nicklas, University of 
Michigan, Ann Arbor, MI
The purpose of this study was to develop a multivariable model that best predicted 
mortality to determine the relative prognostic power of each variable obtained during 
cardiopulmonary exercise testing. 
Methods and Results: Heart failure patients (n=356, 145 events, 51 ± 10 years) had 
mortality and transplantation follow-up that lasted for at least 5 years from the date of 
the exercise test. A base model that best predicted mortality included: sex (100 females), 
etiology (159 ischemic/197nonischemic), peak VO2 (17.3 ± 5.0 ml·kg
-1·min-1), peak VE/
VCO2 slope (37.3 ± 10.8), left ventricular ejection fraction (21.5 ± 7.7), systolic blood 
pressure ≤ 100 mm Hg, and resting heart rate ≥ 80 beats per minute. The inclusion of 
peak VE/VCO2 slope to the model increased the explained mortality variation (generalized 
R2) by 5%, from 18 to 23%. No other single variable increased the generalized R2 by more 
than 1% above the base model. An interaction between peak VO2 and peak VE/VCO2 
slope was almost signiﬁcant (p=0.055); the combination of both a high slope and a low 
peak VO2 was associated with an even greater mortality risk than what would be expected 
from the combined risks. Conclusion: When considered in a multivariable model, peak 
VE/VCO2 slope was the most predictive single variable of mortality but peak VO2 adds 
to the predictive ability of peak VE/VCO2 slope. Therefore, when evaluating patients with 
heart failure with cardiopulmonary exercise testing both peak VO2 and VE/VCO2 slope 
should be determined.
1019-146 Ventilatory Response To Exercise As An Independent 
Risk Factor For Patients With Chronic Heart Failure And 
Moderate Exercise Intolerance
Dimitrios Sakellariou, Seraﬁm Nanas, Stavros Dimiopoulos, Ourania Papazachou, 
Smaragdo Kapsimalakou, Sotirios Gyftopoulos, Christina Mpatziou, Panagiotis 
Papazoglou, John Venetsanakos, Maria Anastasiou-Nana, Charalampos Roussos, 
University of Athens, Athens, Greece
Background: Patients with chronic heart failure (CHF) are characterized by 
hyperventilation during exercise. The role of this hyperventilation in risk stratiﬁcation, 
especially in patients with moderate exercise capacity (VO2peak between 10 and 18 ml/
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Kg/min) is not well established. We investigated the prognostic role of VE/VCO2 slope in 
risk stratiﬁcation in a cohort of CHF patients with moderate exercise intolerance.
Methods: The study group consisted of 98 consecutive patients with CHF (90males 
and 8females). All patients underwent symptom-limited treadmill exercise testing 
(CPET). Exercise capacity was evaluated by using VO2 peak, anaerobic threshold (AT), 
VE/VCO2 slope (from the beginning of exercise to the anaerobic threshold). Right-heart 
catheterization and radionucleoid ventriculography were performed in all patients within 
72 hours of CPET. The patients were followed up for a period of 20 ± 6 months. Cardiac 
mortality was considered as the primary end point. Ejection fraction (LVEF) was 31 ± 12 
and pulmonary capillary wedge pressure (PCWP) was 13.8 ± 7.9 mmHg. Continuous 
variables are expressed as mean ± SD.
Results: Forty-ﬁve (45) patients of the study group had VO2 peak between 10 and 18 
ml/Kg/min. Sixteen of these patients (36%) died from cardiac reasons during the follow-up 
period. Total cardiac mortality rate was 62% in patients with VE/VCO2 ≥ 34 and 13% in 
patients with VE/VCO2 < 34. Kaplan-Meier survival curves analysis showed a statistically
signiﬁcant difference (log rank:12.2;p12mmHg,VE/VCO2 slope ≥or<34 and LVEF 
<or≥25%, the steep VE/VCO2 slope was the only independent prognostic factor (OR:6.2; 
95%CI:1.7-22.2; p=0.002).
Conclusion: The VE/VCO2 slope is an independent predictor of mortality in patients with 
intermediate exercise capacity where VO2peak fail to improve risk stratiﬁcation.
1019-147 Heart Rate Recovery Predicts Better Mortality Than 
Chronotropic Response In Patients With Chronic Heart 
Failure
Stavros Dimopoulos, Maria Anastasiou-Nana, George Alexopoulos, Konstantinos 
Stamatelopoulos, Dimitrios Sakellariou, Smaragdo Kapsimalakou, Konstantinos Kritikos, 
Sotiris Gyftopouls, Seraﬁm Nanas, Charalampos Roussos, Cardiopulmonary Exercise 
Laboratory and Rehabilitation Center, Athens, Greece
Background: Imbalance of the autonomic nervous system is a common ﬁnding in patients 
with chronic heart failure (CHF) and is strongly related to their high cardiac mortality 
risk. Impaired chronotropic response and abnormal heart rate recovery reﬂect autonomic 
abnormalities during and after exercise, but their prognostic role in these patients hasn’t 
been well established yet.
Methods: Ninety-two (83M/9F) consecutive CHF patients underwent symptom-limited 
cardiopulmonary exercise test. We measured maximal oxygen uptake (Vo2 peak,ml/kg/
min), anaerobic threshold (AT,ml/kg/min) and ventilatory response to exercise (VE/VCO2 
slope). Heart rate recovery (HRR,b/min) was deﬁned as the HR difference from peak to 1 
min after exercise and chronotropic response was evaluated by percentage proportion of 
chronotropic reserve [% CR= (peak HR-resting HR / 220-age-resting HR) x100]. The mean 
follow-up period was 21±6 months and the primary end-point was cardiac mortality.
Results: Twenty-four (23M/1F) patients (26.1%) died from cardiac events during follow-
up period. HRR and % CR were lower in non-survivors than in survivors (11.4±6.4 vs 
20.6±8.1; p<0.001 and 52.6±21.5 vs 70.2±18.2; p<0.001; respectively). Both HRR 
and % CR as continuous variables were univariate predictors of mortality (OR:0.871; 
95%CI:0.82-0.93; p<0.001 and OR:0.97; 95%CI:0.95-0.98; p<0.001; respectively), but in 
a Cox regression multivariate survival analysis, including HRR, % CR, Vo2 peak, VE/VCO2 
slope, AT, HRR was the only independent predictor of mortality (OR:0.87; 95%CI:0.82-
0.93; p<0.001),
Conclusions: In patients with chronic heart failure, both chronotropic response and heart 
rate recovery are related to a higher cardiac mortality risk, but only heart rate recovery is 
an independent prognostic risk factor in CHF patients and may play an important role in 
their risk stratiﬁcation.
1019-148 Prognostic Value of Exercise Versus Recovery 
Electrocardiographic Analysis
Riccardo Bigi, Lauro Cortigiani, Dario Gregori, Benedetta De Chiara, Cesare Fiorentini, 
University Medical School and A.De Gasperis Foundation, Milan, Italy
Background. Heart rate-adjusted ST-segment depression (ST/HR) analysis improves 
diagnostic accuracy of exercise testing, but its prognostic value has not been evaluated 
in unselected populations. We prospectively used comparative exercise-recovery ST/HR 
analysis to predict outcome in a consecutive cohort of outpatients referred for exercise 
testing.
Methods. Stress-Recovery Index (SRI), deﬁned as the difference between ST/HR areas 
during exercise and recovery was derived in 1,163 subjects, median age 60 (interquartile 
range 54 to 65) years. All-cause mortality and the combination of death or non-fatal 
myocardial infarction were target end-points. The individual effect of clinical and exercise 
testing data on outcome was evaluated by Cox’s regression analysis using separate 
models for each group of variables. Model validation was performed by bootstrap adjusted 
by the degree of optimism in estimates. Survival analysis was performed using product-
limit Kaplan-Meier method.
Results. During 33-month follow-up 48 deaths and 72 non-fatal myocardial infarctions 
occurred. After adjusting for confounding variables, hypertension [hazard ratio 1.8, 95% 
conﬁdence interval (CI) 1.26-2.59), ST/HR Index (hazard ratio 1.32, 95%CI 1.04-1.66 
for interquartile difference in kilopounds per minute), and SRI (hazard ratio 0.75, 95%CI 
0.65-0.86 for interquartile difference) were predictive of death or non-fatal myocardial 
infarction, whilst hypertension (hazard ratio 3.67, 95% CI 2.00-6.73) and SRI (hazard ratio 
0.55, 95%CI 0.48-0.63 for interquartile difference) were predictive of all-cause mortality. 
SRI increased the prognostic power of the model on top of clinical and exercise testing 
variables and provided signiﬁcant discrimination of survival.
Conclusions. Exercise-recovery ST/HR analysis improves the prognostic capacity of 
standard exercise electrocardiography.
1019-149 Prognostic Signiﬁcance Of Peak Oxygen Pulse In 
Patients With Chronic Heart Failure
Smaragdo Kapsimalakou, Dimitrios Sakellariou, Stavros Dimopoulos, Petros Roditis, 
Ourania Papazachou, Maria Anastasiou-Nana, George Alexopoulos, Konstantinos 
Stamatelopoulos, Seraﬁm Nanas, Charalampos Roussos, Kapodestrian University of 
Athens, ATHENS, Greece
Background: Patients with congestive heart failure (CHF) are charecterized by a reduced 
cardiac pump function reserve that can be predicted by peak oxygen pulse (O2 pulse), 
which is a non invasive indicator of stroke volume and arteriovenous O2 difference. 
However, only limited data are available for the prognostic value of this parameter.
Materials and methods: We have studied 94 (86males and 8females) consecutive 
ambulatory patients with chronic heart failure who underwent a symptom-limited exercise 
testing on a treadmill. Exercise capacity was evaluated by using VO2 peak, anaerobic 
threshold (AT) and ventilatory response (VE/VCO2 slope). Peak O2 pulse was measured 
as the ratio of VO2 and HR at the peak of exercise. A right catheterization was performed 
in all patients within 72 hours of CPET and pulmonary capillary wedge pressure (PCWP) 
was determined. All patients were followed up for 20 ± 6 months, in order to determine 
the impact of peak O2 pulse in cardiac mortality. Continuous variables are expressed as 
mean ± 2SE.
Results: Patients were subdivided using 0.10 ml/kg/beat as cut off point of peak O2 pulse 
in group A (Abnormal peak O2 pulse ≤ 0.1) and in group B (Normal peak O2 pulse>0.1) 
Twenty eight patients (30%) have died from cardiac causes during follow-up period. Non 
survivors compared to survivors had a lower peak O2 pulse [0.12 ± 0.03 vs 0.14 ± 0.04; 
p:0.002]. A univariate Cox regression survival analysis showed that patients with peak O2 
pulse ≤ 0.1 were in a higher mortality risk (OR:3.0; 95%CI: 1.42-6.35; p=0.004). Cardiac 
mortality rate in group A was 52% and in group B was 22%. A statistical signiﬁcant 
difference among Kaplan-Meier curves (log rank: 9.25; p=0.002).
Conclusions: Peak oxygen pulse is a predictive risk factor in patients with CHF which can 
improve the prognostic signiﬁcance of VO2 peak and may be included in risk stratiﬁcation 
of these patients.
1019-150 Early Heart Rate Recovery Kinetics Is Related To 
Exercise Capacity, Ventilatory Response And Resting 
Hemodynamic Measurements In Chf Patients
Stavros Dimopoulos, Maria Anastasiou-Nana, Dimitrios Sakellariou, Smaragdo 
Kapsimalakou, Petros Roditis, Konstantinos Kritikos, Christina Mpatziou, George 
Maroulidis, Konstantinos Stamatelopouls, Seraﬁm Nanas, Charalampos Roussos, 
Kapodestrian University of Athens, Athens, Greece
Background: Patients with chronic heart failure (CHF) seem to present a delayed heart 
rate decline during recovery period immediately after peak exercise reﬂecting a withdrawal 
of parasympathetic activity. However, early recovery heart rate kinetics in CHF patients 
hasn’t been thoroughly studied in relation to exercise capacity, ventilatory response to 
exercise and hemodynamic measurements at rest.
Materials and Methods: Ninety-two (83M/9F) consecutive CHF patients underwent 
symptom-limited cardiopulmonary exercise test, right catheterization and radionuclide 
ventriculography. We measured maximal oxygen uptake (Vo2peak,ml/kg/min), anaerobic 
threshold (AT,ml/kg/min), ventilatory response to exercise (VE/VCO2slope), left ventricular 
ejection fraction (LVEF,%) and pulmonary capillary wedge pressure (PCWP,mmHg). Early 
heart-rate recovery (HRR) kinetics was evaluated by HRR deﬁned as the HR difference 
from peak to 1 min after exercise, considered “abnormal” if 12 or less, and by the ﬁrst 
degree slope of HR for the 1st min of recovery period (HR/t slope,b/min2), calculated by a 
linear regression model using an appropriate computerized statistical program.
Results: Patients with “abnormal” HRR (≤12b/min) presented a lower Vo2peak (14.9±3.9 
vs 20.6±5.6; p<0.001), AT(11±2.9 vs 14.6±3.7; p<0.001), a higher VE/VCO2slope (34.6±7.8 
vs 29.1±5.3; p<0.001), a lower LVEF (24.9±11.3 vs 32±11.4; p<0.02), a higher PCWP 
(19.3±9.9 vs 11.5±5.9; p<0.001) and a lower HR/t slope (12.3±5.7 vs 26.2±9.5; p<0.001) 
than patients with “normal” HRR (>12b/min). HRR was correlated with Vo2peak (r=0.47; 
p<0.01), AT (r=0.45; p<0.01), VE/VCO2slope (r=-0.4; p<0.01), LVEF (r=0.37; p<0.01) and 
PCWP (r=-0.45; p<0.01). There was also a strong positive correlation between HRR and 
HR/t slope (r=0.79; p<0.01).
Conclusions: Early heart rate recovery kinetics was delayed in CHF patients with an 
impaired exercise capacity and ventilatory response, as well as with severe hemodynamic 
measurements. These ﬁndings suggest that HRR and HR/t slope expressing early heart 
rate recovery kinetics are related to functional status of CHF patients and may be used to 
their global clinical assessment.
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1047  Myocardial Function and Heart Failure: 
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1047-143 Tissue Inhibitor of Matrix Metalloproteinase-3 (TIMP-3) 
Cell-Based Gene Delivery After Myocardial Infarction 
Preserves Heart Function
Denis Angoulvant, Shaﬁe Fazel, Richard D. Weisel, Paul W. Fedak, Amy P. Wong, Shahin 
Rafati, Charit K. Seneviratne, Liwen Chen, Rama Khokha, Ren-Ke Li, Toronto General 
Hospital, Toronto, ON, Canada, Ontario Cancer Institute, Toronto, ON, Canada
Background: We have recently reported that knock out mice lacking Tissue Inhibitor 
of Matrix Metalloproteinase (TIMP)-3 serve as a model of dilated cardiomyopathy. 
We hypothesized that cell based gene therapy designed to restore regional TIMP-3 
expression in TIMP-3-/- mice would prevent progression to overt heart failure following 
myocardial infarction (MI). Methods: Bone marrow cells (BMC) from C57BL/6 mice were 
harvested and expanded before being transfected with murine TIMP-3 cDNA. Quantity 
and activity of TIMP-3 transfected (BMC T3+) and untransfected (WT BMC) BMC were 
evaluated by Western blot and reverse zymography. BMC T3+ were injected in the 
anterior wall of TIMP-3-/- BL/6 mice hearts immediately after coronary ligation. WT BMC 
or media injections served as controls. Heart function was assessed by echocardiography 
calculating fractional shortening (FS) at baseline, day 3, 7 and 28 after MI. Biochemical, 
immunohistochemical and morphological analysis were performed at the same endpoints. 
Results: Western blot showed a signiﬁcant 53% increase in TIMP-3 expression after BMC 
transfection. Gelatine zymography showed a lower activity of matrix metalloproteinases 
(MMP)-9 and MMP-2 in the BMC T3+ mice hearts at day 3 followed by a bounce effect at 
day 7. Tunnel staining at day 7 showed less apoptosis in the border zone of BMC T3+ and 
WT BMC mice compared to medium. At day 3, BMC T3+ mice, compared to WT BMC and 
Medium, showed signiﬁcant preservation in systolic function (FS 29.4±6.1 vs 22.8±6.3, 
19.1±5.2%, all P<0.05). FS at day 28 was close to baseline for BMC T3+ mice (38.1±6 
vs 38.9±2%), non signiﬁcantly lower for WT BMC mice (32.5±4%) and signiﬁcantly 
altered for medium mice (17.1±1%, P<0.05). Morphometry analysis at day 28 showed 
signiﬁcantly smaller left ventricular volume (2.4 and 2.1 vs 6.3 ml/Kg) and % of scar 
area (10.4 and 10.7 vs 37.1%) in BMC T3+ and WT BMC mice compared to medium (all 
P<0.05). Conclusion: These data suggest an intricate dose- and time-dependant effect of 
TIMP-3 over expression in modulating post MI cardiac remodelling and systolic function. 
The results highlight the efﬁcacy and the synergistic beneﬁt of cell-based gene therapy for 
prevention of heart failure after MI.
1047-144 Delayed Regional Activation After MI Increases 
Borderzone Work
Landi M. Parish, Hiroaki Sakamoto, Benjamin M. Jackson, Bradley Leshnower, Ahmad 
Zeeshan, Joseph H. Gorman, III, Robert C. Gorman, University of Pennsylvania School 
of Medicine, Philadelphia, PA
Background: After infarction, increased strain in the normally-perfused borderzone 
(BZ) contributes to adverse remodeling. We hypothesized that increased BZ strain after 
infarction is caused by delayed initiation of BZ contraction. 
Methods: We used an ovine (n=13) anteroapical infarct model (20% LV mass) and 16 
sonomicrometry transducers placed from base to apex on the anterior wall to assess 
areal strain, contractility, and timing of contraction in four regions of myocardium - infarct 
(I), BZ, remote (R) and far remote (FR) - before and during ischemia. Values are reported 
as mean ± standard error of the mean. 
Results: Prior to ischemia, the initiation of contraction after end diastole was shortest 
at the base and longest at the apex (FR= 42±6.1ms, R= 42 ± 7.9ms, BZ= 68±4.7ms, 
I=81±4.7ms). During ischemia contraction started earlier in the basilar regions 
(FR=7.0±7.6ms, R=22±11ms) and later in the BZ (BZ=88±5.4ms). The BZ stretched 
5.9±0.9% at end isovolemic contraction due to ischemia. BZ shortening velocity at mid-
ejection was 0.5±.00 s-1 before infarction and decreased to 0.28±.00 s-1 after infarction.
 
Conclusion: The relative delay between initiation of contraction in remote and BZ regions 
is prolonged by acute ischemia. This phenomenon is associated with increased BZ strain 
before ejection and decreased BZ contractile function
1047-145 In-Vivo Interleukin Converting Enzyme Inhibition Reduces 
Inﬂammatory Cytokine Maturation and Attenuates 
Ventricular Remodeling in Rats With Anterior MI
Y. Chandrashekhar, Ruth Anway, Soma Sen, Inder Anand, VA Medical Center, 
Minneapolis, MN, University of Minnesota, Minneapolis, MN
Background: Interleukin Converting Enzyme (ICE) generates mature inﬂammatory 
cytokines, like IL-1beta and IL-18, which mediate ﬁbrosis, myocardial dysfunction & cell 
death. ICE inhibition (ICE-I) is beneﬁcial during ischemia-reperfusion. However, ICE-I has 
not been well studied in chronic heart failure (HF).
Hypothesis: Myocardial IL-1 beta & IL-18 will be up-regulated in HF & contribute to its 
worsening. ICE-I will attenuate myocyte loss & decrease remodeling.
Methods: We measured IL-1, IL-18 & ICE mRNA (RT-PCR) and Protein (westerns) in non-
infarct myocardium of rats with anterior MI given ICE-I [zAdCB, 2 mg/day, n= 8] or vehicle 
[V] (n=6) for 4 wks & in sham-operated rats (n=3). This was correlated with Myocyte Loss 
[Cytochrome C release (westerns) & Apoptosis (Apologix)] & LV Remodeling (Echo).
Results: Infarcts were 38±4% & comparable in MI groups. IL-1 & IL-18 mRNA & protein 
levels were increased in HF & both were decreased by ICE-I. ICE-I] also signiﬁcantly 
reduced apoptosis & cytochrome C release. Additionally, ICE-I reduced heart/body 
wt ratio (3.56+0.1 vs. 5.11+0.4, p < 0.05), & LV end-diastolic size and attenuated LV 
dysfunction compared to V.
Conclusions: Inﬂammatory cytokine message & protein, is increased in the failing 
myocardium. This could worsen remodeling. Chronic ICE-I, started in peri-MI period, 
decreases myocardial cytokine levels, reduces myocyte loss, and attenuates LV 
dysfunction & LV remodeling. ICE-I may have important therapeutic implications
1047-146 Safety and Feasibility of Endocardial Autologous 
Skeletal Myoblast Transplantation in a Porcine Model of 
Myocardial Infarction
Nabil Dib, Ann Campbell, Thomas Mattioni, Vijendra Swarup, Amir Gahremanpour, 
Brigitte Meidzybrocki, Alice Dayoub, Shaun Opie, Noreen Goodwin, Edward Diethrich, 
Arizona Heart Institute, Phoenix, AZ
Background: Cell therapy is a promising new treatment for myocardial infarction (MI). 
Although direct epicardial cell injection has been successful, a less invasive approach is 
preferred. Methods: Six swines underwent a randomized, controlled study. A skeletal muscle 
biopsy was excised from the hind limb of each animal and myoblasts were expanded. MI 
was induced by coil deployment in the left anterior descending artery. An implantable 
loop recorder was placed to continuously monitor the heart rhythm and introgated 28 
times. One month after MI, cells or medium were delivered to the infarcted myocardium 
by endocardial injection using the Biosense system. Swines were separated into control, 
low and high dose treatment groups (Table). Echocardiography, left ventriculography 
and NOGA mapping were done at baseline, transplant and harvest. Results: All animals 
survived after transplantation and there were no complications related to the procedures. 
No arrhythmias were detected post-transplant. Two months after cell delivery, the uni-
polar voltage of the transplant zone improved by 27.5% (p<0.04) in the treated group and 
deteriorated by 6.5% (p=NS) in the control group. There was a trend toward improvement 
in EF by echocardiography from 45.5% to 52.5% in the treated group and a deterioration 
from 48.5% to 43.5% in the control group. Conclusion: Endocardial cell delivery is feasible 
and safe. There was a trend toward inprovement in heart function and voltage.
Group Cell Count (million) No of Inj Vol/inj (ml) Total vol (ml) Cell Viability%
Control #1 0 20 0.15 3 0
Control #2 0 38 0.1 3.8 0
2 300 19 0.1 1.9 66
2 600 35 0.15 5.25 66
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1047-147 Biodistribution and Bioretention of Autologous Skeletal 
Myoblast After Percutaneous Transplantation in a 
Coil-infarcted Swine Myocardium Using The Biosense 
System
Nabil Dib, Ann Campbell, Amir Gahremanpour, Shaun Opie, Brigitte Meidzybrocki, Alice 
Dayoub, Edward Diethrich, Jonathon J. Dinsmore, Arizona Heart Institute, Phoenix, AZ
Background:Epicardial cell transplantation is feasible and safe. Bioretention and 
biodistribution of stem cells by endocardial delivery is not known. We evaluated the 
bioretention and biodistribution of iridium-labeled autologous skeletal myoblast (ASM) 
following percutaneous delivery to a swine model of myocardial infarction.Methods: An 
apical myocardial infarction was created by percutaneous coil deployment into left anterior 
descending artery. Skeletal muscle biopsy was taken from the hind limb of the animal to 
isolate and expand myoblast. Forty million myoblasts were mixed with 13.4 x 1010 iridium 
particles and incubated for 2.5 hrs at 37 oC. Unabsorbed particles were removed by 
extensive washing. The remaining cells (6 x 106 viable cells) were mixed with unlabelled 
cells to formulate the ﬁnal product (79 x 106 viable cells/ml, 231 x 106 total cells, 59.6% 
viability). One month after infarction, the iridium-labeled ASM were transplanted into the 
infarcted zone via endocardial delivery using NOGA mapping and the Biosense injection 
catheter. After 2 hours the animal was sacriﬁced, samples from the heart, brain, kidneys, 
liver, lungs and spleen were analyzed for the presence of iridium particles. The samples 
were exposed to high-energy neutrons allowing the iridium atoms in the cells to capture 
incident neutrons. Then the samples were placed in a high-resolution gamma-detection 
monitor to measure the the number of emitted gamma particles. A standard curve from 
a sample of known number of iridium-labeled cells was applied to convert the gamma 
particle emission to the number of iridium-labeled cells. Results: The apex of the heart, 
lungs and spleen contained 4.6%, 5.1% and <0.1% of the cells, respectively. No ASM 
were detected in the brain, kidneys or liver. In conclusion: Myoblasts can be accurately 
transplanted into infarction regions by endocardial delivery. Cells can be expected to be 
found in lung secondary to venous drainage of the LV. There was no signiﬁcant risk of cell 
leakage into the systemic circulation in this study.
1047-148 Chronic Therapy With the Acorn Cardiac Support Device 
Reduces mRNA Gene Expression and Protein Levels of 
Tumor Necrosis Factor-α and Interleukin-6 in Dogs With 
Heart Failure
Sharad Rastogi, Sudhish Mishra, Ramesh C. Gupta, Makoto Imai, Hani N. Sabbah, 
Henry Ford Health System, Detroit, MI
Background: The cytokines tumor necrosis factor-α (TNF-α) and interlukin-6 (IL-6) are 
important mediators of immune response and their overexpression in heart failure (HF) 
may contribute to disease progresssion. Increased circulating plasma levels of TNF-α 
correlate with the severity of HF and overexpression of TNF-α in tansgenic mice leads to 
dilated cardiomyopathy. We showed that therapy with the Acorn Cardiac Support Device 
(CSD) prevents progressive LV dilation and improves LV function in dogs with HF. This 
study examined the effects of long-term (3 months) CSD therapy on mRNA and protein 
expression of TNF-α and IL-6. 
Methods: The CSD was implanted in 6 dogs with coronary microembolization-induced 
HF. Six untreated HF dogs served as controls. LV tissue from all HF dogs and from 6 
normal (NL) dogs was used to extract RNA. mRNA expression was measured using 
RT-PCR. Protein levels were determined in SDS-extract of LV homogenate using 
speciﬁc antibodies. Bands obtained from RT-PCR and Western blots were quantiﬁed in 
densitometeric units (du). 
Results: Data are shown in the table. Compared to NL, mRNA and protein expression of 
TNF-α and IL-6 increased in untreated HF controls. CSD therapy reduced expression of 
both cytokines. Conclusions: In dogs with HF, long-term CSD therapy reduces mRNA 
and protein expression of TNF-α and IL-6. This down-regulation of key cytokines may 
explain, in part, the improvement in LV function and remodeling previously reported with 
long-term CSD therapy.
NL HF-Untreated HF+CSD
TNF-α mRNA (du) 41 ± 2 71 ± 8* 49 ± 4**
TNF-α Protein (du) 42 ± 7 130 ± 6* 71 ± 13**
IL-6 mRNA (du) 20 ± 2 73 ± 1* 45 ± 1**
IL-6 Protein (du) 70 ± 6 140 ± 10* 112 ± 16**
*=p<0.05 vs NL; **=p<0.05 vs HF-Untreated
1047-149 Adenoviral Gene Transfer of Sarcoplasmic Reticulum 
Calcium ATPase (SERCA2a) Improves Left Ventricular 
Function in a Porcine Model of Heart Failure
Thanh-Thao Ton-Nu, Federica del Monte, Tom G. Neilan, Hayase Motoya, Jennifer 
MacGregor, Yoshiaki Kawase, Kozo Hoshino, Roger Hajjar, Robert A. Levine, Judy 
Hung, Massachusetts General Hospital, Boston, MA
Introduction. Sarcoplasmic reticulum calcium ATPase (SERCA2a) levels are decreased 
in heart failure (HF). Increasing SERCA2a in HF may be important therapeutic targets. We 
aimed to assess regional and global left ventricular (LV) function following percutaneous 
catheter delivery of SERCA2a in a mitral regurgitation (MR)-induced HF model. 
Methods. MR was created percutaneously in six pigs (4 SERCA2a and 2 Sham) by 
catheter disruption of mitral valve chordae, followed 4 weeks later with adenoviral gene 
transfer of SERCA2a via intracoronary injections into the left anterior and circumﬂex 
arteries. Sacriﬁce occurred one week post gene transfer. 2D echo (parasternal and short 
axis views) with tissue Doppler imaging (TDI) was performed (GE Vivid 7) to measure LV 
dimension at end-diastole (LVED) and end-systole (LVES) and tissue Doppler indices at 
anterior and inferior LV walls. 
Results. All pigs developed chronic severe MR. At sacriﬁce, LVEF increased with 
SERCA2a versus controls (60 ± 8 vs 41 ± 10 %, p=0.02); there was no change in LVED 
(48 ± 8 vs 46 ± 10 mm, p=ns) or LVES (30 ± 6 vs 36 ± 11 mm, p=ns). With SERCA2a, 
peak systolic tissue velocity (TV), peak strain (S), and peak strain rate (SR) improved in 
the anterior wall; in the inferior wall, only TV and SR increased with SERCA2a. 
Conclusions: Percutaneous adenoviral gene transfer of SERCA2a resulted in improved 
global and regional LV systolic function parameters in a porcine model of chronic heart 
failure with a greater regional effect in the anterior wall.
 
Anterior Wall Control SERCA2a P value
Peak tissue velocity (cm/s) -0.18 ± 0.30 -2.75 ± 1.48 0.01
Time to peak velocity (s) 0.08 ± 0.03 0.06 ± 0.03 0.34
Peak strain (%) 7.12 ± 4.66 28.15 ± 14.17 0.02
Time to peak strain (s) 0.29 ± 0.05 0.25 ± 0.06 0.39
Peak strain rate (1/S) 0.57 ± 0.49 1.61 ± 0.59 0.01
Time to peak strain rate (s) 0.15 ± 0.01 0.09 ± 0.04 0.06
Inferior Wall
Peak tissue velocity 3.49 ± 0.29 4.34 ± 4.46 0.09
Time to peak velocity 0.12 ± 0.05 0.05 ±0.05 0.02
Peak strain 17.65 ± 7.50 48.28 ± 11.72 <0.01
Time to peak strain 0.26 ± 0.05 0.28 ± 0.06 0.66
Peak strain rate 1.44 ± 0.76 2.27 ± 0.72 0.09
Time to peak strain rate 0.11 ± 0.05 0.07 ± 0.08 0.42
1047-150 Role Of MCP-3 As A Mesenchymal Stem Cell Homing 
Factor For Myocardial Regeneration
Soren Schenk, Ming Zhang, Niladri Mal, Zoran Popovic, Reiner Koerfer, Matthew 
Kiedrowski, Patrick McCarthy, Marc S. Penn, Cleveland Clinic Foundation, Cleveland, OH
Increased engraftment of mesenchymal stem cells (MSC) has been shown to improve 
cardiac function in acute MI. We hypothesized that sustained expression of a MSC homing 
factor could allow for serial infusions of MSC in order to increase cardiac function in ischemic 
cardiomyopathy (ICM). However, to date, no MSC homing factor has been identiﬁed. MSC 
do home transiently to the freshly infarcted myocardium. In order to identify a MSC homing 
factor, we determined the expression proﬁle of an array of chemokines as a function of time 
after MI. We merged this database with an array of chemokine receptors that are expressed 
at least 10 fold greater on MSC compared to cardiac ﬁbroblasts (CF). Chemokine receptor 
expression signiﬁcantly greater in MSC than CF were considered to be potentially involved 
in MSC homing since MSC do home infarcted myocardium, and CF do not. This analysis 
revealed CCR1, CCR2 and CCR5 as potential receptors involved in MSC homing, and 
MCP-1, MCP-3, MIP-1α and MIP-1β as potential MSC homing factors. We made CF that 
were stably transfected with an MCP-3 expression vector. To determine if MCP-3 can served 
as an MSC homing factor, 1 million control or MCP-3 expressing CF were transplanted into 
the infarct border zone 2 months after MI. Three days later 4 million BrdU labeled MSC were 
infused via the tail vein. Three days later, we observed a greater number of MSC in the 
infarct zone of those animals that received MCP-3 expressing CF compared to control (18.6 
± 4.7 vs. 7.4 ± 3.0 MSC/mm2, n=4 per group, p<0.05). We then studies animals 2 months 
post-MI and 1 week post injetion of control or MCP-3 expressing CF. The animals received 
6 intravenous infusions over 14 days of 1 million MSC per infusion. In those animals that 
received MCP-3 expressin CF, we observed a signiﬁcant increase in shortenting fraction 
4 weeks later in those animals that received MCP-3 expressing CF (10.0 ± 1.5% vs. 16.6 
± 3.2%, p<0.005), but not control CF (10.0 ± 1.5% vs. 16.6 ± 3.4%, p=NS). These data 
indicate that MCP-3 may be an MSC homing factor, and that transplantation of MCP-3 
expressing cells may serve as a strategy to optimize MSC engarftment in CHF.
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1048-165 Effects of Human Atrial Natriuretic Peptide on 
Myocardial Performance and Energetics in Patients With 
Heart Failure due to Previous Myocardial Infarction.
Toru Ozawa, Jyunya Shite, Toshiro Shinke, Satoshi Watanabe, Hiromasa Otake, Daisuke 
Matsumoto, Mitsuhiro Yokoyama, Cardiovascular and Respiratory Medicine, Kobe 
University Graduate School of Medical Science, Kobe, Japan
Background: Human atrial natriuretic peptide (hANP) and nitric oxide (NO) share cyclic 
guanosine monophosphate (cGMP) as a second messenger and modulate myocardial 
performance. We examined the effects of hANP on left ventricular (LV) mechano-
energetics in comparison with spontaneous NO donor, sodium nitroprusside (SNP) in 
patients with heart failure (HF). 
Methods: Eight patients with HF due to previous myocardial infarction (MI) (LV ejection 
fraction; 40±2%) were instrumented with conductance and coronary sinus thermodilution 
catheters. LV contractility (Ees; the slope of end-systolic pressure-volume relation), time 
constant of LV pressure decay (Tau) and mechanical efﬁciency (the ratio of LV stroke work 
(SW) to myocardial oxygen consumption (SW/MVO2)) were measured in response to the 
intravenous infusion of hANP (0.05 µg/kg/min) and SNP (0.3µg/kg /min). Plasma levels of 
cGMP were assessed by radioimmunoassay in each condition. 
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Results: The infusion of SNP did not change Ees, Tau, SW nor MVO2, resulting in 
unchanged SW/MVO2. Whereas, the infusion of hANP increased Ees, shortened Tau and 
decreased MVO2 with preserved SW, resulting in improved SW/MVO2. Plasma levels of 
cGMP elevated after infusion of hANP, whereas they did not change after infusion of 
SNP. 
Conclusion: HANP enhances LV contractility and relaxation as well as improves 
myocardial efﬁciency in patients with HF due to previous MI. HANP-dependent elevation 
of cGMP may ameliorate myocardial inotropy, lusitropy and energetics in HF.
 
*p<0.05 versus control ,#p<0.05 versus SNP 
control SNP hANP
Ees (mmHg/ml) 2.36±1.26 3.53±2.22 4.90±3.32 *#
Tau (msec) 49.1±6.5 45.2±9.4 43.6±8.4 *
SW (J) 0.67±0.20 0.61±0.31 0.71±0.30 #
MVO2 (J/beat) 1.72±0.68 1.68±0.68 1.55±0.45
SW/MVO2 43.2±19.8 42.5±26.3 48.7±24.0 *#
cGMP (pmol/l) 8.9±3.6 10.7±6.0 29.1±11.5 *#
1048-166 Cardioprotection by Carperitide (hANP) May be 
Attenuated More Than One Week of Infusions in 
Patients With Severe Congestive Heart Failure
Chitose Ishikawa, Takayoshi Tsutamoto, Hiroshi Sakai, Keijin Ohno, Minoru Horie, Shiga 
University of Medical Science, Otsu, Japan
Background: We reported that the cardioprotective effect of atrial natriuretic peptide 
(ANP) was mainly due to the suppression of renin-angiotensin-aldosterone system and 
endothelin-1 (ET-1). Although short-term infusion of human exogenous ANP (carperitide) 
has beneﬁcial effects, those of long-term infusion may be attenuated due to down-
regulation of biological receptors coupled to guanylate cyclase. Therefore, it is not 
known whether long-term infusion of carperitide has a beneﬁcial effect on neurohumoral 
regulation in patients with congestive heart failure (CHF).
Purpose and Methods: We evaluated the effects of long-term infusion of low dose 
carperitide on the neurohumoral factors in patients with CHF. The subjects were 38 
patients with severe CHF hospitalized at our institutions. They were treated with long-
term infusion of low dose carperitide (0.01-0.1; mean 0.02 µg/kg/min, 2-28; mean 8.6 
days). After the improvement of symptoms due to CHF, we measured plasma levels of 
neurohumoral factors before and 1 hour after stopping the infusion of carperitide.
Results: In all patients, there was no signiﬁcant change of heart rate and blood pressure 
before and 1 hour after stopping carperitide. Plasma levels of norepinephrine and active 
renin did not change after stopping carperitide, but aldosterone (ALD) and ET-1 were 
signiﬁcantly increased. Patients were divided into two groups the short-term group (group 
1, n=21, within 7 days), and long-term group (group 2, n=17, more than 7 days). In group 1, 
the plasma levels of ALD and ET-1 were signiﬁcantly increased after stopping carperitide. 
In contrast, plasma levels of ALD and ET-1 did not change after stopping carperitide in 
group 2. The molar ratio of plasma cyclic guanosine monophosphate (cGMP)/ANP before 
stopping carperitide was signiﬁcantly lower in group 2 than in group 1.
Conclusions: Cardioprotective effect (inhibition of ALD and ET-1) was maintained for at 
least 1 week of low dose carperitide infusion but the beneﬁcial effect on neurohumoral 
factors was attenuated after more than 1 week of continuous infusion probably due to 
down-regulation of biological receptors coupled with guanylate cyclase in patients with 
severe CHF.
1048-167 NT-proBNP as a Screening Test for Left Ventricular 
Structural and Functional Abnormalities: Results from 
the Dallas Heart Study
James A. de Lemos, Darren K. McGuire, Amit Khera, Sabina A. Murphy, Sandeep Das, 
Duwayne Willett, Ronald Peshock, Mark H. Drazner, Donald W. Reynolds Cardiovascular 
Clinical Research Center, UT Southwestern Medical Center, Dallas, TX
Background: Studies evaluating NT-proBNP and BNP for early detection of LV systolic 
dysfunction (LVSD) or LV hypertrophy (LVH) have used homogeneous populations with 
few black and Hispanic participants, and are limited by the use of echocardiographic 
measures of cardiac structure and function.
Methods: We measured NT-proBNP (Elecsys® proBNP, Roche Diagnostics) in 3557 
participants (52% black, 17% Hispanic) from the Dallas Heart Study, a multiethnic, 
population-based sample of subjects age 30-65. Among 2763 subjects who also 
underwent cardiovascular magnetic resonance imaging (CVMRI), we determined the 
association between NT-proBNP and the combined endpoint of LVSD (LVEF <55%) or 
LVH (LV mass/Fat free Mass >3.7g/kg), which was present in 238 (8.6%) subjects.
Results: NT-proBNP levels were higher among those with vs without LVSD or LVH 
(p<0.0001 for each). The probability of LVSD or LVH increased stepwise with higher NT-
proBNP levels, from 5% in subjects with NT-proBNP <75th percentile to 78% for those 
>99th percentile (p<0.0001 for trend). Operating characteristics at various thresholds are 
shown in the table. The area under the ROC curve (AUC) in the entire population was 0.71 
(95% CI 0.67-0.75), in hypertensives (n=910) was 0.74 (0.69-0.79) and in subjects > 50 
yrs old (n=794) was 0.76 (0.71-0.81).
Conclusions: In a multiethnic population in which CVMRI was used to deﬁne cardiac 
structure and function, NT-proBNP measurements were speciﬁc but not sensitive 
screening tests for occult LVSD or LVH.
Operating Characteristics for NT-proBNP 
Threshold (percentile) Sensitivity Speciﬁcity PPV NPV
61 pg/mL (75th) 55 78 19 95
126 pg/mL (90th) 37 93 34 94
198 pg/mL (95th) 26 97 48 93
368 pg/mL(97.5th) 24 99 67 93
881 pg/mL (99th) 8 99.8 78 92
1048-168 Using Changes in B-Type Natriuretic Peptide Levels 
Between Hospital Admission and Discharge to Predict 
Mortality of Patients with Heart Failure
Thom G. Dahle, Leslie W. Miller, University of Minnesota, Minneapolis, MN
Background: When determining the appropriate time for discharge of patients with heart 
failure, physicians rely on improvement of clinical exam and symptoms. This study was 
designed to determine whether change in B-type natriuretic peptide (BNP) levels from 
admission to discharge of heart failure patients may be used as a predictor for death or 
re-admission and thus a guide for discharge.
Methods: BNP levels were measured at the time of admission and discharge of patients 
admitted with decompensated heart failure. Patients were followed for up to one year for 
death or re-admission.
Results: Of the 46 patients who completed the study, 14 patients died during the follow up 
period and 22 patients were readmitted. Proportional hazard regression analysis revealed 
statistically signiﬁcant increased risk of death associated with increased percentage 
change in BNP (hazard ratio [HR] = 1.13 [95% conﬁdence interval {CI} 1.03 to 1.22], p = 
0.006), increased absolute change in BNP (HR = 1.08 [95% CI 1.02 to 1.15], p = 0.009), 
and increased discharge BNP level (HR = 1.05 [95% CI 1.01 to 1.09], p = 0.007). There 
was no signiﬁcant association with readmission. The percent change of BNP (ﬁgure 1) 
and the discharge BNP were the strongest predictors for mortality of the variables.
Conclusion: The percentage and absolute change in BNP levels from admission to 
discharge as well as the discharge BNP level may be used as reliable markers to identify 
patients with heart failure who are at higher risk for mortality following discharge. 
1048-169 Echocardiographic Determinants of NT-proBNP Levels 
in Dyspneic Patients: the Importance of Right Heart 
Structure and Function. Results from the ProBNP 
Investigation of Dyspnea in the Emergency Department 
(PRIDE) Echocardiographic Substudy
Annabel A. Chen, Malissa Wood, Roderick Tung, Daniel G. Krauser, Aaron L. Baggish, 
Saif Anwaruddin, James L. Januzzi, Massachusetts General Hospital, Boston, MA
Background: N-terminal pro-Brain natriuretic peptide (NT-proBNP) levels may be 
elevated in patients with right ventricular (RV) dysfunction; the relative importance of RV 
structure and function on NT-proBNP levels is not known.
Methods: NT-proBNP (Elecsys® proBNP, Roche Diagnostics, Indianapolis, IN) was 
measured in 599 dyspneic patients. Transthoracic echocardiography (echo) was 
performed as standard of care in 134 patients an average of 51 ± 42 hours after 
enrollment. Congestive heart failure (CHF) was the ﬁnal diagnosis in 66%. Echo 
measurements, including cardiac chamber size/function and cardiac valve function, were 
obtained by observers blinded to NT-proBNP level and clinical diagnosis. Associations 
between NT-proBNP and echo parameters were assessed with Spearman correlation. 
Comparisons between groups were performed using nonparametric testing. Multivariable 
linear regression analysis identiﬁed independent predictors of NT-proBNP levels.
Results: The average RV fractional area change was 40±10%. Twenty-seven patients 
had RV hypokinesis. Tricuspid regurgitation (TR) was absent or trace (n = 66), mild (n 
= 26), moderate (n =32) or severe (n = 10). Average TR velocity for all patients was 
2.9±0.5 m/s. Several right heart factors correlated with NT-proBNP levels, including RV 
hypokinesis (p=0.004), TR severity (p<0.001) and TR velocity (Rho=0.460, p<0.001). 
While RV size did not signiﬁcantly correlate with NT-proBNP levels, RV fractional area 
change was inversely related (Rho=-0.169, p=0.06). In multivariate analysis including 
echo parameters, RV hypokinesis (p=0.006), TR severity (p=0.001) and TR velocity 
(p=0.007) all remained independent predictors of NT-proBNP levels. 
Conclusion: RV abnormalities are highly prevalent in dyspneic patients with elevated NT-
proBNP levels. Right heart structure and function are important independent determinants 
of NT-proBNP levels.
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1048-170 NT-proBNP Is Superior to BNP for the Evaluation of 
Patients with Dyspnea and non-Systolic Congestive 
Heart Failure: A ProBNP Investigation of Dyspnea in the 
Emergency Department (PRIDE) Substudy
Michelle O’Donoghue, Annabel Chen, Aaron Baggish, Saif Anwaruddin, Daniel G. 
Krauser, Roderick Tung, James L. Januzzi, Massachusetts General Hospital, Boston, MA
Background: Congestive heart failure (CHF) with preserved left ventricular ejection 
fraction is common. The performance of N-terminal pro-brain natriuretic peptide (NT-
proBNP) and B-type natriuretic peptide (BNP) in the presence or absence of impaired 
left ventricular ejection fraction has not been compared. We used the data from the 
ProBNP Investigation of Dyspnea in the Emergency Department study to determine the 
relationship between NT-proBNP, BNP and left ventricular ejection fraction in subjects 
with acute CHF.
Methods: Of 209 study subjects diagnosed with acute CHF, 153 (73%) had available 
left ventricular ejection fraction data. These subjects were subdivided into those with 
non-systolic CHF (NS-CHF, EF=50%) and those with systolic CHF (S-CHF, EF<50%). 
Median NT-proBNP (Elecsys® ProBNP, Roche Diagnostics, Indianapolis, IN) and BNP 
(Advia BNP, Bayer Inc., Tarrytown, NY) levels for both categories were compared utilizing 
non-parametric testing. The relationship between left ventricular ejection fraction and 
natriuretic peptide levels was analyzed using multivariable linear regression analysis.
Results: 49.7% of the 209 total study subjects had NS-CHF . Median NT-proBNP and 
BNP levels were signiﬁcantly lower in subjects with NS-CHF compared to those with S-
CHF (2849 vs. 6196 pg/ml, p=0.005, and 259 vs. 592 pg/ml, respectively, p<0.001). Left 
ventricular ejection fraction was an independent predictor of the level of both biomarkers 
(p<0.001). Using optimal cutpoints, a false negative rate of 7% was observed for both 
assays in subjects with S-CHF however BNP had a higher false negative rate than NT-
proBNP in patients with NS-CHF (20% versus 9%, p<0.001). In subjects with NS-CHF, 
NT-proBNP, but not BNP, signiﬁcantly correlated with CHF symptom severity based on 
New York Heart Association classiﬁcation
Conclusion: Both NT-proBNP and BNP are signiﬁcantly lower in subjects with acute NS-
CHF than in subjects with acute S-CHF. NT-proBNP is superior to BNP for evaluation of 
CHF patients with preserved left ventricular ejection fraction.
1048-171 Utility of B-type Natriuretic Peptide and N-terminal B-
type Natriuretic Peptide in Evaluation of Respiratory 
Failure in Critically Ill Patients
Dane Jeﬁc, John W. Lee, Jeﬁc Dijana, Howard S. Rosman, Saint John Hospital and 
Medical Center, Detroit, MI
Background: B-type Natriuretic Peptide (BNP) and N-terminal B-type Natriuretic Peptide 
(NT-proBNP) have been shown to correlate with pulmonary arterial wedge pressure 
(PAWP) and prognosis in patients with heart failure. Proposed use for BNP and NT-
proBNP is to differentiate high- vs. low-PAWP conditions.
Methods: Primary objective was to evaluate whether NT-proBNP and BNP can 
differentiate high- vs. low-PAWP respiratory failure in ICU patients. 41 consecutive patients 
with hypoxic respiratory failure undergoing right heart catheterization were enrolled. BNP 
and NT-proBNP were run on a sample of a venous blood. Hemodynamic variables and 
30-day survival were documented.
Results: BNP and NTproBNP did not correlate with PAWP. They correlated signiﬁcantly with 
each other (r=0.656, p <0.001) and inversely with hemodynamic markers of contractility: 
Correlation Coefﬁcients Area under the ROC Survivors
(pg/ml)
Non-survivors
(pg/ml)PAWP CI LVSWI LVSWI<35(g/beat/m2)
LVSWI<30
(g/beat/m2)
BNP 0.190 -0.481* -0.384* 0.643 0.754* 909 841
NT-pro BNP 0.109 -0.441* -0.623** 0.885* 0.884** 11631 11778
* p<.02;**p<.001
Receiver operating characteristic curve (ROC) for detection of contractile dysfunction 
were created by using the different Left Ventricular Stroke Work Index (LVSWI) cutoffs. 
Areas under the ROC were larger and more consistent for NT-proBNP than for BNP. Mean 
NP concentrations did not differ between the survivors and non-survivors.
Conclusions: 1. NT-proBNP and BNP failed to differentiate high- vs. low-PAWP 
respiratory failure 2. NT-proBNP and BNP inversely correlated with indices of cardiac 
contractility. 3. NT-proBNP may be a more discerning marker than BNP 4. Neither NP 
predicted short-term mortality.
1048-172 Effect of Exercise on B-Type Natriuretic Peptide Levels 
in Patients With Congestive Heart Failure: Implication 
for It’s Use in Ambulatory Settings
Mustafa H. Hassan, Paul M. Sheils, Case Western Reserve University, MetroHealth 
Campus, Cleveland, OH, Midland’s Regional Hospital at Tullamore, Tullamore, Ireland
Background: B-type natriuretic peptide (BNP), a neurohormonal marker for congestive 
heart failure (CHF), reﬂects disease severity and correlates with prognosis. It is increasingly 
being used for diagnosis and follow up of heart failure patients in the ambulatory clinic 
settings using a rapid assay test. It is unknown if exercise exerted by patients on their way 
to the clinic can affect BNP levels, we sought to study the effect of exercise on BNP levels 
in patients with CHF.
Methods: Patients with CHF who were able and willing to exercise on a treadmill were 
enrolled. Whole venous blood samples were obtained after a period of 15 minutes rest, 
subjects were then exercised on a treadmill according to the Bruce protocol. Immediately 
after exercise and 30 minutes later two more blood samples were taken, blood samples 
were analysed for BNP level using the rapid Triage BNP analyser.
Results: Forty CHF patients were enrolled, 23 males, average age was 51±11, 25 were New 
York Hear Association (NYHA) class I-II and 15 were NYHA class III-IV. Patients exercised for 
an average of 6±1 metabolic equivalents (METs) there was no signiﬁcant rise in BNP after 
exercise, mean difference between BNP after and before exercise was 6±2 pg/ml.
Conclusion: BNP level is not signiﬁcantly affected by exercise and in the case of patients 
seen and evaluated in the ambulatory clinic settings, prior activity shouldn’t affect it, hence 
any change in BNP level should be considered to reﬂect a change in the patient’s clinical 
condition.
1048-173 Baseline B-Type Natriuretic Peptide Identiﬁes Patients 
With Type 2 Diabetes and Class I/II Heart Failure at Risk 
of Fluid Retention When Treated With Rosiglitazone.
Henry Dargie, Per R. Hildebrandt, Gunter Riegger, John PH Wilding, John McMurray, 
Steve McMorn, Jeremy N. Roberts, Andrew Zambanini, Murray W. Stewart, Western 
Inﬁrmary, Glasgow, United Kingdom
Background: Thiazolidinediones may contribute to ﬂuid retention which in some patients 
with established congestive heart failure (CHF) may precipitate or exacerbate symptomatic 
CHF. B-type natriuretic peptide (BNP) may help to identify patients with type 2 diabetes 
(T2D) and New York Heart Association class I/II CHF who are at risk of developing ﬂuid 
retention when treated with rosiglitazone (RSG). 
Methods: Patients with T2D and class I/II CHF were randomized to receive RSG (4-
8mg daily) or placebo (PLB) in addition to background anti-diabetic agents for 52 weeks. 
Background T2D medications were uptitrated as required to achieve the glycemic target 
of fasting plasma glucose <126mg/dL and CHF medications (including diuretics) were 
changed as appropriate. BNP was measured using the Peninsula method. Endpoints 
were adjudicated by an independent committee.
Results: 224 patients were randomized in the study (110 RSG, 114 PLB). At baseline, 
geometric mean concentrations of BNP were lower in the RSG group (34.9pg/ml, n=71) 
compared to PLB group (46.1pg/ml, n=74). After 52 weeks of treatment, BNP in the 
RSG group had risen to a concentration similar to the PLB group (RSG 55.0pg/ml, n=71, 
p=0.0001; PLB 49.8pg/ml, n=74, p=0.45; 95% conﬁdence interval between treatment 
groups -3.2% - 67.6%, p=0.083). Irrespective of the treatment received, patients in both 
groups who subsequently developed adjudicated events of CHF, edema or dyspnea had 
higher BNP at entry to the study compared to patients who did not subsequently develop 
ﬂuid related events.
Conclusions: Following 52 weeks of treatment, BNP increased in the RSG group but 
was not clinically or statistically signiﬁcantly higher in the RSG group compared to PLB. 
However, in both treatment groups, higher baseline BNP was associated with future 
ﬂuid related events. BNP may be a useful tool for identifying patients at risk of clinically 
important ﬂuid retention when treated with RSG.
1048-174 Relationship Between Renal Function and Plasma Level 
of BNP and N terminal proBNP in Patients with Heart 
Failure
Takayoshi Tsutamoto, Atsuyuki Wada, Masanori Fujii, Hiroshi Sakai, Keijin Ohno, 
Chitose Ishikawa, Takashi Yamomoto, Tomoyuki Takayama, Tomohiro Dohke, Hiroyuki 
Takashima, Minoru Horie, Shiga University of Medical Science, Otsu, Japan
Background. Plasma level of brain natriuretic peptide (BNP) and N terminal proBNP 
(NT-proBNP) is elevated and useful prognostic predictor in congestive heart failure 
(CHF) patients in whom renal function is often disturbed. However, which is important 
of hemodynamic overload or renal clearance in the elevation of plasma level of BNP and 
NT-proBNP remains unknown in CHF patients. 
Methods. We measured plasma level of NT-proBNP in the aortic root (AO) and coronary 
sinus (CS) in 398 consecutive patients with CHF [ age=62y (18-88y), male: n=312, 
ejection fraction left ventricular (LV) ejection fraction (LVEF)=49%(10-84%); serum 
creatine=1.0 mg/dL (0.39-8.7mg/dL), ischemic heart disease(IHD):n=279, non-IHD:
n=119 ]. Patients with acute myocardial infarction were excluded. Estimated glomerular 
ﬁltration rate (GFRc), using the Cockcroft-Gault equation was used as an indicator for 
renal function. To determine the independent factors to regulate the tanscardiac increase 
(CS-AO) of BNP and NT-BNP, and plasma levels of BNP and NT-proBNP, 14 variables 
such as age, gender, etiology, hemoglobin, GFRc and hemodymamic parameters were 
entered into multivariate analysis. 
Results. Transcardiac increase of BNP and NT-proBNP were regulated by hemodymamic 
parameters such as LVEF (p<0.0001) and LV end-diastolic pressure (LVEDP) (p<0.0001) 
and anemia (p<0.01) and atrial ﬁbrillation (p<0.01) but not GFRc, age or gender. Plasma 
level of BNP and NT-proBNP in the AO was also independently regulated by GFRc 
(p<0.0001). The patients were divided to two groups (group I: GFRc > 80 ml/min, n=240; 
group II: GFRc < 80 ml/min, n=158). There was no difference of transcardiac increase 
of BNP (group I: 202±24 vs. group II :204±15 pg/ml) and NT-proBNP ( group I: 397±120 
vs. group II :410±56 pg/ml) between the two groups. However, plasma levels of BNP ( 
group I: 109±16 vs. group II :172±15 pg/ml, p<0.001) and NT-proBNP ( group I: 597±118, 
group II :1450±276pg/ml, p<0.001) in the AO were signiﬁcantly higher in group II than 
group I. Conclusions. These ﬁndings suggest that decrease of clearance from the kidney 
contributes the elevated BNP and NT-proBNP in CHF patients with renal dysfunction.
1048-175 Time Course and Prognostic Value of NT-proBNP 
Plasma Levels in the Patients with Acute Heart Failure
Marco Metra, Savina Nodari, Loretta Brentana, Patrizia Rocca, Francesco Fracassi, 
Carlo Lombardi, Enrico Vizzardi, Rossella Danesi, Ermanna Chiari, Livio Dei Cas, 
Cattedra di Cardiologia, Università, Brescia, Italy
Background. The changes and the prognostic value of plasma NT-proBNP levels in acute 
heart failure (HF) are still unclear.
Methods. We measured NT-proBNP plasma levels in 55 patients (pts) with a clinical 
diagnosis of acute HF before i.v. therapy (baseline, BSL), after 12, 24 and 48 hours and 
at the time of hospital discharge (DS). Last values before death were used as DS in the 
pts who died in-hospital. The prognostic value of NT-proBNP was compared with that of a 
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persistent left ventricular ﬁlling pattern at Doppler-echocardiography (restr) and with the 
lack of improvement in clinical signs (clin) from BSL to DS.
Results. BSL NT-proBNP plasma levels, median (25th - 75th percentiles), were 5843 (1724-
12440) pg/mL in the 45 pts with acute worsening of chronic HF, 2514 (1276-3989) pg/mL in 
7 pts with pulmonary edema and 274 (254-380) pg/mL, (p<0.0001 versus the others) in 3 
pts with non cardiac (pulmonary) causes of dyspnea. Nine pts (16%) died during the initial 
hospitalization (hosp), 2 after discharge, 13 other pts (24%) had another HF hosp. 
Time course of NT-proBNP (median, 25th-75th percentiles) 
BSL 12 hs 24 hs 48 hs Discharge
No events 2919 (867-5690) 2361 (771-5562) 1646 (694-4761) 1396 (624-3399) 1649 (564-3812)
Death / hosp 10983 (4882 - 23447) 12643 (683-48890) 9444 (4935-19962) 7463 (4097-20510) 6775 (4065-15367)
Amongst the 24 pts with death or hosp, 17 (71%) had a BSL NT-proBNP > 5000 pg/mL 
and 19 (79%) had a DS NT-proBNP > 3000 pg/mL (median values of all pts). Similarly, 19 
pts had restr while only 9 (38%) had lack of clin. The negative predictive values of BSL 
NT-proBNP <5000, DS NT-proBNP <3000, no restr and clin were 75%, 79%, 79% and 
63%, respectively.
Conclusions. NT-proBNP plasma levels decline < 48 hs. after treatment of acute HF and 
they are powerful predictors of major events.
1048-176 Amino-Terminal proB-Type Natriuretic Peptide and 
B-Type Natriuretic: Determinants and Detection of 
Systolic Dysfunction in the Community
Lisa C. Costello-Boerrigter, Margaret M. Redﬁeld, Richard J. Rodeheffer, Lynn H. Urban, 
Douglas W. Mahoney, Steven J. Jacobsen, Guido Boerrigter, Denise M. Heublein, John 
C. Burnett, Jr., Mayo Clinic and Mayo College of Medicine, Rochester, MN
Background: Amino-terminal proBNP (NT-proBNP), a BNP prohormone fragment, is 
a new heart failure biomarker that complements the use of BNP as a diagnostic. We 
hypothesized that NT-proBNP would have equal or superior diagnostic characteristics 
compared to BNP in the detection of left ventricular systolic dysfunction in a large 
community sample. We also evaluated the impact of factors such as gender, age, and 
renal function on NT-proBNP levels in normal subjects.
Methods: A random Olmsted County, MN sample (n=2042, age>44) was clinically 
characterized and underwent detailed echocardiography as previously reported. Plasma 
NT-proBNP was measured with the Elecsys® proBNP sandwich immunoassay (Roche 
Diagnostics). BNP was measured by immunoassay (Biosite) as reported. The ability of 
BNP and NT-proBNP to detect subjects with an EF≤40% and an EF≤50% was determined 
by receiver operator characteristic (ROC) curves. Areas under the curves (AUC) were 
compared for the two assays. The inﬂuence of age, gender, creatinine (Cr), and calculated 
glomerular ﬁltration rate (GFR) was assessed by linear least-squares regression analysis 
with log-transformed NT-proBNP values.
Results: 1869 subjects had both assays performed, of whom 37 had an EF≤40% and 115 
had an EF≤50%. For detecting an EF≤40%, NT-proBNP had a signiﬁcantly higher AUC 
than BNP overall (0.94 vs. 0.89; p=0.01), in males (p=0.02), and in subjects≥65 years 
(p=0.04). For detecting an EF≤50%, the AUC for NT-proBNP was signiﬁcantly higher 
than that for BNP in all subjects (0.78 vs. 0.72; p<0.0001), subjects≥65 years (p=0.001), 
subjects<65 years (p<0.0001), males (p<0.0001), males≥65 years (p=0.004), males<65 
years(p=0.0002), and females<65 years (p=0.03). On multivariate analysis in a clinically 
normal subgroup (n=746), gender and age were strongly and positively associated with 
NT-proBNP. After accounting for age and gender, no independent correlation with Cr or 
calculated GFR existed in this population.
Conclusions: We report here that in a large community sample NT-proBNP is affected by 
gender and age, as is seen with BNP. Most importantly, NT-proBNP outperforms BNP in 
the detection of reduced left ventricular systolic function.
1048-177 Body Mass Index Is Inversely Related to Both Amino-
Terminal Pro-Brain Natriuretic Peptide and B-Type 
Natriuretic Peptide in Acute Congestive Heart Failure: 
A ProBNP Investigation of Dyspnea in the Emergency 
Department (PRIDE) Substudy
Daniel G. Krauser, Donald M. Lloyd-Jones, Claudia U. Chae, Renee Cameron, Saif 
Anwaruddin, Aaron L. Baggish, Annabel Chen, Roderick Tung, James L. Januzzi, 
Massachusetts General Hospital, Boston, MA
Background: Obesity is associated with lower B-type natriuretic peptide (BNP) levels in 
healthy individuals. Whether obesity affects natriuretic peptide levels among patients with 
acute congestive heart failure (CHF) is not known.
Methods: The associations of amino-terminal pro-BNP (NT-proBNP) and BNP with body 
mass index (BMI) were examined in 204 subjects with acute CHF. Multivariable regression 
analyses were performed to identify factors independently related to NT-proBNP and BNP 
levels.
Results: Across clinical strata of normal (<25 kg/m2), overweight (25-29.9 kg/m2), and 
obese (>30 kg/m2) patients, median NT-proBNP and BNP levels decreased with increasing 
BMI (p<0.001). In multivariable analyses adjusting for covariates known to affect B-type 
natriuretic peptide levels, the inverse relationship between BMI and both NT-proBNP and 
BNP remained (p<0.05). Using a cut-point of 900 pg/mL, NT-proBNP was falsely negative 
in up to 10% of CHF cases in overweight patients and 15% in obese patients. Using the 
standard cut-point of 100 pg/mL, BNP testing was falsely negative in 20% of CHF cases 
in both overweight and obese patients. NT-proBNP and BNP exhibited similar overall 
sensitivity for the diagnosis of CHF.
Conclusions: When adjusted for covariates, compared to lean counterparts, overweight 
and obese patients with acute CHF have lower NT-proBNP and BNP levels, suggesting a 
BMI-related defect in natriuretic peptide secretion. When used as a diagnostic tool both 
markers may have reduced sensitivity. 
1048-178 The Value of NT-proBNP for the Evaluation of Acute 
CHF: A Multicenter, International Meta-Analysis of 1256 
Subjects
James L. Januzzi, Jr., Roland RJ van Kimmenade, John Lainchbury, Antoni Bayes-
Genis, Yigal M. Pinto, A. Mark Richards, Massachusetts General Hospital, Boston, MA
Background: The use of NT-proBNP for the diagnosis or exclusion of acute congestive 
heart failure (CHF) has been explored in several prospective studies however optimal NT-
proBNP cutpoints for diagnosing or excluding acute CHF remain to be established.
Methods: We performed a meta-analysis of NT-proBNP data from 3 prospective clinical 
trials and 1 CHF registry from 3 continents. NT-proBNP levels (Elecsys® proBNP, Roche 
Diagnostics, Indianapolis, IN) in subjects with and without acute CHF were compared 
using non-parametric tests. Age stratiﬁed analyses identiﬁed optimal cutpoints for 
diagnosis and exclusion of acute CHF. Cutpoint values were evaluated using receiver 
operating characteristic curves. The role of NT-proBNP in the diagnosis of acute CHF was 
evaluated using multivariable logistic regression analysis.
Results: Of the 1256 subjects, 720 (57%) had acute CHF; these subjects had higher 
median NT-proBNP levels than those without acute CHF (5669 vs 177 pg/ml, p<0.00001). 
An optimal cutpoint strategy using age stratiﬁcation to rule in acute CHF was developed, 
while an age-independent rule out cutpoint was also identiﬁed (Table). Multivariable 
logistic regression analysis identiﬁed an elevated NT-proBNP as the strongest predictor 
of acute CHF in this dataset (odds ratio=24; 95% conﬁdence interval=13-39; p<0.00001).
Conclusion: In this analysis of 1256 subjects from 3 continents, we have identiﬁed 
optimal NT-proBNP cutpoints to both rule in and rule out acute CHF with high accuracy.
Optimal NT-proBNP Cutpoints for Diagnosing or  
Excluding Acute CHF 
Age (years)
Optimal 
cutpoint 
(pg/ml)
Sensitivity 
(%)
Speciﬁcity 
(%)
Positive Predictive 
Value (%)
Negative 
Predictive 
Value (%)
Accuracy
Rule In
<50 (n=183) 450 97 93 76 99 95
50-75 (n=554) 900 90 82 82 88 85
>75 (n=519) 1800 85 72 92 55 83
Rule Out
All patients 300 99 60 77 98 83
1048-179 Reduction of Natriuretic Peptides in Obese Patients 
With Systolic Heart Failure is Independent of Peptide 
Types and Echocardiographic Indices of Myocardial 
Performance: Analysis From ADEPT Neurohormonal 
Substudy
W. H. Wilson Tang, Richard W. Troughton, Patrick Nash, Sanjeev Bhavnani, Gary S. 
Francis, Randall C. Starling, A. Mark Richards, Tim Yandle, Allan L. Klein, Cleveland 
Clinic Foundation, Cleveland, OH
Background: Obesity has been associated with lower plasma BNP levels in patients 
with heart failure (HF), which may be due to upregulated clearance of BNP by adipocyte 
receptors in obese patients. The effect of obesity on NT-proBNP is unclear.
Methods: We compared plasma NT-proBNP levels (Elecsys® proBNP, Roche Diagnostics, 
Indianapolis, IN) and BNP (Christchurch assay) to clinical and echocardiographic parameters 
in 139 HF patients (LVEF <35%, NYHA II-III) stratiﬁed according to their body mass indices 
(BMI in kg/m2) into lean (BMI<25), overweight (BMI 25-29.9) and obese (BMI ≥30).
Results: Overweight and obese patients have signiﬁcantly lower mean and median BNP 
and NT-proBNP levels compared to lean patients (Figure). Mean BMIs were also similar 
across tertiles of NT-proBNP to BNP ratio (p=0.65). There were no statistically signiﬁcant 
differences between lean/overweight and obese patients in terms of left ventricular (LV) 
ejection fraction, LV end-diastolic volume index, and indices of LV ﬁlling pressures (E/Ea, E/
Vp). Also, there were similar proportions of patients with signiﬁcant mitral regurgitation, right 
ventricular dysfunction, and advanced stages of diastolic dysfunction in the two groups.
Conclusion: Both plasma BNP and NT-proBNP levels are signiﬁcantly reduced in obese 
compared to lean/overweight patients despite similar echocardiographic parameters. 
Factors independent of peptide types or myocardial performance may be responsible for 
these observations.
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1048-180 Using B-Type Natriuretic Peptide to Diagnose Heart 
Failure in Obese Patients
Lori B. Daniels, Paul Clopton, Albert Chiu, James McCord, Judd E. Hollander, Philippe 
Duc, Torbjorn Omland, Alan B. Storrow, Alan H.B. Wu, Gabriel Steg, Arne Westheim, 
Catherine Wold Knudsen, Howard C. Herrmann, Peter A. McCullough, Alan S. Maisel, 
University of California at San Diego Medical Center, San Diego, CA, Veteran’s Afﬁars 
San Diego Healthcare System, La Jolla, CA
Background: B-type natriuretic peptide (BNP) is valuable in the diagnosis of heart failure 
(HF), but its utility in obese patients is unknown. Studies have suggested a cut-point of 
BNP > 100 pg/mL for the diagnosis of HF; however there is an inverse relation between 
BNP levels and body mass index (BMI). This study sought to determine whether the 
optimal cut-point for BNP in diagnosing acute HF changes with BMI, and if so to develop 
an algorithm to improve diagnosis.
Methods: The Breathing Not Properly Multinational Study was a 7-center, prospective 
study of 1,586 patients who presented to the Emergency Department with acute 
dyspnea and had BNP measured on arrival. Data on height and weight were available 
for 1,368 participants. The ﬁnal diagnosis, which was adjudicated by 2 independent 
cardiologists who reviewed all clinical data and were blinded to BNP results, was HF in 
631 patients (46.1%).
Results: Mean BNP levels (pg/mL) in lean, overweight/obese, and severely/morbidly 
obese patients were 643, 462, and 247 for those with acute HF, and 52, 35, and 25 in 
those without HF, respectively (p<0.05 for all comparisons except 35 and 25). The optimal 
cut-point to maintain 90% sensitivity for the diagnosis of CHF in each BMI group is shown 
in the Figure.
 
Conclusion: BMI inﬂuences the optimal cut-point for BNP in diagnosing acute heart 
failure such that a lower cut-point (BNP > 54 pg/mL) should be used in severely obese 
patients. A higher cut-point in lean patients (BNP > 170 pg/mL) could be used if increased 
speciﬁcity was needed.
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1049-157 Circulating Antiheart and Other Autoantibodies: 
Evidence of Autoimmunity in Idiopathic Recurrent 
Acute Pericarditis
Alida L. Caforio, Antonio Brucato, Giovanni Brambilla, Francesco Tona, Anna Ghirardello, 
Stefania Bottaro, Annalisa Vinci, Maria Grazia Leone, Corrado Betterle, Luciano 
Daliento, Sabino Iliceto, Gaetano Thiene, Andrea Doria, University of Padua, Padua, 
Italy, Niguarda Hospital, Milan, Italy
Background. Idiopathic recurrent acute pericarditis (IRAP) is a suspected immune disease. 
Methods. We assessed the frequency of anti-heart autoantibodies (AHA) and of non 
organ-speciﬁc (O-s) autoantibodies in 37 IRAP patients, 22 male, aged 38±16 years. 
All patients had typical chest pain with or without a pericardial friction rub, abnormal 
electrocardiogram, pericardial effusion, normal biventricular function and no regional 
wall motion echocardiographic abnormalities, normal myocytolitic enzymes. AHA 
were detected by indirect immunoﬂuorescence on human myocardium and skeletal 
muscle. AHA control groups included patients with non-inﬂammatory cardiac disease 
(NICD) (n=160), with ischemic heart failure (n=141) and normals (n=270). Other O-s 
autoantibodies, including anti-thyroid, gastric parietal cell, islet cell, adrenal cell, were 
tested by indirect immunoﬂuorescence. Non O-s autoantibodies, e.g. anti-nuclear (ANA) 
and anti-mitochondrial autoantibodies were detected by indirect immunoﬂuorescence on 
rat liver and kidney, anti-Ro/SSA, anti-La/SSB by ELISA (Inova Dgn, USA). ANA controls 
by indirect immunoﬂuorescence included 200 normals. Frequencies of autoantibodies in 
IRAP vs controls were compared by ANOVA. 
Results. AHA were found in 22 (59%) IRAP patients (cross-reactive-1 in 46%, cross-
reactive-2 in 8% and O-s in 5%). The frequency of cross-reactive-1 AHA was higher (46%) 
in IRAP than in NICD (4%), ischemic (1%) or normal subjects (3%)(p=0.0001). Conversely, 
the frequency of cross-reactive-2 and O-s AHA were similar in IRAP (8%; 5%), in NICD 
(3%; 1%), IHF (6%; 1%) or normals (3%; 2.5%) respectively (p=NS). Other O-s antibodies 
were all negative, but 2 (5%) parietal cell antibody positive patients. IRAP patients and 
controls were negative for anti-mitochondrial autoantibodies; ANA frequency tended to 
be higher in IRAP (16%) vs normals (7.5%, p=0.08). Anti-Ro/SSA autoantibodies were 
positive in 2 IRAP patients (5%), anti-La/SSB were positive in 1 (2.5%). Overall 25 (67%) 
IRAP patients were positive for AHA and/or other autoantibodies. 
Conclusion. The ﬁnding of AHA and other autoantibodies supports the involvement of 
autoimmunity in 2/3 of patients with IRAP.
1049-158 The New Diagnostic Role of Brain Natriuretic Peptide 
in the Differentiation of Constrictive Pericarditis From 
Restrictive Cardiomyopathy.
Dinesh Arab, Ferdinand Leya, Leslie Cho, Bruce E. Lewis, Lowell H. Steen, Jr., Loyola 
University, Chicago, IL
Background: The differential diagnosis of constrictive pericarditis and restrictive 
cardiomyopathy is a source of debate, with considerable overlap of hemodynamic 
criteria.
Objective: To determine the role of plasma brain natriuretic peptide (BNP) in the diagnosis 
and differentiation of constrictive pericarditis (CP), from restrictive cardiomyopathy (RC).
Methods: We prospectively studied the plasma levels of BNP in patients undergoing 
cardiac catheterization, to help differentiate CP and RC. A total of 10 patients were 
identiﬁed. All patients underwent trans-septal catheterization to measure the left atrial 
(LA) pressure. BNP levels were drawn during the procedure.
Results: Seven patients were diagnosed as having CP and three patients had RC by 
history, non invasive evaluation and traditional invasive hemodynamic criteria. All patients 
had elevation and equalization of diastolic pressures in all four cardiac chambers. All 
patients with CP had evidence of ventricular discordance. Five of these patients were 
conﬁrmed to have CP at surgery. One patient is awaiting surgery and one patient refused 
surgery. The mean LA pressure and left ventricular end diastolic pressure was not 
signiﬁcantly different in the two groups (24±4 and 23±2 in CP vs 28±3 and 21±3 in RC). 
The mean pulmonary arterial pressure was higher in the RC group (48±8 vs 33±8, p= 
0.07). The BNP was signiﬁcantly higher in the RC group when compared to the CP group 
(848±180 vs. 164± 76, p< 0.02 by the student t test).
Conclusions: 1) The BNP levels are low in CP, when compared to RC for a similar 
LA pressure and left ventricular end diastolic pressure. We postulate that this is due to 
inability of the chambers to stretch, as they are encompassed by rigid pericardium. BNP 
levels have been shown to be grossly elevated in RC in previous studies.
2) BNP levels can be used to help differentiate CP from RC. This is the ﬁrst study to 
describe the new role of BNP to help evaluate this complex disorder.
1049-159 Initial Report of the Initiative to investigate the optimal 
Management of Tuberculous Pericarditis In Africa (IMPI) 
Registry
Charles Shey Wiysonge, Mpiko Ntsekhe, Bongani M. Mayosi, The IMPI Registry Study 
Group, University of Cape Town, Cape Town, South Africa
Background: Tuberculous (TB) pericarditis is a major public health problem in Africa 
as a result of the HIV/AIDS epidemic. There are no evidence-based guidelines for the 
diagnosis and management of the disorder. Futhermore, the clinical characteristics, 
morbidity and mortality associated with TB pericarditis in the HIV era are not known. 
We have established a multi-centre registry to document the clinical presentation, 
management, and outcome of TB pericarditis in Africa.
Methods: Fifteen hospitals in Cameroon, Nigeria, and South Africa are participating in 
the registry. Incident cases who presented between March 1, 2004 and August 31, 2004 
were enrolled consecutively on commencement of treatment for suspected TB pericarditis. 
Each patient is followed up at three-, six- and 12-months intervals to establish the vital 
status and response to treatment.
Results: 162 patients were recruited in the 6 month enrolment period. Mean age was 28 
years; 78 (48%) were male. Sixty-four patients (40%) were clinically immuno-compromised, 
44 (27%) tested HIV-positive; 82 (51%) were of unknown HIV status. The diagnosis was 
based on clinical evaluation and echocardiography (without microbiological conﬁrmation 
of TB) in the majority of cases (74%). Pericardiocentesis was performed in 30% of cases. 
Six percent had bacteriological conﬁrmation of TB infection of the pericardial ﬂuid, while 
eighteen percent had adenosine deaminase level above 40 IU/ml, which is suggestive 
of TB pericarditis. The pericardial syndrome was effusive in 83%, effusive/constrictive 
in 15%, and constrictive in 2% of participants. Ninety-six percent were put on the 4-drug 
and the rest on the 5-drug anti-TB regimen. Ninety-seven patients (60%) received an 
adjuvant oral steroid treatment. Three-month follow-up information, which was available 
for 50 participants, indicated 20% mortality rate.
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Conclusion: The initial results of this study, the largest prospective study of TB pericarditis 
in the HIV era, indicate that TB pericarditis is associated with an early mortality of 20%. 
The analysis of the complete follow-up of this cohort is expected to provide information on 
the determinants of the mortality and morbidity in TB pericarditis.
1049-160 111In-White Blood Cell Scan in the Assessment of 
Myocardial Inﬂammation in Vaccinia-Associated 
Myopericarditis
Sean P. Javaheri, Eric Shry, Sr., Robert Eckart, Sr., J. Edwin Atwood, Sr., John 
Grabenstein, Sr., Brooke Army Medical Center, San Antonio, TX
OBJECTIVES: The purpose of this study was to assess the value of radiotracer labeled 
(111In) white blood cell (WBC) scan on the evaluation of patients with smallpox vaccine-
associated myopericarditis.
BACKGROUND: On December 13, 2002, the Department of Defense resumed widespread 
smallpox vaccination. Since that time, DoD identiﬁed an elevated risk of myocarditis and 
pericarditis among vaccinees, especially young men given smallpox vaccine for the ﬁrst 
time. We describe a cohort of these myopericarditis patients who underwent testing with 
an 111In-WBC scan to assess for recurrent or persistent myocardial inﬂammation.
METHODS: Patients with clinical suggestion of recurrent myopericarditis or following 
resolution of symptoms had radiotracer studies performed using autologous leukocyte 
administration with 111In-WBC and 99mTc-Sestamibi (In WBC).
RESULTS: From December 2002 to July 2004, 78 military personnel were diagnosed 
with myopericarditis within 30 days after smallpox vaccination. Of these, 9 patients had 
persistent chest discomfort on follow-up. Seven patients underwent 11 studies utilizing 
radiotracer imaging. The average length of time from vaccination to imaging was 298 
± 239 days (median 345 days). Of the 8 studies performed on patients with continuing 
chest discomfort, 6 studies (75%) demonstrated focal areas of inﬂammation. Three of 
these areas were in the proximal septum and apex, one in the apex, one in the lateral wall 
and one in the distal anteroseptal wall and apex. Of the three patients who were imaged 
following symptom resolution, none had inﬂammation on 111In-WBC.
CONCLUSIONS: Radiotracer imaging has not been previously evaluated in patients 
with vaccinia-associated myopericarditis, but may be a useful adjunct in the evaluation of 
recurrent or ongoing vaccinia-associated myopericarditis. In this preliminary evaluation, 
most patients who have persistent chest discomfort appear to have objective evidence 
of myocardial inﬂammation by 111In WBC, while inﬂammation was not seen in 111In WBC 
scans following symptom resolution.
1049-161 Acute Pericardial Disease as First Evidence of 
Malignancy
Massimo Imazio, Brunella Demichelis, Enrico Cecchi, Federico Beqaraj, Elisa Favro, 
Franco Pomari, Daniela Demarie, Aldo Ghisio, Riccardo Belli, Rita Trinchero, Cardiology 
Department. Maria Vittoria Hospital., Turin, Italy
Background: Most patients with a malignant pericardial disease are known to have a 
malignant tumour but sometimes an acute pericardial disease has been described as 
the ﬁrst manifestation of cancer. Aim of this work is to evaluate the frequency and clinical 
features of acute pericardial disease as ﬁrst manifestation of malignancy, and to identify 
possible clinical clues to diagnosis.
Methods: We prospectively studied all consecutive patients with a diagnosis of an acute 
pericardial disease (acute pericarditis and cardiac tamponade) from January 1996 to 
December 2003.
Results: In the study period we recorded 450 patients (mean age 52.6 ± 18.1, range 
16-90 years, 237 males) with a diagnosis of acute pericardial disease (440 new cases 
of acute pericarditis, and 10 patients with isolated cardiac tamponade). A neoplastic 
etiology was found in 23 of 440 (5.2%) cases of acute pericarditis, and in all cases of 
cardiac tamponade without pericarditis. Altogether neoplastic etiology was found in 33 of 
450 cases of acute pericardial disease (7.3%). An acute pericardial disease was the ﬁrst 
manifestation of a previous unknown malignancy in 18 of 450 patients (4.0%). Detected 
malignancies were: secondary neoplastic disease in 17 of 18 cases (94.4%: carcinomas 
of the lung in 13 cases, breast cancer in 2 cases, and lymphomas in 2 cases) and primary 
neoplastic disease of the pericardium in a case of pericardial mesothelioma (5.6%). 
Lung cancer was the most common etiology in these patients (72.2%, p=0.02). After 
multivariate analysis the following clinical characteristics were associated with a higher 
probability of a neoplastic etiology: history of malignancy (OR 19.8, 95% CI 7.0-56.0; 
p<0.001), cardiac tamponade at presentation (OR 7.0, 95% CI 1.3-38.2; p=0.023), lack of 
response to non-steroidal anti-inﬂammatory drugs and recurrent or incessant course (OR 
10.0, 95% CI 3.6-27.1; p<0.001).
Conclusion: Acute pericardial disease may be the initial clue to malignancy and this is 
not uncommon in lung cancer. Malignancy must be excluded in every case of an acute 
pericardial disease with cardiac tamponade at presentation, lack of response to non-
steroidal anti-inﬂammatory drugs and incessant or recurrent course.
1049-162 Expression of E-selectin in Coxsackievirus B3 
Myocarditis
James SM Yeh, Steven Tracy, Kristen M. Drescher, Jason Sunde, Ken Kono, Nora 
Chapman, Joseph Boyle, Tracy Hussell, Charles Sennoga, Robert Eckersley, Martin 
Blomley, Dorian Haskard, Petros Nihoyannopoulos, National Heart Lung Institute, 
Imperial College University of London, London, United Kingdom, University of Nebraska 
Medical Center, Omaha, NE
Background: Myocarditis is a classic inﬂammatory condition of the heart, commonly 
due to coxsackievirus B3 (CVB3) infection. The progression from acute myocarditis to 
chronic myocarditis and dilated cardiomyopathy, or resolution is not well understood. 
Type 1 helper T cell (Th1)-dominated responses are associated with the induction of 
myocarditis, whilst Th2-dominated responses are associated with enhanced recovery. 
Recent evidence indicates that E-selectin (an endothelial adhesion molecule expressed 
only on activated endothelium) is involved in the selective recruitment of Th1 cells in vivo. 
However to date, the expression of E-selectin during the course of CVB3 myocarditis has 
not been studied.
Methods: We inoculated 5-6 week old male C3H/HeJ mice intraperitoneally with 1x105 
50% tissue culture infective dose (TCID50) of CVB3/28 in a volume of 100 µl or an equal 
amount of viral diluent. Animals were sacriﬁced at day 7 post inoculation. Hematoxylin and 
eosin staining and immunohistochemisty were performed on the frozen hearts.
Results: Extensive acute myocarditis was present in all infected C3H/HeJ mice (3 out of 
3), accompanied by E-selectin expression that was spatially more widespread than the 
distribution of the myocarditic lesions. The expression of E-selectin was predominantly on 
endothelial cells of the intra-myocardial capillaries, suggesting that these vessels are the 
route of transmigration of leukocytes to the myocardium. Myocarditis and E-selectin were 
absent in all non-infected controls (2 out of 2 animals).
Conclusion: These data demonstrate that E-selectin is expressed in acute CVB3 
myocarditis in C3H/HeJ mice, therefore it may play a role in the selective recruitment 
of helper T cell subsets in CVB3 myocarditis. Furthermore, E-selectin is a good target 
for imaging of activated endothelium in the assessment of inﬂammatory activities in 
myocarditis using novel techniques such as E-selectin targeted microbubble contrast 
enhanced echocardiography.
1049-163 Pulsus Paradoxus in Obesity
Joseph C. Lee, Hyun J. Lee, Dimitri C. Cassimatis, Allen J. Taylor, J. Edwin Atwood, 
Walter Reed Army Medical Center, Washington, DC
Background: Pulsus paradoxus (PP), deﬁned as an inspiratory drop in systolic blood 
pressure > 10mmHg, is generally regarded as a sign of pericardial or severe respiratory 
disease. In the cardiac catheterization lab, we have observed PP in otherwise healthy 
obese individuals. We hypothesized that obesity (body mass index >30 kg/m2) may lead 
to greater respiratory ﬂuctuation in intracardiac ﬁlling and PP.
Methods: 100 patients without known or suspected pericardial or pulmonary disease 
were prospectively studied. Pericardial effusion was excluded with transthoracic echo. 
Non-invasive measurement of PP with manual sphygmomanometry was performed 
in the supine position. Invasive measurement of PP was recorded via arterial sheath 
and catheter in the ascending aorta during normal tidal respirations. PP was manually 
calipered from paper tracings over ﬁve respiratory cycles.
Results: Mean PP was signiﬁcantly higher in obese patients (n=38) than non-obese 
patients (n=62) with both non-invasive and invasive methods (Table).
Abnormal PP was signiﬁcantly more common in obese patients by both invasive (OR 2.8, 
95%CI 1.2-6.6) and non-invasive techniques (OR 8.3, 95%CI 1.9-28.5).
Conclusion: In obesity, increased inspiratory changes in blood pressure and the presence 
of a false positive diagnosis of an abnormal PP are signiﬁcantly more common than in 
non-obese patients. Obesity should be considered in the differential diagnosis of PP. 
Table 
Non-invasive PP 
(mmHg) - Mean
95% Conﬁdence 
Interval
Invasive PP 
(mmHg) - 
Mean
95% Conﬁdence 
Interval
Obese 7.2 6.0-8.3 10.2 8.7-11.8
Non-obese 5.3 4.7-5.9 8.1 7.3-9.0
p=0.007 p=0.016
1049-164 Assessment of Vaccinia-Associated Myopericarditis 
with Cardiac Magnetic Resonance Imaging
Sean P. Javaheri, Eric Shry, Sr., Robert Eckart, Sr., Dimitri Cassimatis, Sr., J. Edwin 
Atwood, Sr., John Grabenstein, Sr., Brooke Army Medical Center, San Antonio, TX
OBJECTIVES: The purpose of this study was to assess patients after development of 
smallpox vaccine-associated myopericarditis (MP) using cardiac magnetic resonance 
imaging (CMR).
BACKGROUND: On December 13, 2002, the Department of Defense(DoD) resumed 
widespread smallpox vaccination. Since that time, DoD identiﬁed an elevated risk of 
MP among vaccinees. CMR imaging has previously demonstrated superior resolution 
for assessment of myocardial scarring. CMR was performed to determine if persistent 
myocardial damage resulted from smallpox vaccine-associated MP.
METHODS: Imaging was performed using multiple projections, including T1- and T2-
weighted magnetic transfer cine acquisitions with gating and a delayed gadolinium 
enhancement protocol. Myocardial imaging was performed after intravenous 
administration of a gadolinium contrast agent (0.2 mmol/kg injected over 20 seconds, with 
imaging beginning 10 minutes later). Examination included evaluation of ventricular sizes, 
synchronous motion for regional wall motion abnormality and assessment for presence of 
scar, infarction, or inﬂammation.
RESULTS: Of the 78 patients diagnosed with MP, 29 patients received 37 CMR studies 
at a mean of 236±234 days (median 232 days) following vaccination. The average left 
ventricular ejection fraction based on cine-CMR images was 64±11%.. The average left 
ventricular diastolic and systolic dimensions were 56±12mm and 38±15mm, respectively. 
Of the 29 patients, 4 showed evidence of persistent myocardial inﬂammation (13.8%) at 
a mean of 274 ± 147 days (median 232 days) following vaccination. Of the 4 cases that 
showed persistent myocardial inﬂammation, three of the patients have had resolution of 
inﬂammation and one patient is pending follow up. The mean period of time to resolution 
of inﬂammation in the three patients was 372 ±51 days (median 311 days). Using delayed 
gadolinium enhancement, 0 of the 37 CMRs in the 29 patients showed any evidence of 
scar formation.
CONCLUSIONS: CMR has demonstrated no evidence of permanent myocardial damage 
following smallpox vaccine-associated MP. Inﬂammatory changes are rare when imaged 
late after the initial presentation, and appear to resolve over time.
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1074-157 Eplerenone Prevents Adverse Cardiac Remodeling 
Induced by Pressure Overload in Atrial Natriuretic 
Peptide Null Mice
Veronica Franco, Yiu Fai Chen, Ji An Feng, Dajun Wang, Suzanne Oparil, Gilbert J. 
Perry, University of Alabama at Birmingham, Birmingham, AL
Background: We have shown that atrial natriuretic peptide (ANP) null mice (Nppa-/-) 
exhibit exaggerated cardiac remodeling with increased interstitial and perivascular 
ﬁbrosis and left ventricular (LV) dysfunction in response to transverse aortic constriction 
(TAC)-induced pressure overload stress. Since ANP reduces aldosterone production, we 
hypothesized that the mineralocorticoid receptor blocker eplerenone (Epl) would prevent 
the exaggerated LV remodeling/ﬁbrosis and dysfunction after TAC in ANP null mice.
Methods: Nppa-/- and wildtypes Nppa+/+ mice fed Epl supplemented chow (~200 mg/
kg/d) since weaning were subjected to TAC or sham operation. Vehicle (Veh)-treated mice 
were controls. At 1 wk after TAC, LV size and function were evaluated by echocardiogram; 
LV cross sections were stained with picrosirius red for collagen volume measurement.
Results: Epl attenuated the TAC-induced increase in LV weight and completely prevented 
the LV dilation, systolic dysfunction and interstitial and perivascular collagen deposition 
seen in Nppa-/- mice after TAC. Epl did not modulate these parameters in sham-operated 
or Nppa+/+-TAC mice. Results are means±SE. Normalized LV weight and LVEDD were 
determined by ANCOVA with body weight as a covariate. G x Epl = genotype x Epl 
interaction by 2-way ANOVA. * p<0.05 vs. Veh; † p<0.05 vs. Nppa+/+.
Conclusions: Eplerenone prevents adverse cardiac remodeling related to systolic 
overload in ANP deﬁcient states, mainly due to an anti-ﬁbrotic effect.
1074-158 Ciliary Neurotrophic Factor Ameliorates Leptin 
Deﬁciency Mediated Left Ventricular Hypertrophy In ob/
ob Mice.
Shubha V. Raju, Alexander C. Phan, Koenraad M. Vandegaer, Djahida Bedja, Kathleen 
L. Gabrielson, Christopher P. O’Donnell, Dan E. Berkowitz, Lili A. Barouch, Joshua M. 
Hare, Johns Hopkins Medical Institutions, Baltimore, MD, University of Pittsburgh School 
of Medicine, Pittsburgh, PA
Background: Ciliary Neurotrophic Factor (CNTF) activates a parallel signal transduction 
pathway to leptin and has similar effects on body metabolism. As leptin reverses 
established left ventricular hypertrophy (LVH) in the leptin deﬁcient obese ob/ob mouse, 
we hypothesized that the CNTF receptor is present in cardiac tissue and that its activation 
with recombinant CNTF (CNTFAx15, Axokine
Tm) reverses established LVH in ob/ob mice.
Methods and Results: Immunoblots with mouse anti-CNTFRα monoclonal antibody 
demonstrated the presence of CNTF receptor in C57B6/J mice heart extracts. The ob/ob 
mice were randomized to 3 groups and treated for 4 weeks. The ﬁrst group received 
CNTFAx15 (n=6, 5-6 months old, weight: 73±2 g), the second group was calorie restricted 
(n=5, 5-6 months old, 71±2 g), and the third group was fed ad libitum as controls. (n=6, 
5-6 months old, 70±1g). Body weight decreased by 43±2% with CNTFAx15 (0.1 mcg/g/
day)and 37±4% with calorie restriction, and increased by 3±2% in the control group. 
Echocardiography showed that CNTFAx15 reduced cardiac hypertrophy, with decreases in 
posterior wall thickness in the CNTFAx15 group (-27±6%, p <0.01)compared to no change 
in the calorie restricted (-3±7%) and ad libitum groups(+1±5%). CNTFAx15 did not affect LV 
chamber size or functional status.
Conclusion: These ﬁndings identify a novel cardiac signal transduction pathway 
participating in obesity related cardiac hypertrophy. Moreover, CNTFAx15 may have 
therapeutic value in treating LVH in patients with leptin resistance.
1074-159 Gap Junction Remodeling Is an Arrhythmogenic 
Substrate During the Development of Heart Failure in a 
Cardiomyopathic Hamster
Takashi Sato, Tomoko Ohkusa, Haruo Honjo, Shinsuke Suzuki, Tomo Matsumoto, 
Yuji Hisamatsu, Masafumi Yano, Itsuo Kodama, Masunori Matsuzazki, Yamaguchi 
University, Ube, Japan, Research Institute of Environmentao Medicine, Nagoya 
University, Nagoya, Japan
In the clinical setting, lethal ventricular arrhythmias occur during development of heart 
failure. Electrical coupling in the heart is mediated by gap junctions (GJs) and changes 
of GJs are considered to be an important factor in the origin of reentrant arrhythmias. We 
investigated the alterations in connexin (Cx)43 during transition to heart failure in UM-X7.1 
cardiomyopathic hamster (CM) hearts. Methods: We analyzed Cx43 expressions (protein 
and mRNA) of the left ventricular (LV) myocardium by western blotting and RT-PCR at the 
age of 6, 10, and 20w. Echocardiographic and electrophysiological data were obtained. 
Results: In CM, LV hypertrophy had developed at 10w, LV global hypokinesis started at 
20w, and died at 25~28w with overt heart failure. In CM at 20w, QRS interval was markedly 
prolonged (~1.2 fold) and conduction velocity measured by optical mapping system was 
signiﬁcantly decreased compared with golden hamster (G), and random reentry was 
induced easily by burst pacing. The interstitial ﬁbrosis was signiﬁcantly increased in CM 
(8.5±2.6%) compared with G (1.9±1.1%, p<0.05) at 20w. The relative expression level of 
Cx43 protein and mRNA were signiﬁcantly lower in CM at 20w than in G (0.52±0.29 vs 
1.20±0.12, 0.58±0.14 vs 0.87±0.12, p<0.05, respectively). In CM, Cx43 expressions at 
transverse portion of cardiomyocyte were markedly decreased. Interestingly, the relative 
expression level of serine255-phosphorylated Cx43, which initiates the down-regulation 
of gap junctional intercellular communication, was markedly increased in CM (1.1±0.4) 
compared with G (0.4±0.4, p<0.01) at 20w. Serine255-phosphorylated Cx43 was over-
expressed at cytoplasmic area in CM. Conclusions: In cardiomyopathic hearts, in addition 
to interstitial ﬁbrosis, downregulation and abnormal serine-phosphorylation of Cx43 may 
result in abnormal cell-to-cell communication and alter the electrophysiologic properties 
of the ventricle, leading to the initiation and perpetuation of ventricular arrythmias.
1074-160 Down Regulation of Connexin40 is Associated 
with Sudden Death and Conduction Abnormalities 
in Transgenic Mice with Cardiac Restricted Over 
Expression of Tumor Necrosis Factor
Sam E. Sawaya, Yadavendra S. Rajawat, Tapan G. Rami, Gabor Szalai, Robert L. 
Price, Sivasubramanian Natarajan, Dirar S. Khoury, Douglas L. Mann, Baylor College of 
Medicine, Houston, TX, University of South Carolina, Columbia, SC
Background: The incidence of sudden death increases in cardiac conditions associated 
with inﬂammation (e.g. viral myocarditis). However, the mechanism is unknown. Based on 
previous reports that tumor necrosis factor (TNF) down regulates the gap junction protein 
connexin43 (Cx43), we examined Cx43 expression in transgenic mice with targeted over 
expression of TNF (MHCsTNF). Western blot analysis and immunohistochemistry showed 
decreased phosphorylation and dispersion of Cx43 away from the intercalated disks of 
cardiac myocytes. We hypothesized that Cx43 disruption causes ventricular conduction 
abnormalities and sudden death in MHCsTNF mice.
Methods: We recorded ECGs, measured ventricular conduction velocity during LV 
epicardial mapping, and performed intracardiac electrophysiology (EP) studies in 6 
MHCsTNF mice and in 6 wild type (WT) mice.
Results: The ECG showed diminished heart rate and wide QRS complex in MHCsTNF 
mice compared to WT (RR = 171 vs. 120 ms, p = 0.01; QRS = 23 vs. 9 ms, p < 0.001). 
Although Cx43 was disrupted in MHCsTNF mice, LV conduction velocity in MHCsTNF 
mice was similar to WT (0.6 vs. 0.6 m/s), suggesting that the disruption in Cx43 was not 
functionally signiﬁcant in MHCsTNF mice. Additional EP studies showed that MHCsTNF 
mice developed AV junctional rhythm and bundle branch block along with sinus and AV 
nodal dysfunction. While no ventricular tachyarrhythmias were induced in MHCsTNF 
mice, atrial tachycardia was induced in 3/6 mice and ventricular bigeminy in 2/6 mice. 
However, no arrhythmias were induced in WT mice. Since Cx40 is known to be present 
in regions where the electrical abnormalities were observed, we performed further 
immunohistochemistry and found that Cx40 was down regulated in MHCsTNF mice 
compared to WT.
Conclusion: Contrary to our initial hypothesis, disruption of Cx43 expression does 
not appear to alter ventricular conduction velocity or engender ventricular arrhythmias 
in MHCsTNF mice. Electrical abnormalities observed in the atrium and the specialized 
conduction system are consistent with down regulation of Cx40. Therefore, inﬂammation-
induced abnormalities in atrial and AV conduction may predispose MHCsTNF mice to 
sudden death.
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1075-143 Inability to Tolerate Optimal Neurohormonal Blockade 
Predicts Poor Survival in Heart Failure
Catherine Fallick, Jon Fryzek, Suzanne Wingate, Colleen Healey, Pam Barnett, Deborah 
Grinder, Cecelia Gramsky, John Golden, Kaiser Permanente Mid-Atlantic States, 
Rockville, MD, International Epidemiology Institute, Rockville, MD
Background: Though the concept of neurohormonal blockade is well-established in heart 
failure (HF) treatment, associated therapies remain underutilized. This has impeded the 
development of a fuller understanding of the current natural history of HF progression. We 
evaluated patients (pts) in a large HMO HF disease management program emphasizing 
optimization of therapy in an effort to determine the extent to which optimal neurohormonal 
blockade has modiﬁed disease course. 
Methods: We retrospectively analyzed data on 1121 pts referred to our Heart Failure 
Treatment Program (HFTP) with HF due to left ventricle systolic dysfunction (mean LVEF 
23.5 +/-7.9%). Mean age was 62.4+/-13.3 years, 66% were male, 55% African American, 
and 42% diabetic. 93% were treated with an ACE-inhibitor (ACE-I) or angiotensin receptor 
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blocker (ARB), 84% with a beta blocker(BB), and 33% with Spironolactone(S). We deﬁned 
optimal care as BB+ACE-I or ARB for NYHA class I & II pts and BB+S+ACE-I or ARB for 
NYHA class III & IV pts. We analyzed survival, stratifying by the use of or intolerance to 
optimal therapy. 
Results: Pts were followed for a mean of 2.4+/-1.7 years. 80% of NYHA class I-II and 
75% of NYHA class III-IV pts were treated with optimal therapy. After adjusting for gender, 
race, age, weight, diabetes, ejection fraction, and NYHA class, pts receiving optimal care 
had a statistically signiﬁcant survival advantage [RR 0.35 for all NYHA classes receiving 
optimal care (CI: 0.26-0.48)]. Multivariate analysis revealed optimal medical therapy to 
be the most powerful predictor of 5-year survival [NYHA I & II pts with 82% survival with 
optimal therapy, 57% survival without optimal therapy; NYHA III & IV pts with 65% survival 
with optimal therapy, 32% survival without optimal therapy]. 
Conclusions: The inability to tolerate optimal therapy confers extremely poor survival 
in HF pts with LV systolic dysfunction. Conversely, the comprehensive implementation of 
neurohormonal blockade in such pts dramatically improves survival in high-risk patient 
subsets. These data lend support to the continued growth of care systems incented to 
optimize evidence-based medical therapy.
1075-144 Increased Levels Of C-Reactive Protein Are Related To 
Reduced Regional Left Ventricular Function Detected 
By Tagged MRI In Asymptomatic Individuals: The Multi-
ethnic Study Of Atherosclerosis (MESA)
Boaz D. Rosen, Mary Cushman, Khurram Nasir, David A. Bluemke, Thor Edvardsen, 
Veronica Fernandes, Shenghan Lai, Russell Tracy, Joao AC Lima, Johns Hopkins 
Hospital, Baltimore, MD, University of Vermont, Burlington, VT
Background: C-reactive protein (CRP) is a marker of increased risk for heart failure, but 
the relationship between CRP and subclinical LV dysfunction has not been evaluated . We 
investigated the association between CRP and regional LV function in participants of the 
Multi-Ethnic Study of Atherosclerosis.
Methods: Regional function was determined by peak systolic circumferential strain 
(Ecc) using Harmonic Phase method in 1,164 study participants who underwent tagged 
MRI. Relationship between CRP levels and Ecc was studied by stepwise regression 
after adjusting for age, waist circumference, hypertension, hyperlipidemia, drug therapy, 
smoking, diabetes and hormone replacement therapy. Regions were deﬁned by coronary 
territories. Since the distribution of CRP was skewed data were analyzed using log-CRP. 
Relationship between log CRP and Ecc is shown as regression coefﬁcients.
Results: (Table) Gender was a signiﬁcant effect modiﬁer (p<0.05). In men, higher CRP 
was signiﬁcantly associated with lower (absolute) average peak systolic Ecc overall 
(p<0.01) and in LAD and LCX regions (p<0.05 for both). The association between Ecc 
and log-CRP was weaker in the RCA region (p=0.09). Among women there was no 
association between CRP and peak systolic Ecc before and after adjusting for all potential 
confounders.
Conclusion: Higher CRP levels were associated with regional LV dysfunction in men, but 
not women, after controlling for traditional risk factors and preventive therapy for coronary 
artery disease.
Table: Relationship between regional peak systolic  
strain and log-CRP 
Coronary region Men Women Gender interaction
Regression 
coefﬁcient*
Conﬁdence intervals
(p value)
Regression 
coefﬁcient*
Conﬁdence 
intervals
(p value)
(p value)
LAD 0.37 0.09-0.65(<0.01) -0.01 -0.38-0.35 (0.9) 0.05
LCX 0.37 0.06-0.69 (0.02) -0.20 -0.64-0.24 (0.4) 0.02
RCA 0.25 -0.04-0.53 (0.09) -0.16 -0.53-0.20 (0.4) 0.03
Mean Ecc 0.34 0.09-0.6 (<0.01) -0.09 -0.43-0.25 (0.6) 0.05
* Regression coefﬁcient is deﬁned as difference in Ecc(%) per 1 unit increase in log-CRP. CRP is in mg/L 
units. Coronary territories: left anterior descending [LAD], left circumﬂex [LCX], right coronary artery [RCA]. 
Systolic Ecc values are normally negative and a more positive Ecc reﬂects lower regional function.
1075-145 Population Trends in Congestive Heart Failure Incidence 
and Survival
Russell V. Luepker, Susan J. Duval, Joseph Kim, Cheryl A. Barber, Sharon J. Rolnick, 
Jody M. Jackson, Kristi J. Paulsen, David R. Jacobs, Jr., University of Minnesota, 
Minneapolis, MN, HealthPartners Research Foundation, Minneapolis, MN
Background: Congestive heart failure (CHF) is increasing, a trend often attributed to 
improved survival from coronary heart disease (CHD) and hypertension. CHF is often 
fatal. However, most reports are based on hospitalized case series which may over-
estimate severity and underestimate incidence.
Hypotheses: Population rates of new CHF (incidence) are increasing. Outpatient (OP) 
diagnosis contributes signiﬁcantly to population levels but has a better prognosis.
Population: Members of Health Maintenance Organization (HMO) age 35-84 resident in 
the Minneapolis-St. Paul area.
Methods: All medical records for years 1995-1998 were reviewed by trained abstracters 
to conﬁrm the CHF diagnosis and collect associated characteristics. All-cause mortality 
was based on death certiﬁcates and patient records. Rates were age-adjusted to the 
2000 census.
Results: A total of 793 new cases of CHF met study criteria. Annual age-adjusted 
incidence of CHF was 370/100,000 in men and 257/100,000 in women. Incidence 
increased with age. The majority of cases were diagnosed in the OP setting (59% men 
and 61% women). Overall age-adjusted ﬁve-year mortality was substantial at 39% for 
men and 34% for women. For those ﬁrst diagnosed in the inpatient (IP) setting, ﬁve-year 
mortality was 41% and 42% for men and women respectively. In the OP setting, ﬁve-
year mortality was 37% for men and 29% for women. Time trends in CHF differed by 
gender and site of diagnosis. For men, age-adjusted CHF incidence was ﬂat (345/100,000 
in 1995 and 339/100,000 in 1998) but a substantial shift occurred from initial IP to OP 
diagnosis. Five-year mortality declined from 44% to 34%. For women, age-adjusted CHF 
incidence rose from 215/100,000 in 1995 to 328/100,000 in 1998, mainly due to increased 
OP diagnosis. Five-year mortality increased from 32% to 34%.
Conclusions: CHF remains a common and frequently fatal disease. The use of both 
OP and IP data allows a more complete picture of the burden. Patients diagnosed in 
the OP setting have a somewhat better prognosis but still suffer substantial mortality. 
The differences associated with site, gender and changes over time may be the result of 
earlier diagnosis, differential treatment or other factors.
1075-146 Low Voltage on the Electrocardiogram Is a Novel Risk 
Factor for Adverse Outcomes in Patients with Heart 
Failure Due to Systolic Dysfunction
Sandeep A. Kamath, Januario de P. Meo Neto, James A. deLemos, Mark H. Drazner, 
University of Texas Southwestern Medical Center, Dallas, TX, INCOR, Sao Paulo, Brazil
Background: The frequency and prognostic implications of low QRS voltage on the 
electrocardiogram (ECG) in heart failure (HF) are not well characterized.
Methods: We manually measured and summed the QRS voltage in all 12 leads of the 
ECG (ΣQRS) in two cohorts: 1) a consecutive series of 420 HF patients with a low ejection 
fraction followed in a HF clinic (“clinic cohort”) and 2) subjects (n=100) with advanced 
HF who had an ECG within 6 months preceding cardiac transplantation (“advanced HF 
cohort”). Low voltage was deﬁned as the lowest quartile of the clinic cohort (ΣQRS <12 mV). 
The association of low voltage and 1-year outcomes was assessed in the clinic cohort. We 
compared the prevalence of low voltage in the clinic and advanced HF cohorts, reasoning 
that if low voltage was an adverse risk factor it would be more common in the latter. In 
the transplant cohort, we compared the pathologically measured cardiac mass and left 
ventricular wall thickness of the explanted heart in those with or without low voltage.
Results: The clinic cohort was predominantly African American (65%), female (58%), with 
a nonischemic cardiomyopathy (63%) while the advanced HF cohort was predominantly 
white (79%), male (78%) with an ischemic cardiomyopathy (56%). After 1 year of follow-
up in the clinic cohort, patients with versus without low ECG voltage were more likely 
to have died (14% versus 5%, p=0.008) or met the composite endpoint of death or HF 
hospitalization (35% versus 20%, p=0.004). These associations persisted in multivariable 
analysis after adjusting for body mass index, systolic blood pressure, serum creatinine, 
and β-blocker use. The frequency of low voltage in the advanced HF cohort (50%) was 
twice that of the clinic cohort (24%, p<0.001). In subgroup analysis, the association 
between low voltage and advanced HF persisted in whites and was irrespective of gender 
and HF etiology (P<0.005 for all). Low voltage was associated with lower heart mass (490 
± 125 vs. 557 ± 147 grams, p=0.02) and left ventricular wall thickness (1.6 ± 0.5 vs. 1.8 
± 0.4 cm, p<0.01).
Conclusion: Low ECG voltage is a novel risk factor in systolic HF, is more prevalent 
in advanced HF, and is associated with reduced cardiac mass and left ventricular wall 
thickness.
1075-147 Pacing-Induced Mechanical Alternans Is a Good 
Indicator of Poor Prognosis in Idiopathic Dilated 
Cardiomyopathy With Sinus Rhythm
Akihiro Hirashiki, Hideo Izawa, Fuji Somura, Kohzo Nagata, Tomoko Kato, Hiroyuki 
Asano, Satoru Ohshima, Akira Yamada, Yosuke Murase, Akiko Noda, Koji Obata, 
Masahiko Maeda, Toyoaki Murohara, Mitsuhiro Yokota, Chita City Hospital, Chita, Japan, 
Nagoya University, Nagoya, Japan
Background: Little studies have attempted to ﬁnd prognostic indicators in ambulatory 
patients with idiopathic dilated cardiomyopathy (IDCM) in sinus rhythm. The relation 
between pacing-induced mechanical alternans and prognosis was investigated in 
patients with IDCM in sinus rhythm . We also investigated the myocardial expression of 
Ca2+-handling protein genes associated with the mechanical alternans.
Methods: Left ventricular (LV) pressure was measured during atrial pacing in the 36 IDCM 
patients and 8 controls. LV endomyocardial biopsies were performed and the abundance 
of Ca2+-handling protein mRNAs in the biopsy specimens were determined by quantitative 
RT-PCR. We also followed these IDCM patients for a mean period of 3.7 years.
Results: Under baseline conditions, no patient exhibited mechanical alternans. We could 
devided two groups of IDCM patients. Group A consisted of 22 IDCM patients who did 
not develop mechanical alternans at heart rates up to 140 bpm. Group B consisted of 
14 IDCM patients who developed pacing-induced mechanical alternans. There were no 
signiﬁcant differences in LV ejection fraction or plasma brain natriuretic peptide between 
Groups A and B. In endomyocardial biopsy specimens, the ryanodine receptor-2 mRNA 
level was signiﬁcantly lower in patients with Groups A and B than in controls, but there 
were no signiﬁcant differences between Groups A and B. The sarcoplasmic reticulum 
Ca2+-ATPase mRNA level was signiﬁcantly lower in Group B than in Group A or controls. 
The 3- and 5-year cumulative event-free survival rates in Group A were 89.1% and 66.9%, 
respectively. The 3- and 5-year cumulative event-free survival rates in Group B were 
62.5% and 31.3%, respectively. The event-free survival rates in Group A was signiﬁcantly 
higher than that in Group B by the log-rank test (p=0.022).
Conclusions: Pacing-induced mechanical alternans is a good indicator of poor prognosis 
in IDCM patients with sinus rhythm. Abnormal expression of Ca2+-handling proteins, 
resulting in altered intracellular Ca2+-levels, may play a central role in pacing-induced 
mechanical alternans in IDCM patients.
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1075-148 Improvement in Hyponatremia During Hospitalization 
for Worsening Heart Failure Is Associated With 
Improved Outcomes: Insights From the Acute 
and Chronic Therapeutic Impact of a Vasopressin 
Antagonist in Chronic Heart Failure (ACTIV in CHF)
Mihai Gheorghiade, Kirkwood Adams, Christopher O’Connor, Christopher Zimmer, 
Frank Czerwiec, Ouyang John, Orlandi Cesare, Feinberg School of Medicine- 
Northwestern University, Chicago, IL
Background: Hyponatremia (HYPO) is a known predictor of mortality in pts hospitalized 
for worsening heart failure. However, it is not known whether improving sodium levels 
in hyponatremic patients would lead to improved outcomes. We studied the relationship 
between changes in serum sodium during hospitalization and mortality in hyponatremic 
patients admitted for decompensated heart failure (HF) in a post-hoc analysis of the 
ACTIV in CHF trial.
Methods: The ACTIV in CHF trial randomized 319 pts with systolic dysfunction hospitalized 
for worsening HF to receive placebo or 30, 60, or 90 mg tolvaptan, a novel vasopressin 
V2 receptor antagonist. Cox proportional hazards regression-analysis was used to explore 
the relationship between HYPO (Na+<136 mEq/L) at baseline and improvements ≥2 mEq/
L in serum sodium by hospital discharge, and mortality within sixty days.
Results: Mild to moderate HYPO was observed in 69 patients (21.6%), with median 
(IR) levels of 133 (131, 134) mEq/L at baseline. After adjustment for other covariates, 
HYPO was a highly statistically signiﬁcant predictor of mortality at 60 days post hospital 
discharge (p<0.005). At hospital discharge, 45 out of 69 pts (65.2%) had improvements 
in serum sodium levels ≥2 mEq/L. These pts had a median (IR) baseline sodium of 133 
(131, 134) mEq/L, as compared with 133 (132, 135) mEq/L in those who did not improve 
by hospital discharge. Pts with a serum sodium improvement at discharge had a mortality 
rate of 15.6% at 60 days post discharge, as compared with a 30.4% mortality rate in those 
showing no improvement (p=0.0842, log-rank). After adjustment for other covariates, 
change in serum sodium at hospital discharge was a statistically signiﬁcant predictor of 
mortality at 60 days post hospital discharge (p<0.0269). 
Conclusions: Hyponatremia appears to be a modiﬁable therapeutic target and not purely 
a marker of disease severity. Improvements in serum sodium levels during hospitalization 
were associated with improved mortality at 60 days. Prospective studies are necessary 
in this population to assess if therapies aimed at increasing serum sodium will result in 
improved outcome.
1075-149 Hemodynamic Characterization and Prognostic Value of 
Persistent Hyponatremia in Patients With Severe Heart 
Failure in the ESCAPE Trial
Mihai Gheorghiade, Anne S. Hellkamp, Ileana L. Pina, Gregg C. Fonarow, Teresa De 
Marco, Daniel F. Pauly, Joseph Rogers, Thomas DiSalvo, Javed Butler, Joshua M. Hare, 
Gary S. Francis, Christopher M. O’Connor, Northwestern Feinberg School of Medicine, 
Chicago, IL
Background: The signiﬁcance of hyponatremia (HN) and its correlation with 
hemodynamics have not been studied in heart failure (HF) patients (pts). 
Methods: The ESCAPE trial randomly assigned 433 pts with severe HF to receive therapy 
guided by pulmonary artery catheter or by clinical assessment alone. Of these, 400 pts had 
serial serum Na measurements during hospitalization. Persistent HN was deﬁned as Na 
≤ 134 mEq/L throughout hospitalization. Cox proportional hazards models, with discharge 
Na as a continuous variable and adjusted for other predictors, were used to examine the 
association of Na and postdischarge outcomes. Results: At baseline, 82 pts (21%) had 
HN; 71 of them had HN at discharge. Also at baseline 318 pts (79%) had normal Na; of 
these, 266 had normal Na throughout hospitalization, while 52 had a decline by discharge. 
Discharge Na was a signiﬁcant predictor of subsequent mortality (p=0.003; HR=1.25; 
95% CI=1.08, 1.46 for each 3-mEq/L decrease) (Table) and of rehospitalization for HF 
(p=0.034; HR=1.11; 95% CI=1.01, 1.23 for each 3-mEq/L decrease). Conclusions: In pts 
with severe HF, HN is relatively common and usually not corrected during hospitalization. 
Compared with pts with normal Na, pts with HN have a higher pulmonary capillary wedge 
pressure and right atrial pressure after treatment, despite receiving higher diuretic doses 
and undergoing similar reductions in body weight. HN at discharge is associated with very 
high risk of early mortality and rehospitalization for HF.
Characteristic
Normal Na
(n=266)
median(25th,75th)
Persistent Hyponatremia
(n=71)
median (25th,75th)
p
Baseline ejection fraction (%) 20 (15, 25) 16 (14, 20) 0.006
Baseline BUN (mg/dL) 18 (13, 26) 33 (24, 56) 0.001
Baseline systolic blood pressure (mm Hg) 111 (97, 126) 102 (89, 116) 0.037
Baseline cardiac index (L/min/m2) 1.94 (1.60, 2.40) 1.80 (1.57, 2.10) 0.073
Baseline PCWP (mm Hg) 24 (18, 32) 27.5 (19, 32) 0.62
Last measured PCWP (mm Hg) 16 (12, 20) 21 (16.5, 25) 0.015
Change in weight (kg) -2.5 (-5.5, -0.6) -3.7 (-8.1, -0.1) 0.21
Furosemide dose (mg/day) 133 (60, 218) 186 (108, 292) 0.003
Death within 6 months 15% (41) 31% (22) 0.003
1075-150 Total Hospitalizations in Advanced Heart Failure: 
Results from COMPANION
Peter Carson, Christopher O’Connor, JoAnn Lindenﬁeld, Jalal Ghali, Brian Jaski, 
Jonathan Steinberg, Jodi Barnet, Inder Anand, Department of Veterans Affairs Medical 
Center, Washington, DC
Background: Despite frequent hospitalizations in heart failure (HF) pts, little data is 
available on the all cause hospitalization (ACH) burden. No clinical trial has ever reported 
a total database of adjudicated hospitalizations. Most data concern HF hospitalizations, 
as part of a primary endpoint.
Methods: The COMPANION study, in an advanced HF population, offers a unique 
opportunity to examine ACH database as adjudicated by an endpoint committee. The 
current analysis involves the optimal pharmacologic therapy (OPT) cohort of COMPANION 
(308 pts) followed for a median of 11.7 months. Hospitalizations were required to be of 24 
hours duration or involve a calendar date change.
Results: A total of 210 pts (68% of total pts) experienced 523 ACH. 176 pts had a 
cardiac admission (75% of all hospitalizations) and 106 had a HF admission (42% of 
all hospitalizations). Cardiac procedures accounted for 19% of total events. Non cardiac 
hospitalizations comprised 24% with pulmonary and GI the leading causes.
Conclusion: In an advanced HF population with QRS widening, ACH occurred frequently. 
While HF was the highest single category, non HF hospitalization predominated. The 
nature of the population and study contributed to more hospitalizations for cardiac 
procedures than anticipated but this may be an accurate reﬂection of the effect of recent 
device trials on current clinical practice. This data emphasizes the importance of non HF 
and non-cardiac morbidity in this population.
Reasons for Hospitalization 
Total Cardiac Hospitalization 395 Total Non Cardiac Hospitalization 126
Heart Failure 220 Pulmonary 32
Unstable Angina/MI 36 Vascular 15
Arrhythmia 9 Non cardiac chest pain 12
Deﬁbrillator or pacemaker implant 67 Gastrointestinal disorder 21
Electrophysiology study 13 Renal disorder 2
Cancer related 2
Medication (non cardiac) related 3
Other 39
1075-173 Serum Level of Uric Acid, Partly Secreted From The 
Failing Heart, is a Prognostic Marker in Japanese 
Patients with Congestive Heart Failure
Hiroshi Sakai, Takayoshi Tsutamoto, Takashi Tsutsui, Chisato Ishikawa, Keijin Ohno, 
Minoru Horie, Shiga University of Medical Science, Otsu, Japan
Background. Serum uric acid (UA) is reported to be elevated and may be a prognostic 
indicator in congestive heart failure (CHF). Activation of xanthine oxidase (XO) is a 
mechanism for elevation of serum UA in CHF. Activated XO, in the failing heart, produces 
free radicals and may contribute to oxidative damage in the failing myocardium and 
the progression of heart failure. However, whether UA is secreted from the failing heart 
remains unknown. 
Objective. To evaluate serum UA is secreted from the failing heart and to estimate the 
prognostic role of UA in Japanese patients with CHF. 
Methods. 1). We measured the serum UA in the Aortic root (AO) and in the coronary 
sinus (CS) in 58 patients with CHF and 13 control subjects. 2). In150 CHF patients, we 
measured plasma levels of norepinephrine, brain natriuretic peptide (BNP), UA, and left 
ventricular ejection fraction (LVEF) and monitored for more than one year prospectively 
(mean follow-up periods=3 years). 
Results. In 58 CHF patients, serum UA level in the AO increased with the severity of 
CHF and serum UA level was signiﬁcantly higher in the CS than the AO (6.7±0.23 vs. 
6.9±0.21, p<0.0001). The transcardiac gradient of UA (CS-AO) increased with severity 
of CHF and inversely correlated with LVEF and positively correlated with LV end-diastolic 
volume index. During the long-term follow-up, 26 patients died of cardiac event. In150 
CHF patients, high plasma levels of UA (p<0.001) and BNP (p<0.001) were shown to be 
independent predictors of mortality by multivariate stepwise analysis. Twenty patients died 
( mortality rate=40%) in 49 patients (BNP>130 pg/mL and UA>6mg/dL) . Only one patient 
died in 53 patients (BNP<130 pg/mL and UA<6mg/dL). 
Conclusions. These ﬁndings suggest that activated XO system in the failing heart 
contributes to the left ventricular dysfunction and the high plasma UA level is an 
independent prognostic predictor of BNP in Japanese patients with CHF.
1075-174 Elevated Troponin T is Associated With Increased 
Left Ventricular End-diastolic Pressure and 
Electrocardiographic Left Ventricular Hypertrophy in 
Congestive Heart Failure Patients With no Coronary 
Artery Disease
George O. Angheloiu, Mohamad H. Yamani, Randall C. Starling, James B. Young, The 
Cleveland Clinic Foundation, Cleveland, OH, University of Pittsburgh Medical Center, 
Pittsburgh, PA
Background: Congestive heart failure (CHF) can be a cause of elevated troponin T 
(tnT). Little is known about the etiology of tnT elevation in CHF patients free of coronary 
disease.
Methods: We studied the records of 525 CHF patients that visited the Cleveland Clinic 
emergency department between 1998-2002, had at least one tnT value measured and 
subsequently underwent cardiac cath. Patients with no disease on coronary angiogram 
were entered into the study. We recorded 17 clinical and laboratory variables, and 
investigated the association between them and tnT greater than 0.1 and 0.01 ng/ml 
respectively.
Results: Seventy-eight patients were included. Peak tnT values were greater than 0.1 
and 0.01 ng/ml in 13 and 50 patients respectively. Five variables were associated with 
tnT greater than 0.1 ng/ml, and three with tnT levels of 0.01 ng/ml or more (Table). After 
comparing the effects of these variables by means of multivariate analysis, increased left 
ventricular end diastolic pressure (LV EDP) was associated with tnT greater than 0.1 ng/
ml (P=0.01), electrocardiographic left ventricular hypertrophy (ECG-LVH) with tnT of 0.01 
ng/ml or greater (P=0.03), and the combination of these two variables with tnT greater 
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than both 0.1 and 0.01 ng/ml (P=0.04 and 0.05 respectively).
Conclusion: Increased LV EDP and ECG-LVH are associated with elevated tnT levels 
in CHF patients with no coronary disease, suggesting that left ventricular load and 
hypertrophy are a cause for myocardial ischemia and tnT release.
 
Variable tnT ≥ 0.01* tnT < 0.01* P tnT ≥ 0.1* tnT < 0.1* P
Female gender 54% 59% 0.33 62% 54% 0.42
AA race 59% 59% 0.29 77% 62% 0.23
SBP ≥ 160 mm Hg 30% 35% 0.47 40% 31% 0.48
DBP ≥ 100 mm Hg 23% 27% 0.41 30% 24% 0.47
ECG-LVH 76% 38% 0.004 80% 57% 0.16
Creatinine ≥ 1.2 mg/ml 53% 19% 0.004 69% 33% 0.04
LV mass ≥ 300 gm 79% 48% 0.01 100% 61% 0.01
LV EF ≤ 35 % 55% 59% 0.74 64% 55% 0.42
Diastolic dysfunction 57% 44% 0.22 64% 50% 0.31
RV dysfunction 36% 26% 0.26 64% 27% 0.02
RVSP ≥ 40 mm Hg 67% 47% 0.17 60% 58% 0.66
LV EDP ≥ 12 mm Hg 83% 60% 0.08 100% 65% 0.05
LV SP ≥ 160 mmHg 33% 30% 0.54 63% 25% 0.05
Diabetes 34% 31% 0.59 39% 34% 0.49
HTN 71% 59% 0.18 85% 63% 0.11
Hyperlipidemia 20% 21% 0.63 15% 22% 0.81
Smoking 18% 24% 0.82 15% 22% 0.81
* ng/ml
1075-175 Chromogranin A is an Independent Prognostic Marker 
in Postinfarction Heart Failure
Mette Elise Estensen, Aina Hognestad, Unni Syversen, Iain Squire, Leong Ng, Kenneth 
Dickstein, Torbjorn Omland, Akershus University Hopsital, Nordbyhagen, Norway, 
Central Hospital in Rogaland, Stavanger, Norway
Background: Chromogranin A (CgA) is widely distributed throughout the neuroendocrine 
system and may, due to its long in vivo and in vitro half-life, be an attractive candidate 
for assessment of overall neuroendocrine activity. Recently, increased plasma levels of 
CgA have been found in patients with chronic heart failure and related to the severity of 
symptoms and prognosis. The prognostic value of CgA in postinfarction heart failure is 
unknown. 
Methods: We assessed the association between serum CgA levels obtained during the 
subacute phase and time to hospitalization or death in 217 patients with postinfarction 
heart failure included in the OPTIMAAL trial . This trial evaluated the effect of losartan vs 
captoril on mortality in a randomized, double-blind fashion.
Results: During a median follow-up time of 1017 days 32 patients died and 12 patients 
were hospitalized with congestive heart failure. By univariable Cox proportional hazards 
regression CgA (p<0.0001), patient age (p<0.0001), serum creatinine (p<0.0001), N-
terminal proBNP (p<0.0001), a history of myocardial infarction or angina (p=0.001), 
diabetes (p=0.024) were signiﬁcantly associated with outcome, whereas gender, 
randomization status, history of hypertension, CRP, and the presence of in-hospital 
heart failure were not. In a stepwise, forward multivariable model CgA (p<0.0001), 
patient age (p<0.0001), history of diabetes (p=0.008) and female gender (p=0.044) were 
independently predictive of adverse outcome. 
Conclusion: Circulating levels of CgA are independently predictive of mortality and heart 
failure development in patients with postinfarction heart failure. CgA appears to be a 
stronger prognostic indicator than other biomarkers, including CRP and NT-proBNP.
1075-176 Prognostic Value of Uric Acid and Renal Function in 
Heart Failure. Results From Val-HeFT
Inder S. Anand, Michael A. Kuskowski, Areef Ishani, Robert Glazer, Roberto Latini, 
Serge Masson, Aldo P. Maggioni, Allen Hester, Jay N. Cohn, VA Medical Center and 
University of Minnesota, Minneapolis, MN
Background: Uric acid (UA) is considered to play a role in the progression of heart 
failure (HF) and may be a prognostic factor for worse outcomes. These ﬁndings have led 
to clinical trials to test the hypothesis that reducing UA may be beneﬁcial in HF. However, 
it is unclear whether the prognostic effect of UA is independent of renal function. We 
compared the prognostic value of baseline UA and renal function using GFR (MDRD 
equation), and of changes in these variables over 12 months in moderate to severe HF.
Methods: This analysis was done on the Val-HeFT database. Univariate and multivariate 
Cox proportional hazard analyses were done to determine the relation between UA, GFR 
and mortality. 
Results: GFR and UA were signiﬁcant univariate predictors of mortality, with a 2.9% 
increase in mortality for every 1 ml decrease in GFR and a 5.1% increase in mortality 
for every 20Âµmol/L (0.3mg/dL) increase in UA. Whereas change in GFR from baseline 
to 12 months was also predictive of mortality in a univariate analysis, change in UA was 
not (Table). In a stepwise multivariate analysis that included 40 univariate predictors of 
mortality except for markers of renal function, UA emerged as the second most powerful 
independent predictor of mortality after BNP. However, when GFR was included in 
the model, the predictive power of uric acid was completely lost and was replaced by 
furosemide dose and GFR. 
Conclusions: Whereas uric acid is an important univariate predictor of mortality in HF, 
its effects appear to depend on renal function.
Uric acid (per 20 Âµmol/L) GFR (ml/min/1.73m2)
RR (95% CI) p-Value RR (95% CI) p-Value
Baseline (n=5003) 1.051 (1.041-1.061) <0.001 Baseline (n=5002) 0.971 (0.967-0.975) <0.001
Change - baseline to 
12 months (n=3936) 1.017 (0.998-1.037 0.087
Change - baseline to 
12 months (n=3934) 0.982 (0.973-0.991) <0.001
1075-177 Electrocardiographic Left Ventricular Hypertrophy is 
Associated With Worse Clinical Outcomes in Heart 
Failure: Evidence From the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity 
(CHARM) Programme
Nathaniel M. Hawkins, Duolao Wang, Stuart J. Pocock, John J. V. McMurray, Marc A. 
Pfeffer, Karl Swedberg, Christopher B. Granger, Salim Yusuf, Francis G. Dunn, CHARM 
Investigators and Committees, Glasgow, United Kingdom
Background: Electrocardiographic left ventricular hypertrophy (ECG LVH) is a powerful 
independent predictor of cardiovascular morbidity and mortality in hypertension. The 
contemporary prevalence and prognostic implications of ECG LVH in a broad spectrum of 
patients with chronic heart failure (CHF) with and without reduced left ventricular ejection 
fraction (LVEF) is unknown.
Methods: The Candesartan in Heart failure: Assessment of Reduction in Mortality and 
morbidity (CHARM) programme randomized patients with CHF into one of three parallel 
clinical trials according to LVEF and angiotensin converting enzyme inhibitor (ACE-I) 
treatment: CHARM-Preserved LVEF > 0.40; CHARM-Alternative LVEF ≤ 0.40 and ACE-I 
intolerant; and CHARM-Added LVEF ≤ 0.40 and ACE-I treated. The primary outcome 
comprised cardiovascular death or hospital admission for worsening CHF. Secondary 
endpoints included cardiovascular death, death from any cause, hospital admission for 
CHF, non-fatal myocardial infarction and stroke. The median follow-up was 37.7 months. 
Investigators completed a structured report on electrocardiographic ﬁndings on all 
patients at baseline. The relationship between ECG LVH and outcome was examined in a 
Cox model, adjusting for up to 30 co-variates of prognostic importance.
Results: The prevalence of ECG LVH was similar in all 3 CHARM trials (overall 15.7%), 
despite a more frequent history of hypertension in CHARM-Preserved. However, in each 
trial, patients with ECG LVH had a higher baseline blood pressure than those without 
(difference 4.9/2.2 mmHg overall, p<0.0001). In the overall CHARM programme, ECG 
LVH was an independent predictor of worse prognosis: relative risk of primary outcome 
1.13 (95% conﬁdence interval 1.02-1.26), p=0.023. ECG LVH was also associated 
with an increased risk of non-fatal myocardial infarction: 1.52 (1.12-2.06), p=0.008 and 
hospitalization for CHF: 1.13 (0.99-1.30), p=0.070.
Conclusion: ECG LVH was equally common in patients with CHF regardless of LVEF. The 
simple clinical ﬁnding of ECG LVH was an independent predictor of a worse clinical outcome 
in a broad spectrum of patients with CHF receiving extensive contemporary treatment.
1075-178 Prognosis Determination in Heart Failure: Effects of 
Aggressive Therapy
Carrie Geisberg, Joann Goring, Ghazanfar Khadim, Kimberly Champney, Javed Butler, 
Vanderbilt University, Nashville, TN
Background: Most recent studies assessing heart failure (HF) prognosis have been 
cross sectional in design where medical therapy was not maximized in all eligible patients. 
In this study, we sought to assess the relative prognostic value of peak VO2 in relation to 
medical therapy in a contemporary group of HF patients treated from 1999-2003.
Methods: We assessed the event-free (death+ventricular assist device placement) 
survival, based on peak VO2, at one year among 362 HF patients. Outcomes were also 
assessed in two sub-groups: group I (n=156) patients on maximal care deﬁned as: on 
therapy (unless speciﬁc allergy or intolerance documented) with ACE inhibitor (ACEI), at 
least 50% of recommended dose of beta-blockers (BB) unless hypotensive or bradycardic, 
spironolactone (RALES criteria plus BB criteria), and deﬁbrillator (MADIT II criteria with 
QRS duration >120 msec), and group II (n=34) comprising group I patients with BiV pacer 
implantation (COMPANION criteria).
Results: Mean duration of follow-up was 448±295 days. Mean age of the study population 
was 55±11 years, ejection fraction was 23±08%, and peak VO2 was 12.4±3.6 ml/min/kg. 
One-year event-free survival for patients based on peak VO2 was as follows: peak VO2 <10 
ml/min/kg (n=87, 24%) 65%, peak VO2 10-14 ml/min/kg (n=156, 43%) 81%, and peak VO2 
>14 ml/min/kg (n=119, 33%) 90%. Sub-group analysis of Group I patients with peak VO2 
<10 ml/min/kg (n=40) showed 72%, those with peak VO2 10-14 ml/min/kg (n=74) 91%, 
and those peak VO2 >14 ml/min/kg (n=42) 94% one-year event free survival. Group II 
patients with peak VO2 between 10-14 ml/min/kg had had 90% 1-year event free survival. 
Patients in group I who were not on ACEI or BB therapy due to intolerance (excluding 
allergies) had the worst survival (peak VO2 10-14, 74% 1-year event free survival).
Conclusion: Assessment of adequacy of medical therapy is essential prior determining 
HF prognosis for e.g. transplant eligibility. Cross sectional determination without therapy 
consideration may be misleading. Aggressive medical therapy in many patients currently 
considered eligible for transplant is associated with outcomes similar to or better than with 
medical therapy as compared to transplantation.
1075-179 Long-Term Prognosis of Patients With CHF Associated 
With Depression
Wei Jiang, Maragatha Kuchibhatla, Michael S. Cuffe, Greg L. Clary, Eric Christopher, 
Jude Alex, Ranga R. Krishnan, Christoher M. O’Connor, Duke University Medical Center, 
Durham, NC
Background: Results of previous studies demonstrated that depression is associated 
with increased short-term mortality in patients with chronic heart failure (CHF). This study 
designed to examine the effects of depression on the long-term prognosis of CHF patients 
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and to explore which cut-off value of Beck Depression Inventory (BDI) scale to better 
predict the outcome of CHF.
Method: We measured symptoms of depression using the BDI scale in a sample of 
1005 patients with CHF when they were hospitalized because of various cardiac events. 
We then followed these patients for all cause mortality during a 7-year period. Cox-
proportional hazard model was utilized to assess the predictability of depression for long-
term mortality. We compared the mortality of CHF patients with the existing cut-off BDI 
score (≥10) as well as with other possible cut-off points to explore the best predictability 
of depression. The interaction of other risk factors with depression and mortality were 
also investigated.
Result: The mean BDI score is 8.0±6.95 for the entire sample. The average days of 
follow-up was 971±730. BDI score was linearly associated with increased long-term 
mortality (Hazard ratio (HR) = 1.02, p=0.002). HR was 1.44 for patients whose BDI scores 
≥10 (p=0.0004). The highest HR (HR=1.51) was yielded when the cut-off BDI score was 
set at ≥7 (p=<0.0001). The adverse association of depression and increased long-term 
mortality was independent of age, marriage, cardiac function, and etiology of CHF.
Conclusions: The results of this study demonstrate a long term adverse impact on 
the prognosis of patients with HF. Furthermore, the negative impact of depression on 
mortality begins at a low depressive level as measured by BDI, suggesting that even mild 
forms of depressive illness identify a subset of HF patients at high risk who may beneﬁt 
from aggressive HF/antidepressant therapy.
1075-180 Comparison of the Effects of Xanthine Oxidase 
Inhibitor, Allopurinol, and Uricosuric Agent, 
Benzbromarone, on Clinical Outcome in patients with 
Chronic Heart Failure and Hyperuricemia
Takahisa Yamada, Naoyuki Misaki, Mitsutoshi Asai, Nobuhiko Makino, Hidetaka Kioka, 
Yasumasa Tsukamoto, Shunsuke Tamaki, Masaharu Masuda, Takaki Matsumoto, Keiji 
Okuda, Masatake Fukunami, Osaka General Medical Center, Osaka, Japan
Background: Elevated serum uric acid is highly predictive of mortality in patients 
with chronic heart failure (CHF). Xanthine oxidase inhibitors (e.g., allopurinol(Allo)) or 
uricosuric agents (e.g., benzbromarone(Benz)) can lower elevated uric acid level, but 
it is unknown whether these agents reversibly impact clinical outcomes. We sought to 
compare the effects of Allo and Benz on mortality and morbidity in CHF patients with 
hyperuricemia.
Methods: We studied 85 consecutive patients admitted for worsening CHF (LV ejection 
fraction (LVEF):35±14%) with elevated serum uric acid (11.2±2.7 mg/dl). There were no 
signiﬁcant differences in age, gender, NYHA class, LVEF, serum creatinine level at the 
entry, serum uric acid level before and after the administration of these agents, or the 
content of anti-heart failure therapy between patients with Allo (n=47) and Benz (n=38).
Results: During the follow-up period of 30±21 months, hospitalization for worsening heart 
failure was signiﬁcantly infrequently observed in patients with Allo than those with Benz 
(34% vs 66%, p=0.0028, odds ratio 0.27, 95% CI 0.11-0.66). Cardiac and sudden death 
were signiﬁcantly infrequently observed in patients with Allo than those with Benz (cardiac 
death;11% vs 35%, p=0.0061, odds ratio 0.20, 95% CI 0.07-0.63, sudden death; 2% vs 
16%, p=0.018, odds ratio 0.12, 95% CI 0.01-1.01).
Conclusion: In CHF patients with hyperuricemia, allopurinol might improve the morbidity 
and mortality as compared with benzbromarone. 
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1076-165 Right Ventricular Myocardial Performance Index 
in Probands from the Multicenter Study of 
Arrhythmogenic Right Ventricular Dysplasia
Danita M. Yoerger, Frank Marcus, Duane Sherrill, Hugh Calkins, Wojciech Zareba, 
Jeffery A. Towbin, The Multicenter Study of Arrhythmogenic Right Ventricular Dysplasia 
Investigators, Michael H. Picard, Massachusetts General Hospital, Boston, MA, 
University of Arizona, Tucson, AZ
Background: Echocardiographic (echo) diagnosis of Arrhythmogenic Right Ventricular 
(RV) Dysplasia (ARVD) remains challenging. Two-dimensional (2-D) echo assessment of 
RV function can be limited by inadequate visualization of RV walls due to the RV geometry. 
The myocardial performance index (MPI) is a simple Doppler measure of myocardial 
function that does not rely on geometric assumptions. The purpose of this study was 
to assess the utility of the RV MPI in ARVD. Methods: Detailed echocardiograms were 
performed in 19 probands and analyzed at a core laboratory and compared to 19 normal 
controls matched for age, sex, body size and year of echo. RV systolic function was 
calculated as RV fractional area change (FAC). RV MPI was calculated as the ratio of 
Doppler-derived tricuspid regurgitation duration minus pulmonary outﬂow duration 
(PVD) divided by PVD. Results: The mean age was 35.6 ± 14.5 years and 68% were 
male. There were signiﬁcant differences in RV dimensions and FAC between the 2 
groups. The MPI was signiﬁcantly increased in ARVD probands compared with controls 
(Table). In the subgroup of probands with normal FAC (n=6), the MPI was signiﬁcantly 
increased compared with the matched controls (0.31 ± 0.13 versus 0.14 ± 0.06, p=0.04) 
Conclusions: RV MPI is signiﬁcantly increased in ARVD probands versus controls and 
could differentiate probands from controls even when FAC is normal. The RV MPI may be 
useful as an adjunct to 2-D imaging for the assessment of RV function in ARVD.
Indices of RV Size and Function 
ARVD Probands (n=19) Matched Controls(n=19) P-value
RVOT end-diastolic dimension 
(mm) 37.4 ± 6.3 26.1 ± 5.2 <0.00001
RV FAC (%) 29.6 ± 14.2 40.5 ± 6.9 0.0095
RV MPI 0.32 ± 0.15 0.16 ± 0.08 0.006
1076-166 Diagnosis of Arrhythmogenic Right Ventricular 
Cardiomyopathy by 3 Different Sets of Criteria.
Philippine Kiès, Marianne Bootsma, Jeroen J. Bax, Katja Zeppenfeld, Annemarie E. de 
Koning, Fleur Vriend, Ernst E. van der Wall, Martin J. Schalij, Leiden University Medical 
Center, Leiden, The Netherlands
Introduction: Diagnosis of arrhythmogenic right ventricular dysplasia / cardiomyopathy 
(ARVD/C) has major implications for the management of patients and their ﬁrst-degree 
relatives. Diagnosis may be difﬁcult and is based on a set of criteria proposed by the 
International Task Force (TF) for Cardiomyopathies in 1994. More recently, diagnostic 
criteria based on MRI or ECG only have been suggested in the literature. We evaluated 
the consistency in outcome between 3 different sets of diagnostic criteria.
Methods and Results: A total of 52 patients (33 male, mean age 46±11 yrs) were evaluated 
for the possible occurrence of ARVD. Patients were evaluated because of ventricular 
arrhythmias (16), palpitations/ (pre) syncope (31), ECG changes during routine analysis 
(4) or a family history of ARVD (1). All patients were analysed based on the TF-, MRI- and 
ECG criteria and their concordance was calculated. According to the TF-criteria 27 (52%) 
patients were diagnosed with ARVD. MRI was performed in 45 (86%) patients (7 patients 
were excluded because of prior ICD implant) of whom 20 (45%) were diagnosed with ARVD. 
Twenty patients (39%) fulﬁlled the ECG criteria for ARVD. A moderate concordance was 
found between diagnoses based on the TF- and the MRI criteria (kappa = 0.49) and a fair 
concordance was found between the TF- and the ECG-criteria (kappa=0.25). We found only 
a slight concordance between the MRI-and ECG diagnoses (kappa=0.08).
Conclusion: These results indicate that there is not a strong concordance between the 
3 diagnostic sets. Therefore we conclude that the clinical diagnosis of ARVD has to be 
based on TF-criteria, and cannot be replaced by a single diagnostic technique.
1076-167 Regional Contractility Is Reduced and Phase 
Heterogeneity of Tissue Doppler Is Increased in Isolated 
Noncompaction of the Ventricular Myocardium
Brian D. Hoit, Oleg Chebotarev, Keith Fox, Rebecca Ameduri, Frank V. Brozovich, Mark 
T. Johnson, Case Western Reserve University, Cleveland, OH, University Hospitals of 
Cleveland, Cleveland, OH
Background Isolated noncompaction of the ventricular myocardium (INVM) is an 
increasingly recognized form of heritable cardiomyopathy characterized by highly 
trabeculated myocardium and LV chamber dysfunction. However, myocardial contractile 
abnormalities in this disorder are poorly deﬁned.
Methods Affected members from a kindred with INVM (n=6) were compared to age-
matched controls (n= 8) with tissue Doppler strain analysis using a GE Vivid 7 and 
dedicated software. Tissue Doppler velocity, longitudinal strain (S, cm) and strain rates 
(SR, 1/s) from the 4-and 2-chamber apical views were averaged over 3 cycles at base, 
mid, and apical LV sites. In addition, basal and mid lateral LV tissue Doppler velocities 
curves were correlated over 3 cycles every 10 ms to obtain a novel index of cardiac phase 
heterogeneity.
Results S and SR were regionally and only modestly reduced in INVM compared to 
controls, affecting the basal and apical (but not mid-LV) segments: 
S Base S Mid S Apex SR Base SR Mid SR Apex
INVM 15.7±6.5* 16.9±6.6 9.9±5.9* 1.3±0.5* 1.4±1.1 0.8±0.8*
Controls 20.9±4.8 17.9±6.3 14.1±6.9 1.7±0.6 1.4±0.3 1.2±0.5
*p<0.05 vs controls
Phase heterogeneity correlation coefﬁcients were signiﬁcantly and strikingly lower in 
INVM than control (.76± .09 (SD) vs .93± .02, p<0.001), suggesting dyssynchronous 
contraction and relaxation. The correlation between LV ejection fraction (range: 23-61%) 
and heterogeneity coefﬁcient was poor (r= .41, p=n.s.).
Conclusion. Thus, regional myocardial contractility is impaired in INVM, and with 
spatiotemporal heterogeneity of contraction and relaxation, may underlie the abnormal 
chamber function in this disorder.
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1076-168 Corticosteroid Therapy Prevents Cardiac Remodeling 
and Improves the Prognosis in Patients With Cardiac 
Sarcoidosis
Hideo Okamura, Shiro Kamakura, Satoshi Nakatani, Kazuhiro Satomi, Kazuhiro 
Suyama, Wataru Shimizu, Takashi Kurita, Naohiko Aihara, National Cardiovascular 
Center, Suita, Japan
Background : Corticosteroid therapy for patients with cardiac sarcoidosis is widely 
accepted, but how much it affects on the cardiac function and the prognosis is not fully 
investigated. In this study, we compared patients treated with corticosteroid to those 
treated without it aiming to conﬁrm its beneﬁcial effect and to provide the information on 
the patient selection.
Methods : We studied 23 patients who were treated with oral corticosteroid (steroid group) 
and 15 patients treated without it (control group) retrospectively on their echocardiographic 
data and the incidences of death on any cause or repeated hospitalization due to heart 
failure. Patients were divided into two subgroups according to the diastolic diameter of the 
left ventricle (LVDd) ≤54mm or >54mm at the point of diagnosis. The changes of LVDd and 
percent fraction of shortening (%FS) in each group and in each subgroup were examined.
Results : LVDd increased from 49 to 57mm in the control subgroup≤54mm (p=0.043) in 
contrast to the steroid subgroup≤54mm (p=0.29). On the other hand, LVDd increased in 
the steroid subgroup>54mm from 61to 68mm (p<0.01), not in the control subgroup>54mm 
(p=0.36). The change of %FS did not reach the statistical difference. The event-free survival 
was 22% in the control group and 59% in the steroid group (p=0.014). More patients in the 
control group suffered the events in the early period than in the steroid group.
Conclusion : Corticoteroid therapy not only prevents the cardiac remodeling but also 
improves the prognosis in patients with cardiac sarcoidosis.
1076-169 Genotype-Phenotype Correlations in Familial 
Amyloidotic Cardiomopathy
Letizia Riva, Enrica Perugini, Fabrizio Salvi, Letizia Bacchi Reggiani, Paolo Ciliberti, 
Alessandra Ferlini, Marinella Ferlito, Angelo Branzi, Claudio Rapezzi, University of 
Bologna, Bellaria Hospital, Bologna, Italy, S.Anna Hospital, Ferrara, Italy
Background. Transthyretin related amyloidosis (ATTR) is highly heterogenic both 
genotypically and phenotypically. We investigated associations between genotype and 
frequency/severity of cardiac involvement.
Methods. We analyzed clinical and echocardiographic ﬁndings of three groups of 
consecutive ATTR patients (follow-up, 24±26 mo) with different mutations.
Results. Deﬁnite cardiomyopathy was present in 4/8 (50%) patients with Val30Met; 7/7 
(100%) with Glu89Gln, and 15/21 (71%) with other mutations. Data on these patients are 
shown in the Table and Figure
Val30Met
(n=4)
Glu89Gln
(n=7)
Other mutations
(n=15) p value
Age (yr) 52 + 6 53 + 14 33 + 1 0.02
LV mass (g/sqm) 156 + 53 246 + 79 159 + 49 0.01
E wave Deceleration time (msec) 216 + 61 149 + 45 176 + 51 0.04
Neurological progression 3 (37%) 6 (86%) 5 (24%) 0.01
Liver and heart transplantation 0 4 (57%) 0 0.001
Conclusion. The Glu89Gln mutation is associated with a paticularly high frequency of 
severe myocardial involvement with major cardiovascular events. Combined heart/liver 
transplantation should be strongly considered for this subgroup.
1076-170 Selective Myocardial Uptake of 99mTc-DPD in 
Transthyretin-Related Amyloidosis: Implications for 
Recognition of Cardiac Involvement and Differential 
Diagnosis with AL Amyloidosis
Enrica Perugini, Claudio Rapezzi, Fabrizio Salvi, Letizia Riva, Paolo Ciliberti, Francesco 
Fallani, Pierluigi Guidalotti, Cinzia Pettinato, Letizia Bacchi Reggiani, Angelo Branzi, 
Policlinico S.Orsola, Bologna, Italy, Ospedale Bellaria, Bologna, Italy
Background We investigated the diagnostic value of 99mTc-DPD scintigraphy in the 
recognition of cardiac involvement in transthyretin-related, TTR, vs AL amyloidosis.
Patients and Methods Group A (TTR CA): 12 pts (59±16 yr) with DNA-proven TTR 
amyloidosis and echocardiographically demonstrated cardiac amyloidosis (CA) . Group 
B (AL CA): 6 pts with AL amyloidosis (56±7 yr) and CA. Group C (normal controls): 10 
subjects (64.2±12.2 yr) without any evidence of cardiac disease. Group D (amyloidosis 
without CA): 6 pts (46±15 yr) with either TTR mutations (n=4) or systemic AL amyloidosis 
(n=2) but no cardiac involvement The study population received 740 MBq of 99mTc-DPD 
i.v. Scans were conducted 5 min and 3 h after injection.
Results. Groups A and B were comparable as regards LV mass and renal function. 
99mTc-DPD uptake was strong in all pts in group A pts, but was absent in groups B, C and 
D. Group A pts were also submitted to 99mTc-MDP scintigraphy: no pt showed detectable 
myocardial uptake of this tracer.
Group A (TTR CA) Group B (AL CA) Group C (Controls)
Sensitivity % 100 0 /
Speciﬁcity % 100 100 /
Accuracy% 100 0 /
Whole body tracer retention % 71+ 13§ 69 + 6.3 56 + 11
Heart tracer retention % 7.3+ 1.7 *§ 3.9 + 0.8 3.1 + 0.7
Heart/whole body % 9.8 + 1.8 *§ 6.2 + 2.1 5.3 + 0.6
* p< 0.05 A vs B; § p< 0.05 A vs C (analysis of variance and Bonferroni t-test)
Conclusions: The etiology of amyloidosis is an important determinant of the scintigraphic 
variability in this disease. The selective uptake of 99mTc-DPD in patients with TTR CA 
could be used 1) for accurate diagnosis of cardiac involvement in patients known to have 
TTR amyloidosis, 2) as a ﬁrst step in the workup of differential diagnosis of TTR vs. AL 
etiology in pts with documented CA.
1076-171 Preclinical Impairment Of Coronary Flow Reserve In 
Patients With Rheumatoid Arthritis
Luigi Delﬁno, Maksim Llambro, Rossana Peretti, Daniela Mornati, Giuseppe De Blasio, 
Fabiola Atzeni, Piercarlo Sarzi-Puttini, Matteo Longhi, Maurizio Turiel, Galeazzi Institute, 
University of Milan, Milan, Italy
Background: Cardiovascular involvement in rheumatoid arthritis (RA) is common, 
although the true prevalence of cardiac abnormalities is difﬁcult to measure, as much 
disease remains clinically silent. The pathogenesis of cardiac lesions in RA is related 
to the primary disorder of microcirculation with diffuse arteriolar and capillary lesions. 
Previous studies demonstrated that coronary ﬂow reserve (CFR) is impaired in patients 
(pts) with connective tissue disorders. Our aim was to investigate whether CFR impairment 
is present in RA pts without clinical evidence of ischaemic heart disease.
Methods: We studied 41 RA pts (M 7, F 34; aged 61 ± 12 yrs, disease duration 93 ± 70 mts) and 
20 controls matched in age and gender. We evaluated CFR by transthoracic echocardiography 
in the anterior descending coronary artery at rest and after maximum vasodilatation by 
dipyridamole infusion (0.84 mg/ kg in 6’). CFR ≤ 2.5 was considered impaired.
Results: In RA pts, CFR was impaired (2.38 ± 0.64 vs 3.26 ± 0.67 in controls, p < 
0.005). A signiﬁcantly percentage of RA pts (59%) showed a CFR reduction (Table). Left 
ventricular mass and ejection fraction were not statistically different in the two groups. A 
non-signiﬁcant trend between mean CFR and duration of the disease was observed.
Conclusion: CFR is early reduced in RA pts without clinical evidence of heart disease as 
a result of impaired microcirculation. CFR is an useful technique able to follow up RA pts 
and to assess therapeutical effects on microcirculation.
Controls (n=20) RA pts (n=41) CFR > 2.5 (n=17) CFR ≤ 2.5 (n=24)
Parameters Rest Stress Rest Stress Rest Stress Rest Stress
S 0.13±0.05 0.28±0.14 0.17±0.03 0.34±0.13 0.17±0.03 0.37±0.14 0.18±0.04 0.32±0.12
D 0.19±0.05 0.64±0.25 0.29±0.07 0.67±0.2 0.26±0.06 0.77±0.16 0.31±0.08 0.61±0.2
DSVR 1.63±0.61 2.66±1.11 1.74±0.37 2.16±0.87 1.67±0.32 2.30±1.18 1.78±0.40 2.06±0.57
CFR 3.26±0.67 2.38±0.64 2.95±0.37 2.01±0.5
S=systolic peak; D=diastolic peak; DSVR=diastolic/systolic velocity rate.
1076-172 In-vivo Assessment Of Myocardial Force Frequency 
Relationships During Exercise In Children
Olli M. Pitkanen, Claudia Almeida, Michael Cheung, Lee Benson, Mikiko Shimizu, Anne 
Dipchand, Andrew Redington, Jeffrey Smallhorn, Hospital for Sick Children, Toronto, 
ON, Canada
Background: The myocardiac force frequency relationship (FFR) describes heart-rate 
related changes in contractility. It has not been previously measured non-invasively. 
Isovolumic wall acceleration (IVA) is a relatively load-independent tissue-Doppler (TDE) 
contractile index which we have used to measure FFR with atrial pacing. In this study we 
measured IVA in exercising healthy children and patients after anthracycline therapy to 
determine the FFR non-invasively. 
Methods: Healthy volunteers (n=33), and patients (n=5), aged 7-17 years, underwent 
echocardiographic measurements at baseline and during exercise on a semi-supine 
adjustable cycle ergometer with continuous ECG and respiratory monitoring. Cineloops 
of TDE data were recorded in digital format at 15 bpm increments in HR up the target of 
160-170 bpm. IVA and systolic wall velocity (SWV) were measured off-line using Echopac 
software. Results: Baseline left ventricular EF of the patients was 50 + 12%. The Z-scores 
for LVEDD, LA-size, VCFc were 0.8 + 0.8, 0.5 + 0.6, and 1.0 + 0.2 (circ/s), respectively, 
reﬂecting apparently normal cardiac function in all subjects. However, patients had 
a signiﬁcantly attenuated response of IVA to exercise (p<0.05; analysis of covariance, 
Fig), whereas SWV was similar to controls. Conclusion: Ventricular myocardial FFR’s can 
be assessed by measuring IVA during exercise. This non-invasive technique may prove 
useful in detection of occult cardiomyopathy. 
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1077-161 The Inﬂuence of Age, Gender and Training on Aerobic 
Capacity and Exercise Efﬁciency
Joan S. Woo, Christina Derleth, John R. Stratton, Wayne C. Levy, University of 
Washington, Seattle, WA
Background: Although many studies have demonstrated a decrease in aerobic function 
with aging, few have examined the inﬂuence of gender, and none have characterized the 
combined effects of aging, gender and training on exercise efﬁciency (energy output/
energy input).
Methods: 61 healthy subjects, divided into 4 groups of younger women (20-33 years, 
n=15), younger men (20-30 years, n=12), older women (65-79 years, n=16), and older 
men (65-77 years, n=18), underwent cardiopulmonary exercise testing (CPET) to analyze 
aerobic parameters before and after 3-6 months of supervised aerobic exercise training.
Results: Younger subjects had a 42% higher peak VO2 (ml/kg) than older subjects 
(p<0.0001) before exercise training. At baseline, the elderly had an 8% lower efﬁciency (20.4 
± 3.7% vs. 22.2 ± 2.4%, p=0.03) and a 17% higher O2 debt (20.8 ± 4.3% vs. 17.7 ± 5.0%, 
p=0.012) than the young. Peak VO2 was 32% higher (p<0.0001) in men than in women at 
baseline. In all subjects, training resulted in an increase in peak VO2 (+14%, p<0.0001), an 
increase in peak Watts/kg (+21%, p<0.0001), a decrease in the O2 debt (-24%, p<0.0001), 
and an improvement in exercise efﬁciency (+17%, p<0.0001). An age effect was seen in 
combination with these training effects, with older subjects displaying a larger increase in 
peak Watts/kg (+27% vs. +12%, p=0.001) and a larger decrease in O2 debt (-28% vs. -17%, 
p=0.01) than the young. The older subjects also showed a signiﬁcantly larger increase in 
exercise efﬁciency (absolute increase of 6% vs. 1%, p<0.0001), but a smaller increase in 
peak VO2 (+11% vs. +15%, p<0.003) with training as compared to the young.
Conclusion: Older age is associated with a marked decline in aerobic capacity. The age-
related decline is also associated with decreased exercise efﬁciency and an increased 
O2 debt. This translates into a higher VO2 and a greater O2 debt during matched absolute 
workloads in the elderly. These age-related changes may be reversed with aerobic 
exercise training, which improves exercise efﬁciency and lowers the O2 debt to a greater 
degree in the elderly than in the young.
1077-162 Biochemical Evidence of Myocardial Injury Among 
Participants in Endurance Sports
Malissa Wood, Tom G. Neilan, Danita Yoerger, Kent Lewandrowski, Arthur Siegel, 
Elizabeth Lewandrowski, Michael Picard, James Januzzi, Massachusetts General 
Hospital, Boston, MA
Background: Rare deaths have been reported with marathon running. While some 
deaths have been attributed to hyponatremia, the contribution of myocardial injury remains 
unclear. We sought to determine whether biochemical evidence of myocardial injury could 
be demonstrated following completion of a marathon and its possible association with 
hyponatremia.
Methods: We recruited 35 Boston Marathon runners. Testing, including serum N-terminal 
proBNP (NTproBNP), troponin T (cTnT), C-reactive protein (CRP), ischemia modiﬁed 
albumin (IMA) and serum Na, was performed prior to and immediately post marathon. 
Results: The group included 22 males and 13 females with a mean age of 34.3±9.3 
years and mean ﬁnish time of 4 hours 24± 48 min. Signiﬁcant changes in mean heart rate 
(63.9± 11.9 pre to 102.7±15 beats/minute post (p<0.0001) and weight (69.4±10.8 kg pre 
to 66±15.5 kg post (p=0.05) were observed. Signiﬁcant increases in cTnT and NT-proBNP 
and decreases in Na and IMA were observed; CRP did not change (table). Post Na was 
not correlated with levels of cTNT or NT-proBNP. Age was positively correlated with the 
post NT-proBNP (r2=0.11, p=0.049). Finish time did not correlate with NT-proBNP, cTnT, 
CRP, IMA or Na. 
Conclusions: Biochemical evidence of myocardial injury was demonstrated in marathon 
runners and was not related to change in Na. The mechanism of cardiac injury may not be 
due to myocardial ischemia, as IMA, a sensitive marker of ischemia, fell following exercise.
Mean Changes in Serum Biomarkers 
Pre Post p value
cTnT (ng/ml) <0.010 0.127±0.21 <0.0001
NT-pro BNP (pg/ml) 33.9± 23.6 152.1±109 <0.0001
Na (mg/dl) 138.8±2.2 137.5±3.1 p=NS
IMA (units) 94.4±7.4 73.5±10.3 <0.0001
CRP (mg/L) 1.2±1.3 1.3±1.4 p=NS
1077-163 Exercise Training Improves Hemodynamic And 
Oxidative Stress Proﬁle After Estrogen Privation
Katia De Angelis, Janaina Paulini, Karin Flues, Lucinar JF Flores, Adriane Bello-Klein, 
Maria Claudia Irigoyen, Heart Institute (InCor), Medical School, University of Sao Paulo, 
Sao Paulo, Brazil, Sao Judas Tadeu University and Federal University of Rio Grande do 
Sul, Sao Paulo and Porto Alegre, Brazil
The protection of young women from coronary events is sharply reduced with menopause. 
Oxidative stress and impairment in baroreﬂex control of circulation have been 
demonstrated to increase cardiovascular risk. On the other hand exercise training has 
been indicated as non-pharmacological treatment for many cardiovascular and metabolic 
diseases. The aim of the present study was to evaluate the effects of exercise training on 
blood pressure, heart rate, baroreﬂex sensitivity and oxidative stress in ovariectomized 
rats. Female Wistar rats (251 ± 10g) were divided in sedentary ovariectomized (SO, n=8) 
and trained ovariectomized (TO, n=7). TO group was submitted to an exercise training 
protocol on treadmill for 8 weeks (1h/day; 5 days/week). After training period, blood 
pressure signals were recorded in conscious animals using a data acquisition system 
(CODAS, 1 KHz). The baroreﬂex sensitivity was evaluated by the tachycardic (TR) and 
bradycardic (BR) reﬂex responses to arterial pressure changes induced by sodium 
nitroprusside and phenylephrine crescent doses injections, respectively. Oxidative stress 
was evaluated by chemiluminescence (CL) in myocardium and in gastrocnemius muscle. 
The TO group showed mean arterial pressure reduction (111 ± 2 mmHg) as compared 
to SO group (124 ± 3 mmHg). Exercise training induced resting bradycardia (325 ± 4 vs. 
356 ± 12 bpm in SO) and improvement in TR (4.4 ± 0.6 vs 2.8 ± 0.4 bpm/mmHg in SO) 
and BR (-2 ± 0.1 vs. -1.2 ± 0.2 bpm/mmHg in SO) in TO rats when compared to SO rats. 
The myocardium and gastrocnemius CL were reduced in TO animals (5895 ± 126 and 
1562 ± 217 cps/mg protein) in relation to SO animals (6980 ± 218 and 2306 ± 149 cps/mg 
protein). Myocardium CL was inversely correlated with the TR (r=-0.8) and the BR (r=-
0.7). These results indicated that exercise training in ovariectomized female rats induces 
improvement in resting hemodynamic status and in reﬂex control of circulation probably 
associated with the oxidative stress reduction, suggesting a homeostatic role of exercise 
training in reducing cardiovascular risk in postmenopause women.
Financial Support: FAPESP, E.J. Zerbini Foundation, USJT.
1077-164 Arterial Wave Reﬂection is Associated with 
Cardiorespiratory Fitness in Men
Josepha Binder, James Seward, Takamu Kunihiro, Kent Bailey, Ray W. Squires, Donald 
Hensrud, Iftikhar J. Kullo, Mayo Clinic, Rochester, MN
Background. By increasing myocardial work, increased arterial wave reﬂection may 
limit exercise capacity. We investigated whether the aortic augmentation index (AIX), a 
measure of arterial wave reﬂection, is associated with cardiorespiratory ﬁtness in men 
without known coronary heart disease (CHD).
Methods. We studied 201 asymptomatic men (mean age 51±9.2 years) referred for 
screening exercise electrocardiography. Subjects with exercise electrocardiograms 
suggestive of ischemia were excluded. A physical activity score was generated from a 
validated physical activity questionnaire. Radial artery pulse waveforms were obtained 
by applanation tonometry and an ascending aortic pressure waveform was derived by 
a validated transfer function. AIX is the difference between the ﬁrst and second systolic 
peak of the ascending aortic pressure waveform, expressed as a percentage of the 
pulse pressure. Cardiorespiratory ﬁtness was assessed by maximal oxygen consumption 
(VO2max, L/min) during a symptom-limited graded exercise test. Multiple regression models 
were constructed to identify signiﬁcant determinants of AIX and VO2max.
Results. Type II diabetes was present in 5% of subjects, 34% had history of smoking, 
and 46% were hypertensive. Mean AIX was 20.0±9.0 and mean VO2 max was 3.01±0.52 
L/min In a multiple regression model, age, systolic blood pressure, and history of smoking 
were associated with greater AIX, whereas heart rate, height, and body mass index 
(BMI) were associated with lower AIX. After adjustment for age, heart rate, height, and 
BMI, augmentation index was signiﬁcantly (P=0.003) associated with VO2 max. Each 10% 
increase in augmentation index was associated with a 3.6% reduction in VO2 max. The 
association remained signiﬁcant (P=0.035) after additional adjustment for the physical 
activity score and history of smoking.
Conclusion. These ﬁndings indicate that increased arterial wave reﬂection is associated 
with decreased cardiorespiratory ﬁtness. Causality cannot be inferred in this cross-
sectional study but a possible mechanism may be an increase in cardiac work, limiting 
maximal cardiac output during exercise.
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ORAL CONTRIBUTIONS
810  Cardiac Transplantation: Rejection and 
Remodeling
Monday, March 07, 2005, 11:00 a.m.-12:15 p.m.
Orange County Convention Center, Room 414C
11:00 a.m.
810-3 Doppler Evaluation of Cardiac Allograft Dysfunction 
in Long-Term Heart Transplantation Recipients With 
Normal Coronary Angiograms
Francesco Tona, Alida LP Caforio, Antonio Gambino, Giuseppe Feltrin, Giuseppe 
Toscano, Diego Calzolari, Cristiano Sarais, Omar Pacagnella, Annalisa Vinci, Maria 
Grazia Leone, Annalisa Angelini, Angelo Ramondo, Gaetano Thiene, Gino Gerosa, 
Sabino Iliceto, Cardiology, University of Padova, Padova, Italy, Cardiovascular Surgery, 
University of Padova, Padova, Italy
Background. Chronic cardiac allograft dysfunction with normal coronary angiograms 
is poorly understood. We studied Doppler-derived systolic and diastolic function indexes 
in long-term heart transplantation, to identify early non-invasive markers of allograft 
dysfunction. 
Methods. We studied 154 stable heart transplantation recipients (125 male, aged 51 ± 
13 years) with normal left ventricular echocardiographic ejection fraction (63 ± 6 %), free 
from acute rejection and without allograft vasculopathy. Doppler parameters were: mitral 
E and A wave velocities, E/A ratio, mitral deceleration time (DT), isovolumic relaxation 
time (IVRT), isovolumic contraction time (IVCT), ejection time (ET) and Tei index (IVCT 
+ IVRT/ET). Mean follow up from heart transplantation to Doppler examination was 6.6 
± 4.3 years. Rejection scores (RS) on endomyocardial biopsy were calculated (ISHLT 
grades: 0=0; 1A=1; 1B=2; 2=3; 3A=4; 3B=5; 4=6) in the ﬁrst year, in the second year and 
during the whole follow-up. RS including only severe grades (≥3A) were also calculated. 
Pearson’s test was used to correlate quantitative data. 
Results. E/A ratio and Tei index were inversely related with donor age (r=-198, p=0.02 
and r=-232, p=0.004 respectively) and directly related with mean time from heart 
transplantation (r=190, p=0.03 and r=309, p<0.0001 respectively). IVRT was inversely 
related with ischemic time and with RS in the second year (r=-213, p=0.01 and r=-0.202, 
p=0.02). DT was inversely related with RS in the ﬁrst year, in the whole follow up, and 
with RS including only severe grades in the ﬁrst year and in the whole follow-up (r=-207, 
p=0.002; r=-261, p=0.01; r=-224, p=0.006 and r=-220, p=0.04 respectively). Tei index was 
directly related with all RS and RS for severe grades in the ﬁrst year (r=209, p=0.01 and 
r=242, p=0.005 respectively). 
Conclusion. These correlations suggest a progressive impairment of myocardial 
performance, directly associated with acute rejection burden, in long-term heart 
transplantation recipients free from cardiac allograft vasculopathy and with normal left 
ventricular ejection fraction. This may indicate early graft dysfunction, reﬂecting subtle 
chronic rejection changes.
11:15 a.m.
810-4 Coronary Endothelial Dysfunction in Cardiac Transplant 
Recipients is Related to Elevated Levels of ADMA
William F. Fearon, Bing-yin Wang, Atsushi Hirohata, Mamoo Nakamura, Luciano Potena, 
Hannah A. Valantine, Alan C. Yeung, John P. Cooke, Stanford University, Stanford, CA
Background: The pathophysiology and course of coronary endothelial dysfunction after 
cardiac transplantation (Tx) remains incompletely deﬁned. Elevated levels of asymmetric 
dimethylarginine (ADMA), the endogenous inhibitor of the nitric oxide synthase (NOS) 
pathway, may play a role.
Methods: Coronary angiogaphy was performed in 55 recent cardiac transplant recipients. 
Quantitative coronary angiography of the proximal left anterior descending artery (LAD) 
was performed at baseline and after an intracoronary bolus of acetylcholine (Ach; 50ug). 
Aortic and coronary sinus blood was drawn for calculation of basal and stimulated plasma 
nitrogen oxide (NOx) levels using the Griess reaction, and ADMA levels using ELISA.
Results: Of the 55 cases, 28 were within 8 weeks of Tx, 19 were 1 year post-Tx, and 7 
were 2 years post-Tx. In the entire cohort there was signiﬁcant endothelial dysfunction 
based on paradoxical LAD vasoconstriction after Ach (mean LAD diameter decreased 
from 3.12 ±0.49 to 2.83 ±0.57 mm, p<0.001), on lack of change in transmyocardial NOx 
generation after Ach infusion (plasma levels of NOx in the coronary sinus versus aorta, 
64.8 ±28.5 vs. 60.9 ±30.7 µM, p=NS), indicating severe inhibition of endothelial nitric oxide 
synthesis, and on elevated mean ADMA levels (0.77 ±0.28 µmol/L, normal ≤0.60 µmol/L 
for this assay). By contrast, endothelium-independent vasodilation to nitroglycerin was 
preserved (mean LAD diameter increased from 3.12 ±0.49 to 3.31 ±0.38 mm, p<0.001). 
The 19 cases which were 1 year post-Tx had similar evidence of signiﬁcant endothelial 
dysfunction. By contrast, the 7 cases which were 2 years post-Tx had less prominent 
vasoconstriction after Ach (2.75 ±0.58 to 2.58 ±0.53 mm, p=NS) and manifested an 
increase in transmyocardial NOx generation (36.3 ±12.5 vs. 52.3 ±25.4 µM, p=0.26). The 
mean ADMA level was signiﬁcantly lower at 2 years post-Tx compared to the level within 
8 weeks of Tx (0.58 ±0.18 vs. 0.85 ±0.25 µmol/L, p=0.03).
Conclusion: Endothelial dysfunction is present early and persists after cardiac 
transplantation with gradual improvement over time. The observed impairment of the NOS 
pathway is likely due to elevated levels of ADMA, the endogenous inhibitor of NOS.
11:30 a.m.
810-5 Increased Density of Chlamydia Pneumoniae but 
Not of Mycoplasma Pneumoniae in Graft Coronary 
Atherosclerosis
Nadia V. Sambiase, Maria L. Higuchi, Marcia M. Reis, Suely A. Palomino, José A.F. 
Ramires, Sergio A. Oliveira, Heart Institute (InCor), São Paulo, Brazil
Background: Co-infection by Chlamydia pneumoniae (CP) and Mycoplasma 
pneumoniae (MP) have been described in coronary fatty atheromas, and MP has been 
suggested to induce immunodepression, favoring CP proliferation. High amount of CP 
antigen was present mainly in adventitia in association with high number of lymphocytes. 
Here we tested the hypothesis that CP but not MP is increased in accelerated coronary 
graft atherosclerosis (ACGA), probably due to proliferation of pre-existent quiescent 
infection induced by immunosupression.
Methods: Epicardial coronary arteries from 35 autopsies of heart transplanted patients 
grouped according to the graft survival time: G0 (n=6): >3 days; GI (n=12): more 
than 3 and less than 160 days; GII (n=17): >160 days of transplant. Intimal and total 
vessel cross-sectional areas, mean numbers of CP+ cells/400x ﬁeld of adventitia (by 
immunohistochemistry) and % atheroma area of MP-DNA (by in situ hybridization) and 
adventitial inﬂammation (0=zero, + mild, ++ moderate and +++ severe) were evaluated.
Results: The mean numbers of CP+ cells /400x ﬁeld and of inﬂammation were 
respectively, in groups 0, I and II: 1.36 (+/-0.38); 15.45 (+/-8.09); 10.01 (+/-7.60) and 0.53 
(+/-0.94); 0.81 (+/-0.66); 1.10 (+/-0.92). There was signiﬁcant higher density of CP+ cells 
in groups I and II than in group 0 (p<0.001), and a positive correlation between: quantity 
of CP+ cells and inﬂammation (r=0.47, p<0.001); intimal vs total vessel areas (r=0.76, 
p<0.001) and intimal area vs graft survival time (r=0.47, p<0.05). The percentage mean 
areas of MP-DNA in the atheroma were respectively 0.65 +/- 0.51; 0.96 +/- 0.75 and 
0.78 +/- 0.66 without statistical difference (p=0.63). Group II showed a positive correlation 
between numbers of CP+ cells and adventitial inﬂammation (r=0.57; p<0.05) and also with 
intimal area (r=0.48, p=0,05). This group showed correlation between intimal and total 
vessel areas (r=0.84, p<0.001).
Conclusions: CP but not with MP is related with the intensity of ACGA. CP was present in 
almost all heart donnors and its proliferation could be related with the immunosupressive 
therapy. Differently from the usual atherosclerosis, MP does not have a role in ACGA.
11:45 a.m.
810-6 Vascular Remodeling Patterns One Year After Cardiac 
Transplantation.
Haiyan Li, Koji Tanaka, Ankush K. Chhabra, David Vadnais, Jon Kobashigawa, Jonathan 
Tobis, University of California Los Angeles, Los Angeles, CA
Background: The contribution of vascular remodeling and intimal hyperplasia as a cause 
for luminal narrowing in cardiac allograft vasculopathy (CAV) is controversial. The purpose 
of this study was to evaluate the relationship between vascular remodeling, intimal 
hyperplasia and luminal narrowing one year after orthotopic heart transplantation (OHT).
Methods and results: Serial intravascular ultrasound data was obtained in 190 recipients 
at baseline and at one year after OHT. We matched 625 segments from 190 coronary 
arteries between studies one year apart. In each segment, lumen area (LA), external 
elastic membrane area (EEM area), and intimal area (IA) were calculated. In the ﬁrst year 
post-OHT, the coronary artery LA decreased by 5.7%(ΔLA=-0.78±2.91mm2,p<0.0001) 
and the IA increased by 39.6%(ΔIA=0.74±1.76mm2, p<0.0001), but the average EEM 
area did not change signiﬁcantly (ΔEEM area=-0.04±2.71mm2, p=0.7). In segments 
with a decrease in LA of >10% there was a signiﬁcant decrease in EEM area (ΔEEM 
area=-2.09±2.55mm2, p<0.0001) and an increase in IA (ΔΙA=1.42±2.27 mm2, p<0.0001). 
In segments with a LA increase of >10%, the EEM area increased signiﬁcantly (ΔEEM 
area=2.75±2.30 mm2, p<0.0001) but the IA did not change signiﬁcantly (ΔIA=0.14±1.20 
mm2, p=0.2). Of the 625 segments, 52% had no remodeling, 25% were dilated and 
23% had EEM shrinkage in the presence of variable intimal growth (ΔIA=0.73±1.70mm2 
p<0.0001; ΔIA=1.23±2.02mm2, p<0.0001; ΔIA=0.20±1.40mm2, p=0.09, respectively). In 
76% of arteries, segments showed discordant remodeling patterns (positive and negative 
remodeling within different segments of the same artery).
Conclusions: In the ﬁrst year after OHT, remodeling occurs in 48% of segments and the 
majority of coronary arteries had discordant remodeling patterns. In segments with lumen 
loss, the contribution of change in EEM area was greater than that of intimal thickening. 
Compensatory enlargement (positive remodeling) is associated with intimal growth, but 
vessel shrinkage (negative remodeling) is not directly linked to any decrease in intimal 
hyperplasia. These results support the hypothesis that the decrease in EEM area is due 
to the inﬂammatory process of CAV.
Noon
810-7 Diltiazem Improves Survival in Heart Transplant 
Recipients: Stanford Experience
Shao-Zhou Gao, Bernard Cantin, Dada Weisshaar, Hemal Parekh, Sharon Hunt, John 
Schroeder, Stanford University School of Medicine, Stanford, CA, Kaiser Permanente, 
San Jose, CA
Background: Prior studies of diltiazem (CCB) showed retardation of coronary disease 
(CAD) in heart transplant (Tx) recipients. Effects of CCB on survival is unknown.
Methods: 598 adults had heart Tx between 7/87 and 12/01. Patients (pts) were grouped 
into, no CCB and no statin (n=176), no CCB with statin (n=47) and all CCB (n=375) 
users. Post-Tx drugs were: (7/87-12/93) cyclosporine, prednisone, azathioprine, OKT3, 
ganciclovir and diltiazem; with addition of. mycophenolate mofetil, tacrolimus and statin 
since 1/94. Cardiac death includes TX CAD and re-transplant for CAD.
Results: Freedom from all cause death (Kaplan-Meier) for all no CCB pts was 72%, 58% 
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and 55% (1,5,7 years) vs. 89%, 75% and 69% for CCB pts post-Tx (p<0.0001 by log-rank 
method). Freedom from cardiac death for all no CCB pts was 98%, 89% and 87% vs. 99%, 
95% and 93% in CCB pts (p=0.018). Comparison of all CCB pts, no CCB with statins 
pts and no CCB and no statins pts showed pts in the CCB group had lowest risk for all 
cause mortality (p<0.0001) and cardiac death (p=0.013), independent of statin use. Risk 
factors including recipient and donor age, rejection episodes, CMV infection and lipids 
were comparable between groups.
Conclusion: Diltiazem in heart Tx recipients lowers all cause and cardiac mortality 
rates.
ORAL CONTRIBUTIONS
811  Experimental Models of Heart Failure 
and Hypertrophy
Monday, March 07, 2005, 11:00 a.m.-12:15 p.m.
Orange County Convention Center, Room 230B
11:00 a.m.
811-3 mRNA Gene Expression and Protein Levels for 
Granulocyte Colony Stimulating Factor Are Increased in 
Left Ventricular Myocardium of Dogs With Heart Failure
Meiyi Huang, Sharad Rastogi, Victor G. Sharov, Ramesh C. Gupta, Makoto Imai, Hani N. 
Sabbah, Henry Ford Health System, Detroit, MI
Introduction: Granulocyte colony stimulating factor (G-CSF) is a cytokine that stimulates 
the survival, proliferation, and differentiation of primitive bone marrow stem cells. In mice 
with acute myocardial infarction secondary to coronary artery ligation, G-CSF-mediated 
translocation of bone marrow stem cells was shown to result in signiﬁcant myocardial 
tissue regeneration. In this study, we tested the hypothesis that mRNA and protein 
expression of G-CSF is increased in the failing left ventricle (LV) of dogs as a possible 
response to ongoing injury, degeneration and loss of cardiomyocytes. 
Methods: mRNA and protein expression of G-CSF were measured in LV myocardium 
of 6 dogs with heart failure (HF) produced by multiple sequential intracoronary 
microembolizations (LV ejection fraction <30%) and in LV myocardium of 6 normal (NL) 
dogs. Tissue samples from both groups were used to isolate total RNA. mRNA expression 
for G-CSF was measured using reverse transcriptase polymerase chain reaction (RT-
PCR). Protein expression was determined in SDS-extract of LV tissue homogenate using 
speciﬁc antibodies. Bands obtained from RT-PCR and Western blots were quantiﬁed in 
densitometeric units (du). 
Results: mRNA expression of G-CSF was signiﬁcantly increased in LV myocardium of HF 
dogs compared to NL dogs (37 ± 1 vs. 24 ± 2 du, p<0.05). Similarly, protein expression of 
G-CSF was signiﬁcantly increased in LV myocardium of HF dogs compared to NL dogs 
(33 ± 4 vs. 21 ± 3 du, p<0.05). 
Conclusions: In LV myocardium of dogs with experimentally-induced HF, mRNA and 
protein expression of G-CSF are upregulated. This ﬁnding may represent an intrinsic 
adaptation aimed at stimulating the translocation of primitive bone marrow stem cells 
to the failing myocardium to potentially counteract ongoing degeneration and loss of 
functional cardiomyocytes.
11:15 a.m.
811-4 Undifferentiated Human Embryonic Stem Cells Are Not 
Guided to Form New Myocardium by Transplantation 
into Normal and Infarcted Heart
Jonathan Leor, Sharon Gerecht-Nir, Smadar Cohen, Liron Miller, Parvin Zarin, Radka 
Holbova, Anna Ziskind, Michal Shachar, Esther Guetta, Joseph Itskovitz-Eldor, Neufeld 
Cardiac Research Institute, Tel-Hashomer, Israel
Background: We aimed to test the hypothesis that both the normal and infarcted heart 
will provide tissue speciﬁc milieu to guide differentiation of implanted undifferentiated 
human embryonic stem cells (hESCs) into mature myocardium.
Methods: Human ES cell lines H9.2 and I6 were grown on inactivated mouse embryonic 
ﬁbroblasts or cultivated in suspension to form differentiating human embryoid bodies 
(hEBs). hESCs (0.5-1x10e6); hEBs (4-8 days; 0.5-1x10e6); 0.1 mm pieces of ES-derived 
myocardial beating tissues or PBS (control) were injected into normal (n=18) or infarcted 
(n=9) myocardium of athymic nude rats either by direct injection into normal heart muscle, 
scar or into pre-implanted 3-D alginate scaffold sutured onto the heart. By two to four 
weeks after transplantation, heart sections were processed and examined to detect the 
presence of human donor cells and differentiation by ﬂuorescent in situ hybridization 
(FISH) using DNA probes speciﬁc for human sex chromosomes and HLA-DR or HLA-
ABC immunostaining.
Results: Microscope examination revealed that the implanted donor cells survived in 
the normal and, to a lesser extent in the infarcted myocardium (p<0.05). The donor cells 
developed into a conﬂuent connective tissue when implanted onto alginate scaffold. 
Positive HLA immunostaining was observed in a few vessels and cardiomyocytes 
suggesting rare differentiation of the engrafted hESCs or EBs into mature cardiomyocytes, 
endothelial or smooth muscle cells. Surprisingly, in one heart of seven animals treated 
with hESC-derived cardiomyocytes, typical teratoma had been developed at the site of 
implantation.
Conclusions: Undifferentiated human embryonic stem cells or ES-derived 
cardiomyocytes can survive transplantation into normal or infarcted myocardium of 
athymic nude rat. The implanted cells, however, are not directed to form new myocardium 
and may rarely form teratomas. Our work suggests that elimination of undifferentiated 
cells is critical prior to ES-derived cardiomyocyte transplantation into the heart.
11:30 a.m.
811-5 Non-Excitatory Cardiac Contractility Modulation Electric 
Signals Normalize Phosphorylation and Expression 
of the Sodium Calcium Exchanger in Left Ventricular 
Myocardium of Dogs with Heart Failure
Ramesh C. Gupta, Sudhish Mishra, Sharad Rastogi, Makato Imai, Walid Haddad, Yuval 
Mika, Hani N. Sabbah, Henry Ford Health System, Detroit, MI, Impulse Dynamics, 
Mount Laurel, NJ
Background: The sodium-calcium exchanger (NCX) is hyperphosphorylated in heart 
failure (HF) and its mRNA and tissue protein expression are up-regulated; maladaptations 
that can contribute to progression of HF. In HF dogs, delivery of non-excitatory cardiac 
contractility modulation (CCM) electric signals to LV muscle during the absolute refractory 
period improves LV function. This study explored whether this functional improvement is 
associated with normalized expression and phosphorylation of NCX (P-NCX). 
Methods: CCM signals were delivered for 4 hours from epicardial leads placed on the 
LV anterior wall (AW) of 6 dogs with microembolization-induced HF. At the end of therapy, 
total RNA was extracted from the LV AW. RNA was also extracted from LV AW of 6 normal 
(NL) and 6 dogs with untreated HF. mRNA expression for NCX was determined using RT-
PCR and normalized to GAPDH. Tissue homogenate was used to isolate phosphorylated 
proteins using a Phosphoprotein enrichment kit. Total and P-NCX protein were quantiﬁed 
using Western blots. P-NCX was normalized to total NCX protein. 
Results: Compared to NL, mRNA expression for NCX increased in untreated HF dogs. 
CCM normalized mRNA expression of NCX. Total and P-NCX protein increased in 
untreated HF dogs compared to NL. CCM normalized total and P-NCX (Table).
Conclusions: In HF dogs, short-term CCM therapy normalized P-NCX and NCX mRNA 
and protein expression. This ﬁnding may explain, in part, improvement of LV function seen 
in HF dogs during CCM therapy.
*=p<0.05 vs NL; **=p<0.05 vs HF-Untreated 
NL HF Untreated HF + CCM
NCX mRNA/GAPDH 2.11±0.13 3.83±0.11* 2.93±0.23**
Total NCX Protein 0.39±0.02 0.62±0.03* 0.43±0.02**
P-NCX/Total NCX Protein 0.41±0.03 0.83±0.06* 0.48±0.04**
11:45 a.m.
811-6 C-ﬂip, A Protein Required For Embryonic Heart 
Development, Is Markedly Increased In Pressure 
Overload Myocardial Hypertrophy.
Antonio Rapacciuolo, Emma Sanzari, Giovanni Esposito, Elisa di Pietro, Francesco 
Borgia, Luigi Di Seraﬁno, Emilia Mayo, Dario Leosco, Gerolama Condorelli, Massimo 
Chiariello, Division of Cardiology, Federico II university, Naples, Italy
Background: Cardiac hypertrophy (CH) is an independent risk factor in the development 
of heart failure (HF). A number of molecular mechanisms could be involved in the 
transition from CH to HF. C-Flip is a protein expressed mostly in kidney and heart. Both 
forms of C-Flip (long and short) have an antiapoptotic role interfering with caspase 8 
downstream signaling. C-Flip knock-out mice embryos do not survive past day 10.5 of 
embryogenesis exhibiting impaired heart development. No data are available regarding 
the actual role of C-Flip in the normal adult heart and in pathophysiological settings such 
as pressure overload CH.
Methods and results: 7 days after transverse aortic constriction (TAC) in C57Bl6 mice, 
a signiﬁcant increase in left ventricle to body weight ratio (3.20 in control animals (N=9) 
vs 4.82 in TAC animals (N=7), p<0.05) was associated to an increase of p-ERK1/2 and 
p-AKT already known to be activated by pressure overload. A signiﬁcant 2.2 fold increase 
(p<0.002) in total C-Flip expression was found by western blot after TAC especially in 
its long form (see ﬁgure). However, caspase 8 and caspase 3 were not activated. 
Conclusions: A signiﬁcant C-Flip increase occurs after TAC, in an apoptosis independent 
manner. The long and short forms are potentially recruited in different intracellular 
phenomena. It has been recently demonstrated that HF is associated to a reduction in 
C-Flip levels suggesting that the regulation of this molecule could be also important in the 
transition from CH to HF.
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811-7 Troponin I Phosphorylation Alterations Associated 
With Heart Failure Impair Left Ventricular Relaxation 
Response to Afterload, Force-frequency Response, and 
Systolic Function
Kenneth C. Bilchick, Jennifer G. Duncan, Eiki Takimoto, Hunter C. Champion, Linda B. 
Stull, David A. Kass, Anne M. Murphy, Johns Hopkins Medical Institutions, Baltimore, MD
In cardiac failure, the regulatory thin ﬁlament troponin I (TnI) displays reduced 
phosphorylation at protein kinase A (PKA) sites and increased phosphorylation at 
protein kinase C (PKC) sites. The speciﬁc functional consequences of these changes 
are unknown. Therefore we generated a transgenic (TG) mouse model with Ser22Ala/
Ser23Asp (PKA sites; partial dephosphorylation) and Ser42Asp/Ser44Asp (PKC sites; 
constitutive phosphorylation). Founders were genotyped and the two highest expressing 
lines bred, with partial replacement of mutant TnI conﬁrmed. TG mice had reduced 
fractional shortening (35±1% v. 41±2%, p=0.02) but no chamber dilation. In vivo cardiac 
pressure-volume studies were performed using graded descending aorta occlusion to 
vary afterload and assess the load-relaxation interaction. TG showed delayed relaxation 
(greater %�tau) per change in afterload (Ea), (p<0.001 for TG v. NTG; Figure). This was 
unaltered by isoproterenol infusion. These data are consistent with our prior study in 
which mice having constitutively active PKA sites had reduced load-relaxation sensitivity. 
TG also had a blunted contractile response to increasing heart rate (400-800 min-1) (p< 
0.001 for TG v. NTG), but this was normalized by isoproterenol infusion consistent with a 
more dominant effect of phospholamban phosphorylation. Abnormal TnI phosphorylation 
as observed in cardiac failure may explain exacerbated relaxation delay in response to 
afterload and contribute to blunted chronotropic reserve. 
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1103  Heart Failure: Therapy
Monday, March 07, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 3:30 p.m.-4:30 p.m.
1103-143 Clinical Safety and Feasibility of G-CSF mobilized 
Peripheral Blood Stem Cell Therapy in Myocardial 
Infarction patients: MAGIC Cell investigator [Myocardial 
Regeneration and Angiogenesis in MI with G-CSF 
Mobilization and Intra-Coronary Cell Infusion]
Sang-Hoon Na, Hyun-Jai Cho, Shu-Ying Zhang, Hwa-Pyung Kim, Jin-Wook Chung, 
Joo-Yong Hahn, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Dae-Won Sohn, 
Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Sik Choi, Hyo-Soo Kim, Seoul 
National University Hospital, Seoul, South Korea
BACKGROUND: Intracoronary infusion of peripheral blood stem cells(PBSC) mobilized 
with G-CSF stimulation has been shown to improve cardiac function in myocardial 
infarction(MI)patients.Aging and other risk factors have been reported modifying factors 
for efﬁcacy of G-CSF induced PBSC mobilization in healthy bone marrow donor.We 
examined the safty and feasibility of G-CSF stimulated peripheral blood apheresis for 
stem cell source in MI patients. 
METHODS AND RESULTS: From Feb 2003 to Aug 2004, 51 MI patients were included 
in this study.PBSC apheresis product collections after G-CSF stimulation were performed 
with a COBE cell separator.FACS analysis was done with apheresis products.Study 
group was composed of 20 AMI and 31 OMI patients,with a mean[SD] age of 58.7[10.3].
During G-CSF injection and peri-apheresis period,we did not observe aggravation of 
angina,any ECG changes suggesting ischemia or substantial arrhythmia,or thrombotic 
complication.We collected 7.6[2.7]x109leucocytes(mononuclear cells:86.5%[12.0],CD34+ 
cells:9.7%[9.4]) during apheresis,and infused 1.43[0.4]x109collected leucocytes(volume: 
9.3 mL [3.7],1.32[1.34]x108CD34+cells) by over-the-wire balloon angioplasty catheter 
after PCI.In FACS analysis,apheresis cell products were composed of subpopulation 
of cells:KDR+(10.3%[10.9]), CD31+(50.5%[13.2]), vWF+(2.4%[4.9]), VE-cadherin+(1.
8%[3.6])[endothelial marker]; AC133+(1.1%[2.7]), CD34+(9.7%[9.4])[stem cell]; CD14
+(38.8%[19.3])[monocyte]; CD45+(94.1%[3.3])[common leukocytes]; SH2+/SH3+(0.34
%[0.52])[mesenchymal stem cells];and KDR+/CD34+(3.4%[5.3])[endothelial progenitor 
cells].Age,diabetes,hypertension,presence of acute ischemia,and LV dysfunction did not 
show any difference with collected stem cell population numbers in subgroup analysis. 
CONCLUSIONS: G-CSF injection and G-CSF stimulated apheresis show no adverse 
effect in MI patients. There is no signiﬁcant difference in mobilized stem cell population 
regardless of age, diabetes, presence of acute ischemia and LV dysfunction. This study 
suggests that G-CSF based PBSC therapy in MI is safe and feasible.
1103-144 Intracoronary Transplantation of Autologous Bone 
Marrow-Derived Mononuclear Cell (BMMC) Improves 
Outcomes of Patients With Refractory Chronic Heart 
Failure
Lian Ru Gao, Zhi ming Zhu, Zhi Guo Wang, Yu Xing Fei, Ye Yang, Sheng He, Zhang You 
Huang, Yu Cheng, Navy General Hospital, Beijing, People’s Republic of China
Background: The annual mortality in patients with end-stage heart failure (ESHF) is as 
high as 50%. Heart transplantation is the only effective treatment. Aim: We asked whether 
BMMC infusion could replace heart transplantation and improve the outcomes in ESHF. 
Methods: A total of 28 ESHF patients were randomly divided into 2 groups. (1) BMMC 
treatment: standard CHF medication and BMMC transplantation; (2) Controls received 
standard medication only. BMMC were collected from each patient one day before 
intracoronary infusion (4x106 cells /2 ml x 6-8 times). Clinical manifestations, biochemical 
assays (ANP, BNP, endothelin), Holter and echocardiograms were recorded prior to and 
after cell implantation. 
Results: Fourteen patients underwent transplantation. Two patients experienced chills 
and one had premature ventricular contractions. All patients showed relief of heart failure 
symptoms within 3 days. As measured at 1 week and 3 months after the procedure, LVEF 
increased by 44% at both times and SV increased by 77% and 52% (P<0.05, P<0.01, 
respectively). NYHA class improved from 3.5±0.14→2.4±0.17 (P<0.01). After 3 months, 
diuretic use decreased by 30.5% (P<0.05). At 3 and 7 days, plasma BNP decreased by 69% 
and 70%, whereas ANP level increased by 1.3- fold at 7 days compared to baseline (P<0.05, 
P<0.01 respectively). None of the treated patients died after 6 months, and only one patient 
was re-admitted for recurrent heart failure symptoms. Conversely, heart failure in 14 controls 
showed no improvement. LVEF decreased by 19.4% (P<0.01) compared with the baseline 
measured at admission. 10 patients (71%) were re-admitted and 2 patients died in 6 months. 
Conclusion: BMMC transplantation is a feasible and safe therapeutic strategy for 
improving symptoms and prolonging life in patients with refractory CHF..
1103-145 Effects of Stem Cell Transplantation on Cardiac 
Function
Anjan K. Sinha, Aravind R. Nemarkommula, Behzad Molavi, Jawahar L. Mehta, 
University of Arkansas for Medical Sciences, Little Rock, AR
Background: Studies in animal models with myocardial infarction have shown 
improvement in cardiac function after stem cell transplantation. Purpose of this study 
was to examine if autologous peripheral stem cell transplant in myeloma patients would 
improve left ventricular ejection fraction.
Methods and Results: Retrospective review of 193 patients receiving autologous 
peripheral blood stem cell transplantation (CD 34+) at the University of Arkansas for 
Medical Sciences was performed. All patients had pre and post transplant quantitative 
left ventricular ejection fraction (LVEF) assessments by multiple gated acquisition scan 
(MUGA). At 3-5 months, there was no signiﬁcant change in overall LVEF (63±2 vs 63±2%, 
mean ± SE). 8 (mean age 62 ±10 years) out of 193 patients had baseline reduced LVEF 
(< 50%). In 7 of these 8 patients, there was an improvement in global LVEF (from 47± 1% 
to 54±2 %, P<0.02). No changes were made in medical therapy for their baseline cardiac 
conditions. When correlated with the number of coronary risk factors (prior myocardial 
infarction, diabetes, hypertension, dyslipidemia, smoking and family history as potential 
homing factors) the percentage improvement in LVEF revealed a correlation with the risk 
factor score (R=0.55)
Conclusions: Stem cell transplantation has the potential to improve cardiac function in 
patients with low LVEF. These data also suggest that traditional coronary risk factors may 
serve as homing factors for stem cells into the dysfunctional myocardium.  
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Table 1: 
Age Sex Pre transplant Ejection Fraction
Post transplant 
Ejection Fraction
Percentage Increase 
in Ejection Fraction Risk factor Score
66 F 38% 50% 32 16
52 M 46% 57% 24 2
67 M 47% 58% 23 4
59 M 50% 61% 22 2
71 M 48% 56% 17 2
61 F 47% 53% 13 0
59 M 46% 51% 11 2
60 M 50% 46% -8 2
Mean 47% 54% 16.75
SEM 1.4 1.8 4.3
1103-146 Intra-coronary Injection o Mesenchymal Stem Cells in 
Patients With Severe Ischemic Cardiomyopathy
Eva Goncalvesova, Jan Lakota, Viliam Fridrich, Juraj Fabián, Slovak Inst Cardiovasc 
Disease, Bratislava, Slovakia
Backgroud Mesenchymal stem cells (MSC) have been used only in animal models of 
cardiac regeneration. Aim of our pilot study was to evaluate the safety and feasibility 
of the intracoronary instillation of autologous MSC in patients with advanced ischemic 
cardiomyopathy.
Patient and methods: Five male heart failure patients with a history of anterior myocardial 
infarction and severe systolic dysfunction without signiﬁcant coronary stenoses of left 
anterior descending coronary artery (LAD) were included. 30 ml of bone marrow blood 
from iliac crest were obtained. The MSC were isolated and expanded ex vivo. Mean time 
of expansion was 19.2+/-4.5days. Standard coronary catheterization was performed 
using an over-the-wire balloon catheter. Suspension of MSC was injected in four 3 ml 
boluses during low pressure LAD occlusions lasting 3 minutes. Mean number of cells 
injected was 1,7+/-0.6x107.
Results : No clinical, ECG or humoral signs of acute myocardial lesion were observed . No 
symptomatic or signiﬁcant dysrhythmias occurred. The patients were clinically improved 
and all reported decrease in dyspnea and fatigue. The results of the initial and repeated 
after 10 weeks evaluations are in table ( LVdD-left ventricular end diastolic diameter ).
Pt 1.pVO2 2.pVO2 1.LVdD 2.LVdD 1.EF 2.EF 1.BNP 2.BNP
(ml/kg/min) (mm) (%) (pg/ml)
1 14,1 16,5 84 85 14 12 480 398
2 14,6 24,1 76 71 13 11 207 87
3 20,5 23,7 72 66 18 16 38 58
4 21,3 22,3 69 57 14 13 2080 1600
5 14,3 18,4 62 58 14 16 440 320
Conclusion: Intracoronary injection of MSC is safe and feasible. Changes of some 
parameters 10 weeks after the procedure are promising but more data are needed to 
evaluate efﬁcacy and medical beneﬁt of this technique.
1103-147 Testosterorone Improves Insulin Sensitivity and Body 
Composition in Men with Congestive Heart Failure.
Chris J. Malkin, Hugh T. Jones, Kevin S. Channer, Royal Hallamshire Hospital, Shefﬁeld, 
United Kingdom, The University of Shefﬁeld, Shefﬁeld, United Kingdom
Background: Congestive heart failure is characterised by catabolism and resistance to 
anabolic hormones including insulin. The normal insulin mediated uptake of glucose and 
fatty acids is disturbed resulting in early anerobic metabolism and poor exercise tolerance; 
in advanced heart failure muscle quality and mass is affected leading to cachexia. Studies in 
non-heart failure populations have found an inverse relationship of testosterone with insulin 
sensitivity. In this pilot study we report the effects of physiological testosterone replacement 
on insulin sensitivity and body composition in men with advanced heart failure.
Methods: We performed a randomised placebo controlled crossover study to test 
whether physiological testosterone therapy (2 injections of intramuscular Sustanon 250, 
over 1 month) improves insulin sensitivity in men with heart failure. The primary outcome 
was an index of insulin sensitivity-the homeostatic index (HOMA-IR) calculated from the 
mean fasting glucose and insulin, and body composition by bio-electrical impedance. 
Complete data were available on 13 men (mean ± sem) age 74.1 ± 2.3 years; ejection 
fraction 30.5% ± 1.3; baseline total testosterone 14.3 ± 2.1nmol/L who completed the 
treatment and placebo phases separated by a 1 month washout period. Analysis was 
by unpaired t-test on the mean delta (change in HOMA-IR on testosterone v change in 
HOMA-IR on placebo).
Results: Testosterone levels on treatment reached a high physiological range (mean 
total testosterone 29.5 ± 4.1nmol/L (normal range 7.5-35nmol/L) an increase of 13.3 
± 4nmol/L, p=0.003 compared to placebo. The treatment effect of testosterone therapy 
was a signiﬁcant reduction of serum fasting glucose (-0.61 ± 0.2mmol/L, p=0.03) and a 
borderline reduction of fasting insulin (-5.4 ± 2.7mmol/L, p=0.06). This led to an overall 
reduction of HOMA-IR (-1.9 ± 0.8, p=0.03). Total body mass increased on testosterone 
therapy (+1.5 ± 0.5kg, p=0.008) but this was not explained by alterations in fat mass since 
this fell overall (-0.8 ± 0.3kg, p=0.02).
Conclusions: Short-term physiological testosterone therapy improves fasting insulin 
sensitivity and body composition in men with moderate to severe heart failure.
1103-148 Unexpected and Potentially Beneﬁcial Effect of 
Testosterone on the Myocardium of Men with 
Congestive Heart failure.
Chris J. Malkin*^, Peter J. Pugh*^, Hugh T. Jones^, Kevin S. Channer*, *Department of 
Cardiology, Royal Hallamshire Hospital, Shefﬁeld, United Kingdom, ^Academic Unit of 
Endocrinology, Division of Genomic Medicine, The University of Shefﬁeld, Shefﬁeld, 
United Kingdom
Background: High dose androgens are widely reported to induce myocardial hypertrophy 
but the effects of physiological testosterone replacement on the myocardium are unknown. 
We have previously reported that testosterone replacement increases cardiac output and 
improves the functional capacity of men with congestive heart failure.
Methods: We performed a double blind placebo control trial to examine the effect of 
physiological testosterone therapy on haemodynamic and echocardiographic parameters 
in 76 men with conﬁrmed heart failure (mean ± s.e.m; age 64.1 ± 1.2 years; ejection 
fraction, 32.5% ± 1.3%). Treatment was with a transdermal patch system (Andropatch) 
with maximum follow up to 12 months. Analysis was by intention to treat using univariate 
analysis of the variance, data are presented as the mean delta (difference between study 
groups) at 1 year.
Results: Testosterone appeared to increase systolic blood pressure (+ 6 ± 3.6mmHg, 
p=0.013) in the treatment group, but the actual effect was due to a reduction of blood 
pressure in the placebo group (- 4.6 ± 2.3mmHg, p=0.05 compared to baseline), there 
were no changes to Simpson’s ejection fraction (+ 0.86 ± 3.1%, p=0.73), end-diastolic 
diameter (+ 0.7 ± 2.9mm, p=0.48), or the cross-sectional area of left ventricular cavity 
(- 8.9 ± 8mm, p=0.2). There was a signiﬁcant increase in the left ventricular cavity length 
(+ 8.4 ± 0.28mm, p<0.0001) in the testosterone group but this was not explained by an 
increase in hypertrophy since there was a borderline reduction in left ventricular mass 
index when corrected for body surface area (- 12.7 ± 7.4g/m2, p=0.055).
Conclusions: The effect of testosterone was to maintain systolic blood pressure and 
reduce LV mass, two outcomes that may be of beneﬁt in advanced heart failure. These 
effects are unexpected since LV mass is related to a higher blood pressure and/or 
worsening heart failure. We conclude that physiological testosterone replacement in men 
with congestive heart failure has a beneﬁcial effect on cardiac morphology and prevents 
the deterioration of systolic blood pressure that may be a marker of decompensation in 
these patients.
1103-149 Effect of Spironolactone on the Spatial Dispersion of 
Filtered QRS Duration in Patients With Mild to Moderate 
Chronic Heart Failure
Takahisa Yamada, Naoyuki Misaki, Mitsutoshi Asai, Nobuhiko Makino, Hidetaka Kioka, 
Yasumasa Tsukamoto, Shunsuke Tamaki, Masaharu Masuda, Takaki Matsumoto, Keiji 
Okuda, Masatake Fukunami, Osaka General Medical Center, Osaka, Japan
Background: It has been shown that spironolactone reduces the mortality in patients 
with advanced chronic heart failure (CHF). However, the mechanism of the effect of 
spironolactone in patients with CHF remained to be fully clariﬁed from the viewpoint 
of spatial dispersion of QRS duration (S-QRSd), which we reported to be a prognostic 
marker of the mortality in CHF patients.
Methods: We prospectively studied 123 CHF patients with radionuclide left ventricular 
ejection fraction < 40% (29±7%), who were followed-up for three years. Signal-averaged 
ECGs were repeated before and every year after the entry. Signal-averaged ECG was 
recorded from the standard 12 leads and 10 extra-precordial leads (two intercostal spaces 
upper and lower V1, V2 and V4-6). Spatial dispersion of QRS duration (S-QRSd) was 
deﬁned as the difference between the maximum and minimum of ﬁltered QRS duration in 
all of the leads. Abnormal S-QRSd was deﬁned as greater than 25 ms (mean+2SD in 31 
age and gender-matched normal controls).
Results: There were no signiﬁcant differences in age, gender, NYHA class, left ventricular 
end-diastolic dimension or ejection fraction at the entry or the content of anti-heart 
failure drugs (beta-blockers and angiotensin converting enzyme inhibitors) between 
patients with (n=76) and without spironolactone (n=47). After the follow-up period of 
31±7 months, S-QRSd tended to decrease in patients with spironolactone (23.7±7.7 
to 22.7±7.0 ms, p=0.07), while there was a signiﬁcant increase in S-QRSd in patients 
without spironolactone (26.2±8.8 to 28.8±8.9 ms, p=0.03). The change of S-QRSd was 
signiﬁcantly different between the two groups (ANOVA, p=0.006). Although there was no 
signiﬁcant difference in the incidence of abnormal S-QRSd at the entry between patients 
with (36%) and without spironolactone (51%), the incidence of abnormal S-QRSd at 
the last follow-up was signiﬁcantly (p=0.0007) lower in patients with (29%) than without 
spironolactone (60%).
Conclusion: Spironolactone might inhibit the progression of S-QRSd in patients with mild 
to moderate CHF, probably via alteration in myocardial ﬁbrosis.
1103-150 Clinical Value of Measuring Intra-Thoracic Impedance 
in Patients with Chronic Heart Failure - Fluid 
Accumulation Status Trial (FAST)
William Abraham, Blair Foreman, Robert Fishel, Nathalie Odryzynski, Medtronic, Inc., 
Minneapolis, MN, The Ohio State University, Columbus, OH
Background: Patients with advanced heart failure (HF), receiving optimal drug and 
device therapy are still at risk of clinical decompensation, associated with total body and 
thoracic ﬂuid volume overload. The ability of an implantable device to continuously monitor 
thoracic ﬂuid status could be a valuable adjunct to existing tools used to assess the risk 
of worsening HF.
Methods: Patients implanted with an InSync Marquis system received the thoracic ﬂuid 
status (TFS) software download, allowing the device to collect and store Daily Impedance 
(Z). The TFS software also derives the Reference Z and Cumulative Difference (CD) from 
the Daily Z value. The Reference Z is essentially a slow moving average used to detect 
changes in the Daily Z. The CD is the accumulated difference between the Daily Z and 
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Reference Z. The Z data, collected daily by the device, was not available to physicians 
or patients. All patients were managed using the conventional standard of care. All 
episodes of worsening HF were documented, where worsening HF was deﬁned as HF 
hospitalizations with signs and symptoms of ﬂuid overload or outpatient visits with signs 
and symptoms of ﬂuid overload and either treatment with an IV diuretic use or a doubling 
of diuretic dose. To characterize the change in daily impedance pre and post Clinically 
Relevant (CR) event, the Daily Z values three days pre and post CR hospitalization and 
Daily Z values one-day pre and post CR outpatient visits are presented.
Results: A total of 44 patients have been enrolled, with a mean follow-up time of 32.5 
days. Thirty-two of the patients were followed > 1 month; of those 32, 7 patients had a HF 
event. The 7 patients with HF events (11.0Ω + 2.7Ω), had signiﬁcantly higher daily Z then 
the 25 HF event free patients (P=0.0010, 6.1Ω + 2.2Ω). In addition, the average change 
in daily Z 3 days pre and post CR hosp was 2.17Ω (N=4, 5.5% change), suggesting that 
these events could be predicted by changes in intra-thoracic Z.
Conclusion: Ambulatory Z data from a CRT-D device may be a useful tool to monitor the 
TFS in HF pts and hence may contribute to better management of these HF pts.
1103-173 Repeated Thermal Therapy Increases Serum Level of 
Ghrelin, and Improves Appetite-Loss in Patients With 
Chronic Heart Failure
Tsuyoshi Fukudome, Masaaki Miyata, Takashi Kihara, Takuro Shinsato, Akinori Masuda, 
Yoshiyuki Ikeda, Sadatoshi Biro, Shinichi Minagoe, Chuwa Tei, Kagoshima University, 
Kagoshima, Japan
Background: We have previously reported that repeated thermal therapy improves 
cardiac function and vascular endothelial function in patients with chronic heart failure 
(CHF). Ghrelin, a novel growth hormone-releasing peptide isolated from stomach, 
stimulates food intake and growth hormone secretion. It was reported that ghrelin levels 
were elevated in patients with CHF and infusion of ghrelin decreased systemic vascular 
resistance and increased cardiac output in patients with heart failure. Therefore, we 
investigated the effect of repeated thermal therapy on serum ghrelin levels and indices of 
cardiac function in patients with CHF.
Methods: Twenty four patients (68±8 years old) with NYHA functional class II or III CHF 
were studied. They were divided into Control (n=11) and Sauna group (n=13). Sauna 
group underwent the thermal therapy in a far infrared-ray dry sauna system at 60 degrees 
centigrade for 15 minutes and then kept on bed rest with a blanket for 30 minutes, daily 
for 2 weeks. Before and after 2-week treatment, serum levels of ghrelin, growth hormone 
(GH), atrial natriuretic peptides (ANP), brain natriuretic peptides (BNP), and noradrenalin 
were measured, and a self-assessment questionnaire for appetite-loss was performed.
Results: In Sauna group, repeated thermal therapy for 2 weeks improved cardiac 
function (ejection fraction: 31±8 to 36±9%, P<0.01; LV Tei index: 0.82±0.29 to 0.69±0.22, 
P<0.01). Repeated thermal therapy decreased serum levels of ANP (138±27 to 103±19 
pg/ml, P<0.01), BNP (453±102 to 324±85 pg/ml, P<0.01), and noradrenalin (442±212 
to 313±160 pg/ml, P<0.05), and increased serum levels of ghrelin (110±26 to 156±35 
fmol/ml, p<0.05) and GH (2.4±0.9 to 3.6±1.1 ng/ml, P<0.05). In addition, appetite-loss 
improved with 11 (85%) of the 13 patients in Sauna group. On the other hand, in Control 
group, there were no signiﬁcant changes in indices of cardiac function, serum levels of 
ANP, BNP, noradrenalin, ghrelin, and GH or appetite for 2 weeks.
Conclusion: Repeated thermal therapy increased serum concentration of ghrelin, 
and improved cardiac function and appetite-loss in patients with CHF. It seems to be a 
promising comprehensive therapy of CHF.
1103-174 Black Women Hospitalized With Heart Failure Treated 
Less Often With Beta-Blockers
Judith E. Mitchell, John Feng, Meriam F. Caboral, Locquessa Okpala, Luther T. Clark, 
State University of New York Health Science Center @ Brooklyn, Brooklyn, NY
Background. Beta Blocker (BB) therapy reduces morbidity and mortality in patients with 
heart failure (HF) and impaired systolic function (ISF), EF< 40%. Despite the documented 
beneﬁts of this therapy, national HF registries report only 50-60% use in pts with HF.
Method. We sought to examine the pattern of BB utilization in 529 consecutively admitted 
black pts with HF. 
Results. Mean age 70 ±13 (male: 65 ±12 and female: 72 ±14, p<0.001), 64% female, 46% 
diabetic and 64% with ISF (of which 57% were female). Somewhat higher than the national 
statistics, 71% of black pts admitted with HF were treated and discharged on a BB. Its use 
was not related to admission BNP, creatinine, hemoglobin level, diabetic status or age. Pts 
were more likely to be treated and discharged on a BB if: --1. they were admitted with HF 
with ISF (p<0.001; ﬁg.1), --2. the HF was of ischemic etiology (p=0.001) or --3. the pt was 
male (79% vs. 67%; p=0.004; ﬁg.2). Allergy, bradycardia, hypotension, signiﬁcant airway 
disease and heart block were the most commonly recorded reasons for not using BB, but 
combined, cited only 5% of the time. “Contraindication” was noted without clariﬁcation 9% of 
the time. But in 86% of cases no reason for withholding the drug could be found. 
Conclusion. Seventy-one percent of black pts admitted with HF were treated with a BB. 
Male sex, ischemic etiology and HF with ISF were features associated with increased use. 
The disparity in the use of BB in black women requires further studies to identify barriers 
to this treatment.
1103-175 Cost-Effectiveness of Carvedilol in Patients with Left 
Ventricular Dysfunction after Myocardial Infarction-
Results from the CAPRICORN Trial
Dan Greenberg, Elizabeth M. Mahoney, J. Jaime Caro, Khajak Ishak, Gregory L. Smith, 
David J. Cohen, Harvard Clinical Research Institute, Boston, MA
Background: Recently, the CAPRICORN trial demonstrated that long-term use of 
carvedilol in patients with left-ventricular (LV) systolic dysfunction after acute MI, reduced 
the incidence of death and recurrent MI. However, the cost and cost-effectiveness of this 
practice is unknown.
Objectives: To assess the net lifetime cost and cost-effectiveness (C/E) of adding 
carvedilol to routine clinical management of patients with post-MI LV dysfunction from the 
perspective of the US healthcare system.
Methods: Between June 1997 and February 2000, 1,959 patients with a proven acute 
MI and LVEF ≤ 40% were randomly assigned to carvedilol (n=975) or placebo (n=984), 
in a multicenter double-blind controlled trial. We performed an economic analysis, 
using patient-level data from the trial. Inpatient costs for each hospital admission were 
based on mean DRG costs and outpatient costs during follow-up were estimated 
using a large administrative database. Long term life expectancy was modeled using 
piecewise proportional hazards analysis of a cohort of similar patients (n= 15,590) in 
the Saskatchewan health database. Utility weights were derived from a previous study. 
All analyses were performed on an intention to treat basis. Costs and life years were 
discounted annually at 3%.
Results: Carvedilol increased patients’ life expectancy by 0.29 years and quality-adjusted 
life-expectancy by 0.22 quality-adjusted life years (QALYs), but was associated with higher 
lifetime treatment costs ($37,952 vs. $34,801, p<0.001). As a result, the incremental cost-
effectiveness ratio for carvedilol compared with placebo was $14,156 per QALY gained 
and $10,845 per life-year gained. Bootstrap analysis demonstrated that the C/E ratio for 
carvedilol was <$50,000/QALY gained in 86% of simulations.
Conclusions: As performed in CAPRICORN, addition of carvedilol to usual therapy in 
patients with post-MI LV dysfunction provides substantial clinical beneﬁt and is highly 
cost-effective compared with other accepted medical interventions.
1103-176 Beta-Blocker Use and Associated Outcomes Among 
Hospitalized Heart Failure Patients
Javed Butler, James B. Young, William T. Abraham, Robert C. Bourge, Kirkwood F. 
Adams, Jr., Mian A. Hasan, Alain Heroux, Stuart D. Russell, Gary S. Francis, Robert 
Clare, Christopher M. O’Connor, Vanderbilt University Medical Center, Nashville, TN
Background: Although the long-term beneﬁt of outpatient beta-blocker (BB) therapy 
in heart failure (HF) is well documented, the effects of BBs on patients hospitalized for 
decompensated HF (hHF) are not. We sought to evaluate the impact of BB therapy on 
hHF patients. 
Methods: We analyzed the association between BB therapy and outcome in 432 hHF 
patients in ESCAPE, an NHLBI-funded trial comparing therapy guided by pulmonary 
artery catheter (PAC) use or clinical assessment alone. 
Results: Baseline characteristics included mean age, 56±14 years; ejection fraction (EF), 
19±7%; SBP, 106±16 mm Hg; serum creatinine, 1.5±0.6 mg/dL; and, in PAC patients, mean 
wedge pressure, 25±9 mm Hg, and cardiac index, 1.98±0.61 L/min/m2. Of the 432 patients, 
268 (62%) were on BBs before admission. With respect to age, sex, symptoms, EF, and 
sodium and creatinine levels, no statistically signiﬁcant differences were seen between 
patients on BBs and those who were not. Patients on BBs were more likely to be white (64% 
vs. 52%, p=0.02), to have a history of cerebrovascular events (15% vs. 8%, p=0.03), and to 
have used antiarrhythmic medication less often (18% vs. 27%, p=0.03). They had a lower 
prevalence of peripheral edema on presentation (65% vs. 74%, p=0.05), lower baseline 
pulmonary capillary wedge pressure (24±9 vs. 27±9, p=0.019), and higher cardiac index 
(2.05±0.65 vs. 1.83±0.52, p=0.04). Patients on preadmission BB therapy had a signiﬁcantly 
shorter length of stay (7.9±6.3 vs. 9.4±6.7 days, p<0.01) and lower in-hospital (8.5% vs. 4.4%, 
p=0.08) and 6-month mortality rates (16% vs. 24%, p=0.03). Of patients on preadmission 
BBs who were discharged alive, 57 had BBs discontinued during hospitalization. These 
patients had a longer length of stay (10.3±8.3 vs. 7.3±5.4 days, p<0.01) and signiﬁcantly 
higher mortality within 30 days of discharge (12.2% vs. 2.9%, p<0.01). 
Conclusion: Patients taking BBs prior to and during hospitalization for hHF have better 
outcomes than those in whom BBs are discontinued or not prescribed. All patients not 
on BBs should be reevaluated to determine whether a redesigned regimen would allow 
successful maintenance of BB therapy.
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1103-177 Consistent Survival Beneﬁt of Carvedilol Over 
Metoprolol Irrespective of Baseline Characteristics of 
Heart Failure Patients - Mode of Death Evaluation in 
COMET
Willem J. Remme, John G. Cleland, Christian Torp-Pederson, Marco Metra, Andrew 
Charlesworth, Beatrix Lutiger, Philip A. Poole-Wilson, STICARES - Cardiovascular 
Institute, Rhoon, The Netherlands, University of Hull, Kingston upon Hull, United Kingdom
Background: In the COMET study carvedilol resulted in better overall survival than 
metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF < 35%, followed 
for an average of 58 months. Whether this effect is consistent irrespective of mode of 
death and patients baseline characteristics is unknown.
Methods: Of the 1112 total deaths, 972 were adjudicated as cardiovascular (CV), 480 
sudden (SD), 365 circulatory failure (CHF) and 51 stroke deaths. For each mode of death, 
the effect of the following baseline variables were assessed: sex, age, NYHA class, 
ischemic etiology, heart rate, systolic blood pressure, EF, dilated cardiomyopathy, BMI, 
diabetes, atrial ﬁbrillation, previous myocardial infarction or hypertension, hemoglobin, 
creatinine, sodium, and ACE inhibitor, spironolactone, digitalis, aspirin/anticoagulant and 
statin use, and study treatment allocation.
Results: In univariate analyses, carvedilol reduced total and CV mortality, SD and stroke 
death more than metoprolol in all subgroups (hazard ratios (RR) varying between 0.81-
0.85, 0.78-0.81, 0.78-0.82 and 0.31-0.35, resp), but for CHF death only in patients with low 
serum sodium or on digitalis treatment. In multivariate Cox regression analyses carvedilol 
remained signiﬁcantly better than metoprolol for total death (RR 0.80, 95% CI 0.71-
0.91,p=0.0007), CV mortality(RR 0.80, CI 0.7-0.91, p=0.0009), SD (RR 0.77, CI 0.64-
0.93, P=0.0073) and stroke death (RR 0.37,CI 0.19-0.71, p=0.0027), and showed a non-
signiﬁcant trend for CHF death (RR 0.83, CI 0.66-1.04, p=0.1). There were no interactions 
between treatment allocation and any of the prespeciﬁed baseline characteristics.
Conclusion: Carvedilol results in signiﬁcantly better survival in most modes of death and 
a positive trend for CHF death, irrespective of baseline characteristics. This consistent 
better effect of carvedilol in all prespeciﬁed subgroups suggests it to be the preferred 
beta-blocker in the treatment of heart failure.
1103-178 Beneﬁcial Effect of Beta Blockers on Survival in 
Congestive Heart Failure with Normal Ejection Fraction
Padmini Varadarajan, Sanjay Sharma, Siddarth Gandhi, Branavan Umakanthan, 
Ramdas G. Pai, Loma Linda University Medical Center, Loma Linda, CA, USC-Keck 
School of Medicine, Los Angeles, CA
Background: Beta blockers have been shown to prolong survival in congestive heart 
failure (CHF) patients with reduced ejection fraction (EF). However, its effect on survival in 
CHF patients with normal EF is not known.
Methods: Detailed chart reviews of 2246 patients with a discharge diagnosis of CHF from 
a university medical center were performed by medical residents. The diagnosis of CHF 
was conﬁrmed (deﬁnite 87%, probable 13%) by Framingham criteria. Details of clinical, 
echocardiographic and discharge pharmacotherapy data were collected. Effect of beta 
blockers on survival was analyzed.
Results: Off the 2246 patients with CHF, 1079 (48%) had normal EF (>50%). Baseline 
patient characteristics of patients with CHF and normal EF: LVEF 64+8%, age 70+14 
years, males 47%, Caucasians 78%, hypertension 56%, diabetes mellitus 28%. Of these 
patients 62% were on aspirin, 13% on beta blockers, 59% on diuretics, 33% on digoxin 
and 36% on ACE inhibitors at the time of discharge. The 5 year survival for patients treated 
with beta blocker therapy was 65% compared to 50% for those receiving no beta blocker 
therapy (p=0.0007). Adjusting for all comorbidities including age, gender, hypertension, 
diabetes mellitus and presence of coronary artery disease using the proportional hazards 
model, use of beta blockers was associated with a better survival (adjusted p=0.01).
Conclusion: Our observational data supports an independent survival beneﬁt with beta 
blocker therapy in CHF patients with normal EF. 
1103-179 Carvedilol corrects Interventricular And Interventricular 
Dyssynchrony In Chronic Heart Failure.
Pablo F. Castro, Sr., Paul Mc Nab, Sr., Alex Bittner, Sr., Douglas Greig, Sr., Juan Carlos 
Quintana, Sr., Mario Chiong, Sr., Guillermo Diaz-Araya, Sr., Rodrigo Valenzuela, Sr., 
Ismael Vergara, Sr., Ramon Corbalan, Sr., Sergio Lavandero, Sr., P. Catholic University 
of Chile, Santiago, Chile, University of Chile, Santiago, Chile
Carvedilol an adrenergic antagonist, improves left ventricular (LV) remodeling and reduces 
morbility and mortality in chronic heart failure (HF) patients. These salutary effects could 
be related to restoration of cardiac synchrony.
Objective: To evaluate the effects of carvedilol on cardiac contractile synchrony in patients 
with HF and LV systolic dysfunction.
Methods: 31 patients with stable HF, NYHA class II-III, LVEF <40%, under usual treatment, 
except by β-blockers or pacemaker were included. Multigate equilibrium blood pool 
scintigraphy was used to measure interventricular and intraventricular synchrony and LVEF 
at baseline and after 6 months of carvedilol. Phase image analysis was applied to the 
scintigraphic data and mean phase angles computed for the right and LV. Interventricular 
synchrony was calculated as the difference between the mean phase angle of each ventricle 
and the intraventricular synchrony using the standard deviation of the phase angles.
Results: Mean age was 55±13 years, 22 (71%) male, 11 (35%) patients had ischemic 
etiology and 9 (29%) LBBB. After 6 months of therapy with carvedilol (maintenance mean 
dose = 25 mg, range 6.25 to 50 mg per day), there was an improvement in functional 
class and in the 6-min-walk-distance (499±18 to 534±17 meters, p=0.032). The LVEF 
increased from 24%±8.3 to 31%±11.3 (p< 0.001). Patients with the worst synchrony 
under 50th percentile at baseline improved after treatment: intraventricular (113±7 vs. 
94±10 msec, p= 0.02) and interventricular (62.8±7 vs. 39.4 ± 9 msec, p=0.02). The 
patients with non-ischemic etiology had a signiﬁcant improvement in both intraventricular 
(103.8±7 vs. 78.3±12 msec, p=0.04) and interventricular synchrony (68.1±9 vs. 35.3±12 
msec, p=0.02). Patients without LBBB improved the intraventricular synchrony (112.1±8 
vs. 88.5±11.2 msec, p=0.01 ). No signiﬁcant changes were observed in patients with 
ischemic etiology or LBBB.
Conclusion: Carvedilol in patients with heart failure and LV dysfunction improves 
interventricular and intraventricular contractile synchrony. These ﬁndings could be related 
to favourable effects in cardiac remodeling.
Fondecyt 1010992 and FONDAP 1501006
1103-180 B-type Natriuretic Peptide and Doppler Echocardiography 
for Identifying CHF patients at Risk of Acute Heart 
Failure Decompensation during Beta-blockade Titration
Ahmed Ben Driss, Jean-Yves Tabet, Philippe Meurin, Hélène Weber, Nathalie Renaud, 
Anne Grosdemouge, Claude Bourmayan, CRCB, Villeneuve-Saint-Denis, France
Background: As plasma BNP concentrations and Trans Thoracic Echocardiography 
(TTE) parameters are strongly related to outcome of patients with chronic heart failure 
(CHF), we hypothesized that BNP and TTE may predict tolerance during beta-blockade 
titration in stable CHF.
Methods and results: Fifty consecutive stable CHF patients (age: 61±2 years, male: 
88%) with Left Ventricular Ejection Fraction (LVEF) < 40% and creatininemia <250 µmol/l 
were included in the study. Beta-blockers were started and/or increased as recommended 
by ESC Guidelines. Plasma BNP (Biosite) and TTE (GE Vivid 5) were performed the same 
day in a blind manner, at admission then once a week during 3 weeks.
At admission, NYHA class was 2.3±0.1, mean creatininemia: 99±3 µmol/l, plasma BNP: 
489±46 pg/ml, LVEF : 28±1%, E/A ratio: 1.9±0.2, E/Ea ratio : 9.8±0.6, E Deceleration 
Time (EDT) : 160±9 ms, systolic pulmonary artery pressure (PAP): 40±2 mmHg and 
inferior vena cava diameter (IVC): 16±1 mm. Acute heart failure (HF) occurred in 32% of 
the study population (16/50). On univariate analysis, age and admission values of NYHA 
class, plasma BNP concentration, log BNP, E/A ratio, EDT, systolic PAP and IVC diameter 
predicted increased risk of acute HF during beta-blockade titration. On multivariate analysis, 
only BNP concentration predicted acute HF decompensation. The combined inframedian 
BNP (464 pg/ml) and supramedian EDT value (147 ms) was associated with 100% negative 
predictive value of acute HF decompensation during beta-blockade titration.
Conclusions: The combination of plasma BNP and Doppler echocardiography may 
identify stable CHF patients with LV systolic dysfunction at low risk of acute heart failure 
during beta-blockade titration.
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1104-165 Inﬂuence of Donor Transmitted Atherosclerosis on the 
Development of Cardiac Allograft Vasculopathy
Haiyan Li, Koji Tanaka, Hitoshi Anzai, Brandy Oesser, Jon Kobashigawa, Jonathan M. 
Tobis, University of California at Los Angeles, Los Angeles, CA
Background: Following orthotopic heart transplantation (OHT), coronary artery disease 
is a combination of donor transmitted atherosclerosis and new lesions that develop to 
produce cardiac allograft vasculopathy (CAV). This study evaluated the inﬂuence of pre-
existing donor lesions on the development of CAV.
Methods: Intravascular Ultrasound imaging was performed in 301 recipients at 1.3±0.6 
months and again at 12.2±0.8 months after OHT. 1103 segments were matched from 
333 coronary arteries between studies 1 year apart. In each segment, maximum intimal 
thickness (MIT), lumen area (LA), external elastic membrane area (EEM area) and intimal 
area (IA) were measured. Segments with MIT ≥ 0.5mm at baseline were deﬁned as donor 
lesions (DL). New lesions (NL) were deﬁned as lesions with ΔMIT≥ 0.5mm at 1 year and 
baseline MIT <0.5mm.
Results: The mean donor age was 29.6±12.7 years old and 197 segments from 95 
arteries in 89(30%) hearts demonstrated DL. At 1 year after OHT, 16% of recipients with 
DL exhibited an increase ≥ 0.5mm in MIT (progression of DL); 78% had a change <0.5mm 
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in MIT; 6% had a decrease ≥ 0.5mm in MIT (regression of DL); and 10.1% of recipients 
with DL developed NL. Of the 333 arteries, 16 segments had progression of DL and 51 
segments had NL; 18 of 67 segments came from 14 of 95 (15%) arteries with DL, and 
49 of 67 segments came from 36 of 238 (15%) arteries without DL (p=0.9). Lumen loss 
and intimal growth in NL were greater than in DL (ΔLA:-3.5±2.7mm2 vs -0.89±3.0mm2, 
p<0.0001; ΔIA: 4.5±2.1mm2 vs 0.54±2.1mm2, p<0.0001). For the same degree of increase 
in IA (ΔIA: 4.5±2.1mm2 vs 4.1±2.8mm2, p=0.6), the NL tended to have vessel enlargement 
(ΔEEM area=0.93 ± 2.6mm2, p=0.01), and the segments with progression of DL had no 
signiﬁcant change in EEM area((ΔEEM area=0.10±2.0mm2, p=0.8). The presence of NL 
was similar in arteries with and without progression of DL (14.3% vs 8.6%, p=0.6).
Conclusion: In the ﬁrst year after OHT, DL do not act as a nidus for further intimal growth 
and may not be as susceptible to CAV as segments without DL. The presence of a DL also 
does not accelerate intimal thickening elsewhere in the artery. The presence of DL may 
impede compensatory positive remodeling as intimal thickening progresses.
1104-166 High Rejection Score Is Associated With Lower 
Coronary Flow Reserve in Heart Transplantation 
Recipients With Normal Coronary Angiography
Francesco Tona, Alida Linda Caforio, Roberta Montisci, Antonio Gambino, Cristiano 
Sarais, Giuseppe Feltrin, Giuseppe Toscano, Diego Calzolari, Annalisa Vinci, Maria 
Grazia Leone, Annalisa Angelini, Angelo Ramondo, Gaetano Thiene, Gino Gerosa, 
Sabino Iliceto, University of Padova, Padova, Italy, University of Cagliari, Cagliari, Italy
Background. Coronary ﬂow reserve (CFR) is increasingly used to assess the functional 
signiﬁcance of cardiac allograft vasculopathy (CAV). The factors determining CFR in heart 
transplant recipients with normal coronary angiography are ill deﬁned. 
Methods. 36 consecutive patients (24 male, aged 50±13 years at heart transplantation) 
were studied at 6.3±4.5 years after heart transplantation. Rejection scores (RS) on 
endomyocardial biopsy were calculated (ISHLT grades: 0=0; 1A=1; 1B=2; 2=3; 3A=4; 3B=5; 
4=6) in the ﬁrst year and during the whole follow-up. RS including only severe grades (≥3A) 
were also calculated. Coronary blood ﬂow velocity in the left anterior coronary descending 
artery was noninvasively detected by contrast-enhanced transthoracic echocardiography 
(CE-TTE) at rest and during intravenous infusion of adenosine (0.14 mg/kg/min). CFR 
was obtained as the ratio of hyperaemic diastolic peak velocity (DPV) to resting DPV. All 
patients had normal ﬁndings on left ventricular angiography and coronary arteriography 
and a normal left ventricular mass. Comparison of means was made by Student’s t test. A 
p value <0.05 was considered to be signiﬁcant. 
Results. 7 patients (19%) had a CFR< 2.9 (group A) and 29 (81%) had a CFR ≥ 2.9 
(group B). Systolic and diastolic blood pressure, heart rate and blood haemoglobin were 
similar in the two groups. Group A had a higher number of treated rejections in the ﬁrst 
year (4.5±2.6 vs 2.3±2, p=0.01) and in the whole follow-up (5.1±3 vs 2.6±2, p=0.01). 
RS in the ﬁrst year and in the whole follow-up were higher in group A (1.71±0.49 vs 
1.23±0.54, p=0.04; 1.69±0.59 vs 1.16±0.49, p=0.02, respectively) as well as RS including 
only severe grades (≥3A) in the ﬁrst year (0.26±0.14 vs 0.14±0.13, p=0.04) and in the 
whole follow-up (0.23±0.17 vs 0.13±0.09, p=0.04).
Conclusions. In heart transplant patients with angiographically normal coronary arteries, 
CFR by CE-TTE was inversely related to the number of previous rejection episodes. Since 
a high rejection burden is associated with increased risk of CAV, a CFR reduction may be 
an early marker of CAV. Prospective studies are warranted.
1104-167 Anemia is Associated with a Signiﬁcant Increase in 
Mortality in the Orthotopic Heart Transplant Population
Ashley A. Busuttil, Tamara B. Horwich, Gregg C. Fonarow, Jignesh Patel, Jon A. 
Kobashigawa, University of California, Los Angeles, Los Angeles, CA
Background: Reduced hemoglobin (Hb) in orthotopic heart transplant (OHT) patients 
is frequently observed. There is limited data, however, analyzing the relationship 
between anemia and survival in this population. The aim of our study was to evaluate 
this relationship.
Methods: We analyzed a cohort of 813 heart transplant recipients from 1984-2004. The 
cohort was divided into 2 groups of anemic and non-anemic. Anemia was deﬁned as 
Hb<11.0g/dL in women and <12g/dL in men. Hb values were taken from 12-20 weeks 
post OHT.
Results: Mean age was 53 years. The cohort was 74.7% male and 25.3% female. 
Mean Hb was 12.2; values ranged from 5.9 to 16.8. 33.7% of the cohort was anemic. Hb 
groups were similar in gender, BMI, CAD pre-OHT, and use of mycophenolate mofetil 
and tacrolimus. Lower Hb was associated with increased age, higher creatinine (Cr), 
and use of prednisone and cyclosporine. Kaplan Meier survival curves at 1 year showed 
improved survival in non-anemic versus anemic patients (94.5% and 89.4% respectively; 
p value 0.0051). In multivariate analysis adjusted for recipient age, gender, pre-OHT heart 
failure etiology, BMI, Cr, and immunosuppressive regimen, anemia was an independent 
predictor of mortality (relative risk 2.5, 9% CI 1.3 to 4.6).
Conclusions: In the post OHT population anemia is associated with worsened 1-year 
survival independent of renal function. Further investigation into the signiﬁcance of this 
association should be considered. 
1104-168 Efects of Gender on Peak Oxygen Consumption and 
Survival in Ambulatory Heart Failure Patients
Sammy Elmariah, Lee R. Goldberg, Michael T. Allen, Andrew Kao, Hospital of the University 
of Pennsylvania, Philadelphia, PA, Mid-America Heart Institute, Kansas City, MO
Background: The predictive ability of peak exercise oxygen consumption values (PVO2) 
in female heart failure patients (HF pts) is not well established. This study examines 
gender effects on PVO2 and survival in HF pts. 
Methods: 594 consecutive ambulatory HF pts (mean age 52+12 yrs; 28% female; mean 
LVEF 26+12%; 73% on ß blocker) underwent symptom-limited exercise tests with breath-
by-breath expired gas analyses using ramped treadmill protocols. Comparisons between 
groups were made using Student’s t tests or chi-square analyses. Kaplan-Meier survival 
curves were generated for each gender and compared using log rank tests. Results: 
Women had signiﬁcantly lower PVO2 than men (14.0+4.9 vs 16.6+7.1 ml/kg/min; 
p<0.0001), despite being younger (48.9+11.5 vs 53.2+12.4 yrs; p<0.0001) and having a 
higher LVEF (29+13 vs 25+11%; p<0.0003). The 1 year survival was signiﬁcantly lower for 
men than for women (81 vs 94%, p<0.0001). This lower survival in men was seen across 
each Weber functional class. 
One Year Transplant-Free Survival (%) 
Weber Class Men Women
A 95 99
B 90 95
C 77 95
D 59 84
Cox regression analyses conﬁrmed the predictive effects of gender on survival when 
controlling for PVO2, age, race, ß blocker use and type of cardiomyopathy. The PVO2 
associated with 85% 1 year survival was signiﬁcantly higher in men than in women (11.5 
vs 10.0 ml/kg/min). Conclusion: Women had signiﬁcantly lower PVO2 than men, but had a 
better survival at all levels of exercise capacity. The current practice of uniform application 
of PVO2 to determine optimal timing of cardiac transplantation should be re-examined.
1104-169 Human Menstrual Blood Is a Potential Cell Source for 
Cardiac Stem Cell Therapy
Shunichiro Miyoshi, Naoko Hida, Nobuhiro Nishiyama, Tomoko Tanaka, Tohru Kiyono, 
Satoru Kyo, Satoshi Ogawa, Akihiro Umezawa, Keio University School of Medicine, Tokyo, 
Japan, National Research Institute for Child Health and Development, Tokyo, Japan
Mesenchymal stem cell (MSC) transplantation slightly improved impaired cardiac function 
but the improvement was insufﬁcient, because the main effect of MSC was attributable to 
neovascularization, not to cardiomyogenesis (CM). To achieve CM, in vitro selection of a 
monoclonal cell-line with a high rate of CM would be required, because not all MSC have 
the potential for CM. In the present study we focused on the endometrium as a source 
of MSC, because endometrial MSCs (E-MSCs) can be repeatedly, painlessly, and easily 
obtained from a younger and large population than marrow derived MSCs, and thus a cell 
bank system covering all HLA types can be established.
Method and Results. Endometrium-derived cells were obtained from a 52-year-old 
woman by the limiting dilution method. We attempted to prolong the life span of the 
endometrium-derived cells by infecting them with retrovirus encoding HPV16 E6/E7 
and hTERT. The E-MSCs that were established were co-cultured with fetal murine 
cardiomyocytes without treating 5-azacytidine (5-azaC). On day 3 of co-cultivation, the 
GFP-labeled E-MSCs began spontaneously beating, and on day 5 almost all of the E-
MSCs contracted rhythmically and synchronously, suggesting the presence of electrical 
communication between the E-MSCs. The cardiomyocyte-speciﬁc pacemaker-like and 
plateau action potentials were recorded with a microelectrode containing ﬂuorescent dye 
(alexa568), which was simultaneously injected into the cell to conﬁrm the electric potential 
recorded from the E-MSC. The E-MSC-derived cardiomyocytes stained positive for 
cardiac troponin-I (clear striation was observed) and connexin 43 (diffuse dot-like staining 
at the margin of cell) by the immunohistolochemical method. Cardiac troponin-I-positive 
cardiomyocytes accounted for 35 % of the nucleated E-MSCs. E-MSCs were co-cultivated 
in the same dish with mouse cardiomyocytes separated by a collagen membrane, and 
thus cell-fusion was not a major cause of CM in the E-MSC.
Conclusion. For the ﬁrst time we established a human E-MSC cell-line from the 
endometrium whose CM rate was very high without 5-azaC. Human menstrual blood may 
be a major cell source for stem cell therapy to achieve cardiomyogenesis.
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1104-170 Using Flow Cytometry to Eliminate High Risk Donors 
Without the Need for a Direct Prospective Crossmatch 
for Sensitized Pediatric Heart Transplant Recipients
Steven Zangwill, Thomas M. Ellis, Jane Zlotocha, Robert D. Jaquiss, James S. Tweddell, 
Kathy A. Mussato, Stuart Berger, Medical College of Wisconsin, Milwaukee, WI, Blood 
Center of Southeast Wisconsin, Milwaukee, WI
Background: HLA sensitization is a problem for heart transplant (HTx) recipients. To 
limit risks, one may require a prospective crossmatch (XM) severely limiting the donor 
pool. We used recipient ﬂow cytometry and donor HLA typing to predict XM results. 
Methods: Bead-based ﬂow cytometry was used to identify anti-HLA Ab in a child listed 
for HTx. “Donors” were chosen from a pool of HLA typed blood donor samples. Using 
recipient serum, direct T and B cell XM studies were run for potential donors against 
whose HLA type the recipient had speciﬁc Ab (Group 1, n=7) and those without donor 
speciﬁc anti-HLA Ab (Group 2, n=7). Results were expressed as MCD (mean channel 
difference between control and recipient serum). A positive T cell XM was deﬁned as 
MCD>50 whereas MCD>100 constituted a positive B cell result. These are our clinically 
applied standards. Results: Table 1: T cell reactivity was lower in Group 2 than Group 
1 (29% vs. 100%, p=.02); B cell reactivity was also lower for Group 2 (14% vs. 100%, 
p=.005). The predicted XM was 100% speciﬁc in detecting a positive XM for T and B 
cells. Conclusions: Sensitized patients are at risk either due to the wait for a XM or 
undergoing HTx with a positive XM. Currently, potentially suitable donor organs are 
declined for lack of a XM; these organs may then be allocated to more distant recipients 
or not used at all. While further studies are needed, ﬂow cytometry guided screening 
has potential to improve organ availability for sensitized patients as well as the overall 
allocation process.
Table 1: Group 1 = Positive Predicted XM,  
Group 2 = Negative Predicted XM. 
T Cell B Cell
Donor HLA Type MCD MCD
Group 1
1
2
3
4
5
6
7
A74;B45,B78;DR8,DR12
A2,31;B7,35;DR8,DR12
A2,30;B18,60;DR3,7
A25,26;B7,8;DR15,18
A1,2;B14,56;DR7,16
A2,29;B44,60;DR7,12
A2,29;B13,45;DR1,7
86
198
127
172
103
142
107
340
254
270
313
339
355
147
Rate of positivity 7/7 100% 7/7 100%
Group 2
1
2
3
4
5
6
7
A1,2;B18,-;DR8,9
A3,23;B51,57;DR3,11
A11,30;B8,18;DR5,6
A24,28;B14,49;DR1,10
A1,3;B13,27;DR4,6
A23,25;B35,51;DR6,9
A23,28;B39,51;DR8,12
30
4
0
43
49
57
53
35
23
35
59
53
61
215
Rate of Positivity 2/7 29% 1/7 14%
Recipient HLA Ab Speciﬁcity:
A29,B7,B40,B45,DR7,DR16
1104-171 Calcineurin Inhibitor-Free Renal Sparing Protocol For 
Patients with Renal Insufﬁciency After Heart Transplantation: Trouble 
On the Horizon?
Jon A. Kobashigawa, Jignesh K. Patel, Angela Marquez, Brandy T. Oeser, Angela 
Velleca, Roxella Camara, Hillel Laks, University of California at Los Angeles, Los 
Angeles, CA
Background: One of the major complications after heart transplantation is renal 
dysfunction due to the chronic use of calcineurin inhibitors (CI). Recent reports in small 
number of patients have suggested that cyclosporine can be withdrawn safely with 
subsequent decrease in serum creatinine (SCr). We report our experience in heart 
transplant patients on cyclosporine (15) or tacrolimus (3), mycophenolate mofetil (MMF), 
prednisone with regard to withdrawal of CI in patients experiencing renal dysfunction.
Methods: Between 11-02 and 2-04, 18 patients (1-12 years after transplant) with SCr 2.4 mg/dl 
began our renal sparing protocol (RSP). To start the RSP, CI dose was halved with the initiation 
of sirolimus 1-2mg/day added to pre-existing MMF prednisone. After target levels of sirolimus 
(4-6 ng/mL) and MMF (2-5 mcg/mL) were documented, CI was discontinued (d/cd). After d/c of 
CI, an echo was performed 4 weeks later and a biopsy was performed 6 weeks later. 
Results: 11/18 (61%) patients experienced a decrease in SCr within ten months after 
d/c of CI. Seven patients had complications that led to the d/c of RSP. Three patients had 
acute decrease of left-ventricular ejection fraction (40% at 4 mos, 40% at 7 mos, and 20% 
at 10 mos), which required anti-rejection therapy; 1 patient had worsening renal failure 
that led to hemodialysis at 1 mo; 1 patient with profound diarrhea at 7 mos; 1 patient with 
severe sepsis that led to dealth at 3 mos; 1 patient with severe anemia at 4 mos after d/c 
of CI. For the remaining 11 patients in the group, the average peak SCr (between 3 mos 
prior to start of the RSP and 1 mo after the start of the RSP), signiﬁcantly decreased by 
10 mos after d/c of CI, (3.8+0.8 decreased to 2.5+0.8, p=0.002). Echocardiograms for 
these 11 patients at 4 weeks after d/c of CI were normal. Biopsies for these 11 patients at 
6 weeks after d/c of CI were negative for rejection.
Conclusion: Renal sparing protocols involving withdrawal of cyclosporine/tacrolimus 
with maintenance mycophenolate mofetil and siroliumus immunosuppression should be 
performed with careful follow-up to detect any adverse effects. For many patients, this 
protocol appears to be effective in preserving renal function.
1104-172 Biopsy-Proven ISHLT Grades 1A, 1B, and 2 Rejection in 
Heart Transplant Patients: Should We Re-Classify Them 
Into One Mild Rejection Grade?
Jon A. Kobashigawa, Thomas Ro, Michael C. Fishbein, Jignesh K. Patel, Brandy T. 
Oeser, Hillel Laks, University of California at Los Angeles, Los Angeles, CA
Background: The natural history of the progression of ISHLT Biopsy Grades 1A and 
1B to a higher grade rejection (Grade > 3A) has been reported to be low and similar in 
both grades under triple immunosuppression (cyclosporine, prednosone and Imuran). A 
new ISHLT grading scale has been recommended, which will combine ISHLT grades 1A, 
1B, and 2 rejection. This study was performed to assess if the outcomes of grades 1A, 
1B, and 2 are indeed similar and thereby validating combining these grades of rejection. 
Methods: Between 1/15/98 to 12/31/03, 551 biopsies were found to demonstrate ISHLT 
grade 1A, 1B , or 2 rejection. Majority of patients were under tacrolimus, mycophenolate 
mofetil, and corticosteroids immunosuppression. Follow up biopsies were performed at 
2-week intervals. Subsequent biopsies within 3 months of the original ISHLT grade 1A, 
1B, or 2 biopsy were reviewed and divided into 3 groups: Mild Rejection Cleared; Mild 
Rejection Persisted; Mild Rejection Progressed to ISHLT Grade 3A, 3B, or 4. 
Results: Of the 551 ISHLT Grade 1A biopsies, 502 (91%) Cleared, 37 (7%) Persisted, 
and 12 (2%) Progressed. Of the 43 ISHLT Grade 1B biopsies, 39 (91%) Cleared, 1 (2%) 
Persisted, and 3 (7%) Progressed. Mild rejection biopsy episodes were then divided 
into those that occurred less than 3 months and greater than 3 months after heart 
transplantation. There was no signiﬁcant difference in those biopsy episodes that cleared, 
persisted, or progressed between these two time periods. There were 2 episodes of 
ISHLT grade 2 rejection, of which both subsequently cleared.
Conclusion: Mild acute rejection (ISHLT Grades 1A and 1B) does not appear to 
signiﬁcantly progress to a higher form of rejection under the current immunosuppressive 
regimens. Therefore, distinction between ISHLT grades 1A and 1B may not be necessary 
and could be re-classiﬁed into one mild rejection grade.
POSTER SESSION
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1105-157 Chronotropic Incompetence and Its Contribution to 
Exercise Intolerance in Older Heart Failure Patients with 
Diastolic versus Systolic Heart Failure
Peter H. Brubaker, Kee Chan Joo, Kathryn Stewart, Brittany Fray, Brian Moore, Delane 
W. Kitzman, Wake Forest University School of Medicine, Winston-Salem, NC
Background. Chronotropic incompetence (CI) is present in > 30% of middle-aged 
patients with heart failure (HF) with reduced LV ejection fraction (systolic heart failure, 
SHF) and is thought to contribute to their exercise intolerance. Normal aging is associated 
with reduced peak exercise heart rate, and older patients, who comprise the majority 
of HF patients, have particularly severe exercise intolerance. In addition, the majority 
of older HF patients have a normal ejection fraction (commonly termed diastolic heart 
failure, DHF) and the mechanisms of exercise intolerance in these patients are not well 
understood. Therefore, the purpose of this study was to examine the prevalence of CI and 
its contribution to exercise intolerance in older HF patients, particularly those with DHF.
Methods. We studied 60 older (>65 years) with SHF, 59 with DHF, and 28 age-matched 
normal subjects (NL) during upright bicycle ergometer with an incremental protocol to 
maximal effort, breath-by-breath expired gas analysis, and continuous electrocardiographic 
monitoring. Seventeen HF patients were excluded due to atrial ﬁbrillation or permanent 
pacemaker. CI was assessed by the following standardized criteria: 1) failure to achieve 
>85% of age-predicted maximal heart rate despite a peak respiratory exchange ratio > 
1.05; or 2) if respiratory exchange ratio was < 1.05, a ratio of percent heart rate reserve to 
percent metabolic reserve < 0.80 at the submaximal workload (25 watts). 
Results. CI was present in 22% of the HF patients (26 % of SHF and 19% of DHF patients), 
and in only 2 (7%) of the NL subjects (p<0.05). Peak exercise oxygen consumption (VO2) 
was signiﬁcantly lower in patients with CI versus without CI (12.4 + 0.8 vs 14.6 + 0.4 
ml/kg/min; p<0.01). Heart rate reserve (change from reset to peak exercise) correlated 
signiﬁcantly with peak VO2 in both CI (R = 0.39, p = 0.04) and non-CI groups (R = 0.41, 
p = 0.01) and explained approximately 17% of the variance observed in the peak VO2. 
Conclusion. CI is common in older patients with either DHF or SHF and contributes to 
their severe exercise intolerance.
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1105-158 Accurate Detection of Coronary Artery Disease by 
ST-Segment/Heart Rate Hysteresis of the Exercise 
Electrocardiography Test
Rami Lehtinen, Jari Viik, Willi Kaiser, Mari Niemi, Tiit Kööbi, Kari Niemelä, Väinö 
Turjanmaa, Tampere University Hospital, Tampere, Finland, Tampere University of 
Technology, Tampere, Finland
Background: The objective of this study was to evaluate, whether the ST-segment/heart 
rate (ST/HR) hysteresis, which integrates the ST/HR analysis during both exercise and 
postexercise recovery phases of the exercise ECG test, can detect coronary artery disease 
(CAD) more accurately than methods using either exercise or recovery phase alone.
Methods: The study population comprised of 310 patients referred for a routine bicycle 
exercise ECG test at Tampere University Hospital. Of these, 112 had angiographically 
proven CAD, whereas 50 had no CAD according to angiography and 148 were clinically 
normal with respect to cardiac diseases. For each patient, the maximum values of ST/HR 
hysteresis, ST/HR index, end-exercise ST depression and ST depression at 3 minutes 
of recovery were determined from the 12-lead system (aVL, aVR, and V1 excluded). 
In addition, the heart rate recovery from peak exercise to 1 minute of recovery (HR 
Recovery) was calculated. The data were analyzed off-line by a modiﬁed CASE® (GE 
Medical Systems).
Results: The diagnostic properties were compared by receiver-operating characteristic 
(ROC) analysis. The area under the ROC curve (AUC) of ST/HR hysteresis was 88.1 %, 
which was signiﬁcantly (p<0.001) larger than that of the other variables, indicating the 
superior overall diagnostic performance of the ST/HR hysteresis (Fig. 1).
Conclusion: The ST/HR hysteresis can signiﬁcantly improve the diagnostic performance 
and clinical utility of the exercise ECG test for the detection of CAD.
1105-159 Achieving Optimal Stress Level During Exercise 
Testing: Should We Revisit Our Cutoff Points?
Mouaz Al-Mallah, Fadi Alqaisi, Abdulilah Arafeh, Raniah Al-tamsheh, Karthik 
Ananthasubramaniam, Henry Ford Hospital, Detroit, MI
Background: The age-predicted maximal heart rate (PMHR) equation (220 −Age) is 
commonly used as a criterion for predicting maximal heart rate possible during exercise 
testing. Aqeduate stress level is when the patient achieves >85% of this equation. 
Recently, the equation(208−0.7×Age) has been suggested to better estimate PMHR 
especially in elderly patient by 10-20 beats. We tested the hypothesis that 208−0.7×Age 
is a better equation to predict PMHR and in turn better predicts major adverse cardiac 
events (MACE).
Methods: Retrospective study of consecutive patients who had a negative SE between 
1/97-12/97. Age PMHR was calculated using both equations. Patients were divided into 
three groups based on whether they achieved 85% PMHR using neither(G1), 220-age 
formula only (G2) or both equations(G3). Group comparisons were conducted for baseline 
demographics and MACE using chi-square testing and student t-test.
Results: Of the 662 patients with negative SE, 530 patient achieved > 85% PMHR by 
220-Age. Of these, only 489 patients were adequate by 208-0.7×Age. Over a median 
follow up of 73 months, the lowest MACE rate was seen in patients with adequate stress 
level only by >85%(208-0.7×Age) compared to the other groups (11.3%(G1) vs. 9.8%(G2) 
vs. 4.7%(G3), p=0.013).
Conclusion: Adequate stress level estimated by >85%(208 − 0.7×Age) seems to better 
predict MACE compared to the traditional 220-Age formula. Incorporation of this formula 
may achieve better predictive accuracy for exercise stress testing.
 
Variable
G1: Inadequate by 
both equations
(N=132)
G2: Adequate Only 
by >85% (220-Age)
(N=41)
G3: Adequate 
by >85% (208- 
0.7xAge)
(N=489)
p value
Age (Year) 55 60 50 <0.001
Females(%) 47 51 50 0.8
African Americans (%) 14 29 21 0.02
Hypertension (%) 15 17 4 <0.001
Diabetes (%) 13 7 6 0.02
Prior myocardial infarction (%) 22 13 5 <0.001
Prior angioplasty (%) 15 11 3 <0.001
Prior bypass surgery (%) 10 14 3 0.002
MACE (%) 11.4 9.8 4.7 0.013
1105-160 Opposite Response of Core Temperature and Blunted 
Response of Forearm Skin Temperature to Bicycle 
Ergometer Exercise in Chronic Heart Failure
Kyoko Sato, Fumiyasu Yamasaki, Motonori Ando, Hiroaki Kitaoka, Tetsurou Sugiura, 
Takayuki Satou, Yoshinori Doi, Kochi Medical School, Nankoku, Japan
Background: Abnormal thermoregulatory response to exercise chronic heart failure 
(CHF) is hypothesized from abnormal exercise-induced redistribution of cardiac output.
Methods: In 30 CHF patients (62±12 yrs, 14 dilated cardiomyopathy, 3 hypertensive 
heart disease, 13 ischemic heart disease, NYHA Class I-III) and 24 normal age-matched 
subjects performing a recumbent bicycle ergometer exercise at a 50-watt load for 3 min, 
skin temperature (Tskin) at the forearm, core temperature (Tcore) at the external ear 
canal, oxygen consumption, plasma levels of norepinephrine (PNE) and B-type natriuretic 
peptide (BNP) were measured.
Result: The baseline Tcore and Tskin of CHF patients tended to lower, while PNE 
and BNP was signiﬁcantly high (370±190 vs. 222±69 ng/ml, 192 ±300 vs. 17 ±9 pg/ml 
respectively, p<0.05). In exercise, Tcore gradually rose in normal subjects, but dropped in 
CHF; Tskin fell in both, however the degree was signiﬁcantly low in CHF (-0.228±0.16°C 
vs. -0.389±0.252°C, P<0.01). Oxygen consumption was similar in both groups.
Conclusion: Sympathetic activation during mild exercise induced forearm 
vasoconstriction in both normal and CHF subjects. Normally, this response would recruit 
blood ﬂow from nonworking tissue to working muscles. However, in CHF patients, the 
blunt vasoconstrictive response in the forearms allowed heat loss; preventing an increase 
in Tcore despite the increase in oxygen consumption. 
1105-161 A Simpliﬁcation of the Duke Treadmill Score
John R. Schairer, Stephen J. Keteyian, Clinton A. Brawner, Jonathin K. Ehrman, R. 
Hoag, Henry Ford Heart and Vascular Institute, Detroit, MI
Background: ACC/AHA guidelines for exercise testing recommend the use of multiple 
prognostic markers in the interpretation of exercise tests to improve predictive accuracy as 
well as the use of MET rather than minutes exercised to quantitate exercise capacity. The most 
frequently recommended equation is the Duke Treadmill Score (DTS). However, the equation 
for the DTS uses minutes exercised on a Bruce Protocol rather than MET requiring the use of 
a nomogram to calculate risk when other exercise protocols are used. The nomogram is more 
cumbersome to use than the equation for the DTS and not always available. 
Purpose: To compare the DTS with a modiﬁcation of the DTS, based on METs rather than 
minutes exercised, as a means to simplify risk stratiﬁcation of patients after exercise testing. 
Methods: Consecutive exercise treadmill tests (Bruce, n=184, and other protocol, n=145) 
performed between June 2002 and June 2003 (n=329) referred for evaluation of chest 
pain or stable coronary artery disease were included. The DTS was calculated using 
the equation: (Exercise time) - 5x (ST depression) - 4x(Exercise angina index). For non-
Bruce protocols the Duke nomogram was used. On all tests the DTS was compared 
to a modiﬁed DTS using the equation: Modiﬁed DTS = [(MET) - 5x(ST depression) - 
4x(Exercise angina index)] - 1.1. MET was the exercise capacity reported at the end of 
each test. Patients were stratiﬁed into low, intermediate or high risk. 
Results: All patients classiﬁed as low risk (n= 200) by the DTS were also classiﬁed as 
low risk by the modiﬁed DTS. All patients classiﬁed as intermediate risk (n= 126) by DTS 
were also classiﬁed as intermediate risk by the modiﬁed DTS. Three patients with chest 
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pain and ECG changes were classiﬁed high risk by the DTS but intermediate risk by the 
modiﬁed DTS. For the low and intermediate risk group, 100% of the time the modiﬁed 
equation agreed with the DTS. 
Conclusion: Our modiﬁcation of the DTS agrees with the DTS 100% of the time in low 
and intermediate risk patients and eliminates the need for the use of the nomogram. The 
modiﬁed equation is easier to use in practice than the nomogram and conforms to the 
practice of using MET as universal measure of work capacity.
1105-162 Noninvasive Assessment Of Hemodynamic Response 
To Moderate Physical Activity In Patients Undergoing 
Resynchronization Therapy 
Thomas Berger, Ralf Harun Zwick, Franz Xaver Roithinger, Gerhard Poelzl, R. Pﬁster, H. 
Hoertnagl, Otmar Pachinger, Florian Hintringer, Internal Medicine, Innsbruck, Austria
Background: Cardiac resynchronization therapy (CRT) exhibits beneﬁcial effects on 
exercise tolerance and quality of life in patients with congestive heart failure. However, 
little is known about the hemodynamic response to CRT in patients undergoing moderate 
physical activity. The aim of our study was to evaluate noninvasively the immediate effects 
of CRT during submaximal exercise on hemodynamic parameters.
Methods: Eleven patients (4F; age 69±5y; NYHA II-III; LVEF130msec; biventricular 
DDDR pacemaker implantation >3 months) underwent a treadmill exercise test using the 
modiﬁed bruce protocol (2.7km/h; 9% elevation; 4.6 METS).
Heart rate (HR), mean blood pressure (RRmean), cardiac output (CO) and total 
peripheral resistance (TPRI) were obtained noninvasively by means of bioimpedance 
cardiography (TaskForceMonitor™;CNSystems). Measurements were performed during 
a 3-minute exercise period followed by a 10-minute resting period for right-(RV), left-(LV) 
and biventricular (BiV) atrioventricular-synchronized pacing (VDD30) as well as during 
sinus rhythm (VVI30) in each patient. Complete physical recovery in-between the different 
modes was proven by measurements of blood lactate levels.
Results: BiV and LV pacing increased CO (107±14% and 107±12%; P<0.05) as 
compared to RV pacing (given as 100%) and sinus rhythm (99±14%). RRmean was 
increased during BiV and LV pacing (110±22% and 104±15%; P10% increase in CO) had 
signiﬁcant lower basal CO levels (88±22%) as compared to non-responders (103±3%; 
P<0.05). Interestingly, the increase in CO between SR and BIV was slightly augmented 
during excercise as compared to resting conditions (11% vs. 14%, ns). HR, TPRI and 
blood lactate levels did not show any changes within the different pacing modes as 
compared to sinus rhythm.
Conclusion: Biventricular and left ventricular pacing signiﬁcantly increase CO and RRmean 
in patients with congestive heart failure during rest as well as during physical exercise. The 
beneﬁcial effect of CRT may be augmented during moderate physical activity.
1105-163 Evidence That Cerebral Oxygenation Is Impaired During 
Exercise in Patients With Left Ventricular Dysfunction
Akira Koike, Osamu Nagayama, Masayo Hoshimoto, Akihiko Tajima, Keiko Oikawa, 
Tadanori Aizawa, Long Tai Fu, Haruki Itoh, The Cardiovascular Institute, Tokyo, Japan
Background: Quite recently, we reported that the cerebral oxyhemoglobin (O2Hb), a 
parameter reﬂecting cerebral blood ﬂow and cerebral oxygenation, decreased during 
exercise in nearly half of patients with dilated cardiomyopathy. The rate of the decrease 
was even higher among those with lower left ventricular ejection fraction (LVEF). These 
ﬁndings strongly suggest that the decrease in cerebral O2Hb during exercise in these 
patients reﬂects a cerebral hypoxia resulting from impaired O2 transport to the brain. In 
the present study we evaluated whether the inhalation of supplemental O2 diminishes the 
decrease in cerebral O2Hb during exercise in patients with left ventricular dysfunction.
Methods: Ten patients with LVEF of less than 50 % (Age, 62 ± 13 years; mean LVEF, 33 ± 
11 %) and a clearly observable decrease in cerebral O2Hb during preliminarily performed 
exercise testing underwent additional two symptom-limited incremental exercise tests in 
randomized order on different days, one while breathing room air (control) and one while 
breathing 50 % O2. In the latter test, the subjects commenced with normal air and were 
switched over to the 50 % O2 without notiﬁcation when they reached the work rate at which 
cerebral O2Hb had begun to decrease in the preliminarily-performed exercise test. Cerebral 
O2Hb was continuously monitored during exercise using near-infrared spectroscopy.
Results: In the control exercise test, cerebral O2Hb initially remained constant at lower 
work rates, and then began to decrease at higher work rates. When the subjects breathed 
50 % O2, this decrease in cerebral O2Hb was diminished. The change of cerebral O2Hb 
from rest to peak exercise during the test under 50 % O2 was signiﬁcantly higher than 
that during the control test (-0.23 ± 1.89 vs -2.47 ± 1.57 µmol/L, p=0.002). Similarly, the 
change of the cerebral tissue oxygenation index was signiﬁcantly higher in the test under 
50 % O2 (0.45 ± 4.46 vs -3.33 ± 3.06 %, p=0.023).
Conclusion: Our present ﬁndings strongly suggest, ﬁrstly, that exercise of moderate to 
heavy intensity can impair cerebral oxygenation in patients with left ventricular dysfunction, 
and secondly, that breathing of supplemental O2 sets off this impairment.
1105-164 Prognostic Value of Cardiopulmonary Exercise Testing 
in a Group of Female Patients With Heart Failure
Ross Arena, Marco Guazzi, Jonathan Myers, Virginia Commonwealth University, 
Richmond, VA, University of Milano, Milano, Italy
Background: Cardiopulmonary exercise testing clearly holds prognostic value in the heart 
failure (HF) population. Peak oxygen consumption (VO2) and the relationship between minute 
ventilation (VE) and carbon dioxide production (VCO2) have emerged as the most frequently 
assessed variables. Studies supporting the clinical value of these variables in HF have been 
consistently comprised of predominantly male groups. The purpose of the present study is to 
examine the prognostic value of peak VO2 and VE/VCO2 slope in an all-female HF group.
Methods: Sixty-one female subjects diagnosed with HF participated in this study. 
Mean age and ejection fraction were 55.8 years (±11.3) and 31.3% (±12.2). Cox 
regression analysis examined the ability of peak VO2 and VE/VCO2 slope to predict all-
cause mortality. Receiver Operating Characteristic (ROC) analysis determined optimal 
prognostic threshold values for peak VO2 and VE/VCO2 slope.
Results: Mean peak RER, peak VO2, and VE/VCO2 slope values were1.0 (±0.1), 13.0 
mlO2•kg
-1•min-1 (±4.0), and 35.9 (±8.1) respectively. There were 16 deaths during the 
tracking period [(mean = 27.2 months (±8.1)]. Peak VO2 (Chi-square: 5.5, p=0.02) and 
VE/VCO2 slope (Chi-square: 14.1, p<0.001) were both univariate predictors of mortality. 
Peak VO2 did not add additional predictive value to VE/VCO2 slope in a multivariate model 
(Residual Chi-square: 0.63, p=0.43). The optimal prognostic threshold values for peak 
VO2 and VE/VCO2 slope were 12.1 mlO2•kg
-1•min-1 (60% sensitivity, 62% speciﬁcity) and 
35.5 (71% sensitivity, 69% speciﬁcity) respectively.
Conclusion: The results of the present study indicate peak VO2 and VE/VCO2 slope hold 
similar prognostic characteristics in an all-female HF group compared to previous investigations 
primarily using male subjects. Speciﬁcally, peak VO2 and VE/VCO2 slope are prognostically 
signiﬁcant although the latter variable outperforms the former. Optimal threshold values for 
these variables were also found to be similar to ﬁndings reported in other investigations. 
Separate, gender-based, prognostic classiﬁcation schemes may therefore not be necessary 
for individuals with HF undergoing cardiopulmonary exercise testing.
ORAL CONTRIBUTIONS
817  Resynchronization Therapy
Monday, March 07, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 414C
2:00 p.m.
817-3 Is Left Ventricular Remodeling Related to the Clinical 
Response to Cardiac Resynchronization Therapy?
Barbara Vidal, Marta Sitges, Alba Marigliano, Lluis Mont, Manuel Azqueta, Ernesto 
Díaz-Infante, David Tamborero, Josep Brugada, Carles Paré, Cardiovascular Institute, 
Hospital Clinic, Barcelona, Spain
Background: Cardiac resynchronization therapy (CRT) has shown to reverse left 
ventricular (LV) remodeling in patients with congestive heart failure (CHF), but its 
relationship with clinical response has not been assessed. The objective of this study was 
to analyze if patients who improve clinically have greater LV remodeling than those who 
do not respond (NR).
Methods and results: Forty-eight consecutive patients with end-stage CHF,left bundle 
branch block and LV ejection fraction (EF)<35% treated with CRT were included. Echo-
Doppler scans were taken just before and immediately after the implantation of the 
pacemaker, and at 6 month follow-up. We compared LV diameters, volumes and ejection 
fraction(obtained by M mode and Simpson’s method). We considered responders those 
patients who improved by 10% or more in the 6 minutes walking test, did not die or need 
a heart transplantation during follow-up. Nine out of 48 patients (19%) did not respond to 
CRT. There were no differences in baseline LV dimensions between responders and NR. 
At follow-up, LV volumes and diameters decreased signiﬁcantly in responders, but did not 
change in NR (graph). Also, LV EF improved only in responders (22 ± 6 to 27 ±7 %, p < 
0.05 in responders vs. 24 ± 7 to 30 ± 10% in NR, p=NS).
Conclusions: 1- LV remodeling was only observed in patients who clinically responded 
to CRT at 6 months follow-up. 2- The effect of CRT on ventricular remodeling should 
explain at least in part, the clinical response. 
 2:15 p.m.
817-4 Biventricular Pacing Increases Left Anterior 
Descending Flow Reserve in Patients With Heart Failure
George Athanassopoulos, Themistoklis Maounis, Evangelos Leontiades, George 
Hatzigeorgiou, Stefanos Karagiannis, George Karatasakis, Dennis V. Cokkinos, Onassis 
Cardiac Surgery Center, Athens, Greece
INTRODUCTION: Biventricular pacing (Biv) has been introduced in heart failure 
treatment but the underlying mechanisms of Biv effects remain under investigation. There 
are still very few data concerning the effect of Biv on myocardial perfusion. Transthoracic 
Doppler echo provides an accurate means to evaluate perfusion in the distal left anterior 
descending artery (LAD) bed through the respective ﬂow reserve (CFR). Aim of the study 
was to interrogate the potential effect of Biv on LAD CFR.
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METHODS: 17 consecutive pts (all with LBBB,QRS> 160msec (193+14msec), 13 with 
idiopathic dilated cardiomyopathy, 4 with ischemic cardiomyopathy, 16 males, aged 46-70 
years, left ventricular ejection fraction (EF) 24+6%, left ventricular enddiastolic diameter 
(LVDD) 74+13 mm) were studied without (Nopace) and with Biv. CFR in the distal 
LAD territory (modiﬁed 2 chamber apical view, 7MHz transducer) was estimated post 
adenosine infusion 140mg/kg/min for 4 min (CFR=ratio of velocity-time integral -VTI’s of 
diastolic phase post adenosine/baseline). CFR was evaluated at No pace and Biv. Study 
conditions were changed on a random sequence.
RESULTS: Diastolic velocity proﬁles were similar between Nopace /Biv at rest (cm: 
7.4+2.8 /7.5+2.8). However, they were greater post adenosine in Biv (11+7 vs 13.4+9 
p=0.05) resulting in greater CFR (1.46+0.5 vs 1.79+0.6, p=0.001). The % increase of CFR 
(%d) during Biv was 25+0.35 (p<0.05). CFR Biv was related to CFR Nopace (CFRbiv=0.
5+0.88*CFRNopace, r=0.76, p=0.01). Moreover, the %dCFR was inversely related to the 
degree of LV dilatation: (% dCFR vs LVDD: r=0.70, p=0.024) as well as to the EF (r=0.56, 
p=0.06). QRS was not related to any of the CFR parameters.
CONCLUSION: In patients with severe left ventricular systolic dysfunction and left bundle 
brunch block, biventricular pacing was related to an improvement of CFR at the LAD.
Baseline CFR as well as the degree of LV dilatation and dysfunction affected the CFR 
changes. Thus, changes of microvascular hemodynamics in the LAD territory, related to 
the respective CFR, might be a parameter contributing to the beneﬁcial effects exerted by 
biventricular pacing since decreased CFR is the hallmark of myocardial hibernation.
2:30 p.m.
817-5 Heart Rate Variability Predicts Adverse Outcome 
Among Cardiac Resynchronization Therapy Patients
F. R. Gilliam, Maureen McGuire, Gerrard M. Carlson, Tim Pratt, Duke University Medical 
Center, Durham, NC, Guidant Corporation, St. Paul, MN
Background: Cardiac resynchronization therapy with deﬁbrillation (CRT-D) provides 
useful therapy in the treatment of congestive heart failure (HF). Decreased heart rate 
variability (HRV) is an indicator of autonomic dysfunction and is regarded as a predictor of 
HF mortality. The present study evaluated the utility of HRV measured via the implanted 
CRT-D device in predicting future mortality. 
Design: The Heart Failure-Heart Rate Variability (HF-HRV) Registry is an ongoing study 
that has enrolled 1409 HF patients who received a Guidant CONTAK RENEWAL CRT-D. 
Patients are followed for one-year post-implant. Patients’ Activity Log (a device measure of 
activity level) and quality of life (QOL; Minnesota Living with Heart Failure Questionnaire) 
data were obtained at implant. HRV measures included: mean, minimum, and maximum 
heart rate, SDANN (standard deviation of average ﬁve-minute intrinsic RR intervals), and 
HRV Footprint; these measures were collected at the 2-week follow-up. These baseline 
measures were used to predict mortality. 
Results: Independent baseline predictors of mortality are shown in the Table. Stepwise 
logistic regression analysis indicated that, together, baseline HRV Footprint and Activity 
Log were the most signiﬁcant predictors of future mortality. 
Conclusion: These data suggest that HRV and activity levels soon after implant predict 
future mortality. Future analyses will evaluate how changes over time in these variables 
are related to mortality and morbidity.
Death
(n=77)
No Death
(n=1331) p-value
HRV Footprint 22+9 31+11 <0.0001
SDANN 51+18 70+24 <0.0001
Minimum Heart Rate 70+13 64+10 0.0024
Mean Heart Rate 79+14 75+11 0.0576
Maximum Heart Rate 96+15 95+13 0.9440
Activity Log 3+2 5+3 <0.0001
QOL 60+24 55+24 0.0847
2:45 p.m.
817-6 Left Ventricular Dyssynchrony Predicts Prognosis After 
Cardiac Resynchronization Therapy
Gabe B. Bleeker, Jeroen J. Bax, Sander G. Molhoek, Eduard R. Holman, Paul Steendijk, 
Ernst E. van der Wall, Martin J. Schalij, Leiden University Medical Center, Leiden, The 
Netherlands
Background Cardiac resynchronization therapy (CRT) is considered a major 
breakthrough in the treatment of patients with dilated cardiomyopathy and advanced heart 
failure. However, not all patients respond, and therefore pre-implantation identiﬁcation of 
responders is needed. In the present study, the prognostic value of LV dyssynchrony in 
patients undergoing CRT was assessed.
Methods Eighty-ﬁve patients with end-stage heart failure, QRS duration >120 ms and 
LBBB were evaluated by tissue Doppler imaging before CRT. At baseline and 6 months 
follow-up, NYHA class, quality of life and 6-minute walking distance, LV volumes and LV 
ejection fraction (EF) were determined. Events (death, hospitalization for decompensated 
heart failure) were obtained during 1-year follow-up.
Results Responders (74%) and non-responders (26%) had comparable baseline 
characteristics, except for a larger dyssynchrony in responders (87±49 ms versus 35±20 
ms, P<0.01). Patients with no or minimal dyssynchrony (<40 ms) had a low likelihood 
of improvement in clinical parameters and reverse remodeling, whereas patients with 
extensive dyssynchrony (≥80 ms) had a high likelihood of response. Using a cutoff value 
of 65 ms for LV dyssynchrony, a sensitivity of 81% and speciﬁcity of 81% to predict 
response to CRT were obtained. Patients with dyssynchrony ≥65 ms had an excellent 
prognosis (6% event-rate) after CRT, as compared to a 50% event-rate in patients with 
dyssynchrony <65 ms (P<0.001).
Conclusion Patients with extensive LV dyssynchrony (>65 ms) responded well to CRT 
and had an excellent prognosis at 1 year follow-up.
3:00 p.m.
817-7 Cardiac Resynchronization Therapy for Heart Failure 
Patients With Normal QRS Duration and Coexisting 
Mechanical Asynchrony
Cheuk-Man Yu, Jeffery Wing-Hong Fung, Qing Zhang, Yat-Sun Chan, Chi-Kin Chan, 
Shun-Ling Kong, Gabriel WK Yip, Anna Chan, Eugene B. Wu, John Wong, YY Lam, 
PW Lee, John E. Sanderson, The Chinese University of Hong Kong, Hong Kong, Hong 
Kong, Alice Ho Miu Ling Nethersole Hospital, Hong Kong
Background: Cardiac resynchronization therapy (CRT) is useful to improve clinical status 
and cardiac function in heart failure (HF) patients with prolonged QRS duration. Recently, 
mechanical asynchrony is found in HF patients with narrow QRS complexes (<120ms) 
by tissue Doppler imaging (TDI). This study examined if CRT improved clinical status 
and induced left ventricular (LV) reverse remodeling in HF patients with narrow QRS 
complexes.
Methods: 24 HF patients with NYHA class III or IV (aged 62±13years, 79% male, 63% 
ischemic etiology), narrow QRS complexes (mean duration: 98±12ms), and evidence of 
mechanical asynchrony by TDI based on the 6-basal-6-mid segmental model in the LV, 
were recruited. Echocardiography and clinical assessment (NYHA class, maximal exercise 
capacity on treadmill, 6-minute Hall-Walk distance and quality of life) were performed at 
baseline and 3 months after CRT.
Results: There was signiﬁcant improvement of NYHA class (2.88±0.50 Vs 2.19±0.40, 
p<0.001), maximal exercise capacity (4.0±1.4 Vs 4.7±1.6 mets, p=0.02), 6-Minute Hall-
Walk distance (325±85 Vs 361±72m, p=0.02), but not Minnesota quality of life score 
(28±10 Vs 19±20, p=NS). There was LV reverse remodeling with reduction of LV end-
systolic (119±40 Vs 99±45cm3, p<0.001) and end-diastolic (162±47 Vs 148±52cm3, 
p=0.006) volumes, gain in ejection fraction (31.5±7.3 Vs 36.3±9.1%, p=0.008) and 
increase in sphericity index in both end-systole (1.83±0.30 Vs 1.99±0.43, p=0.01) and 
end-diastole (p=0.03). Mitral regurgitation was reduced (p=0.03) while LV ﬁlling time was 
increased (p=0.04). TDI showed marked segmental variation in time to peak myocardial 
systolic velocity in ejection phase, which was reduced after CRT. Furthermore, signiﬁcant 
septo-lateral delay was present before CRT (p=0.01) which was abolished after CRT.
Conclusions: CRT for HF patients with narrow QRS complexes who had echocardiographic 
evidence of mechanical asynchrony is useful by improving clinical status and systolic 
function. LV reverse remodeling was also observed. These patients showed reduction 
of systolic asynchrony by a mechanism similar to those with wide QRS complexes as 
demonstrated by TDI.
3:15 p.m.
817-8 Cost-Effectiveness of Cardiac-Resynchronization 
Therapy With and Without a Deﬁbrillator in COMPANION 
Heart Failure Patients
Arthur M. Feldman, Gregory de Lissovoy, Michael R. Bristow, Leslie A. Saxon, Teresa De 
Marco, David A. Kass, John Boehmer, Steven Singh, David J. Whellan, Peter Carson, 
Audra Boscoe, Timothy Baker, Matthew R. Gunderman, Jefferson Medical College, 
Philadelphia, PA, University of Colorado Health Sciences Center, Denver, CO
Background: The COMPANION trial concluded that cardiac-resynchronization therapy 
with either a pacemaker (CRT-P) or deﬁbrillator (CRT-D) in combination with optimal 
pharmacological therapy (OPT) decreased combined risk of death from any cause or 
ﬁrst hospitalization compared with OPT alone. We analyzed hospitalization costs and 
incremental cost-effectiveness ratios (ICER) of CRT-P and CRT-D relative to OPT for 
COMPANION patients.
Methods: Intent-to-treat trial data were modeled to project the ICER of CRT-D and 
CRT-P relative to OPT over a base case 5-year treatment episode from a third-party 
payer (Medicare) perspective. Mortality for CRT-P, CRT-D, and OPT was modeled using 
an exponential function that achieved good ﬁt with observed survival data. Monthly 
probability of hospital admission for each arm was derived by averaging 24 sequential 
months of adjudicated case report form data. Cost of hospital admission was calculated 
by mapping adjudicated data to an appropriate DRG and corresponding physician fees. 
All-cause hospitalization and all-cause mortality were used in base case analysis and 
both were discounted at 3% per annum. The beneﬁcial impact of CRT-P or CRT-D on 
quality of life was not incorporated into this analysis.
Results: In the 5-year base case analysis, CRT-D was associated with a 20% (or 
$7,698) reduction in cost of follow-up hospitalization. CRT-D analysis also demonstrated 
increased survival of 0.50 years with additional costs of $18,612 and a resultant ICER of 
$36,870/life-year saved relative to OPT. CRT-P resulted in a similar reduction in cost of 
follow-up hospitalization, but the ICER was not calculated due to absence of a statistically 
signiﬁcant mortality beneﬁt. Sensitivity analysis examining effects of varying survival rates, 
hospitalization rates, and episode duration yielded a range of results, e.g., increasing 
device longevity to 6 years decreased the ICER for CRT-D to $29,128/life-year saved.
Conclusions: For COMPANION patients, CRT-D increased survival while simultaneously 
decreasing costs of follow-up hospitalization with a resultant cost-effectiveness ratio, 
relative to OPT, well within the accepted range for innovative therapy. 
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818  Clinical Aspects of Hypertrophic 
Cardiomyopathy
Monday, March 07, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 230B
2:00 p.m.
818-3 Evidence that Hypertrophic Cardiomyopathy is 
a Disease Characterized By Predominantly Left 
Ventricular Outﬂow Tract Obstruction
Martin S. Maron, Iacopo Olivotto, Andrey G. Zenovich, James E. Udelson, Mark S. Link, 
Natesia G. Pandian, Jeffery T. Kuvin, Susan A. Casey, Stefano Nistri, Franco Cecchi, 
Barry Maron, Tufts-New England Medical Center, Boston, MA, Minneapolis Heart 
Institute Foundation, Minneapolis, MN
Background: Most patients with hypertrophic cardiomyopathy (HCM) are thought to 
have the nonobstructive form of the disease without a subaortic gradient. However, this 
characterization is based predominantly on measurement of left ventricular (LV) outﬂow 
tract obstruction under resting conditions. However, the proportion of patients without 
obstruction at rest who exhibit mechanical impedance to LV outﬂow with physiologic 
provocation remains unresolved. 
Hypothesis: To prospectively deﬁne prevalence and clinical proﬁle of LV outﬂow 
obstruction (i.e., ≥ 30 mmHg) in a large HCM cohort. Methods: We analyzed 221 
consecutive HCM patients from 3 centers in U.S. and Italy (mean age 43±16 years) 
and measured LV outﬂow gradient at rest by continuous wave Doppler. Patients with LV 
outﬂow gradient < 50 mmHg at rest were also studied with Valsalva, and Bruce protocol 
stress echocardiography. 
Results: Of 221 patients, 91 (41%) had an outﬂow gradient ≥ 50 mmHg at rest. Of the other 
130 patients with rest gradient < 50 mmHg, 65 (ie., 50%, and 29% of the 221) developed 
physiologically signiﬁcant mechanical impedance to LV outﬂow following cessation of exercise 
with gradient ≥ 30 mmHg (including 45 patients with gradients 50 to 120 mmHg) measured 
with CW Doppler; the remaining 65 patients had no gradient at rest or with exercise. Therefore, 
for the overall study group (n=221), 156 or 70% of 221 HCM patients exhibited mechanical 
obstruction to LV outﬂow (at rest and/or with exercise). Most patients with latent gradients 
evident only with exercise (38/65; 58%) had no or mild symptoms; only 27 (41%) had severe 
heart failure and were candidates for surgery or alcohol septal ablation. Of the 65 patients 
who developed outﬂow gradients ≥ 30 mmHg with exercise, only 32 (49%) had gradients ≥30 
mmHg provoked with Valsalva (sensitivity = 50%). 
Conclusions: HCM is most appropriately characterized as a predominately obstructive 
disease (ie.,70% of patients) in which physiologically relevant LV outﬂow gradients are 
commonly identiﬁed by exercise testing. These prospective data justify routine stress 
echocardiography to deﬁne obstruction in HCM patients with obvious application to 
management strategies.
2:15 p.m.
818-4 Dilated-Hypokinetic Evolution of Hypertrophic 
Cardiomyopathy: Incidence, Risk Factors, and 
Prognostic Implications in Pediatric and Adult Patients 
at a Nontertiary Cardiological Center
Elena Biagini, Fabio Coccolo, Guido Rocchi, Marinella Ferlito, Maria Letizia Bacchi Reggiani, 
Chiara Pedone, Angelo Branzi, Claudio Rapezzi, S. Orsola Hospital, Bologna, Italy
Background. Hypertrophic cardiomyopathy (HCM) can evolve in to a phase characterized 
by left ventricular (LV) systolic dysfunction, dilatation and wall thinning (dilated-hypokinetic 
(DH) evolution). We investigated incidence, risk factors, natural history and prognosis 
of DH evolution of HCM in a large cohort of patients (pts) followed at a non-tertiary 
cardiological center serving both the pediatric and adult population.
Methods. We prospectively studied 222 consecutive HCM pts (65% men, age at initial 
evaluation 40±20 years, 42 pts (19%) ≤18 years) referred to our institution between 1964 
and 2002 (mean follow-up 11±9 years).
Results. Diagnosis of DH evolution of HCM was made in 12 pts at the ﬁrst evaluation, 
excluding 1 pt who underwent surgical myectomy (prevalence=4.9%). Twelve of the 210 
pts with ‘classic’ HCM at ﬁrst evaluation underwent DH evolution (incidence=5.3/1000 
pt-years). The baseline (pre dilatation) characteristics of these pts (n=12) were compared 
with those of the remaining pts. Pts who developed DH HCM were signiﬁcantly younger 
at ﬁrst evaluation (31±14 vs 41±21 years, p=0.03), and more often had a family history 
of HCM (58% vs 26% p=0.03) or sudden death (50% vs 19%), p=0.02). On morphologic 
grounds, pts who developed DH HCM showed greater LV parietal thickness not only 
of interventricular septum (23±5 mm vs 19±6, p=0.03) but also of posterior wall (15±5 
mm vs 13±4, p=0.03). ROC curves analysis showed that the optimal cut-off value of the 
posterior wall thickness associated to DH HCM development was 14mm (sensitivity=73%, 
speciﬁcity=92%). Heart transplant free survival was signiﬁcantly lower among pts with 
DH HCM at the ﬁrst evaluation (16%/yr vs 2.5 %, p= 0.0001). Cox proportional hazards 
regression analysis identiﬁed LV dilatation (RR = 12, 95% CL 5-28), medical treatment at 
ﬁrst examination (RR = 3.7, 95% CL 1.4-9.6), and NYHA class III/IV at ﬁrst evaluation (RR 
= 2.4, 95% CL 1.1-5.3) as independent predictors of death or heart transplant.
Conclusion. DH evolution of HCM is relatively frequent in both adult and pediatric pts. 
Young age at diagnosis of HCM and LPW thickness ≥14mm are incremental risk factors 
for this evolution which carries on an ominous prognosis.
2:30 p.m.
818-5  Prospective, Randomized Study of Ethanol Dosing in 
Patients Undergoing Percutaneous Septal Ablation for 
Obstructive Hypertrophic Cardiomyopathy
Josef Veselka, Paul Sorajja, Radka Ducho�ová, Šárka Procházková, Jana Pálení�ková, 
David Zemánek, David Tesa�, University Hospital Motol, Prague, Czech Republic, Mayo 
Clinic and Foundation, Rochester, MN
Background: Percutaneous septal myocardial ablation (PTSMA) is a promising therapy 
that leads to clinical and hemodynamic improvement in patients with obstructive 
hypertrophic cardiomyopathy (HOCM). This study examined the relation between ethanol 
dosing and the early hemodynamic and morphologic changes after PTSMA.
Methods: Forty-two patients (53 yrs; 60% women) undergoing PTSMA were randomized 
in 1:1 fashion to receive either >2 cc (group A) or ≤ 2 cc of ethanol (group B). Clinical, 
morphological, and hemodynamic data were obtained at baseline, immediately after 
procedure, and periodically up to 3 months after PTSMA.
Results: There were no differences in baseline characteristics between the 2 patient 
groups. Mean dose of ethanol injected was 2.8 ± 0.6 and 1.5 ± 0.4 cc for group A and B (p 
< 0.001), respectively. Group A patients had greater enzymatic infarct size (peak CK-MB, 
3.79 ± 2.42 µkat/l) than group B patients (2.33 ± 0.85 µkat/l; p = 0.03). In both groups, 
there were signiﬁcant improvements in symptom class, reduction in septal wall thickness, 
and relief of the left ventricular outﬂow tract gradient at three months of follow-up. However, 
there were no differences in therapeutic efﬁcacy according to the dose of the ethanol, 
and no differences in the temporal changes in hemodynamic, electrocardiographic, 
morphologic, and clinical parameters.
Conclusion: In patients with HOCM undergoing PTSMA, small doses of ethanol (≤ 2 cc) with 
resultant smaller myocardial infarctions can achieve signiﬁcant clinical and hemodynamic 
improvements that are comparable to that seen with higher ethanol doses. The early course 
of these changes is not related to use of low (≤2 cc) or standard (> 2 cc) dose of ethanol.
2:45 p.m.
818-6 Regression of Left Ventricular Free Wall Hypertrophy 
After Septal Ablation for Hypertrophic Obstructive 
Cardiomyopathy
Dirk Welge, Lothar Faber, Hermann Esdorn, Hubert Seggewiss, Dieter Fassbender, 
Dieter Horstkotte, Heart Center North Rhine-Westphalia, Ruhr University Bochum, Bad 
Oeynhausen, Germany, Leopoldina Hospital, Schweinfurt, Germany
Background: It has been suggested that left ventricular (LV) unloading following successful 
outﬂow gradient (LVOTO) reduction by percutaneous septal ablation (PTSMA) results in 
regression of LV hypertrophy (LVH) also in areas not targeted by the intervention.
Methods: We studied 42 patients (pts.) who had both echocardiographic and magnetic 
resonance imaging (MRI), and measured wall thickness and LV mass before and 3 
months after PTSMA.
Results: Following a CK rise up to 667±290 U/l after injection of 3.3±1.5 ml ethanol during 
the acute phase, mean NYHA functional class was reduced from 2.9±0.5 to 1.5±0.7 at 
follow-up after 3 months, accompanied by a reduction of LVOTO, pre-obstructive LV inﬂow 
tract (LVIT) pressure, LV wall thickness, and LV mass (see table).
Conclusions: LV unloading due to LVOTO reduction leads to signiﬁcant regression of LV 
free wall thickness and LV mass, supporting the concept that a high LVIT pressure is an 
additional stimulus for LVH in HOCM apart from the genetic predisposition.
Baseline follow-up p value
LVOTO at rest (mm Hg) 58±37 10±20 <0.0001
LVOTO (mm Hg) provoked 128±49 28±33 <0.0001
LVIT pressure (mm Hg) at rest 204±43 153±28 <0.0001
LVIT pressure (mm Hg) 262±52 183±47 <0.0001
IVS (echo) 21±4 16±4 <0.0001
IVS (MRI) 24±6 15±7 <0.0001
LVPW (echo) 14±3 13±3 <0.0001
LVPW (MRI) 15±5 14±4 <0.005
LV mass index (MRI, g/m²) 154±66 127±60 <0.0001
3:00 p.m.
818-7 Gender-Related Differences in the Clinical Presentation 
and Outcome of of Hypertrophic Cardiomyopathy
Iacopo Olivotto, Martin S. Maron, A. Selcuk Adabag, Susan A. Casey, Daniela Vargiu, 
Mark S. Link, James E. Udelson, Franco Cecchi, Barry J. Maron, Referral Center 
for Cardiomyopathies, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, 
The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 
Minneapolis, MN
Background. Little is known regarding the impact of gender on the clinical expression of 
hypertrophic cardiomyopathy (HCM). We have assessed gender-related differences in a 
multicenter HCM patient population from Italy and the US. 
Methods. A total of 969 consecutive HCM patients were studied over 6.2±6.1 years. 
Results. Males had a 3:2 predominance (59%), similar in Italy and the US (p=0.24) and 
were more often diagnosed fortuitously by routine medical examination (41%, versus 23% 
in females, p<0.001). At initial evaluation, females were older and more symptomatic than 
males (47±23 vs. 38±18 years; p<0.001; mean NYHA functional class 1.8±0.8 vs. 1.4±0.6; 
p<0.001), suggesting delayed diagnosis, and also more frequently showed outﬂow 
obstruction at rest (37% vs. 23%; p<0.001). Female gender was independently associated 
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with the risk of symptom progression to NYHA classes III-IV or heart failure death (relative 
hazard 1.5; p<0.001), particularly in patients >50 years old (p<0.005). Overall HCM-related 
mortality and risk of sudden death <age 40 was similar in the two genders. Conclusions. 
Female patients with HCM were diagnosed less frequently, later in life and with more 
advanced disease states; had greater propensity toward symptom progression to NYHA 
functional classes III-IV or heart failure death. These ﬁndings suggest potential biases 
against timely clinical diagnosis for female patients with HCM, as well as the possibility 
of gender-speciﬁc differences in patient susceptibility to disease complications. The data 
underscore the need for a heightened index of suspicion for HCM in women.
3:15 p.m.
818-8 Long-Term Dual-Chamber Pacing for Hypertrophic 
Cardiomyopathy With Left Mid-Ventricular Obstruction- 
Mechanism of Dyssynchronous Activation by Tissue 
Doppler Study
Katherine Fan, Elaine Chau, Wing-Hing Chow, Grantham Hospital, Aberdeen, Hong Kong
Background: Mid-ventricular obstruction due to systolic apposition of left ventricular (LV) wall 
is a less common variant of hypertrophic obstructive cardiomyopathy (HOCM). We studied the 
effects of mechanical asynchrony induced by pacing for relieving mid-LV obstruction.
Methods: 8 patients (pts) (mean age 57 ± 16 yrs) were diagnosed with signiﬁcant mid-
cavity HOCM had pacemaker implanted. Standard and tissue Doppler echocardiogram 
were performed at follow-up (mean 42 ±26 mths). Myocardial velocities and timings were 
measured from 12 LV segments: time intervals from onset of QRS to peak systolic (Ts) 
were compared during pacing and intrinsic rhythm. Coefﬁcient of variation (SD/mean) of 
time intervals were used as index of systolic asynchrony.
Results: There was signiﬁcant reduction in mid -cavity gradient during pacing (119± 33 
vs 26±20 mmHg; p=0.001) at mean optimal AV delay of 108 ± 18 msec. Chronic pacing 
resulted in signiﬁcant prolonged Ts at anteroseptal wall.(graph) There were ﬁxed delay 
in LV apical segment after pacing was turned off. The LV end diastolic (53 ±5 vs 38±4 
ml; p<0.01) and end systolic(ESV) (19 ±8 vs 10±1 ml; p=0.03) volumes increased during 
pacing. The systolic asynchrony index (r= -0.96; p<0.01) and ESV changes (r= -0.86; 
p=0.03) were independent factors correlated with intra-cavity gradients.
Conclusions: Chronic pacing limited cavity obliteration and improved systolic reserves in pts 
with mid-LV HOCM by inducing asynchronous delayed contraction along anteroseptal wall. 
ORAL CONTRIBUTIONS
826  Coronary Revascularization and Heart 
Failure
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 414C
4:00 p.m.
826-3 Percutanoues Versus Surgical Revascularisation in 
Patients With Low Left Ventricle Ejection Fraction: the 
Results of Revascularisation in Ischaemic Heart Failure 
Trial (REHEAT).
Pawel E. Buszman, Iwona Szkrobka, Zoﬁa Tendera, Agata Gruszka, Radoslaw Parma, 
Bozena Bialkowska, Miroslaw Wilczynski, Wojciech Wojakowski, Stefan Radoslaw Kiesz, 
Jack Martin, Andrzej Bochenek, Michal Tendera, Silesian Medical School, Katowice, 
Poland, American Heart of Poland, Ustron, Poland
Revascularisation in Ischaemic Heart Failure Trial (REHEAT) is a case controlled, 
prospective study to compare recent and late result after percutaneous and surgical 
revascularisation in patients with severe ischaemic left ventricle impairement.
Methods. Patients with multi vessel coronary artery disease, left ventricle ejection fraction 
(LVEF) <40% and suitable for percutaneous (PCI) and surgical (CABG) revascularization 
were eligible for the study. The primary end-point of the study was LVEF improvement 
and long term survival, the secondary end-points included angina status and the risk of 
major adverse cardiac events (MACE) at 12 month follow-up. LV function was evaluated 
based on 2-D echo and myocardial viability was assessed according to Selvester QRS 
injury score.
Patient population. Two-hundred seventeen patients (166 males, 76.5%) were screened 
for eligibility for intent-to-stent PCI or CABG. Their mean age was 58.5±9.9, angina status 
according to CCS classiﬁcation was 2.7±0.9 and functional capacity according to NYHA 
was 2.2±1.5. The mean LVEF was 29.6±7.0% and risk of surgical procedure based on 
the Cleveland score was 5.7±3.9. After mean follow-up 12.6±6.0 months survival rate 
approched 94.0%. Case controlled study included 52 patients in PCI and 51 in CABG 
group. Both group did not differ in respect to base demographic, clinical and angiographic 
data. Results. Long term survival was 100% in PCI and 94.1% in CABG group (Cox test 
p=0.369). MACE occured in 21.2% with PCI and 11.8% with CABG (Cox test p=0.41). 
LVEF improved from 31.6±5.5 to 39.3±9.6% in PCI (p=0.005) and from 32.9±5.7 to 
39.2±8.8% after CABG (p=0.055) (2-way ANOVA p=0.541). There was signiﬁcant relief 
of angina in both study arms (PCI: from 2.7 to 1.2, p=0.0001; CABG: from 3.1 to 1.0, 
p=0.0016), but more prominent after CABG (ANOVA: p=0.029). In total cohort of patients 
multivariate regression analysis showed that the only predictor of LV function improvement 
after revascularization was QRS injury score. Long term survival was connected to age, 
LVEF and QRS injury score.
Conclusions: Our results suggest that PCI and CABG were associated with similar late 
outcomes and PCI is valuable method to treat ischaemic heart failure.
4:15 p.m.
826-4 Patients With Hibernating Myocardium Show Altered 
Left Ventricular Volumes and Shape, Which Revert 
Following Revascularization: Evidence That Hibernation 
May Directly Induce Cardiac Remodeling
Erberto Carluccio, Paolo Biagioli, Gianfranco Alunni, Adriano Murrone, Gabriella 
Vincenti, Massimo Politano, Temistocle Ragni, Claudio Giombolini, Carlo Porcellati, 
Giuseppe Ambrosio, University of Perugia, Perugia, Italy
Background: Major changes in left ventricular (LV) volume and geometry (i.e. remodeling) 
may develop after myocardial infarction. Extensive scar formation is thought to be chieﬂy 
responsible for postischemic LV remodeling. However, myocardial necrosis also results in 
loss of contractility. To dissect out the role of regional mechanical dysfunction from that 
of scar formation in LV remodeling, we took advantage of the condition of myocardial 
hibernation, in which severe contractile dysfunction occurs in the absence of scar 
formation and in the setting of preserved myocyte viability, and thus it is also potentially 
reversible
Methods: In 40 patients with chronic dysfunctional but viable myocardium and no 
previous transmural myocardial infarction (66+9 yrs; 34 males), we evaluated (by 2D-
echocardiography) LV global and regional function, LV volumes, and LV sphericity index 
(SI), at baseline and >4 months after coronary revascularization. Myocardial viability was 
also evaluated by low-dose dobutamine echocardiography before revascularization.
Results: At baseline, regional and global function were depressed, and LV dilatation 
was present. Viability was present in 6+3 segments/patient. Revascularization was 
accompanied by extensive recovery of ejection fraction (EF, from 33+6% to 44+11%, 
p<0.0001), and wall motion score index (WMSI, from 2.30+0.32 to 1.75+0.45, p<0.0001), 
with 5+3 segments/patient recovering function. At the same time, after revascularization 
signiﬁcant improvement of end-systolic volume index (ESVI, from 79+23 to 58+24 ml/m2, 
p<0.0001), end-diastolic volume index (EDVI, from 120+26 to 102+27 ml/m2, p<0.0001), 
and LV SI (from 0.69+0.13 to 0.53+0.11, p<0.0001) was observed. Improvement in ESVI, 
EDVI, and SI were all signiﬁcantly correlated to the number of segments showing recovery 
of function after revascularization.
Conclusion: In the present study, myocardial hibernation was associated with major 
alterations in LV volumes and geometry, which signiﬁcantly reverted upon revascularization. 
Thus, our data show that severe impairment of regional function per se is sufﬁcient to 
induce ischemic LV remodeling in patients, in the absence of scar formation.
4:30 p.m.
826-5 Impact of Myocardial Viability Testing With PET and 
Revascularization on Long-Term Prognosis in Patients 
With Ischemic Left Ventricular Dysfunction
Carole Pollack, Jens P. Hellermann, Mehdi Namdar, Pascal Koepﬂi, Patrick T. Siegrist, 
Nina Bartenstein, Ulrich Schurr, Rolf Jenni, Philipp A. Kaufmann, University Hospital, 
Zurich, Switzerland
Background: Most outcome studies in patients with ischemic left ventricular dysfunction 
(LVD) and hibernating myocardium as assessed with PET are limited by short-term follow-
up or small patient populations.
Aim: To assess the impact of myocardial viability testing with PET and revascularization 
(revasc) on long-term prognosis in a large study population with LVD.
Methods: The baseline characteristics and the follow up (f/u) of 246 consecutive patients 
(age 60±10 years) with ischemic LVD who underwent FDG and NH3 PET scan for 
evaluation of hibernating myocardium (=NH3/FDG mismatch) were assessed.
Conclusion: Our results demonstrate a strong association between myocardial viability 
on PET testing and improved survival after revascularization in patients with chronic 
ischemic LVD. Viable tissue seems to represent a risk factor, as lack of revascularization 
is associated with increased mortality. Absence of viability is associated with no signiﬁcant 
difference in outcomes, irrespective of treatment strategy.
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Results: 
Hibernating No Hibernating
Revasc No Revasc Revasc No Revasc
n 49 38 52 107
age, years 58±11 58±10 59±9 60±9
gender, male 87% 82% 83% 88%
LV EF (%) 30±10 29±11 32±5 29±12
3-vessel disease 80% 37% 47% 46%
mean f/u, years 4.5±2.4 4.2±2.8 4.5±2.2 4.3±2.6
annual mortality 12.0% 19.3% 11.0% 9.5%
survivors, end of f/u 63.0% 27.9% 64.0% 53.0%
4:45 p.m.
826-6 Improvement in LV Ejection Fraction After 
Revascularization in Patients With Ischemic 
Cardiomyopathy: Does It Affect Long-Term Outcome?
Vittoria Rizzello, Don Poldermans, Elena Biagini, Eric Boersma, Arend F. Schinkel, 
Filippo Crea, Antonio M. Leone, Jos RTC Roelandt, Jeroen J. Bax, The Thorax Center 
Erasmus MC, Rotterdam, The Netherlands, The Catholic University of The Sacred 
Heart, Rome, Italy
Background. In patients with ischemic cardiomyopathy and substantial amount of viable 
myocardium, left ventricular ejection fraction (LVEF) does not always improve after 
coronary revascularization. Whether patients with viable myocardium and improvement 
in LVEF after revascularization have a different prognosis than those patients who do not 
improve in LVEF was evaluated in this study.
Methods. Before revascularization, myocardial viability was assessed by dobutamine stress 
echocardiography. Patients with 4 or more viable segments were considered to have substantial 
myocardial viability (viable patients). Patients with <4 viable segments were deﬁned nonviable 
patients. Before and at 12 months after revascularization, radionuclide ventriculography 
was performed to assess changes in LVEF. An improvement in LVEF ≥5% was considered 
clinically signiﬁcant. Heart failure symptoms were also assessed before and at 12 months 
after revascularization. Cardiac events were obtained during a 4 years follow-up.
Results. Patients were divided into 3 groups: Group 1, viable patients with LVEF 
improvement (n=27); Group 2, viable patients without LVEF improvement (n=15), Group 
3, nonviable patients (n=48). Preoperative clinical characteristics and baseline LVEF were 
comparable in the 3 groups. After revascularization, the LVEF increased from 32 ± 9% 
to 42±10% in Group 1 (P<0.001), but did not change signiﬁcantly in Group 2 and in 
Group 3. Heart failure symptoms improved both in Groups 1 (NYHA class from 3.1±0.9 
to 1.7±0.7) and 2 (from 3.2±0.7 to 1.7±0.9), but not in Group 3 (from 2.8±1.0 to 2.7±0.5), 
P<0.001 by ANOVA. During the follow-up, the cardiac event rate was low (4%) in Group 1, 
intermediate (21%) in Group 2 and high (33%) in Group 3 (P=0.01).
Conclusion. The ﬁndings in the present study demonstrate that in patients with ischemic 
cardiomyopathy the best prognosis after revascularization may be expected in those viable 
patients who improve in LVEF. Conversely, viable patients without functional improvement 
have an intermediate prognosis. Nonviable patients have the worst prognosis despite 
coronary revascularization.
5:00 p.m.
826-7 Prognostic Value of Myocardial Viability and the 
Impact of Early Surgical or Percutaneous Intervention 
in Patients with Severe Left Ventricular Systolic 
Dysfunction
Khaldoun Tarakji, Richard Brunken, Patrick McCarthy, Obada Al-Chekakie, Ahmed 
Abdel-Latif, Raymond Migrino, Claire Pothier, Eugene Blackstone, Michael Lauer, 
Cleveland Clinic Foundation, Cleveland, OH
Background: The value of revascularization in patients with severe systolic heart failure is unclear. 
Assessment of viability by Positron Emission Tomography (PET) with Fluorodeoxyglucose 
imaging (FDG) may help identify patients for whom intervention may improve survival.
Methods: We analyzed the outcomes of 765 patients (age 64±11) with signiﬁcant LV 
dysfunction (EF≤35%) without valvular disease, who had PET/FDG study between 
1997 to 2002. Early intervention was deﬁned as any cardiac intervention (surgical or 
percutaneous) within the ﬁrst six months. We used propensity analysis to account for 
baseline differences among patients undergoing and not undergoing interventions.
Results: In our cohort, 230 patients (30%) had early intervention, [188 (25%) had open 
heart surgery and 42 (5%) had percutaneous intervention] while 535 (70%) were treated 
medically. We were able to successfully propensity match 159 of these patients to 159 
who did not have early intervention. In this matched cohort, there were 86 deaths during a 
median of 3 years follow up. Early intervention was associated with a markedly lower risk 
of death (3-year death rate 15% vs. 35%, propensity adjusted hazard ratio 0.43, 95% CI 
0.27-0.68, P=0.0004).(Fig) The survival beneﬁt was independent of the amount of viability 
(ischemia and hibernation) identiﬁed by PET/FDG.
Conclusion: Among systolic heart failure patients referred for PET/FDG, early intervention 
is associated with improved survival independent of the degree of viability. 
5:15 p.m.
826-8 Use of Clenbuterol to Improve Skeletal Muscle and 
Cardiac Function in Congestive Heart Failure
Steve Xydas, Donna Mancini, John Lamanca, Brooke McLaughlin, Rebecca Rosen, 
Marco DiTullio, Elizabeth Shane, Yoshifumi Naka, Mehmet Oz, Simon Maybaum, 
Columbia University, New York, NY
Background: Clenbuterol (Clen) is a selective beta-2 agonist with potent anabolic effects 
on skeletal muscle. One prior study has suggested that high doses, given during LVAD 
support, may lead to cardiac recovery. We sought to study the effects of Clen on cardiac 
and skeletal muscle in 2 groups of patients with congestive heart failure (CHF). 
Methods: Group 1- subjects supported with an LVAD are enrolled 4 weeks after device 
implantation and Clen is uptitrated to a maximal daily dose of 720 mcg. Group 2- subjects 
with Class III CHF are randomized to 40 mcg of Clen or placebo. All subjects receive 
standard CHF therapy, including a selective beta-1 antagonist (metoprolol). Subjects 
undergo the following testing at baseline and after 3 months: cardiopulmonary exercise 
testing, body composition analysis, quadraceps strength testing and echocardiography 
(at reduced LVAD support).
Results: Group 1- Five subjects were enrolled 19-32 weeks after LVAD and 4 (2 
ischemic, 2 non-ischemic) have completed the study. Resting heart rate increased 
from 64±8 to 88±9 bpm (p=0.01), with an increase in resting LVAD ﬂow from 4.4±0.6 to 
5.9±1.1 L/min. Left ventricular mass increased from 141±54 to 182±80 gm; however, there 
was no change in ejection fraction or peak oxygen consumption. Maximal quadriceps 
contraction increased from 38.6±20.3 to 48.0±24.8 kg (p=0.047), with an increase in lean 
body weight from 18.7±9.45 to 20.7±10.9 kg. There were no signiﬁcant adverse events or 
episodes of arrhythmia. CPK rose in all patients (range 133-1497 mg/dl) with no clinical 
sequelae. No subjects demonstrated sufﬁcient recovery for device explantation. Group 
2- Thirteen subjects have been randomized and 9 patients have completed the study. One 
asymptomatic episode of slow VT resulted in withdrawal from the study. Muscle cramps 
(6/13) and tremor (5/13) were mild, but necesitated withdrawal in one patient. CPK was 
elevated in 6 subjects (range 300-664 mg/dl). Randomization and data analysis for this 
group will be completed by abstract presentation.
Conclusion: Both dosing regimens used were safe and well-tolerated in this cohort. 
On-going data collection will determine the effect of Clen on skeletal muscle and cardiac 
function in CHF.
 
 
ORAL CONTRIBUTIONS
835  Natriuretic Peptides II
Tuesday, March 08, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 414C
8:30 a.m.
835-3 Cheyne-Stokes Respiration is Associated With 
Natriuretic Peptide Expression and Sympathetic 
Overactivity in Heart Failure Patients
Michele Emdin, Roberta Poletti, Valentina Rosso, Michael Coyle, Claudio Passino, 
Institute of Clinical Physiology, Pisa, Italy, VivoMetrics, Princeton, NJ
Background: Cheyne-Stokes Respiration (CSR) and neuro-hormonal derangement 
are primary determinants of the progression of chronic heart failure (CHF) due to their 
prognostic capabilities. To date, however, the nature of this relationship has not been 
deﬁnitively described.
Methods: To evaluate the relationship between CSR and neuro-hormonal activation, we 
studied 44 patients with CHF either of ischemic (25) or idiopathic (19) origin (34 M, age 67±2 
years, BMI 27±1 Kg/m2, 4 in I, 17 in II and 23 in III NYHA class, ejection fraction 34±2%, 
mean±SEM). The comprehensive assessment included (1) a complete neuro-hormonal 
proﬁle that included plasma assays of renin activity (PRA), as well as concentrations of 
aldosterone, catecholamines, atrial (ANP) and brain naturietic peptide (BNP), and cortisol, 
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and (2) a 12-hour ambulatory cardio-respiratory recording in free-living patients by means 
of a multi-sensor portable system (LifeShirt®, VivoMetrics, USA).
Results: Results of the neuro-hormonal proﬁle were indicative of neurohormonal 
activation (norepinehprine = 640±46 pg/ml; ANP = 121±16 pg/ml; BNP = 268±42pg/ml; 
PRA = 2.96±.47 ng/mL/h, aldosterone = 186±25 pg/ml, cortisol = 175±8 ng/ml). Nighttime 
cardiorespiratory recordings revealed CSR in all patients, while 25 subjects exhibited 
daytime breathing abnormalities. Abnormal breathing time, as deﬁned by presence of CSR 
or periodic breathing, was observed during 40±4% of the time for the total recordings. The 
apnea-hypopnea index was 20±2 events/hr (hypopneas 67 ± 6; apneas = 223±26; mean 
maximum apnea duration = 40±3 sec; mean minimum oxygen saturation = 85.9±0.9). 
The presence of CSR was signiﬁcantly related to BNP (r=0.57, p=0.0001), ANP (r=0.52, 
p=0.0007) and norepinephrine (r=0.35, p=0.03).
Conclusions: These data indicate that breathing pattern abnormalities are frequent in 
patients with CHF and support an association between neuro-hormonal and ventilatory 
dysregulation. The identiﬁcation of neuro-hormonal and ventilatory impairment provides 
additional insight into the multi-systemic complexities of patients with CHF and, ultimately, 
may serve as therapeutic targets to help retard the progression of heart disease.
8:45 a.m.
835-4 Elevated Brain Natriuretic Peptide In Symptomatic 
Acute Cerebral And Peripheral Vascular Syndromes
Robert V. Kelly, Walter A. Tan, Gail Tudor, Hyunsoon Cho, Allan D. Struthers, University 
of North Carolina, Chapel Hill, NC, University of Dundee, Ninewells Hospital, Dundee, 
Scotland, United Kingdom
Background: Brain natriuretic peptide (BNP) has been shown to be elevated in heart 
failure, acute coronary syndrome and LVH patients. It is a valuable marker for diagnosing, 
treating and risk stratifying non-vascular CHF and left ventricular systolic dysfunction 
(LVSD) patients. We have previously showed that CHF occurs in ﬁve times more stroke, 
TIA and peripheral arterial disease (PAD) patients than in age and sex matched controls. 
We sought to examine the role of measuring BNP in patients presenting to hospital with 
their ﬁrst non-cardiac vascular event.
Methods: Baseline BNP levels were measured in 216 prospective consecutive patients 
presenting with their ﬁrst stroke, TIA or new onset of claudication and in 161 age and 
gender matched control patients. LV systolic dysfunction (LVSD) was deﬁned as an 
ejection fraction (EF) ≤45% on echocardiography.
Results: BNP values ranged from 8.8-364 pmol/l.The median BNP was 46.5 pmol/l in 
vascular patients compared with 33pmol/l in the control population (p<0.0001). 
Variable % Stroke/TIA (145) PAD (71) Controls (164)
Mean age (yrs)
Female
63
41%
63
41%
62
47%
Hypertension
Diabetes
Smoking
Lipids
IHD / MI
LVH
Atrial Fibrillation
51%
11%
68%
46%
25%
23%
12%
42%
14%
97%
33%
30%
27%
7%
32%
5%
70%
15%
17%
12%
3%
Median BNP pmol/l 53.4 36.7 32.9
LVSD
DHF (EF>45%)
28%
11%
31%
15%
6%
11%
Conclusions: BNP is signiﬁcantly elevated in all patients with non-cardiac vascular disease 
compared with controls. However BNP is more elevated in cerebrovascular disease than in 
PAD patients despite a similar prevalence of LVSD and of diastolic heart failure.
 
9:00 a.m.
835-5 Change in BNP Level Unrelated to Wall Stress, 
Echocardiographic Indices of Filling Pressure, and 
Volume of Intravenous Fluid Infusion
John B. Fournier, Craig Vinch, Jeffrey C. Hill, Giridhar Logsetty, Dennis A. Tighe, Theo E. 
Meyer, Gerard P. Aurigemma, University of Massachusetts, Worcester, MA
Background: Increased LV ﬁlling pressure and wall stress are proposed stimuli for 
elevated BNP. Sedating medications are known to alter ﬁlling pressures and loading 
conditions. Accordingly, we examined BNP levels and echo hemodynamic indices before 
and after IV conscious sedation (IVCS) and TEE. 
Methods: 23 out-pts (16 male, 61±16 yrs) underwent examination, transthoracic echo, 
and BNP determination before and after IVCS/TEE. IVCS was achieved with midazolam 
and fentanyl. Pre- and post-BNP levels were obtained 49±13 min apart. PCWP was 
estimated by previously validated regression technique. 
Results: (see table) IVCS was associated with decreased systolic and diastolic BP, Mitral E wave , 
PASP, and wall stress. Deceleration time increased. There were trends towards lower E:E’ ratio and 
estimated PCWP. There was no correlation between IV ﬂuid received and change in BNP. Mean 
BNP level increased, and no pt had a fall in BNP. Diastolic wall stress did not change. 
Neuroendocrine and echocardiographic indices  
pre- and post- IVCS & TEE 
Pre-IVCS & TEE Post- IVCS & TEE P value
SBP (mmHg) 149± 24 126± 28* <0.001
DBP (mmHg) 83±14 69±14* <0.001
LVEF (%) 58±17 58±17 0.5
LVIDd (cm) 4.3±0.8 4.5±1.0 0.67
Circumferential wall stress (g/cm2) 88±57 71±60* <0.001
Meridonial wall stress (g/cm2) 44±33 36±35* <0.001
E (cm/sec) 82±23 76±22* 0.02
DT (cm/sec) 207±53 238±75* <0.001
E’ (cm/sec) 10.5±4.1 9.8±2.6 0.6
E:E’ ratio 8.6±3.4 8.3±3.0 0.06
PASP (mmHg) 31±10 29±13* 0.01
Estimated PCWP (mmHg) 12.6±4.2 12.2±3.7 0.06
Diastolic wall stress (g/cm2) 21±9 20±7 0.49
BNP (pg/ml) 195±400 238±451* <0.001
* p<0.05
Conclusions: IVCS is associated with lower BP and echo evidence of decreased 
ﬁlling pressure. The hemodynamic changes, consistent with vasodilation, coupled with 
unchanged heart size lead to decreased wall stress. However, BNP levels increase in the 
majority of pts. Although, in-vitro and animal experiments have suggested ﬁlling pressure 
and wall stress as triggers for increased BNP, our data suggest that in humans the triggers 
for BNP release are more complicated and may involve counter-regulatory mechanisms.
9:15 a.m.
835-6 Not all Patients with Symptomatic Heart Failure have 
Elevated B-type Natriuretic Peptide Levels
Jochem Hogenhuis, Tiny Jaarsma, Adriaan A. Voors, Johannes L. Hillege, Dirk J. van 
Veldhuisen, University Hospital Groningen, Groningen, The Netherlands
Background: B-type Natriuretic Peptide (BNP) is increasingly used in the management of 
patients with Chronic Heart failure (CHF). A BNP value ≥ 100pg/ml is generally considered 
to be “diagnostic” for CHF. However, recent data in an outpatient population with NYHA 
functional I-III suggest, that a proportion of patients may thus not be detected. 
Methods: We investigated 369 CHF patients who were part of a large-scale study in The 
Netherlands (age 70 ± 12 years old, 58% male, left ventricular ejection fraction [LVEF] 35 ± 14). 
All patients had been admitted for progressive CHF, and BNP levels were measured at discharge, 
when they were classiﬁed as NYHA class II-IV. Cardiologists were blinded to BNP plasma levels. 
Clinical characteristics of patients with BNP plasma levels < and ≥ 100pg/ml were compared. 
Results: Of the present population, 10% of symptomatic CHF patients had BNP plasma 
levels < 100 pg/ml (table). LVEF was higher (44 ± 14% versus 34 ± 13%, P<0.01), and use 
of diuretics was lower (P=0.01) in these patients. For NYHA functional class, medication 
for CHF, underlying etiologies and other demographics the two groups were similar. 
Conclusions: In patients with a recent admission for progressive CHF, 10% of patients 
had BNP plasma levels below what would generally be considered “diagnostic” (100 pg/
ml). Although these patients have a higher LVEF, they are otherwise remarkably similar. 
Further studies are needed to determine the clinical relevance of this ﬁnding
.
Table: Clinical Characteristics. 
BNP <100pg/ml
N=36
BNP>100pg/ml
N=333
Age 70 ± 12 71 ± 12
Gender (male) 53% 57%
LVEF 44 ± 14% 34 ± 13%
NYHA II, III, IV 42%, 55%, 3% 53%, 44%, 3%
Medication
ACE inhibitor and/or ARB 70% 78%
Beta blockers 42% 54%
Diuretics Spironolacton 72% 87%
28% 33%
9:30 a.m.
835-7 B-Type Natriuretic Peptide and Diastolic Function 
Inﬂuence Exercise Tolerance in Patients With Stable 
Congestive Heart Failure
Quirino Ciampi, Gabriele Borzillo, Emanuele Barbato, Bruno Petruzziello, Michele Della 
Porta, Bruno Villari, Fatebenefratelli Hospital, Benevento, Italy, Villa Margherita Hospital, 
Benevento, Italy
Background: B-type natriuretic peptide (BNP) is a diagnostic and prognostic marker 
in patients with congestive heart failure (CHF). We evaluated the relation between BNP 
levels (at baseline and at peak exercise), echocardiographic systolic and diastolic function 
and aerobic exercise capacity in CHF patients.
Methods: 25 CHF patients (age 66±7 years, 55% with an ischemic etiology), underwent 
exercise cardiopulmonary test and standard echocardiography: LV diastolic function was 
evaluated with transmitral ﬁlling patterns and Tissue Doppler. A sample of venous blood 
was taken a rest and at peak exercise to determine the BNP levels.
Results: Ejection fraction was 35±8% and NHYA class 2.04±0.6. 10 CHF patients with 
lower peak oxygen consumption (peak VO2 ≤14 ml/kg/min) showed: a) higher baseline 
(ﬁgure) and peak exercise BNP levels (2.6±0.4 pg/ml vs 2.1±0.4 pg/ml p=.024); b) lower 
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increase in BNP levels during exercise (ΔBNP, ﬁgure); c) impaired diastolic function: 
major incidence of transmitral pattern with elevated LV ﬁlling pressure (pseudonormal 
and restrictive vs normal and abnormal relaxation) (6/10 vs 2/15, p=.015) and higher 
value of ratio E wave mitral ﬂow and early diastolic velocity mitral annulus (17.1±8.6 vs 
10.8±3.8, p=.035); d) no difference in ejection fraction.Conclusions: In patients with 
stable CHF, BNP levels (at baseline and at peak exercise) and worse diastolic function 
predict lower exercise tolerance. BNP increase during exercise was directly related to O2 
consumption.
9:45 a.m.
835-8 Rapid Assay B-type Natriuretic Peptide (BNP) Predicts 
Outcomes and Hemodynamics in Patients Hospitalized 
with Decompensated Heart Failure
Monica R. Shah, Vic Hasselblad, Gudaye Tasissa, Cynthia Binanay, Christopher 
M. O’Connor, E. Magnus Ohman, Lynne W. Stevenson, Robert M. Califf, Columbia 
University Medical Center, New York, NY, Duke Clinical Research Institute, Durham, NC
Background: Rapid assay biomarkers are bedside tools that may predict outcomes in 
patients (pts) with decompensated (decomp) heart failure (HF). We assessed if rapid assay 
BNP (Triage®BNP) and troponin I (TnI) would 1) predict length of stay (LOS) and mortality 
and 2) correlate with pulmonary artery catheter (PAC)-derived hemodynamics (HD).
Methods: There were 105 pts in this cohort study of ESCAPE, which tested PAC in pts 
with severe, decomp HF. Biomarkers were drawn at baseline and discharge (d/c), and 
during 1st, 2nd, and ﬁnal HD in 38 pts with PAC. We used logistic regression to model 
mortality, Cox analysis to model LOS, and correlations to describe relations between BNP, 
TnI, and PAC-derived HD.
Results: Median (25th, 75th) BNP was 783 (329, 1565) pcg/mL at baseline and 468 
(240, 946) pcg/mL at d/c. After HF tx, BNP decreased 144 pcg/mL (-653, 55; p=.004). 
Pts with baseline BNP >1500 pcg/mL had higher mortality at 6 mos (Fig) and almost 
twice the LOS of pts with BNP <500 pcg/mL (10.1 vs 5.7 days; p=.002). TnI did not 
predict these outcomes. The 1st BNP correlated with 1st right atrial pressure (RAP), 
r=.47 (p=.005), and 1st pulmonary capillary wedge pressure, r=.54 (p=.001). Final 
BNP correlated with ﬁnal RAP, r= .63, (p=.001). Conclusions: HF pts with BNP >1500 
pcg/mL had higher mortality and longer LOS than pts with BNP <500 pcg/mL. BNP 
decreased after HF tx and correlated with PAC-derived HD. Rapid assay BNP may help 
clinicians quickly decide how to adjust HF drugs and when to pursue tx such as devices 
and transplant.
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1132-143 Immunomodulatory Effects of Beta-Adrenergic 
Stimulation Through the G-Protein Signaling Pathway 
on the Development of Myocarditis
Hironari Nakano, Takayuki Inomata, Mototsugu Nishii, Ichiro Takeuchi, Toshimi 
Koitabashi, Hisahito Shinagawa, Hitoshi Takehana, Tohru Izumi, Kitasato university 
school of medicine, Sagamihara, Japan
Background: Although it is well known that the sympathetic nervous system activated 
through beta-adrenergic stimulation plays a major role in the development of heart failure, 
its effect on myocardial inﬂammation has not been fully investigated.
Methods and Results: Daily administration of carvedilol (10 mg/kg/d), but not metoprolol 
(30 mg/kg/d), aggravated experimental autoimmune myocarditis (EAM) produced by 
immunizing Lewis rats with cardiac myosin, while the beta2-selective adrenoreceptor 
agonist formoterol (225 micro-g/kg/d) ameliorated EAM when compared with a vehicle 
group [3.8±0.4 (P<0.01), 2.9±0.6 (NS), 1.4±0.5 (P<0.01), 2.8±0.4, respectively (P value vs. 
vehicle), as macroscopic scores (MS) of myocarditis], in conjunction with the modulation of 
the myocardial expression of interferon (INF)-gamma [24.5±7.1 (P<0.01), 13.2±1.9 (NS), 
2.4±0.3 (P<0.01), 13.2±2.1, respectively (P value vs. vehicle), as protein levels of myocardial 
INF-gamma (ng/g heart)] and interleukin-12. Furthermore, a single injection of pertussis 
toxin (4 micro-g/rat) as a Gi protein inhibitor exacerbated EAM in the induction phase [MS: 
4.0±0.0 vs. 2.5±1.0 (vehicle), P<0.01] but ameliorated EAM in the effector phase [MS: 
1.1±0.9 vs. 3.3±0.6 (vehicle), P<0.01] or myocarditogenic-T-cell-transferred myocarditis [MS: 
0.0±0.0 vs. 4.0±0.0 (vehicle), P<0.01] along with the alteration of chemokine expressions. 
In vitro addition of formoterol, but not denopamine as a beta1-selective adrenoreceptor 
agonist, dose-dependently suppressed antigen-speciﬁc myocarditogenic-T-cell proliferation 
along with a decrease in the production of INF-gamma and interleukin-12. Carvedilol as well 
as ICI 118,551, a beta2-selective adrenoreceptor antagonist, reversed the inhibitory effect 
of formoterol against myocarditogenic T cell activity.
Conclusion: beta2-adrenergic stimulation variably modulates the progression of T-cell-
induced autoimmune myocarditis predominantly through the Gi signaling pathway.
1132-144 Selective Upregulation of TGFb1ACT in the Rat Heart to 
Induce Cardioprotection From Ischemia-Reperfusion 
Injury
Kui Chen, Yong Liu, Jiawei Chen, Dayuan Li, Paul L. Hermonat, Jawahar L. Mehta, 
University of Arkansas for Medical Sciences, Little Rock, AR, Central Arkansas Veterans 
Healthcare System, Little Rock, AR
Background: Although there is upregulation of TGFβ1 during ischemic injury to the heart, 
its conversion to active form (TGFβ1ACT) which is cardio-protective is lacking. To examine 
the modulation of cardiac function by TGFβ1ACT, we developed a model of selective 
upregulation of TGFβ1 ACT in the rat myocardium.
Methods and Results: First, we cloned rat TGFβ1 cDNA (position 413-1593, 1172 bp), 
with mutation of cysteine at position 223 and 225 into serine resulting in TGFβ1 ACT. This 
mutated TGFβ1ACT cDNA was ligated into a basic recombinant adeno associated virus 
vector (dl6-95) to give AAV-TGFβ1 ACT. Anesthetized Sprague Dawley rats were subjected 
to thoracotomy and administration of AAV/GFP or AAV/TGFβ1ACT at 4 different sites in 
the left ventricular myocardium. GFP expression was identiﬁed in the myocardium at 2 as 
well as 6 weeks. TGFβ1ACT expression (mRNA and protein) was not seen in the AAV/GFP-
injected rat hearts, but was markedly increased in the TGFβ1ACT-injected hearts at 2 weeks, 
with a further increase at 6 weeks post-injection. Plasma TGFβ1ACT levels were similar 
in all animals, indicating selective TGFβ1ACT expression in the heart. Most importantly, 
whereas the control rats showed a marked decline in ±dP/dt and a large infarct after 
left coronary artery occlusion and reperfusion, the rats overexpressing TGFβ1ACT showed 
preservation of ±dP/dt and much smaller infarct despite the same duration of coronary 
artery occlusion and reperfusion.
Conclusion: These data demonstrate the potential for selective upregulation of TGFβ1ACT 
in the rat heart using rAAV, and preservation of cardiac function from ischemic injury.
1132-145 Effects of AT1 Receptor Blockade on Oxidative 
Stress and Uncoupling Protein-2 Expression in Rat 
Hypertensive Heart Failure
Peng Guo, Akira Nishiyama, Matlubur Rahman, Makoto Ishizawa, Kazushi Murakami, 
Akira Miyatake, Koji Ohmori, Katsufumi Mizushige, Youichi Abe, Takahisa Noma, 
Masakazu Kohno, Kagawa Medical University, Kagawa, Japan
Background: Uncoupling proteins, inner mitochondrial membrane proton transporters, 
are important for regulating myocardial energy efﬁciency. We recently demonstrated 
that left ventricular dysfunction and reduction in high-energy phosphate production are 
accompanied by the elevated expression of uncoupling protein-2 (UCP-2) in failing rat 
hearts, indicating the potential roles of UCP-2 in the progression of heart failure. In this 
study, we examined the effects of angiotensin II receptor blocker (ARB) on the expression of 
UCP-2 and left ventricular (LV) heart failure in Dahl salt-sensitive (DS) hypertensive rats. We 
also investigated the contribution of reactive oxygen species (ROS) to the effects of ARB.
Methods: DS rats were maintained on a high (H: 8.0% NaCl, n=7), low (L: 0.3% NaCl, 
n=6) salt diet, H + candesartan cilexetil (10 mg/kg/day, n=7) or H + a superoxide dismutase 
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mimetic, tempol (3 mmol/L in drinking water, n=7) from 7-weeks-old, and all data were 
collected at age 17-weeks.
Results: DS/H rats represented increases in LV end-diastolic pressure and lung weight, 
indicating the presence of pulmonary congestion caused by congestive heart failure. The 
hemodynamic deterioration was associated with increases in LV mass index, the areas 
of ﬁbrosis and myocardial stiffness and relaxation abnormality. As compared with DS/L 
rats, DS/H rats showed higher p22phox and gp91phox mRNA expression (by 2.3 and 2.9-
fold, respectively), NADPH oxidase activity (by 1.9-fold) and thiobarbituric acid-reactive 
substance (TBARS) contents (19+/-2 vs 52+/-9 microM/g) in LV tissue. UCP-2 mRNA 
expression in LV tissue was also 2.6-fold higher in DS/H rats. In DS/H rats, treatment with 
candesartan or tempol resulted in a marked attenuation of hemodynamic deterioration; 
these cardioprotective effects were accompanied by decreases in NAD(P)H oxidase 
activity, TBARS contents and UCP-2 expression in LV tissue.
Conclusions: These data suggest that NAD(P)H oxidase-mediated ROS production 
and associated UCP-2 gene expression contributes to the progression of LV heart 
failure in DS/H rats, and that the cardioprotective effects of ARB may be partly due to the 
suppression of ROS-dependent UCP-2 expression.
1132-146 The Distinct Effect of Carvedilol and Metoprolol on the 
Mitochondrial Superoxide Production Under Calcium 
Overload of Myocardium
Ryosuke Kametani, Toshiro Miura, Masaki Shibuya, Kazuko Iwamoto, Hong Tan, Ruijuan 
Wang, Nozomu Harada, Shuji Kawamura, Masunori Matsuzaki, Yamaguchi University 
Graduate School of Medicine, Ube, Yamaguchi, Japan
Background: In heart failure or ischemia-reperfusion injury, intracellular calcium 
overload occurs in the myocardium and triggers the subsequent signaling to deteriorate 
the cardiomyocyte function. Additionally failing myocardium have source of oxygen 
free radicals from mitochondrial electron transport complex I. This study is designed 
to demonstrate the key role of mitochondrial complex I as a target of calcium overload 
induced superoxide production and the inhibitory effect of carvedilol and metoprolol on 
the mitochondrial superoxide production.
Methods: Isolated mitochondria from SD rat hearts were loaded in the cuvette mounted 
with Clark oxygen sensor to measure the mitochondrial oxygen consumption. The amount 
of malondialdehyde (MDA) was measured as an index of superoxide production. NADH 
was used to energize the mitochondria at 37°C. Calcium concentration was varied at 
10, 100 µM and carvedilol and metoprolol concentration was varied at 1, 10, 100 µM. 
Rotenone was used for injuring complex I.
Results: The oxygen consumption was signiﬁcantly augmented by increasing the calcium 
concentration from 10 to 100 µM (527±139 vs. 671±138 nmol/mg protein, P<0.05). This 
increase of oxygen consumption was signiﬁcantly suppressed by even 1 µM carvedilol 
(522±88 nmol/mg protein, P<0.01), but no suppression was observed by metoprolol. The 
amount of MDA was not augmented by increasing the calcium concentration from 10 to 
100 µM (6.1±1.5 vs. 6.3±1.0 nmol/mg, ns.), but signiﬁcantly augmented with rotenone 
(P<0.01). Upon injury of complex I, the amount of MDA was signiﬁcantly augmented 
by increasing the calcium concentration from 10 to 100 µM (9.7±1.2 vs. 11.4±1.4 nmol/
mg, P<0.05). This increase of MDA was signiﬁcantly suppressed by carvedilol dose-
dependently (P<0.05), but not attenuated by metoprolol.
Conclusion: These data strongly suggest that the modiﬁcation of mitochondrial oxygen 
consumption or superoxide production during complex I injury caused by calcium overload 
is suppressed by carvedilol but not by metoprolol, which may explain the distinct efﬁcacy 
of carvedilol with antioxidant effect for treating heart failure.
1132-147 Altered Ventricular and Myocyte Functional Response 
to Urotensin II in Heart Failure
Atsushi Morimoto, Heng-Jie Cheng, Qing-Hua Han, Hiroshi Hasegawa, William C. Little, 
Che-Ping Cheng, Wake Forest University School of Medicine, Winston-Salem, NC
Background. Urotensin II (U-II), a somatostatin-like cyclic peptide was recently identiﬁed 
as a potent vasoconstrictor. Clinical observations suggest that in patients with heart failure 
(HF), the myocardial expression and increased plasma levels of U-II may alter cardiac 
contractile behavior. However, the direct cardiac effects of U-II in normal and HF subjects 
are unclear.
Methods. We compared left ventricular (LV) and myocyte contractile and [Ca2+]i transient 
([Ca2+]iT) responses to U-II in 10 normal (N) adult rats and 10 age-matched rats with 
isoproterenol (ISO)-induced HF (4 months after 340 mg/kg, sq, for 2 days). Hemodynamic 
data were measured by using a MIKRO-TIP pressure (P)/volume (V) catheter.
Results. In normal rats, U-II (400 pmol/kg, iv) caused rightward shifts and decreased 
the slopes of P-V relations (R) (EES,15%, 4.8vs5.7 mmHg/ml) and Msw (12%, 67.3vs76.6 
mmHg). In HF rats, U-II resulted in signiﬁcantly greater decreases in EES (45%, 2.3vs4.2 
mmHg/ml) and Msw (33%, 28.4vs42.3 mmHg), indicating enhanced depression on LV 
contractile performance. Consistently, in isolated myocytes, superfusion of U-II (10-
8 to 10-5 M) caused a dose-dependent inhibition of cell contraction and relation in both 
normal and HF myocytes. However, in HF myocytes, U-II (10-5 M) produced signiﬁcantly 
greater reductions in cell contraction (N: 19%, 149vs185; HF: 38%, 62vs100 µm/sec) and 
relengthening (N:16%, 128vs153; HF 35%, 50vs77 µm/sec) accompanied with a larger 
decrease in the peak systolic [Ca2+]iT (N: 19%, 0.21vs0.26; HF: 32%, 0.13vs0.19). These 
myocyte responses were abolished by the pretreatment of myocytes with pertussis toxin, 
PTX (2 µg/ml, 36oC, 6 hr), and dibutyryl cAMP (500 µM).
Conclusion. In HF, U-II produces increased inhibition of LV and myocyte contraction, 
relaxation, and decreased peak systolic [Ca2+]iT. These effects are likely to be mediated 
through cAMP-dependent mechanism and coupled with PTX-sensitive G-protein.
1132-148 Chronic In-vivo Proteasome Inhibition Impairs 
Endothelial Function and Myocardial Perfusion
Ardan M. Saguner, Joerg Herrmann, Xiangyang Zhu, Offer Galili, Katherine J.E. Sattler, 
Daniele Versari, Alejandro Chade, Monica Olson, Lilach O. Lerman, Amir Lerman, Mayo 
Clinic, Rochester, MN
Background: Proteasome inhibitors (PSI) are an emerging class of drugs in cancer 
therapy. Their effects on the heart and coronary circulation with chronic in-vivo remain 
poorly deﬁned. 
Methods and Results: Pigs were studied after a 12-week period without (N) or with 
the boronate-type PSI (N+PSI) MLN-273 (0.08 mg/kg SC twice weekly). As assessed 
by in-vitro organ chamber experiments, maximum coronary vasoreactivity to bradykinin 
(49.5±5.7 vs. 91.0±2.3%, P<0.05) and calcium ionophore (79.7±6.2 vs. 99.7±0.1%, 
P<0.05) but not sodium nitroprusside was attenuated in N+PSI compared to N. As 
assessed by in-vivo electron-beam-CT, baseline left ventricular ejection fraction (LVEF, 
40.3±2.4 vs. 55.7±4.9%, P<0.05) and cardiac output (CO, 4.1±0.5 vs. 6.3±1 l/min, 
P=0.05) were reduced in N+PSI compared to N, as was percent increase in myocardial 
perfusion to adenosine (9.3±16.7 vs. 52.6±7.3, P<0.05) and dobutamine (82.3±19.4 
vs. 209.0±27.0, P<0.05); percent increase in myocardial microvessel permeability to 
adenosine (50.4±22.4 vs. 4.9±5.1, P<0.05) and to dobutamine (138.1±26.8 vs. 3.4±11.6, 
P<0.05) was higher in N+PSI compared to N. As assessed by 3D-micro-CT, myocardial 
spatial microvessel density was not differemt between N and N+PSI . Quantiﬁed trichrome 
staining showed higher collagen content per ﬁeld in the myocardium of N+PSI compared 
to N (1.38±0.15vs 0.99±0.11, P<0.05). Myocardial apoptotic index, assessed by TUNEL-
positive cells, was higher in N+PSI compared to N (1.97±0.29 vs. 0.12±0.05, P<0.001). 
Immunoblotting showed anti-apoptotic Bcl-xl to be similarly, pro-apoptotic Bax and AIF to 
be more expressed in the myocardial tissue of N+PSI compared to N. Immunoblotting for 
ubiquitin/conjugates indicated higher levels in the myocardium of N+PSI compared with 
N, conﬁned mainly to the subepicardial and subendocardial regions of the myocardium as 
observed by immunostaining. 
Conclusion: PSI impairs coronary endothelial function and myocardial perfusion 
and may have direct cardiotoxic effects in vivo, thus warranting careful cardiovascular 
monitoring, especially when combined with other cardiotoxic anticancer agents.
1132-149 Sirolimus Exerts an Acute Negative Inotropic Effect On 
Isolated Human Cardiomyocytes
Helge Möllmann, Holger Nef, Philipp Kahlert, Susanne Möllmann, Christian Holubarsch, 
Albrecht Elsässer, Kerckhoff Heart Centre, Bad Nauheim, Germany
The immunosuppressive drug sirolimus plays a major role in prevention of restenosis 
after coronary stenting. The use of sirolimus-coated stents has been shown to reduce 
restenosis rate signiﬁcantly (RAVEL-study) most likely due to inhibition of proliferation 
and migration of vascular smooth muscle cells. As the impact of sirolimus on cardiac 
contractility is still unknown, we investigated the acute effects of sirolimus (10-9 - 10-5M) 
on shortening of enzymatically isolated cardiomyocytes (n=8) from right human atria 
obtained during routine coronary artery bypass surgery. The use of isolated myocytes 
has been shown to be ideal to examine inotropic effects as diffusions barriers and the 
inﬂuence of non-myocytes can be excluded.
Cells were electrically stimulated at 0.2 Hz (32°C, 1.25 mM Ca2+) and showed a dose-
dependent decrease in systolic cell-shortening for all sirolimus-concentrations examined. 
A statistically signiﬁcant difference was found for concentrations between 10-8 and 10-
6 M (decrease by 14.3±5.6% for 10-8 M, by 24.9±9.9% for 10-7 M and to 25.3±11.1% 
for 10-6 M, p<0.05) compared to control experiments with the utilized solvent (DMSO) in 
corresponding concentrations. In addition we could show a decrease of the diastolic cell 
length with increasing sirolimus-concentrations probably indicating an increased diastolic 
intracellular calcium concentration.
The negative inotropic effect can presumably be explained by an altered function of the sarcoplasmic 
reticulum as it has been shown that sirolimus can modulate cardiac ryanodine receptor function by 
inhibition of FKBP12.6. This leads to a decreased systolic calcium concentration and an increased 
diastolic calcium-leak which explains the reduced diastolic cell length.
Conclusion: Our experiments show for the ﬁrst time an acute dose-dependent negative 
inotropic effect of sirolimus on isolated human cardiomyocytes which is probably due to 
altered function of cardiac ryanodine receptors.
1132-150 A Novel Approach to Increase Total Urine Output in 
Acute Heart Failure: Unilateral Renal Nerve Blockade
Deon W. Vigilance, Christopher J. Mutrie, Geng-hua Yi, Kenwar Yu, Anguo Guo, Mark 
Gelfand, Craig R. Smith, Mehmet C. Oz, Howard Levin, Jie Wang, Columbia University, 
New York, NY
Background: Volume overload in heart failure (HF) results from decreased urine output 
(UOP) and reduced renal blood ﬂow (RBF). Increased renal sympathetic nerve activity 
(RSNA) is a known determinant of the decrease in both RBF and UOP during HF. We 
assessed the hypothesis that blocking RSNA can restore RBF and UOP in acute HF 
without adverse systemic effects.
Methods: Acute HF was induced by coronary microembolization. Left ventricular (LV), 
mean aortic pressure (MAP), LV dP/dt, cardiac output (CO), UOPI (blockaded kidney), 
UOPT (both kidneys) and regional RBF were assessed in the normal and baseline HF 
state and after unilateral RSNA blockade with bupivacaine (10ml injected into the renal 
peri-arterial space (RPA), n=7). Saline was injected in RPA in the control group (n=3). 
Serum and urine creatinine and sodium were also measured; from which glomerular 
ﬁltration rate (GFR) was calculated.
Results: Although systemic hemodynamics were not altered, both UOPI and UOPT were 
signiﬁcantly increased after unilateral RSNA blockade but not in the control group. The 
mean time to peak UOP following RSNA blockade was 44±26 minutes. Total urine sodium 
excretion increased 22% after RSNA blockade while GFR decreased by 14%. Regional 
RBF was not altered by RSNA blockade.
2005_4_CardiacFuncHeartFail.indd   166 12/23/04   10:03:40 AM
JACC February 1, 2005 ABSTRACTS - Cardiac Function and Heart Failure  167A
C
ardiac Function and H
eart Failure
Conclusions: Unilateral RSNA blockade signiﬁcantly increased UOP via both an 
increase in aquaresis and naturesis in acute HF without alterations of regional RBF 
or signiﬁcant adverse effects on GFR or systemic hemodynamics. These ﬁndings may 
provide a new approach to optimize patient’s volume status in HF. Further investigation 
into the underlying mechanisms responsible for this unique diuresis is warranted.
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1133-165 Changes in Vasoactive Therapy and In-Hospital 
Outcomes in Patients Hospitalized with Acute 
Decompensated Heart Failure: An ADHERE® Analysis
J. Thomas Heywood, Gregg C. Fonarow, Clyde W. Yancy, Margarita Lopatin, ADHERE 
Scientiﬁc Advisory Committee and Investigators, Loma Linda University Medical Center, 
Loma Linda, CA
Background: The relationship between changes in intravenous (IV) vasoactive therapy 
and outcomes over time in patients (pts) with acute decompensated heart failure is 
unknown.
Methods: Data from 273 US hospitals and 109,546 hospitalizations from the Acute 
Decompensated Heart Failure National Registry (ADHERE®) were analyzed. The use of 
inotropes (INO), nitroglycerin (NTG), nesiritide (NES), as well as mechanical ventilation 
(MV), % pts hospitalized in ICU, and mortality were measured over 8 quarters (1/2002-
12/2003). Q1 vs Q8 were compared using chi-square test; trends were assessed using 
Cochran-Armitage. Multiple linear regression was used to assess relationships between 
changes in therapy and outcomes across hospitals.
Results: INO use decreased 25%, NTG use decreased 5%, and NES use increased 
238% (all p<0.0001). MV decreased 21% and % ICU patients decreased 9% (both 
p<0.0001) (Figure). In-hospital mortality decreased from 4.5% to 3.9% (RR 0.86, p=0.03). 
Trend analysis conﬁrmed signiﬁcant changes in INO, NTG, NES, MV and % ICU pts 
(p<0.0001) with borderline trend in mortality (p=0.06). Changes in IV therapy alone 
explained 6%, 16% and 22% of variability in per hospital changes in mortality, MV and % 
ICU pts, respectively.
Conclusions: Reductions in INO and NTG with an increase in NES use occurred over 
time. Concurrently, reductions in MV and % pts hospitalized in the ICU were observed. 
These data suggest that changes in IV vasoactive therapies may partially explain 
improvements in outcomes. 
1133-166 A High Prevalence of Left Ventricular Systolic 
Dysfunction in Rheumatoid Disease Patients
Gurbir S. Bhatia, Michael D. Sosin, Jeetesh V. Patel, Karl A. Grindulis, Fazal H. Khattak, 
Gregory Y. Lip, Russell C. Davis, University Department of Medicine, City Hospital, 
Birmingham, United Kingdom
Background: Cardiovascular mortality is increased in Rheumatoid Disease (RD) patients, 
who are at an increased risk of developing chronic heart failure and ischaemic heart 
disease (IHD). However, there have been few large echocardiographic studies to identify 
objective evidence of cardiac dysfunction in RD. We hypothesised that left ventricular 
systolic dysfunction (LVSD) would be more prevalent in RD patients than in the general 
population.
Methods: 226 hospital out-patients with RD (65% women) underwent clinical evaluation, 
electrocardiography (ECG) and echocardiography. Prevalence ratios standardised for age 
and gender were calculated for the RD population using estimates derived from a large 
(n=3960) study of the general population in this region.
Results: The table shows that ‘any’ LVSD (left ventricular ejection fraction, LVEF <50%) 
occurred in 10.2% of RD patients: standardised prevalence ratio (SPR) 1.92, 95% CI 
1.22-2.88. ‘Deﬁnite’ LVSD (LVEF <40%) occurred in 5.3% of the RD group, and was three 
times more prevalent than in the general population: SPR 3.20, 95%CI 1.65 - 5.59.
Conclusion: Any LVSD occurred almost twice as often in RD compared to the general 
population. Of note, deﬁnite LVSD was three times more common, and was particularly 
prevalent among RD women. Given the prognostic beneﬁts of treatment of LVSD, 
echocardiographic screening of RD populations may be worthwhile. Absolute and 
standardised prevalence of LVSD in RD patients.
LVSD prevalence General populationn=3960
Rheumatoid population
n=226
Standardised prevalence ratio 
(95% CI) in RD
Deﬁnite, n
(%, 95% CI)
72
(1.8, 1.4-2.2)
12
(5.3, 2.4-8.2)
Men 2.41 (0.89-5.25)
Women 4.74 (1.74-10.3)
Overall 3.20 (1.65-5.59)
Any, n
(%, 95% CI)
211
(5.3, 4.6-6.0)
23
(10.2, 6.2-14.1)
Men 2.36 (1.29-9.95)
Women 1.48 (0.68-2.81)
Overall 1.92 (1.22-2.88)
1133-167 Prevalence of Electronically Detected Abnormal Heart 
Sounds in Decompensated Heart Failure Patients 
Before and After Treatment
Sean Collins, Christopher Lindsell, W. Frank Peacock, Virginia Hedger, Alan Storrow, 
University of Cincinnati, Cincinnati, OH, Cleveland Clinic, Cleveland, OH
Background: Abnormal diastolic heart sounds (S3 and S4) may suggest decompensated 
heart failure (HF). We hypothesized the prevalence of an electronically detected S3 or S4 
would be higher in HF patients than in patients without HF and that both would decrease 
after treatment with diuretics or nitroglycerin.
Methods: We collected baseline demographic, clinical and laboratory data in a 
convenience sample of emergency department patients with suspected decompensated 
HF. The presence of an S3 or S4 was determined using the Audicor system (Inovise 
Medical Inc.), a validated device that algorithmically detects S3 and S4 heart sounds. 
Patients were stratiﬁed by diagnosis: primary diagnosis of HF, secondary diagnosis of 
HF, and no diagnosis of HF. Diagnoses were based on attending physician discharge 
summary. χ² tests were used for comparing proportions.
Results: Of the 439 patients enrolled, 113 were excluded because of missing data. 
The mean age was 60.5 (SD=16.3) with 52.8% African-American and 46.3% male. 
The prevalence of an S3 was 39.5% in Primary HF (N=76), 27.0% in Secondary HF 
(N=37) and 11.3% in No HF patients (N=213). The prevalence of an S4 was 19.7% in 
Primary HF, 18.9% in Secondary HF and 10.8% in No HF patients. In primary HF patients 
with heart sounds analysis before (n=51) and after (n=25) diuretics, the prevalence of 
S3 and S4 decreased from 47.1% and 29.4% to 24.0% (p=0.05) and 0.0% (p=0.003), 
respectively. In primary HF patients with heart sounds analysis before (n=58) and after 
(n=18) nitroglycerin the prevalence of S3 and S4 decreased from 44.8% and 24.1% to 
22.2% (p=0.09) and 5.6% (p=0.08), respectively.
Conclusions: Patients with decompensated heart failure are more likely to have 
abnormal diastolic heart sounds than patients with dyspnea not related to heart failure. 
Prior treatment with diuretics and vasodilators should be considered when interpreting 
heart sounds.
1133-168 Mid-term Results of Bone Marrow Cell Mobilization by 
Granulocyte-Colony Stimulating Factor Associated or 
Not With Intracoronary Stem Cell Infusion for Severe 
Congestive Heart Failure Treatment
Edimar A. Bocchi, Fernando Bacal, Victor Issa, Marcus Coimbra Resende, Guilherme 
Guimarães, Fátima Cruz, Antonio Esteves-Filho, José Franchini Ramires, Alfredo 
Mendroni, Dalton Chamone, Heart Institute(InCor) of the São Paulo University Medical 
School, São Paulo, Brazil
Background Bone marrow stromall cells(BMC)when implanted into myocardial in 
animal models can undergo mileu-dependent differentiation and express cardiomyogenic 
phenotypes. Myocardium regeneration is emerging as a new option in the treatment 
of heart failure(HF). Preliminary results showed short-time beneﬁcial effects of BMC 
treatment in selected HF patients (pts). However, mid-term results are unknown.
Methods We prospectively studied 16 patients, mean age 50±16 years, 9 male, under 
maximal tolerated optimized treatment with indication of heart transplantation. The etiology 
was chagasic in 6 pts, hypertensive in 3 pt, idiopathic dilated cardiomyopathy in 4 pts, alcoholic 
1 and peripartum 2. CHF pts were divided in two groups: (1) 5 pts with suitable peripheral 
venous access for apheresis procedure who underwent BMC mobilization and collection of 
mononuclear cells (MNC) followed by MNC intracoronary infusion; and (2) 11 patients without 
suitable venous access who underwent only BMC mobilization. BMC are mobilized (cycle) 
by 600 mg GCS-F per day during at least 5 days until peripheral blood CD 34+ cells levels 
achieve > 6/mm3 by ﬂow cytometric analysis.Three pts died < 3m follow-up.
Results after 7 months follow-up: improvement in NYHA functional class persisted (pre: IV 25% 
of pts, III intermittent with IV 75%; after at 7m follow-up III 14%, II 71%, I 15%; at 10m III 17%, II 
33%, I 50%; at 13 m III 17%, II 33%, I 50%) (p=0.03). The peak oxygen consumption (ml/kg/min) 
was pre 10.3±2.9, at 7 m 13.9±4, at 10 m 14±5.5, and at 13m 14.7±4 (p=0.01). The Minnesota 
Living with Heart Failure score results were pre 67±15, after at 7 m 29±14, at 10 m 38±24, and 
at 13m 34±14, (p=0.0001). The left ventricular ejection fraction was (in %) pre 21±6, at 7 m 
27±11, at 10 m 26±6, and at 13 m 27±6. No patient died in the mid-term follow-up.
Conclusion The mobilization of BMC followed or not by MNC intracoronary infusion 
can be associated to mid-term maintenance of improvement in functional class, exercise 
capacity and quality of life. The mid-term effects of BMC mobilization suggest that it has 
potential to become a new hope in treatment of CHF.
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1133-169 Comparison Between Cases of New Onset Heart Failure 
and Acutely Decompensated Heart Failure:  
An ADHERE® Analysis
Gregg C. Fonarow, Lynne Warner Stevenson, J. Thomas Heywood, Margarita Lopatin, 
ADHERE Scientiﬁc Advisory Committee and Investigators, University of California Los 
Angeles, Los Angeles, CA
Background: Little is known as to whether patients (pts) hospitalized with a new-onset of 
heart failure (HF) differ in characteristics, treatments, and outcomes from pts with acute 
decompensation of pre-existing HF.
Methods: We used Acute Decompensated Heart Failure National Registry (ADHERE®) 
data to compare pts with no history of HF (new-onset) to those with decompensation of 
pre-existing HF by ANOVA, Wilcoxon, or chi-square tests. Logistic regression was used 
to adjust mortality analysis for gender, age, and previously identiﬁed mortality risk factors 
(BUN, systolic BP and serum creatinine).
Results: Of 105,386 pts, 25,832 (25%) were new-onset. Compared with pre-existing HF 
pts, new-onset pts had less history of CAD and atrial ﬁbrillation. New-onset pts had higher 
systolic BP, lower BUN, similar hemoglobin, and higher LVEF at presentation. New-onset 
pts more often received ACE inhibitors (60% vs 56%, P<0.0001) as in-pts; beta-blocker 
use was similar (60%). Mean ICU length of stay (LOS) and total LOS were similar between 
groups. Fewer new-onset pts died in-hospital (3.0% vs 4.3%, OR=0.67, P<0.0001). Risk-
adjusted mortality was, however, similar between groups (OR=1.0, P=0.95).
Conclusions: One in four HF hospitalizations is for new-onset HF. Medical therapies 
and cardiac procedures were employed at the same or higher frequency in new onset 
HF. Despite differences in characteristics and management, new onset HF pts had 
comparable LOS and risk-adjusted hospital mortality to pre-existing HF pts.
 
New-onset HF 
(n=25,832)
Decompensation 
of pre-existing HF 
(n=79,554)
P-value
Sex, % male 45.5 49.0 <0.0001
Mean age, years 71.6 72.6 <0.0001
Coronary artery disease, % 39.3 62.8 <0.0001
Atrial ﬁbrillation, % 19.6 34.4 <0.0001
Mean Systolic BP, mm Hg 151.9 141.2 <0.0001
Mean BUN, mg/dL 26.3 33.6 <0.0001
Mean hemoglobin, g/dL 12.6 12.4 <0.0001
Mean LVEF, % 42.5 35.9 <0.0001
Cardiac catheterization
(left heart), % 16.8 8.0 <0.0001
Pulmonary artery catheterization, % 5.3 4.2 <0.0001
Mechanical ventilation, % 5.4 4.7 <0.0001
ACE inhibitor at discharge for LV 
systolic dysfunction, % 73.8 63.1 <0.0001
Smoking cessation counseling, % 43.9 38.5 <0.0001
Discharge instructions, % 31.6 32.6 0.016
LV function assessment, % 82.6 82.7 0.74
Mean ICU LOS, days 3.8 4.0 0.012
Mean hospital LOS, days 5.7 5.9 <0.0001
1133-170 Pulmonary Artery Catheterization and Mortality In 
Acute Decompensated Heart Failure Patients: An 
Observational Analysis From ADHERE®
Clyde W. Yancy, James A. Hill, Lynne Warner Stevenson, Gregg C. Fonarow, Margarita 
Lopatin, ADHERE Scientiﬁc Advisory Committee and Investigators, University of Texas 
Southwestern Medical Center, Dallas, TX
Background: The safety and utility of pulmonary artery catheterization (PAC) use in HF 
management is inconclusive. This analysis compared in-hospital outcomes in patients 
with and without PAC using data from the ADHERE® Registry.
Methods: Previous classiﬁcation and regression tree risk score deﬁned patients at 
high-risk (HR) for in-hospital mortality. Patient characteristics and in-hospital outcomes 
(mortality, total LOS, and ICU LOS) were compared in HR patients with and without PAC. 
Chi-square tests, ANOVA, multiple logistic and linear regressions were utilized.
Results: 1,965 out of 102,524 ADHERE patients were identiﬁed as HR. 7.6% of HR 
patients received PAC; mean SCr was 4.0 mg/dL. PAC patients were younger, more 
often male, in academic hospitals, and had lower systolic BP and LVEF than patients 
without PAC. PAC patients had higher mortality, LOS, ICU LOS, inotrope and vasodilator 
use (Table). After adjustment for age, systolic BP, BUN, SCr, inotrope and vasodilator 
use, PAC was not associated with increased mortality (OR=1.40, p=0.10) but still had 
longer mean ICU (6.5 vs 4.3 days, p<0.0001) and total LOS (12.5 vs 8.2 days, p<0.0001). 
Inotrope use was associated with increased mortality (OR=3.54, p<0.0001).
Conclusion: When adjusted for baseline characteristics and in-hospital therapies, 
PAC use was not associated with increased risk of death in HR patients. Other clinical 
variables, such as inotrope use, may contribute to the mortality risk associated with PAC 
in critically ill HF patients.
Categories High Risk1
PAC No PAC p-value
N 149 1816 NA
Demographics
Mean age, years 68 74 <0.0001
Gender, % male 73 67 0.15
Academic hospitals, % 53 34 <0.0001
Initial Evaluation
Mean SCr, mg/dL 4.0 4.2 0.24
Mean systolic BP, mm Hg 94 99 <0.0001
BUN, mg/dL 86 82 0.15
Mean LVEF2 0.28 0.32 0.02
LVEF <0.40, %2 77 67 0.06
IV Medications
Inotropes, % use 83 41 <0.0001
Vasodilators, % use 30 20 0.0025
Outcomes
Mortality, % 30.9 18.6 0.0003
Mean LOS, days 13.2 7.6 <0.0001
Mean ICU LOS, days 7.5 4.3 <0.0001
1High-risk patients deﬁned as BUN ≥43 mg/dL, systolic BP <115 mmHg, and SCr ≥2.75 
mg/dL.
2Based on available in-hospital evaluations.
1133-171 Effect of Ethnicity on Likelihood of Admission for Heart 
Failure
Lori B. Daniels, Paul Clopton, Judd E. Hollander, David Guss, Peter McCullough, Richard 
Nowak, Gary Green, Mitchell Saltzberg, Stefanie R. Ellison, Meenakshi Awasthi Bhalla, 
Vikas Bhalla, Robert Jesse, Alan Maisel, University of California at San Diego Medical 
Center, San Diego, CA, Veteran’s Affairs San Diego Healthcare System, La Jolla, CA
Background: Previous studies have shown that in patients presenting to the Emergency 
Department (ED) with heart failure, there is a disconnect between the perceived severity 
of CHF by physicians and the severity as determined by BNP levels. Whether ethnicity 
plays a role in this discrepancy is unknown.
Methods: The Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) 
was a 10-center trial of 464 patients seen in the ED with acute dyspnea and BNP level 
>100 pg/mL upon arrival. Physicians were blinded to BNP levels. Patients were followed 
for 90 days after discharge.
Results: 151 patients identiﬁed themselves as Caucasian (32.5%), and 292 as African 
American (62.9%). Of these, 90% were hospitalized. African Americans were more 
likely to be perceived as NYHA class I or II than whites (p=0.013.) The BNP level of 
those discharged from the ED versus those admitted is shown in the Figure. African 
Americans who were discharged had higher median BNP levels than Caucasians who 
were discharged (1293 vs. 533, p=0.004). After adjusting for age, weight, and gender, the 
difference persisted (p=0.003). The median BNP of African Americans who were admitted 
was actually lower than the median BNP of those who were discharged (769 vs. 1293, 
p=0.044); the same did not hold true for Caucasians.
 
Conclusion: In patients presenting to the ED with heart failure, the disconnect between 
perceived severity of CHF and severity as determined by BNP levels is most pronounced 
in African Americans.
1133-172 Early Enalapril Therapy Confers Long-Term Protection 
Against Cardiac Ischemic Events : Evidence for a 15-
Year Beneﬁt on Plaque Stability
Michel F. Rousseau, Sylvie A. Ahn, Philip Jong, Hubert G. Pouleur, University of Louvain, 
Brussels, Belgium
Background : The Studies of Left Ventricular Dysfunction (SOLVD) demonstrated that, 
over 3-4 years, enalapril therapy decreased mortality and morbidity in patients with low 
ejection fractions and reduced the incidence of cardiac ischemic events. The aim of this 
study was to determine if this early beneﬁt of enalapril on atherosclerotic complications 
confers long-term protection. 
Methods : From the initial cohort of 558 Belgian patients included in SOLVD, data on post-
trial deaths or morbid events were collected on all 433 survivors at close-out (enalapril 
n=218, placebo n=215). At the end of follow-up (December 2003-February 2004), 145 
patients were still alive (80 enalapril vs 65 placebo). Use of ACE-Inhibitor (85% vs 79%, 
p=0.40) and other cardiovascular drugs post trial were similar between enalapril and 
placebo groups. No patients were lost to follow-up. 
Results : The median duration of follow-up was 15.5 years from randomization or 12.2 
years from close-out. The risk of death or non fatal cardiac ischemic events (myocardial 
infarction, coronary angioplasty, coronary bypass surgery) was signiﬁcantly lower in the 
early enalapril group than in the delayed enalapril group [148/218 (68%) vs 167/215 
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(78%); Wilcoxon p=0.0013]. Even in patients still alive at follow-up, early enalapril therapy 
was associated with a 14% absolute risk reduction in non fatal myocardial infarction, 
coronary angioplasty or coronary bypass surgery when compared to the delayed enalapril 
group [10/80 (12%) vs 17/65 (26%); p=0.03]. Moreover, Cox’s regression showed that the 
initial in-trial use of enalapril was associated with a statistically signiﬁcant risk reduction in 
cardiac ischemic events (HR: 0.43, 95%CI: 0.20 to 0.95, p=0.04). 
Conclusions : Our data indicate that, beyond the original trial period, a signiﬁcantly lower 
risk of cardiac ischemic events is present for at least 15 years in early enalapril group 
as compared to delayed enalapril group. This suggests that earlier treatment initiation 
produces sustained beneﬁcial effect on plaque stability.
1133-173 Quality of Life Among Patients with Heart Failure 
and Preserved Ejection Fraction versus Low Ejection 
Fraction: Does Ejection Fraction Matter?
Eldrin F. Lewis, Gervasio A. Lamas, John McMurray, Jonas Carlsson, Chris Granger, 
Mark E. Dunlap, Eileen O’ Meara, Karl Swedberg, Jean L. Rouleau, Marc A. Pfeffer, 
Brigham and Women’s Hospital, Boston, MA, Mount Sinai Medical Center, Miami, FL
Background: Despite the large number of patients (pts) with heart failure with preserved 
systolic function (HF-PSF), little is known about the impact of disease on their quality of life 
(QOL). We utilized the CHARM experience to test the hypothesis that there is no difference 
in QOL between pts with HF-PSF and those with HF and low ejection fraction (HF-LEF).
Methods: CHARM enrolled 7599 pts with chronic HF (NYHA Class II-IV) randomized to 
candesartan or placebo. A subset of 2709 (35.6%) completed the Minnesota Living with 
Heart Failure questionnaire (LHF). Differences in LHF scores were assessed between 
HF-PSF (EF>40%) and HF-LEF (EF<40%) using t-test.
Results: There were 1097 pts with HF-PSF and 1612 pts with HF-LEF. HF-PSF pts were 
more likely women, more often NYHA Class II, had a higher systolic blood pressure, 
and less likely to have a prior MI (Table). There was no difference in overall LHF scores 
(40.8±23.9 vs. 40.3±23.8, p=0.61) or emotional dimension scores (8.3±7.2 vs. 8.4±7.2, 
p=0.61) in HF-PSF pts compared with HF-LEF. HF-PSF pts had more impaired physical 
limitations than HF-LEF pts (19.3±11.1 vs. 18.2±10.9, p=0.02). The correlation coefﬁcient 
between LHF scores and EF was 0.02.
Conclusion: Pts with HF-PSF have similarly impaired overall QOL as pts with HF-LEF 
despite more pts with NYHA Class II. There is no correlation between EF and QOL. These 
ﬁndings warrant future studies to better characterize the determinants of QOL and impact 
of therapies on QOL in this growing patient population with HF-PSF.
Baseline characteristics 
Characteristic HF-Low EF n=1612 HF-Preserved Systolic Function n=1097 p-value
Age (years) 65.1+11.6 66.6+11.4 <0.001
Male (%) 73.4% 57.2% <0.001
Systolic Blood Pressure (mm Hg) 124.7+18.5 132.9+17.5 <0.001
NYHA
(Class III/IV) 71.1% 52.6% <0.001
Prior Heart Failure Hospitalization 69.0% 65.3% 0.04
Prior Myocardial Infarction 59.1% 44.0% <0.001
History of Hypertension 60.4% 75.8% <0.001
Diabetes Mellitus 35.1% 40.0% 0.009
Prior Stroke 10.5% 10.5% 1.0
1133-174 Long Term Follow Up After A Telephone Intervention In 
Heart Failure: Dial Trial
Daniel Nul, Daniel Ferrante, Carola Zambrano, Saul Soifer, Sergio Varini, Hugo 
Grancelli, Hernan Doval, GESICA Foundation, Buenos Aires, Argentina
Background: in spite of the body of evidence supporting the effectiveness of disease 
management programs in heart failure (HF), there is scarce data about long term beneﬁt 
of these interventions. Our objective was to
evaluate the incidence of admission for worsening HF or death after 6 months and a year 
after the end of the intervention in DIAL Trial
Methods: From DIAL trial (n=1518, randomized controlled clinical trial of a nurse telephone 
intervention program vs. control), the incidence of admission for worsening HF or all cause 
death was analyzed at 6 months and a year after trial completion. The following analyses 
were performed: 1) Beginning to 6 months after trial completion, 2) Beginning to one year 
after trial completion, 3) End of trial to 6 months , 4) End of trial to one year. Log rank tests 
and relative risks (RR) were used to estimate the intervention effect. End points considered: 
primary end point (HF admission or death), HF admission, death.
Results: the incidence of the primary end point was lower in the intervention group 
during long term follow up, at 6 months ( Intervention 31.97% vs. Control 38.39%, RR 
0.78 (0.65-0.93), p=0.0049) and at one year (Intervention 37.23% vs. Control 42.61%, RR 
0.81 (0.69-0.96) p=0.013). This beneﬁt was attributable to a reduction in HF admissions. 
Considering those events occurred after trial completion, intervention group showed lower 
rate of events. However, this effect tapered in function of time. Considering the effect 
of the intervention on primary end point from trial completion to 6 months the RR was 
0.70(0.46-1.06) p=0.082, and to one year RR 0.87(0.63-1.19), p=0.380. (Cox regression 
with intervention as time dependent covariate: time-intevention interaction p<0.05)
Conclusions: the beneﬁt continues to increase during the ﬁrst 6 months after trial 
completion, and is maintained at one year. The sustained beneﬁt could be explained 
through the impact of the educational intervention on patients´ behaviors. Although the 
beneﬁt diminished after trial completion, the effect was maintained after the intervention 
was suspended.
1133-175 Repetitive Worsening Of Chronic Heart Failure 
Promotes Myocardial Fibrosis Through Enhanced 
Oxidant Stress In Vivo
Megumi Kunishige, Yoshiyuki Kijima, Yusuke Nakagawa, Akira Nishibe, Nobuyuki 
Ogasawara, Tamayo Ishiko, Hiroko Hanasaki, Takeshi Hata, Higashi-osaka City General 
Hospital, Higashi-osaka, Japan
Backgroud: Progression of myocardial ﬁbrosis of chronic heart failure(CHF) is vital for 
prognosis of the disease. It has been suggested that oxidant stress regulates myocardial 
collagen metabolism. In this study we attempted to clarify a possible link between acute 
worsening of the disease, oxidant stress and collagen metabolism. 
Methods: Nineteen patients with CHF were enrolled at admission because of worsening 
of the disease. After treatment(20±12days), serum level of brain natriuretic peptide was 
decreased from 965.5±704.8 (acute phase) to 311.5±271.4pg/ml (chronic phase). We 
monitored urinary excretion of immunoreactive 8-iso-prostaglandin F2α (8-isoPGF2α), 
a marker for oxidant stress in vivo, serum total anti-oxidant status (TAS), serum levels 
of procollagen type I carboxyterminal peptide (PIP) and carboxyterminal collagen type 
I telopeptide (CITP), biochemical markers for collagen synthesis and degradation, 
respectively at two phases. 
Results: 8-isoPGF2α and PIP level were enhanced at acute versus chronic phase 
(353.9±329.8 vs. 221.2±131.2pg/mg creatinine, P=0.01; 150.7±55.8 vs. 99.7±39.1ng/ml, 
P=0.001; respectively). TAS did not change (0.95±0.15 vs. 0.96±0.16mM). CITP level was 
increased at chronic phase (7.4±4.1 vs. 13.0±8.2ng/ml, P=0.0001). 
Conclusions: Oxidant stress and collagen synthesis were enhanced at the acute 
worsening of CHF. These results suggest repetitive worsening of the disease promotes 
myocardial ﬁbrosis through oxidant stress leading to individual death.
1133-176 Analysis of Black Patients with Heart Failure and End 
Stage Renal Disease on Hemodialysis.
Judith E. Mitchell, Meriam F. Caboral, Locquessa Okpala, John Feng, Luther T. Clark, 
State University of New York Health Science Center @ Brooklyn, Brooklyn, NY
Background. Blacks comprise a higher percentage of patients (pts) with end stage renal 
disease (ESRD) on hemodialysis (HD). Development of HF is accelerated in the ESRD 
pts and the prognosis is worse. We sought to analyze the demographic and clinical proﬁle 
of black pts with ESRD on HD who were hospitalized with HF.
Methods. Of 550 pts with HF consecutively admitted to an inner-city medical center from 
4/03 to 7/04, 503 (91%) were black.
Results. Analysis of these 503 pts revealed: 37% male, 27% < 60 year old, and 57% 
EF < 40%; 9% had ESRD on HD. The HD/HF cohort was signiﬁcantly (p=0.001) younger 
than the general HF population (70 vs. 63). Pts < 60 were more than twice as likely to be 
on HD as those > 60. No signiﬁcant gender difference between the groups was observed 
(p=0.07) and the proportion of pts with EF < 40% vs. > 40% was similar (p=NS). Pts in 
the general population and the HD/HF group were twice as likely to have HF due to non-
ischemic vs. ischemic disease. Diabetes prevalence was 43% and 46% in the HF and HD/
HF groups respectively (p=NS). Although a history of HTN was similar in both groups, the 
HD/HF group had signiﬁcantly higher mean systolic BP (167 vs. 151 mmHg; p<0.01). The 
diastolic BPs were comparable (86 vs. 90 mmHg; p=NS). On admission and on discharge 
the HD/HF group weighed signiﬁcantly less (155 vs.180 lbs; p<0.001 and 153 vs.173 lbs; 
P=0.019 respectively) but the change in weight during the admission was not different 
(5.3 vs. 6.6 lbs; p=NS). Mean hemoglobin was signiﬁcantly lower in the HD/HF pts (12 
vs. 11; p<0.01). Treatment with beta-blockers was not different but the HD/HF group was 
2.5 times less likely to receive either an ace-inhibitor (ACEI) or an angiotensin receptor 
blocker (ARB) (p<0.01). Aldosterone antagonist (AA) was used in only 7% of the HD/HF 
group vs. 31% of the non-HD/HF group (p<0.001). Median duration of hospitalization was 
longer (5 vs. 4 days; p<0.05) for the HD/HF cohort.
Conclusion. Black pts with HF are almost twice as likely to be on HD compared with 
registry data of HF pts. HD/HF pts are younger, have higher presenting systolic BP, lower 
Hgb, lower weight and less use of ACEI/ARB/AA. Findings have important implication for 
pt outcome and treatment management and warrant further studies.
1133-177 Initial Clinical Experience With a Novel Ultraﬁltration 
Device as a Treatment Strategy for Diuretic Resistant, 
Refractory Heart Failure
Kelly V. Liang, Ann R. Hiniker, Amy W. Williams, Barry L. Karon, Eddie L. Greene, 
Margaret M. Redﬁeld, Mayo Clinic, Rochester, MN
Background: Diuretic resistance (DR) during heart failure (HF) therapy increases length 
and cost of HF hospitalizations. Ultraﬁltration (UF) has been reported to restore diuretic 
responsiveness in some HF patients (pts). The novel System 100 UF device allows UF 
via peripheral access on a standard nursing unit by non-nephrologists and is approved 
for use in HF.
Objective: We report our initial experience with use of this system in DR HF pts by HF 
cardiologists.
Methods: Eleven HF pts (mean age 70±7 yrs) with documented (n=9) or suspected (n=2) 
DR underwent 2-5 UF treatments (UFRx) each (total 32 UFRx). The goal was to remove 
4 liters of ﬂuid per 8-hour UFRx.
Results: Baseline creatinine (Crt) was 2.2±0.8 mg/dl while Crt clearance calculated using 
ideal body weight was 35±17 mL/min. Nine pts had documented RV dysfunction, 6 with 
severe tricuspid regurgitation. Average daily out-pt furosemide dose was 176+104 mg 
(po). Average in-pt dose was 258+121 mg (iv). Four pts had received nesiritide, 4 pts 
had received dopamine and 7 pts had recieved zaroxylyn prior to UF. Of the 32 UFRxs, 
13 (41%) removed >3500 mL, 11 (34%) removed 2500-3500 mL, and 8 (25%) removed 
<2500. Positional variation in blood ﬂow was the primary reason for failure to achieve 
goal ﬂuid removal. Only one UFRx was aborted due to hypotension. Five pts (45%) 
experienced an increase in Crt of > 0.3 mg/dl. Five pts required dialysis for persistant 
DR state. At an average follow-up of eight months, mortality was 55%. Costs exceeded 
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reimbursement by $211,000 in these 11 hospitalizations. Third party payor was Medicare 
in all but 2 pts. Costs were high as all but 2 pts had extended standard therapy prior to UF 
and 4 of the 5 pts ultimately needing dialysis underwent dialysis on the same admission. 
There were no signiﬁcant complications related to UFRx.
Conclusions: These data underscore the high mortality, morbidity and cost of advanced, 
DR HF. In this initial experience, peripheral UF can be effective for short-term ﬂuid removal 
with few complications, but it was not a consistently helpful strategy in terms of clinical 
outcomes in severe DR refractory HF. Use of UF in less advanced HF may hold greater 
promise and remains to be investigated.
1133-178 The Impact of Baseline Glomerular Filtration Rate on 
the Incidence of Worsening Renal Failure in Patients 
Admitted for Acute Decompensated Heart Failure
Ure L. Mezu, Kiran Philip, Gary S. Francis, Randall C. Starling, David O. Taylor, W. H. 
Wilson Tang, Cleveland Clinic Foundation, Cleveland, OH
Background: Renal insufﬁciency is prevalent in patients admitted with acute 
decompensated heart failure (ADHF). However, the incidence of worsening renal function 
(WRF) in relation to the degree of baseline renal insufﬁciency at admission is not clear.
Methods: We identiﬁed 242 consecutive patients (mean age 66 ±14 years, 51% male, 
mean serum creatinine 1.4 ±0.5 mg/dl) admitted for ADHF between 10/02 - 5/03, and 
followed their sequential serum creatinine and glomerular ﬁltration rates (GFR in mL/
min/1.73m2, by MDRD equation). WRF was deﬁned by change in serum creatinine >0.3 
mg/dl (Gottlieb criteria).
Results: In our cohort, 17% had underlying severe (GFR <30), 50% had moderate 
(GFR=30-59), and 33% had normal or mild renal insufﬁciency (GFR ≥60) at admission. 
The 3 groups had similar utilization rates for hemodynamically-guided therapy (33% vs 
28% vs 35%). Overall, 31% and 26% of patients experienced WRF during hospitalization 
and at discharge, respectively. Lower admission GFR was associated with higher 
incidence of WRF, both at peak creatinine rise and at discharge (Figure). In patients 
with moderate or severe renal insufﬁciency, 39% experienced WRF, while 35% showed 
improvement in serum creatinine at discharge.
Conclusion: Over one-fourth of patients admitted for ADHF experienced WRF at 
discharge. Over two-thirds of patients admitted for ADHF had moderate or severe renal 
insufﬁciency, among them 39% experienced WRF while 35% showed improvement in 
serum creatinine at discharge.
1133-179 Both Ramipril and Telmisartan Favourably Affect 
Indices of Early Diabetic Cardiomyopathy
Spyridon Koulouris, Phivos Symeonides, Konstantinos Triantafyllou, Ekaterini Vratsista, 
Ilias Karabinos, Athanasios Kranidis, Ioannis Nanas, Stamatios Stamatelopoulos, Pavlos 
Toutouzas, Antonios Manolis, Evagelismos Hospital, Athens, Greece, Euroclinic, Athens, 
Greece
Background: Left ventricular diastolic dysfunction (LVDD) is considered an early sign of 
diabetic cardiomyopathy. We tested the hypothesis that ramipril (an angiotensin converting 
enzyme inhibitor) and telmisartan (an angiotensin II receptor antagonist) reverse LVDD 
in diabetic patients.
Methods: Fourty patients, 57.3±8.5 years old (17 men, 23 women), with well controlled 
type 2 diabetes without hypertension, coronary artery disease, left ventricular systolic 
dysfunction or microalbuminuria were recruited in this double blind cross-over trial. They 
received randomly ramipril (2.5mg/day), or telmisartan (40mg/day) for 3 months. After a 2 
week wash out period they crossed over to the alternative regimen. Finally, they received 
combination treatment for 3 more months. Plasma brain natriuretic peptide (BNP) and 
transmitral early to late peak ﬂow velocity (E/A) and early to late velocity time integral 
(VTIE/VTIA) ratios were assessed by Doppler echocardiography at baseline and after 
each treatment period (i.e. at 3,6,9 months). Statistical analysis was done with Friedman’s 
analysis of variance.
Results: Ramipril and telmisartan improved diastolic indices and lowered BNP plasma 
levels (Table 1).
Table 1 
E/A VTIE/VTIA BNP (pg/ml)
Baseline 0.84±0.06 0.92±0.09 27.8±21
Ramipril 1.09±0.28 1.10±0.21 25.2±19.9
Telmisartan 1.05±0.15 1.13±0.24 20.8±19.5
Combination therapy 1.15±0.22 1.18±0.35 17.9±12.9
P <0.001 <0.001 <0.001
Blood pressure and blood glucose levels remained unaffected.
Conclusion: Both ramipril and telmisartan reverse LVDD and reduce plasma BNP levels 
in diabetic patients; their combination yields an even better therapeutic effect.
1133-180 Patient Knowledge of Self-Care Activities in Congestive 
Heart Failure: The PaKSAC Study
Evan Lockwood, Marilou Hervas-Malo, Rosa Gutierrez, Kari Olson, Maricel Reddy, 
Marcelo Shibata, Ross Tsuyuki, University of Alberta, Edmonton, AB, Canada
Background: Self-care plays an important role in the successful management of heart 
failure (HF), yet little is known about patients’ knowledge in this area.
Methods: PaKSAC is a study of 300 consecutive patients admitted to hospital with ≥ 12 
month duration of HF. Patients are interviewed using open-ended and prompted questions 
on HF and HF-related self-care activities using a validated survey instrument to determine 
knowledge of heart failure and self-care. Patients who are not responsible for self-care 
are excluded. Clinical events, including all-cause and HF-related hospitalizations, were 
collected for the prior 12 months and adjudicated by an expert panel.
Results: Analysis of the ﬁrst 157 patients shows an average age of 68 (±12); 74% had ≥ 
high school education; and 79% had HF > 48 months. 55% had ≥ 1 clinical event in the 
prior year, with a median of 2 per patient. 94% were aware of their diagnosis, but only 
64% had an understanding of what HF was. Three-quarters of patients were aware of the 
typical symptoms of HF. However, when openly questioning awareness, 35% of patients 
knew to restrict salt, 24% to restrict ﬂuids, and 16% to weigh themselves daily. When 
prompted, 89%, 71%, and 73% of patients felt that salt restriction, ﬂuid restriction, and 
daily weights, respectively, were as important as medications in HF management. Only 
78% had tried a salt restricted diet (45% found it difﬁcult), and only 7% knew to limit salt to 
2 grams. Fifty percent had tried to limit ﬂuid intake and half of these found it difﬁcult. Half 
knew to weigh themselves daily, and although 87% had a scale, only 30% actually did it. 
Of the 92% of patients who knew they were taking medications for HF, 43% felt that the 
medications were “a mystery to me.” Using a knowledge score developed from the survey, 
73% of the patients with at least one clinical event had no knowledge.
Conclusion: High risk HF patients admitted to hospital have a poor awareness and understanding 
of HF and self-care activities in the management of HF. We plan to utilize the information from 
this study to develop and evaluate an educational program targeting these areas.
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1134-157 Association of an Endothelin Converting Enzyme 
Gene (ECE1) Polymorphism (T341I) With Variation 
in Myocardial Blood Flow in Idiopathic Dilated 
Cardiomyopathy
Matthew R. Taylor, Dobromir Slavov, Umberto Startari, Maria G. Colombo, Beatrice 
Dal Pino, Maria P. Pellegrini, Luisa Mestroni, Danilo Neglia, University of Colorado 
Health Sciences Center, Cardiovascular Institute, Denver, CO, CNR Institute of Clinical 
Physiology, Pisa, Italy
Background: Depressed myocardial blood ﬂow (MBF) evaluated by Positron Emission 
Tomography in subjects with idiopathic dilated cardiomyopathy (IDC) predicts an increased 
risk of death and heart failure. We hypothesized that single-nucleotide polymorphisms 
(SNPs) in genes of the endothelin pathway inﬂuence measured MBF parameters.
Methods: We genotyped four candidate SNPs in 104 IDC subjects who had been 
characterized for MBF: endothelin receptor A gene (ETRA) 1363 C/T and H323H (C/
T), endothelin 1 gene (EDN1) K198R, endothelin converting enzyme 1 gene (ECE1) 
T341I. The statistical analysis included T-tests under a dominant model and ANOVA 
under genotype models on the following continuous variables: ejection fraction, end 
diastolic volume (EDD), age of diagnosis, myocardial blood ﬂow (MBF) (baseline-B, after 
dipyridamole-D, reserve-R), ambulatory systolic and diastolic blood pressure (SBP, DBP) 
and heart rate.
Results: Minor allele frequencies were 0.40, 0.27, 0.16, and 0.053 for SNPs 1363 C/T, 
H323H, K198R, and T341I, respectively. For the dominant model, signiﬁcant associations 
were noted for K198R and EDD (p=0.033) and for T341I and MBF-D (p=0.002), SBP 
(p=0.012), and DBP (p=0.019). ANOVA for T341I remained signiﬁcant under the genotype 
model with 341T predicting higher MBF-D, SBP, and DBP.
Conclusions: Our study is the ﬁrst to investigate the effects of candidate SNPs in 
microcirculatory pathways on the phenotype of MBF and the ﬁrst to associate a phenotype 
with the ECE1 T341I SNP. This data suggest that the ECE1 341T allele predicts increased 
MBF response to dipyridamole infusion and higher blood pressures in IDC.
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1134-158 The G212A Polymorphism of the APJ Receptor Gene for 
the Potent Inotrope Apelin has a Prognostic Inﬂuence in 
Idiopatic Dilated Cardiomyopathy.
Riccardo Sarzani, Cinzia Forleo, Francesca Pietrucci, Alessandro Capestro, Elli Soura, 
Francesca Massenzio, Pietro Guida, Sandro Sorrentino, Massimo Iacoviello, Paolo 
Dessì-Fulgheri, Alessandro Rappelli, Mariavittoria Pitzalis, Mariavittoria Pitzalis, Bari, 
Italy, Riccardo Sarzani, Ancona, Italy
Apelin and its receptor APJ increase inotropism at cardiac level and seem to have a role 
in idiopathic dilated cardiomyopathy (IDC) pathophysiology. No data are available on APJ 
gene mutations responsible for IDC and on the role of G212A and T445G APJ receptor 
polymorphisms in predicting heart failure (HF) progression.
We prospectively evaluated 176 consecutive pts (49±14 years, 134 men) with IDC, NYHA 
class 1.9±0.7, ejection fraction (EF) 36±11% while were taking conventional therapy. We 
genotyped all pts for the two polymorphisms by PCR-RFLP analysis and screened the 
APJ gene for mutations in 90 pts by direct sequencing. The correlation between APJ 
polymorphisms and HF progression was studied.
During follow-up (median: 34 months), HF progression was observed in 26 pts (19 were 
hospitalized, 3 underwent cardiac transplant, and 4 died because of HF). At univariate 
analysis, pts with A variant had a signiﬁcantly lower risk for HF events than those who 
were homozygous for the G variant (Figure). At multivariate analysis, considering age, 
NYHA class, and EF, the A variant remained signiﬁcantly related to more favorable 
prognosis (HR: 0.40; p<0.05). No mutations were found in APJ gene.
In conclusion, APJ is unlikely to be a disease-causing gene responsible for IDC. Moreover, 
in these pts, the allele A of G212A APJ receptor polymorphism correlated independently 
with a better prognosis. This variant of the 5’ untranslated mRNA or a linked variant in the 
promoter may regulate APJ expression levels and IDC progression. 
1134-159 Lipid and Glucose Proﬁles are the Main Determinants 
of Coronary Microvascular Impairment in Patients with 
Idiopathic Left Ventricular Dysfunction
Danilo Neglia, Tiziana Sampietro, Patricia Iozzo, Maria Paola Pellegrini, Claudio 
Michelassi, Concetta Prontera, Beatrice DalPino, Federico Bigazzi, Umberto Startari, 
Michele Emdin, Antonio L’Abbate, CNR Institute of Clinical Physiology, Pisa, Italy
Background. In Idiopathic LV dysfunction (ILVDys) myocardial blood ﬂow (MBF) is 
impaired due to coronary microvascular abnormalities and is a powerful predictor of 
long-term prognosis. Purpose of this study was to assess possible determinats of MBF 
impairment in ILVDys patients.
Methods. Forty-two consecutive non-diabetic, non-hypertensive, non-statin treated ILVDys 
pts (LVEF 38+-9%, LV end-diastolic diameter 61+-6mm, Age 60+-9yrs, normal epicardial 
coronary arteries, NYHA I-II in 36 pts) were enrolled. MBF at rest (R) and during i.v. 
dipyridamole (0.56 mg/Kg in 4’) or adenosine (140 µg/Kg/min in 6’) (Max) were quantitatively 
assessed by PET and 13N-Ammonia. Age, sex, NYHA class, LV EF, LV end-diastolic diameter, 
blood pressure, plasma ANP, BNP, noradrenaline, renine, aldosterone, homeostasis model 
assessment index (HOMA), cholesterol and triglycerides values were entered into a stepwise 
multivariate regression analysis to assess independent predictors of MBF.
Results. Table shows F values and regression coefﬁcients (in brackets) for variables with 
signiﬁcant independent predictive value.
HDL Cholesterol LDL Cholesterol HOMA index Age P
MBF Rest 11.8 (.50) 5.5 (-.34) 3.9 (-.27) ns 0.0016
MBF Max ns ns 4.3 (-.31) 3.1 (-.27) 0.0382
Conclusions. Lipid proﬁle and glucose homeostasis are the main determinants of MBF 
impairment in patients with ILVDys. These results strongly suggest a role for metabolic 
risk factors in causing progressive myocardial and coronary microvascular dysfunction 
independently on the presence of recognizable epicardial coronary lesions.
1134-160 Intraventricular Dyssynchrony May Alter Left Ventricular 
Geometry In Dilated Cardiomyopathy
Tatsuji Kono, Akiko Soyama, Takayuki Mishima, Hideaki Morita, Takahide Ito, Michihiro 
Suwa, Yasushi Kitaura, Osaka Medical College, Osaka, Japan
Background: The increased left ventricular (LV) sphericity is proposed to cause mitral 
regurgitation (MR) in dilated cardiomyopthy (DCM). We proposed the hypothesis that 
heterogeneity of longitudinal and radial contraction due to intraventricular dyssynchrony 
may alter LV geometry. 
Methods: Tissue Doppler echocardiography was performed to assess longitudinal strain 
and time from the onset of QRS complex to peak systolic myocardial strain (Ts) at mid-
septum and mid-lateral wall and radial strain at mid-posterior wall in 20 DCM patients with 
MR, in 13 DCM patients without MR and in 8 normal controls. LV sphericity was calculated 
as long-axis diameter divided by minor-axis diameter. 
Results: Septal longitudinal strain and radial strain were lower in DCM patients compared 
to control. Although lateral longitudinal strain was decreased in DCM patients without 
MR compared to control, it was not reduced in DCM patients with MR. The ratio of septal 
longitudinal strain to radial strain was not different among groups. However, the ratio of 
lateral longitudinal strain to radial strain and LV sphericity were increased in DCM patients 
with MR compared to other groups. The difference between septal Ts and lateral Ts was 
increased in DCM patients with MR compared to DCM patients without MR and controls 
(42±63 ms versus -9±31 ms, 3±3ms, p=0.01). 
Conclusion: The late activation of lateral wall may increase longitudinal contraction 
compared to radial contraction at this segment and may increase LV sphericity in DCM. 
DCM with MR DCM without MR Control p
Septal longitudinal strain (%) -13.6±7.7 -12.7±7.3 -21.1±3.5 0.024
Lateral longitudinal strain (%) -16.1±8.1 -10.0±5.1 -19.5±4.8 0.007
Radial strain (%) 11.4±3.9 15.6±10.0 27.5±9.0 <0.0001
Septal longitudinal strain/radial strain 0.94±0.54 0.99±0.66 0.65±0.16 0.36
Lateral longitudinal strain/radial strain 1.29±0.65 0.70±0.42 0.59±0.09 0.003
LV sphericity 1.43±0.19 1.79±0.29 2.43±0.23 <0.0001
1134-161 Increased Inﬂammatory Response In Patients 
With Dilated Cardiomyopathy Is Associated With 
Dyslipidemia. Effects Of Statin Therapy
Panagiotis Iakovis, Alexandros Anyfantakis, Constantinos Limas, Dennis V. Cokkinos, 
ONASSIS CARDIAC SURGERY CENTER, ATHENS, Greece
BACKGROUND: Dilated cardiomyopathy (DCM) is associated with increased 
inﬂammatory response reﬂected in C - reactive protein (CRP) and soluble interleukin 
- 2 receptor (sIL-2R) levels. Statins are effective hypolipidemic and anti-inﬂammatory 
(pleiotropic action) agents . Their use in heart failure is currently under investigation.We 
assessed the hypothesis that enhanced inﬂammatory response in DCM is conﬁned to 
patients with dyslipidemia and consequently, that statin use in dyslipidemic patients with 
DCM ,will attenuate the inﬂammatory response. 
MATERIAL/METHODS: We examined 60 consecutive patients with DCM ( 51 males, 
9 females, 54±16 years ). Thirty of them were dyslipidemic and 30 normolipidemic 
(dyslipidemia is deﬁned as plasma LDL levels >130mg/dl).
Simvastatin therapy 20mg/day was randomly added in 15 dyslipidemic patients and 
hypolipidemic diet therapy in 15 more of them. Patients were re-evaluated 6,2±1,5 
months later .
Group Ia : DCM patients with dyslipidemia , on simvastatin therapy, n=15
Group Ib : DCM patients with dyslipidemia , on diet therapy, n=15
Group II: DCM patients with normal LDL levels, n=30
There were no signiﬁcant differences between the groups Ia, Ib, II, in age / LVEF and no 
signiﬁcant differences between the groups Ia and Ib in LDL levels . 
RESULTS: CRP levels were signiﬁcantly higher in Group I patients vs. Group II patients (19,5±34 
ΙU/ml vs. 3,03±3,5 IU/ml, p=0,012). sIL-2R levels were signiﬁcantly higher in Group I patients 
vs. Group II patients (1136,57±441,1 pg/ml vs. 599,2±234,7 pg/ml, p=0,001). No signiﬁcant 
differences in the follow - up LVEF values between Groups I and II. Group Ia (simvastatin 
therapy) showed a signiﬁcant reduction of CRP and sIL- 2R levels (p < 0,045 and < 0,001 
respectively) after statin therapy. No such difference is observed in Group Ib (diet therapy). 
CONCLUSIONS: DCM patients with dyslipidemia have increased inﬂammatory response 
compared with normolipidemic DCM patients which is reduced after six months of 
simvastatin therapy .
1134-162 Recovery of Impaired Coronary Flow Reserve by 
Carvedilol Therapy in Patients With Idiopathic Dilated 
Cardiomyopathy
Kenichi Sugioka, Takeshi Hozumi, Yasuhiko Takemoto, Keiji Ujino, Yoshiki Matsumura, 
Takashi Muro, Minoru Yoshiyama, Kazuhide Takeuchi, Junichi Yoshikawa, Osaka City 
University Medical School, Osaka, Japan
Background: Impaired coronary ﬂow reserve (CFR) is an indicator of poor prognosis 
in patients with idiopathic dilated cardiomyopathy (IDC). Because acute effects of beta-
adrenergic blocking agents increase CFR, carvedilol theraphy may improve CFR in IDC 
patients. Thus, we evaluated the effect of carvedilol therapy on CFR in patients with IDC.
Methods: We studied 12 IDC patients with left ventricular (LV) systolic dysfunction 
(ejection fraction <40%) who had not taken beta-adrenergic blocking agents. Each patient 
received carvedilol in addition to their usual medications for heart failure. The starting 
dose of carvedilol was 2.5 or 5.0 mg/day, which was then gradually increased to a target 
dose of 20 mg/day or to a tolerated dose. Transthoracic Doppler echocardiography was 
used to assess CFR in the left anterior descending coronary artery at baseline, at 1 
month, and at 6 months during treatment with carvedilol.
Results: Mean maintenance dose of carvedilol was 14±7 mg/day. Whereas the LV 
ejection fraction did not change at 1 month (28±7 % vs. 32±7 %; P=NS), it increased 
signiﬁcantly at 6 months (39±9 %; P<0.05). There was no statistically signiﬁcant change 
in mean resting coronary ﬂow velocity (CFV) at 1 month (24±6 cm/s vs. 22±6 cm/s; 
P=NS) or at 6 month (21±5 cm/s; P=NS). By contrast, adenosine-induced hyperemic CFV 
increased at 1 month (60±21 cm/s vs. 75±15 cm/s; P<0.05) and at 6 months (78±21 cm/s; 
P<0.05). CFR increased signiﬁcantly at 1 month (2.6±0.9 vs 3.5±0.7; P<0.05), with no 
further change at 6 months (3.7±0.6; P<0.05). 
Conclusion: Impaired CFR in IDC patients was improved by the administration of carvedilol, 
followed by improved LV systolic function. The improvement in CFR may be one of the 
mechanisms by which carvedilol has a favorable effect on the prognosis in IDC patients.
1134-163 Unaffected Relatives of Familial Dilated Cardiomyopathy 
Patients Show Early Echocardiographic Abnormalities
Cinzia Forleo, Roberta Romito, Massimo Iacoviello, Elisabetta De Tommasi, Katya 
Lucarelli, Pietro Guida, Maria V. Pitzalis, Maria Vittoria Pitzalis, Bari, Italy
First-degree relatives of idiopathic dilated cardiomyopathy (DCM) patients (pts) have a 
higher risk of developing the disease. It is not known whether unaffected relatives of pts 
with familial (FDCM) and non-familial dilated cardiomyopathy (NFDC) show early cardiac 
structural and functional abnormalities.
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We studied 48 subjects: 12 unaffected offsprings (24±6 years, 6 males) of FDCM pts; 12 
unaffected offsprings (24±6 years, 6 males) of NFDCM pts, and 24 age and sex-matched 
healthy unrelated subjects. All of them underwent echo-Doppler recordings. Indexed left 
ventricular end diastolic diameter (iLVEDD), left ventricular relative wall thickness (RWT) 
and left ventricular fractional shortening (FS) were obtained; predicted left ventricular 
end-diastolic diameter (pLVEDD) was calculated using Henry’s formula; the ratio between 
predicted and observed LVEDD (rLVEDD) was ﬁnally calculated; the ratio between the 
early and late peak ﬂow velocity (E/A) of transmitral ﬂow was also assessed.
FS values were signiﬁcantly lower in FDCM offsprings. The RWT and rLVEDD values were 
signiﬁcantly different in FDCM offsprings in comparison with those of control subjects 
(Table). No differences were found in the iLVEDD and E/A ratio.
Although still within normal ranges, unaffected offspring of FDCM pts show cardiac 
structural and functional modiﬁcations. These ﬁndings suggest the need for wide 
screening of kindred members with FDCM.
Table 
FDCM NFDCM Controls p (ANOVA)
FS (%) 33±4 37±3 37±4 <0.05
RWT 0.15±0.01 0.16±0.02 0.17±0.02 <0.05
pLVEDD (mm) 45.7±1.6 45.5±1.1 45.7±1.8 NS
rLVEDD (U) 1.09±0.04 1.06±0.07 1.01±0.07 <0.05
1134-164 Obese Subjects With Heart Failure Have Lower N-
Terminal pro-Brain Natriuretic Peptide Plasma Levels 
Irrespective of the Ischemic and Dilated Etiology
Raquel Cortes, Miguel Rivera, Antonio Salvador, Vicente Bertomeu, Fernando Garcia 
de Burgos, Rafael Paya, Francisco Salvador, Ricardo Valero, Maria Jose Sancho Tello, 
Begoña Sevilla, Vicente Climent, Alejandro Jordan, Luis Martinez Dolz, Francisco Marin, 
Rafael Peset, Vicente Miro, Vicente Mora, Raquel Talens, Andres Gonzalez Molina, Jose L 
Perez Bosca, Luis Mainar, Jose L Diago, Manuel Portoles, La Fe Hospital, Valencia, Spain
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) may be useful in the 
diagnosis of heart failure (HF) and ventricular dysfunction and obesity is an independent 
cardiovascular risk factor. The purpose of this study was to compare NT-proBNP plasma 
levels in obese and non-obese subjects with HF of ischemic and dilated etiology.
Methods: We have studied 111 patients (34 obese), age 64±13, diagnosed of HF. A 
speciﬁc questionnaire and echo-Doppler study were performed. Blood samples were also 
taken and NT-proBNP levels were analysed. Patients were classiﬁed according to the New 
York Heart Association (NYHA).
Results: For the whole population (NYHA 2.1±0.5), plasma levels of NT-proBNP 
were 1206±1698 pg/ml. In multivariate analysis body mass index (BMI) was inversely 
associated with NT-proBNP plasma levels (p<0.05) and obesity was associated with a 
17% decrement in natriuretic peptide levels (p<0.01). In both the ischemic and dilated 
groups of patients we found a 35% decrease in NT-proBNP plasma levels when comparing 
obese and non-obese patients.
Conclusion: This multicenter study shows that obese subjects with HF have lower NT-
proBNP plasma levels than non-obese subjects. Obesity is an independent prognostic 
factor of NT-proBNP levels, so BMI has to be taken into account when using NT-proBNP in 
HF for diagnostic and prognostic purposes. The same decrease was observed in patients 
with ischemic and dilated cardiomyopathy.
ORAL CONTRIBUTIONS
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843-3 Continuous Recording of the Hemodynamic Response 
to Dialysis in Patients with Impaired Left Ventricular 
Function
Cecilia Linde, Frieder Braunschweig, Mats Soderhall, Barbro Kjellstrom, PierreAndre 
Grandjean, Karolinska University Hospital, Stockholm, Sweden
Background: Intermittent and chronic volume overload might contribute to the onset 
and progression of cardiovascular disease in patients on maintenance hemodialysis. 
Continuous monitoring of central hemodynamic parameters may provide valuable 
information, particularly in patients with left ventricular dysfunction.
Methods: 9 patients with end-stage renal disease, age 53-76, with left ventricular 
dysfunction (EF 20-50%) received an implantable hemodynamic monitor (IHM; Chronicle 
model 9520, Medtronic). The IHM consists of a memory device implanted subcutaneously 
and a transveneous right ventricular (RV) lead with a pressure sensor. It continuously 
records heart rate (HR), RV systolic (RVSP) and diastolic pressure (RVDP) and estimated 
pulmonary artery diastolic pressure (ePAD). All patients underwent hemodialysis 3 times/
week. Averages of hemdodynamic data from the ﬁrst, second and third night after dialysis 
were calculated.
Results: Progressive pressure increments were seen between the ﬁrst, second and third 
night in 7 of 9 patients. The RVSP increased 9%, RVDP 19%, ePAD 11% from ﬁrst night to 
second night after dialysis. The third night the increments were more pronounced - RVSP 
12%, RVDP 28%, ePAD 16%.
Night after dialysis HRbpm RVSPmmHg RVDPmmHg ePADmmHg
1st 63.1±5.3 31.8±5.9 6.7±3.5 17.2±4.2
2nd 62.9±4.8 34.8±5.8* 8.3±3.4* 19.4±4.1*
3d 61.9±4.8 36.1±6.6* 9.2±3.6* 20.5±4.5*
*=p<0.05 vs. ﬁrst night
Conclusion: The IHM was a sensitive indicator for changes in volume load. The 
progressive pressure increments in this study suggest that frequent dialysis is preferable 
and that more than 48 hours between hemodialysis sessions might prove harmful for 
the patient.
10:45 a.m.
843-4 The Prevalence of Cardiorenal Syndrome Is Similar in 
Systolic and Diastolic Heart Failure
Theophilus E. Owan, Regina M. Herges, David O. Hodge, Véronique L. Roger, Margaret 
M. Redﬁeld, Mayo Clinic, Rochester, MN
Background: Worsening renal function with heart failure (HF) therapy (cardiorenal 
syndrome, CRS) is common and predicts length of stay (LOS) and mortality in HF patients 
(pts). Pts with HF and normal (>50%) ejection fraction (EF) (diastolic HF, DHF) may differ 
from those with reduced EF (systolic HF, SHF).
Objective: We sought to determine if the severity of renal dysfunction or the prevalence 
of CRS is different in DHF versus SHF.
Methods: Electronic chart review was performed on all consecutive unique HF pts 
discharged from Mayo Clinic hospitals Rochester MN from 1/1/87 to 12/31/02 (DRG 
127) (n=6440). EF (measured within 30 days of admission) was available in 4610 pts. 
Creatinine (Crt) was examined on and for 14 days after admission. Three month mortality 
and LOS were examined.
Results: See table. Pts with DHF were older, more likely female and had lower baseline 
Crt. Mean Crt clearance (Gault equation) was lower in DHF. The mean change in Crt 
was similar in DHF and SHF. The prevalence of CRS (increase in Crt of > 0.3 mg/dl or > 
25% ) was similar to higher in DHF pts. Controlling for the type of HF and other pertinent 
covariates, baseline Crt was predictive of mortality (odds ratio, OR= 1.01 per 0.1 mg/dl 
increment in baseline Crt, p<0.001) but not LOS. Change in Crt was predictive of mortality 
(OR=1.38 per 1.0 mg/dl increase in Crt, p=0.004) and LOS (t value = 10.44, p<0.001).
Conclusion: CRS is not less common in DHF and the presence of CRS is predictive of 
mortality and LOS regardless of HF type.
Diastolic HF 
(n=2259)
Systolic HF 
(n=2351) p SHF vs DHF
Age (yrs) 75±14 72±12 <0.0001
% male 45% 66% <0.0001
Baseline Crt (mg/dl) 1.55±1.07 1.60±0.97 <0.0001
Baseline Crt Clearance (ml/min) 39.6±24.4 44.8±26.0 <0.001
Mean change in Crt (mg/dl) 0.3±0.6 0.3±0.6 0.39
% with increase Crt >25% 27.34% 24.62% 0.04
% with increase Crt >0.30 23.84% 22.81% 0.42
11:00 a.m.
843-5 Formulas estimating Renal Function give imprecise 
estimates in Heart Failure
Tom D. Smilde, Hans L. Hillege, Gerjan Navis, Adriaan A. Voors, Dirk J. Van Veldhuisen, 
University Hospital Groningen, Groningen, The Netherlands
Background. Glomerular ﬁltration rate (GFR) as an index of renal function has 
consistently been found to be an independent risk factor for CVD outcomes in patients 
with chronic heart failure (CHF). In clinical practice a variety of formulas have been used 
to estimate GFR. To date, no study has compared multiple methods of measuring renal 
function in CHF patients.
Objective. We validated in CHF patients three commonly used formulas estimating 
glomerular ﬁltration rate (GFR) with the gold standard 125I-iothalamate clearance (GFR).
Methods. In 50 CHF patients; age 58 ± 10 years, LVEF 0.28 ± 0.10 and NYHA I/IV, GFR, 
body weight, plasma creatinine and albumin were determined to calculate GFR using 
Cockcroft-Gault (GFRc) and Modiﬁcation of Diet in Renal Disease (MDRD) formulas. The 
GFR and GFRc were corrected for body surface area. The Bland-Altman method was 
used to compare these formulas with the true GFR.
Results. Although, the formulas appeared to correlate well with the GFR, the Bland-
Altman method showed there were important differences and a wide variance in the 
estimated GFR (table). Furthermore, in all formulas gender and serum creatinine were 
the most prominent variables for inaccurately estimating GFR.
Conclusions. In CHF, formulas estimating GFR appeared to be biased and imprecise in 
estimating true GFR, especially in the upper and lower ranges.
True and estimated renal function in CHF (n=50) 
Mean Min/Max Correlation Bland-Altman Bland-Altman
mL/min/1.73m2 mL/min/1.73m2 p-value r Mean Difference ±2SD
GFR 77.8±26.8 14.6-132.5 - - - -
Cockcroft-Gault 67.5±20.3 24.1-122.5 <0.001 0.768 10.2 -25.4/45.4
MDRD 64.3±19.0 26.3-102.4 <0.001 0.815 13.5 -18.0/45.0
Simpliﬁed MDRD 63.7±17.5 26.7-98.9 <0.001 0.792 14.1 -19.4/47.6
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843-6 Adrenomedullin (AM) Reﬂects Cardiac Dysfunction 
Better Than Brain Natriuretic Peptide (BNP) In 
Hemodialysis (HD) Patients With Cardiovascular 
Disease
Fumiki Yoshihara, Takeshi Horio, Masayoshi Yoshii, Satoko Nakamura, Hajime 
Nakahama, Takashi Inenaga, Kenji Kangawa, Yuhei Kawano, National Cardiovascular 
Center, Suita, Osaka, Japan
Background: Plasma AM has been reported to reﬂect cardiac dysfunction and predict 
survival after myocardial infarction in non-HD patients. The present study was designed 
to investigate whether AM reﬂects cardiac dysfunction in HD patients, comparing to 
BNP, and whether mortality and additional cardiovascular events can be predicted by 
AM. Methods: Plasma mature AM and BNP levels before HD were measured in 67 
HD patients with cardiovascular disease along with two-dimensional and Doppler 
echocardiographic variables. 
Results: By univariate regression analysis, log [AM] was positively related to LV 
end-diastolic and end-systolic volume indices (LVEDVI: r=0.32, LVESVI: r=0.36) and 
negatively to LV ejection fraction (LVEF), LV inﬂow velocity rate (A/E), deceleration time 
of the early diastolic ﬁlling wave (DcT) and pulmonary venous ﬂow velocity rate (PVs/
PVd) (r=-0.34, r=-0.37, r=-0.40 r=-0.43). Log [BNP] also was positively related to LVESVI 
(r=0.31) and negatively to LVEF and PVs/PVd (r=-0.34, r=-0.30). Multivariate stepwise 
regression analysis revealed that log [AM] reﬂected all variables better than log [BNP]. 
BNP was signiﬁcantly higher in HD patients with coronary artery disease (CAD) than 
those without CAD, whereas AM, LVEDVI, LVESVI, A/E, DcT and PVs/PVd did not differ 
between the 2 groups. During 1-year follow-up period, 7 patients died and 8 had additional 
cardiovascular events. Kaplan-Meier survival curves based on the median AM (4.6 pmol/
L) showed that patients with high AM had higher mortality and morbidity than those with 
low AM (p=0.0056). By Cox proportional hazards analysis, AM was related to mortality 
and morbidity (HR 4.96 [95% CI 1.4 to 17.7] p=0.013). 
Conclusions: Increased AM may reﬂect cardiac dysfunction better than BNP, resulting in 
a possible predictor of mortality and additional cardiovascular events in HD patients with 
concomitant cardiovascular disease.
11:30 a.m.
843-7 Increased Urinary Albumin Excretion in Non-Diabetic 
CHF is associated with Impaired Renal Function.
Tom D. Smilde, Gerjan Navis, Adriaan A. Voors, Dirk J. Van Veldhuisen, Hans L. Hillege, 
University Hospital Groningen, Groningen, The Netherlands
Background. The prognostic value of renal function for mortality is well established in 
diabetics and non-diabetics. Urinary albumin excretion (UAE) is a known marker for overt 
renal disease in diabetics. It is unknown whether increased UAE is also present in patients 
with chronic heart failure (CHF). We determined the UAE in CHF patients, without primary 
renal disease and evaluated the association between UAE and renal function.
Methods. In 47 CHF patients, age 58±10 years, mean LVEF 0.28±0.10 and mean NYHA 
2.3±0.8, we collected 2x24hours urine and measured the mean UAE. We measured 
glomerular ﬁltration rate (GFR), as the golden standard of renal function, with 125I-
iothalamate clearance. Patients with a history of hypertension, diabetes, nephropathy or 
using renal function compromising medication were excluded. All patients used renin-
angiotensin system inhibiting medication.
Results. Median albumin excretion was 10.2 mg/L (6.8-21.8). MA (30-300 mg/L) was 
present in 16% and 21% had high normal UAE (15-29.9 mg/L). Mean GFR was 93±36 
mL/min. We divided GFR into quartiles and determined the UAE per quartile (ﬁgure). 
Patients with the lowest quartile had a signiﬁcant increase in UAE.
Conclusion.In these non-diabetic CHF patients, without primary renal disease, UAE is 
elevated in the presence of renal function impairment. Elevated UAE is a risk marker in 
various cardiovascular conditions and this study suggests it may be of value to identify 
patients with CHF at risk of developing cardiovascular events.
 
 
11:45 a.m.
843-8 Is Heart Failure Really Renal Failure? Observations 
From 88,075 Admissions With Decompensated Heart 
Failure in the ADHERE® Registry
J. Thomas Heywood, Gregg C. Fonarow, Janet Wynne, ADHERE Scientiﬁc Advisory 
Committee and Investigators, Loma Linda University Medical Center, Loma Linda, CA
Background: Renal dysfunction (RD) is a signiﬁcant risk factor in heart failure (HF). 
How common RD is in hospitalized patients with HF and whether there are signiﬁcant 
differences when deﬁned by serum creatinine or estimated glomeular ﬁltration rate 
(eGFR) has not been well studied.
Methods: eGFR was calculated using the Cockcroft Gault equation for 88,075 patients 
in Acute Decompensated Heart Failure (ADHERE®) Registry. The National Kidney 
Foundation deﬁne individuals with eGFR <60 mL/min/m2 as having kidney disease, with 
eGRF 30-59 mL/min/m2 as moderate disease, eGFR 15-30 mL/min/m2 as severe disease, 
and eGFR <15 mL/min/m2 as renal failure. The percentage of patients at each eGFR level 
were calculated and compared for males versus females using a Chi-Square test.
Results: Serum creatinine was ≥2 mg/dL in 24% of men and only 17 % in women 
(p<0.0001). By eGFR, normal renal function was seen in less than 7% of men and only 
1.7% of women (p<0.0001). Signiﬁcant RD occurred in 71.3% of males and 89.6% of 
women. Renal failure was present in 12% of women and 5.7% of men.
Conclusions: Signiﬁcant RD is very common in patients admitted with decompensated 
HF, with most having at least moderate (Stage III) decrease in eGFR. Simple measurement 
of serum creatinine signiﬁcantly underestimates the degree of RD. RD is a very common 
comorbidity with HF and it may play an important role leading to decompensation and 
hospitalization. 
Males
n=60,234
Females
n=64,639
All Patients
n=124,885
Kidney Function N 43,198 44,877 88,075
Stage I Normal
(GFR ≤90) N (%)
2,974
(6.9)
750
(1.7)1
3,724
(4.2)
Stage II Mild Decrease (GFR 60-89) N (%) 9,393(21.7)
3,909
(8.7) 13,302 (15.1)
Stage III Moderate Decrease (GFR 
30-59) N (%) 20,224 (46.8) 19,228 (42.8) 39,452 (44.8)
Stage IV Severe
(GFR 15-29) N (%)
8,124
(18.8) 15,596 (34.8)
23,720
(26.9)
Stage V Failure
(GFR <15) N (%)
2,483
(5.7)
5,394
(12.0)
7,877
(8.9)
Serum Creatinine (mg/dL)
Stage I Normal
(GFR ≤90)
Mean (SD)
Q1 [Median] Q3
0.9 (0.2)
0.8 [0.9] 1.0
0.6 (0.1)1
0.5 [0.6] 0.7
0.8 (0.2)
0.7 [0.8] 0.9
Stage II Mild Decrease (GFR 60-89) Mean (SD)Q1 [Median] Q3
1.1
(0.2)
1.0 [1.1] 1.2
0.8 (0.2) 1
0.7 [0.8] 0.9
1.0 (0.2)
0.8 [1.0] 1.2
Stage III Moderate Decrease (GFR 
30-59)
Mean (SD)
Q1 [Median] Q3
1.5 (0.4)
1.3 [1.5] 1.7
1.0
(0.2) 1
0.9 [1.0] 1.2
1.3 (0.4)
1.0 [1.2] 1.5
Stage IV Severe
(GFR 15-29)
Mean (SD)
Q1 [Median] Q3
2.6 (0.8)
2.1 [2.5] 3.0
1.6 (0.5) 1
1.3 [1.5] 1.9
2.0
(0.8)
1.4 [1.8] 2.3
Stage V Failure
(GFR <15)
Mean (SD)
Q1 [Median] Q3
7.1 (3.4)
4.6 [6.3] 8.7
4.4 (2.7) 1
2.6 [3.5] 5.4
5.2 (3.2)
2.9 [4.3] 6.7
1p<0.0001 males versus females. 
POSTER SESSION
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Orange County Convention Center, Hall E1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1160-143 Ghrelin Improves Biventricular Function And 
Attenuates Autocrine/paracrine Activation In 
Monocrotaline-induced Pulmonary Hypertension
Tiago Henriques-Coelho, Jorge Correia-Pinto, Roberto Roncon-Albuquerque Jr, Ana 
Beleza-Meireles, André Pedro Lourenço, Antónia Teles, Adelino F. Leite-Moreira, Serviço 
de Fisiologia, Faculdade de Medicina, Porto, Portugal
Background: We recently showed that ghrelin (ghr) attenuates pulmonary hypertension 
(PH), right ventricular and pulmonary vascular remodelling in monocrotaline (MCT) rats. 
In this model of right ventricular (RV) overload, there is failure of the non-overloaded left 
ventricle (LV). In the present study we evaluated the effects of ghr on biventricular function 
and autocrine/paracrine activation in MCT-induced PH.
Methods: Adult Wistar rats were injected with MCT (60 mg/Kg, sc) or just the vehicle (day 
0). One week later, animals treated with MCT were randomly divided and treated with ghr 
(100 µg/Kg, BID, sc) or with a similar volume of vehicle. The study resulted in 3 groups: 
(i) control (Ctrl, n=7), (ii) MCT (n=9), (iii) MCT+ghr (n=9). At days 21-25 the animals were 
instrumented to record RV and LV peak systolic (Psys) pressures, dP/dtmax and time 
constant Tau. RV and LV transmural free-wall samples were collected to quantify, by real 
time RT-PCR, IGF-1, ppET-1 and ACE mRNA levels, which were normalized for GAPDH 
and expressed in arbitrary units (AU).
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Results: Presented as mean±SEM, are summarized in the table (P<0.05: a vs. Ctrl; b 
vs. MCT).
Conclusion: Ghr attenuated LV systolic dysfunction, biventricular diastolic dysfunction 
and increased expression of ppET-1 and ACE induced by MCT. Therefore, Ghr has 
beneﬁcial effects on cardiac remodelling independently of local IGF-1 expression and 
cardiac overload, but potentially related with blunting of local activation of ET-1 and renin-
angiotensin systems.
RV-Ctrl RV-MCT RV-MCT+Ghr LV-Ctrl LV-MCT LV-MCT+Ghr
Psys (mmHg) 25.1±1.7 48.2±1.6 a 35.9±1.9 a,b 98.4±4.3 67.4±3.5 a 85.0±4.2 b
dP/dtmax (ms) 1228±67 1602±91 a 1692±113 a 5513±545 3442±325 a 5510±604 b
Tau (ms) 6.6±0.9 27.8±2.5 a 17.1±1.9 a,b 18±1.2 21.9±0.9 15.9±1.7 b
IGF-1(AU) 1.0±0.2 2.2±0.4 1.8±0.6 1.0±0.1 1.5±0.4 1.3±0.2
ppET-1 (AU 1.0±0.1 4.6±0.8 a 1.9±0.8 b 1.0±0.4 30.1±7.5 a 8.0±1.8 b
ACE (AU) 1.0±0.2 19.8±7.0 a 12.6±9.5 b 1.0±0.2 7.3±2.4 a 4.1±1.3
1160-144 Calmodulin Kinase II Inhibition Protects Against 
Isoproterenol-induced Cardiomyocyte Death In Vivo
Yingbo Yang, Rong Zhang, Michelle S. Khoo, Yue Hou, Jinying Yang, Roger J. Colbran, 
Mark E. Anderson, Vanderbilt University Medical Center, Nashville, TN
Background: Beta-adrenergic receptor activation contributes to the progression of human 
heart failure partly by inducing myoctye death. Here we test the hypothesis that cardiac 
CaMKII inhibition reduces isoproterenol (Iso)-induced cardiomyocyte death in vivo.
Methods: We developed transgenic mice with heart-restricted CaMKII inhibition (AC3-I) 
and control mice (AC3-C) by over-expressing a CaMKII inhibitory peptide or a control 
peptide. Mice were treated with intraperitoneal injection of Iso or saline and sacriﬁced 2 
hours after a single high dose Iso (150mg/kg) or 10 days after low dose Iso (15mg/kg/
day) or saline. Myocyte and non-myocyte necrosis and apoptosis were measured as a 
percentage of endocardial ﬁbrosis and by TUNEL assay on transverse mid left ventricle 
sections.
Results: After 10 days, CaMKII inhibition signiﬁcantly reduced Iso-induced myocyte 
necrosis (AC3-I: 9.8+/-1.8 % and AC3-C: 23+/-3.5%, P=0.001, n=4). CaMKII inhibition 
also signiﬁcantly reduced Iso-induced myocyte apoptosis after two hours (ﬁgure, P=0.007, 
n=3-6). After 10 days of Iso, the difference in myocyte apoptosis between AC3-I and AC3-
C was no longer evident; however non-myocyte apoptosis was signiﬁcantly reduced in 
AC3-I versus AC3-C (ﬁgure, p=0.02, n=4-8).
Conclusions: Cardiac CaMKII inhibition protects against both Iso-induced cardiomyocyte 
necrosis and apoptosis in vivo. There are important time and cell type variations to the 
antinecrosis and antiapoptosis actions of CaMKII inhibition. 
1160-145 The Impact of Angiotensin-Converting Enzyme 
Inhibition on Stiffness and Collagen Cross-Linking 
During LV Assist Device Support
Stefan Klotz, A.H. Jan Danser, Robert F. Foronjy, Mehmet C. Oz, Jeanine D’Armiento, 
Daniel Burkhoff, Columbia University, New York, NY, Erasmus Medical Center, 
Rotterdam, The Netherlands
Background. Mechanical unloading increases LV collagen content and myocardial 
stiffness and might contribute to the low rate of LV functional recovery following left 
ventricular assist device (LVAD) support. Angiotensin-converting enzyme inhibitors (ACE-
I) reduce extracellular collagen matrix (ECCM) synthesis and we therefore hypothesized 
that ACE-I therapy in LVAD patients might prevent this potentially detrimental ECCM 
remodeling.
Methods and Results. LV myocardial samples were obtained in 22 patients with end-
stage congestive heart failure before and after LVAD support, and divided into groups 
who did or did not receive ACE-I (ACE-I and Control group) during similar periods of 
LVAD duration. Measurements were made of tissue angiotensin (Ang) II, and collagen 
characterization. Chamber and myocardial stiffness constants were determined from ex 
vivo pressure-volume relationships.
Tissue Ang II was signiﬁcantly reduced with ACE-I therapy, compared to an increase 
in the Control group (Table). Concomitantly, total and cross-linked collagen increased 
signiﬁcantly in patients without ACE-I, which lead to a tremendous increase in myocardial 
stiffness. ACE-I therapy however prevented these ﬁndings.
Conclusion. ACE-I therapy reduce tissue Ang II levels, myocardial collagen content 
and myocardial stiffness during LVAD support. To the extent that the markedly increased 
ﬁbrosis that occurs during LVAD support may inhibit myocardial recovery, ACE-I treatment 
may be beneﬁcial.
 
ACE-I Control
pre-LVAD post-LVAD pre-LVAD post-LVAD
LVAD Duration (days) 109 ± 22 79 ± 40
Tissue Ang II (foml/g) 163 ± 64 81 ± 7# 109 ± 39 262 ± 41*
Total Collagen (µg/mg) 4.5 ± 0.28 3.3 ± 0.14*# 6.7 ± 0.75 9.1 ± 9.7*
Soluble Collagen (µg/mg) 4.4 ± 0.51 2.6 ± 0.36*# 3.6 ± 0.63 4.7 ± 0.47
Cross-linked Collagen (µg/mg) 6.4 ± 0.76 5.4 ± 0.63* 5.9 ± 1.05 8.4 ± 1.10*
Chamber stiffness 7.54 ± 3.98 8.89 ± 2.99
LVV30 (ml) 153 ± 68 171 ± 54
Myocardial stiffness (mmHg*ml) 23.02 ± 5.84# 31.29 ± 6.44
LV mass (gr) 186 ± 41# 252 ± 48
LVV30, the ex vivo volume at the pressure of 30 mmHg; *P<0.05 vs pre-LVAD (same group); 
#P<0.05 vs post-LVAD (control group)
1160-146 Dilated Cardiomyopathy (DCM) is Associated With 
Increased Myocardial GLP-1 Receptors and Enhanced 
Myocardial Glucose Uptake in Response to GLP-1 
Infusion in Conscious Dogs
Indu G. Poornima, Lazaros A. Nikolaidis, Aaron Doverspike, Lee Zourelias, Laurie 
Machen, Carol Stolarski, Teresa Hentosz, Richard P. Shannon, Allegheny General 
Hospital, Pittsburgh, PA
Background: We have demonstrated that glucagon-like peptide-1 (GLP-1 [7-36] amide) 
improves myocardial glucose uptake (MGU) and LV hemodynamics in conscious dogs 
with pacing induced DCM, although the mechanism of these effects are unclear. The 
GLP-1 receptor (GLP-1R) is a 7 transmembrane G-protein coupled receptor whose 
functional signiﬁcance in the dog heart is unknown.
Objective: We sought to determine if the beneﬁts of GLP-1 on MGU are mediated through 
the insulin signaling cascade in dogs with DCM.
Methods: We performed hyperinsulinemic-euglycemic clamps in 8 conscious dogs with 
DCM, chronically instrumented to measure LV function, coronary ﬂow and transmyocardial 
substrate extraction, and compared to 6 normal dogs. Clamps were performed before 
and after a 48-hour infusion of GLP-1 [7-36] (1.5 pmol/kg/min) during which myocardial 
glucose uptake (MGU) was measured during hyperinsulinemia. Myocardial tissues 
were obtained to measure GLP-1R and the effects of GLP-1 infusion on cellular insulin 
signaling using Western blots.
Results: There was a signiﬁcant increase (+160±23%, p<0.05) in the 65-kDa GLP-1R 
isoform in DCM. GLP-1 infusion was associated with signiﬁcant increases in basal MGU 
(2.6±0.4 to 8.5±1.0 µmol/min, p<0.05) in DCM, where as GLP-1 had no effect in normal 
dogs (4.7±0.7 to 5.1±0.5 µmol/min). The increase in MGU seen with GLP-1 in DCM 
was not associated with an increase in plasma insulin (before: 76±6; after: 82±7 pmol/
L). During clamps, MGU was markedly (p<0.02) impaired in DCM (8.3±0.7 µmol/min) 
compared to normal dogs (17.2±2.3 µmol/min). GLP-1 treatment in DCM improved MGU 
(12.4±1.8 µmol/min, p<0.05) during clamp. DCM was associated with impaired ser 473-
Akt-1 phosphorylation (-73±10%, p<0.01) and GLUT-4 translocation (-51±5%, p<0.05). 
Notably, GLP-1 treatment in DCM did not increase Akt-1 phosphorylation or GLUT-4 
translocation, despite increases in MGU.
Conclusion: GLP-1R are present in the canine myocardium in their active form (65-kDa) 
in DCM. GLP-1 increases MGU in DCM, despite matched insulin levels. Furthermore, 
the insulinomimetic effects of GLP-1 in DCM are not mediated by activation of Akt-1, 
suggesting a unique GLP-1R mediated mechanism.
1160-147 Role Of The Chromatin Remodelling Enzyme p300 In 
Heart Failure Progression And Survival
Jian Qin Wei, James Mitrani, Alex Llanos, Keith Atkinson Webster, Nanette H. Bishopric, 
University of Miami School of Medicine, Miami, FL, Miami Heart Research Institute, Miami, FL
Background: The histone acetyl transferase (HAT) transcription factor p300 is critical in 
regulating cardiac growth and gene transcription during development. However, the role 
of p300 in hypertrophy and the transition to heart failure is unclear. We have developed 
a series of transgenic mouse strains (TG) in which 2-fold elevation of myocardial p300 
is associated with early hypertrophy followed by heart failure and death at 6-8 months. 
Here we explored p300 levels in failing and non-failing human hearts, and asked whether 
manipulation of p300 levels could affect outcome in p300TG mice.
Methods: Human non-failing (n = 9) and failing (both ischemic and idiopathic, n =18) 
myocardial samples were assayed for p300 content by immunoblot. Reduction of p300 
content in p300TG mice was achieved by mating with heterozygous p300-deﬁcient mice 
(KO) and comparing p300 expression levels, heart weights, and 12 month survival for 
each of the 4 resulting genotype offspring (WT, TG, KO, and TG/KO).
Results: In nonfailing, presumably normal human myocardium, p300 levels were low to 
undetectable, but were markedly elevated in failing hearts (25.8-fold ± 5 vs. control, p < 
0.001). In mice, myocardial p300 abundance was directly proportional to calculated p300 
gene dosage in all 4 genotypes at 2 months (TG 2.76± 0.30 density units; KO 0.48 ± 0.08; 
TG/KO = 2.20 ± 0.32, all p<0.01 vs.control; KO and TG/KO p<0.01 vs. TG). Heart weights 
were similar in all genotypes at 2 mo. 1 y survival in TG mice was 18.8% vs. 80.5% WT (n 
= 24 each), and cardiac mass was strikingly increased at 10 mo (10.2 ± 0.14 vs WT 6.22 
± 0.05, heart wt/tibia length). In contrast, survival of p300TG/KO mice was similar to that 
of p300KO mice (57.7 and 62.6%, n = 23 and 12 respectively) associated with reduced 
cardiac mass at 10 mo (8.06 ± 0.10 hw/tl, p<0.01).
Conclusions: Adult human myocardial p300 levels are normally low but are markedly 
induced in cardiomyopathy and failure. Moderate (~20%) reduction in p300 dosage is 
associated with signiﬁcant reduction in cardiac mass and improvement in 1 year survival 
in a p300-driven murine heart failure model, indicating that p300 acetyltransferase content 
or activity could be an important target in the treatment of heart failure.
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1160-148 Effect of b-blocker Administration on Coronary Sinus 
Blood Temperature Measurements
Konstantinos Toutouzas, John Mitropoulos, Maria Drakopoulou, Sophia Vaina, 
Eleftherios Tsiamis, Manolis Vavuranakis, Dimitris Tousoulis, Christodoulos Stefanadis, 
Hippokration Hospital, Athens, Greece
Background: Coronary sinus (CS) temperature is increased in patients (pts) with coronary 
artery disease (CAD) or heart failure. Aim of our study was to investigate the effect of b-
blocker infusion on CS blood temperature in pts without angiographically documented 
CAD and normal ejection fraction. 
Methods: In the study we enrolled 7 pts undergoing electrophysiological study for 
evaluation of the atrioventricular conduction (EPS). Five minutes after EPS a CS 
thermography catheter was advanced 2-4 cm distally to the CS oriﬁce and blood 
temperature was measured without the tip of the catheter being in contact with the 
vessel wall (background temperature). Thereafter, esmolol was administered IV with a 
rate of 100mcg/Kg/min for 5 min. Temperature difference (TD) was designated as the 
blood temperature in the CS during and after esmolol infusion minus the background 
temperature. 
Results: All procedures were successful and uncomplicated. TD at the end of esmolol 
administration was -0.12 + 0.03 oC and 5 minutes after the end of administration was -0.21 
+ 0.04 oC, p<0.001 (mean CS temperature was 37.1 ± 0.03°C at baseline and dropped 
to 36.98 ± 0.04°C at the end of esmolol infusion, reaching ﬁnally a minimum of 36.89 
± 0.03°C) (Figure). Heart rate was reduced by 12% at the end of infusion. CS blood 
temperature decrease was found until 10 minutes after the end of procedure. 
Conclusion: CS blood temperature is decreased during b-blocker administration, possibly 
as a result of decreased heat production from the myocardium. 
1160-149 Neonatal Cardiomyocytes Do Not Require a Cardiac 
Milieu to Establish Contractile Units
Wangde Dai, Sharon L. Hale, Robert A. Kloner, The Heart Institute, Good Samaritan 
Hospital, University of Souther California, Los Angeles, CA
Purpose: To investigate whether immature neonatal cardiomyocytes (Cs) grafted outside 
of the familiar environment of a heart will mature and contract, we implanted Cs into the 
aortic wall, and determined the ability of these cells to mature, contract, connect with each 
other, respond to pacing, generate pressure, and develop a blood supply.
Methods: Recipient adult female Fischer rats received medium only (n=9) or Cs isolated 
from neonatal Fischer rats (n=12, 5×106 cells each). The injection site was the outer wall 
of the abdominal aorta. Six weeks later, the intra-aortic pressure at the grafted site, the 
spontaneous beating and the response of the grafted tissue to pacing was assessed after 
excision of the heart, and the grafted tissue was histologically and immunohistologically 
examined.
Results: Six weeks after implantation, 11/12 aortas in the Cs group, but 0/9 in the medium 
group showed spontaneous rhythmic beating at the grafted site following excision of the 
heart. The spontaneous beating rate was 109 ± 16 beats per minute at 1~2 minutes after 
excision of the heart and changed with pacing frequency. The pulse pressure generated 
by the grafted Cs was 0.36 ± 0.10 mmHg without pacing; during pacing it was 0.78 ± 
0.47 mmHg with systolic pressure up to 4 mmHg. None of the 9 aortas in the control 
group generated intra-aortic pressure. Hematoxylin and eosin staining showed viable 
grafts in the outer wall of the Cs-treated aortas in 12/12 aortas at 6 weeks; and 0/9 aortas 
receiving medium at 6 weeks. Neonatal Cs in the graft had matured with cross strations 
and demonstrated a high degree of vascularization. Immunohistochemical staining of 
the aorta for sacromeric actin was positive in 12/12 aortas at 6 weeks in the Cs group; 
and none of the aortas in the medium group. Staining of connexin 43 showed that some 
grafted Cs formed gap junctions at 6 weeks after implantation.
Conclusion: Neonatal Cs engrafted into wall of aorta can mature, spontaneously and 
rhythmically contract, be paced, generate measurable intravascular pressure, and 
develop a blood supply. Therefore, immature Cs can mature and contract in a hostile and 
unfamiliar environment without the milieu of the heart.
1160-150 Long-Term β-Blockade Therapy Down-Regulates mRNA 
Gene Expression of Peroxisome Proliferator-Activated 
Receptor Gamma Coactivator-1α in Left Ventricular 
Myocardium of Dogs with Chronic Heart Failure
Sharad Rastogi, Sudhish Mishra, Ramesh C. Gupta, Sidney Goldstein, Hani N. Sabbah, 
Henry Ford Health System, Detroit, MI
Background: Myocytes of humans and dogs with heart failure (HF) manifest ultrastructural 
and functional abnormalities of mitochondria including hyperplasia, reduced organelle size 
and abnormal oxidative capacity. Peroxisome proliferator-activated receptor γ coactivator-
1α (PGC-1α) is a regulator of mitochondrial biogenesis and function. Overexpression 
of PGC-1α in mice results in uncontrolled mitochondrial biogenesis, loss of sarcomeric 
structure and dilated cardiomyopathy. This study examined mRNA expression of PGC-1α 
in LV of normal (NL) dogs, dogs with HF and dogs with HF treated with β-blockers.
Methods: Total RNA was isolated from LV tissue of 12 dogs with HF randomized to 3 
months therapy with extended release metoprolol (ER-MET 100 mg, once daily, n=6) or 
to placebo (PL, n=6), 12 dogs with HF randomized to 3 months therapy with carvedilol 
(CARV 1.0 mg/kg, twice daily, n=6) or to PL (n=6) and from 6 NL dogs. mRNA expression 
for PGC-1α was measured using RT-PCR and bands quantiﬁed in densitometeric units 
(du). Results: mRNA expression of PGC-1α increased in PL-treated dogs compared 
to NL (table). Treatment with ER-MET or CARV reduced mRNA expression of PGC-1α 
compared to PL (table). 
Conclusions: The increase in mRNA expression of PGC-1α in LV of dogs with HF may 
explain the observed abnormalities in mitochondria. Long-term therapy with β-blockers 
reduces mRNA expression of PGC-1α. This suggests another molecular mechanism by 
which β-blockade therapy elicits functional improvement in HF.
*=p<0.05 vs NL; 1**=p<0.05 vs HF + PL 
NL HF + PL HF + ER-MET
PGC-1α (du) 27.7±3.6 84.0±5.9* 66.3±2.8**
NL HF + PL HF + CARV
PGC-1α (du) 47.0±2.3 91.0±1.7* 77.8±2.4**
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1161-165 Severity of Mitral Regurgitation in CHF Predicts 
Decreased Peak VO2 and Increased Ventilatory 
Response to Exercise
Maryjane Farr, Seung W. Park, Jennifer Haythe, John LaManca, Spencer Kubo, Jae K. 
Oh, Donna Mancini, Columbia Presbyterian Medical Center, New York, NY, Mayo Clinic, 
Rochester, MN
Background: Functional mitral regurgitation (MR) is common in patients with chronic 
heart failure (CHF) and contributes to rest and exertional symptoms. In the multicenter 
trial using the ACORN Cardiac Support Device, 264 patients (age 52 ± 12 yrs.; 54% 
male; 46% female) with Class II to IV CHF from 19 centers underwent screening 
echocardiogram and cardiopulmonary exercise testing (CPEX). We investigated if resting 
echocardiographic measurement of MR severity could predict peak exercise performance 
and ventilatory response.
Methods: Exercise testing included bicycle and treadmill protocols. Anaerobic threshold 
(AT) was identiﬁed using the nadir of the ventilatory equivalent for VO2 and end-tidal O2. 
Ventilatory response to exercise was measured using the ventilatory equivalent for CO2 
(VE/VCO2) at AT (normal VE/VCO2 = 25). This technique has previously been shown to 
be independent of exercise protocol used. Severity of MR was visually estimated from 0 
to 4+. Core lab personnel analyzed all data.
Results: Using ANOVA, increasing severity of MR predicted a lower Peak VO2 (p< 
0.0001), a higher VE/VCO2 at AT (p< 0.002) and a decreased O2 pulse (p< 0.0001).
MR n = Peak VO2 (ml/min) VE/VCO2 at AT Peak O2pulse (VO2/HR)
0+ 57 1566.2 ± 494.1 33.7 ± 5.3 12.8 ± 4.4
1+ 47 1297.2 ± 480.8 38.0 ± 7.7 11.1 ± 4.3
2+ 47 1172.0 ± 395.1 38.7 ± 8.0 9.6 ± 4.1
3+ 44 1225.2 ± 503.7 38.3 ± 9.9 9.6 ± 3.5
4+ 51 1127.6 ± 353.7 39.3 ± 7.8 9.4 ± 3.7
Conclusion: Severity of mitral regurgitation at rest is associated with diminished 
exercise capacity and a more abnormal ventilatory response to exercise. The results of 
the ACORN trial will elucidate whether correction of mitral insufﬁciency improves both 
exercise capacity and ventilatory efﬁciency in patients with CHF.
1161-166 Functional Capacity as Assessed by Six-Minute Walk 
Test Is Strongly Associated With Cardiac Fibrosis in 
Patients With Chronic Heart Failure
Anca Radauceanu, Jean-Marc Virion, Camille Ducki, Josette Capiaumont, Li Mingjiang, 
Faiez Zannad, CIC-INSERM-CHU of Nancy, Dommartin Les Toul, France
Background: The 6-minute walk test (6MWT) has been recommended as a simple 
and safe indicator of prognosis in patients with chronic heart failure (CHF). So far, the 
mechanisms underlying the relationship between 6MWT and prognosis in CHF are 
unknown. We hypothesize that one possible mechanism could be the excessive extra-
cellular collagen matrix (ECCM) turnover leading to ﬁbrotic cardiac remodeling.
Purpose: Evaluate the association between 6MWT and serum collagen biomarkers 
assessing ECCM turnover, in patients with mild-to-severe CHF.
Methods: In 1009 patients included in the RECOVER trial (II-IV NYHA, LVEF <= 30%, 
6MWT <= 375m, diuretics 99%, ACEI 85%, β-blockers 64%, spironolactone 36%) we 
measured (RIA, ELISA) the biomarkers of collagen synthesis [amino-terminal propeptide 
of type III collagen (PIIINP)] and degradation [total matrix metalloproteinase 1 (MMP1), 
total tissue inhibitor of metalloproteinase 1 (TIMP1)].
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Statistical analysis used linear regression. 
Results: In the study group (64.5± 10.5 y, male 77%, BMI 27.5± 4.8 Kg/m2, NYHA III 
71%, LVEF 24.3± 4.7%, 6MWT 283± 77 m), markers of collagen synthesis (PIIINP = 
4.6± 2.7) and degradation (MMP1= 9.78± 7.1, TIMP1= 1478.4± 556.1) were strongly 
associated to 6MWT (Table). 
Conclusion: We showed that patients with excessive ECCM turnover exhibited a lower 6MWT 
performance level. These results suggest that ﬁbrotic cardiac remodeling could represent the 
“missing link” explaining the increased risk of death in patients with a short 6MWT.
Association of ECCM biomarkers to functional capacity 
Biomarkers 6MWT LVEF
PIIINP (µ g/ml) r = - 0.12 (p< 0.01) r = 0.01 (p=0.58)
MMP1 (ng/ml) r = - 0.14 (p< 0.01) r = 0.07 (p=0.04)
TIMP1 (ng/ml) r = - 0.12 (p< 0.01) r = 0.02 (p=0.61)
1161-167 Six-Minute Walk Distance at Hospital Discharge 
Predicts Mortality in Patients With Advanced Heart 
Failure: An Analysis From the ESCAPE Study
Stuart D. Russell, Lynne W. Stevenson, Mark H. Drazner, Joshua M. Hare, Ileana L. 
Piña, Christopher M. O’Connor, Johns Hopkins Hospital, Baltimore, MD
Background: The 6-minute walk test can predict both mortality and hospitalization in 
stable heart failure (HF) patients (pts) in clinical trials and outpatient settings. Yet the test 
has not been examined as a predictive tool at time of admission or discharge for inpts 
hospitalized for acute decompensation.
Methods: ESCAPE was a prospective, randomized, NHLBI-funded trial comparing 
hemodynamically guided therapy using pulmonary artery catheterization versus standard 
care in pts with acute decompensated HF. Six-minute walk tests were performed at 
enrollment and discharge.
Results: The mean distance for 380 pts who underwent a baseline 6-minute walk test was 
416 feet. For 315 patients who completed a predischarge 6-minute walk test, the mean 
was 690 feet. Both baseline and discharge 6-minute walks predicted re-hospitalization and 
mortality (Fig), but changes in 6-minute walk scores from baseline to discharge did not 
(p=0.8476). The 6-minute walk test remained predictive after adjusting for other covariates 
including pulse pressure, BUN, and hemoglobin. Based on a Cox model analysis, the 
hazard ratio per 100 feet for time to death or re-hospitalization was 0.995 (p=0.0053).
Conclusion: The 6-minute walk predicts both mortality and re-hospitalization in pts with 
decompensated HF. The 6-minute walk at discharge provides useful information on the 
prognosis of a pt and can be easily conducted in the majority of pts with congestive HF.
1161-168 Exercise Ventilation Inefﬁciency and Cardiovascular 
Mortality in Heart Failure: The Critical Independent 
Prognostic Value of the Arterial CO2 Partial Pressure
Marco Guazzi, Giuseppe Reina, Gabriele Tumminello, Maurizio D. Guazzi, 
Cardiopulmonary Laboratory, University of Milano, San Paolo Hospital, Milano, Italy, 
Institute of Biometry and Statistics, Italy
Background. In chronic heart failure (CHF) patients, the ventilation (VE) needed to 
eliminate metabolically produced CO2 during exercise (i.e. VE/VCO2 slope) is a strong 
prognosticator. VE/VCO2 slope determinants are the dead space-tidal volume (VD/VT) 
ratio and the arterial CO2 partial pressure (PaCO2). We probed the prognostic role of 
these two variables.
Methods. 128 stable CHF patients (average left ventricular ejection fraction=34±10%) 
underwent cardiopulmonary exercise testing and blood gas analysis. The prognostic 
relevance of VE/VCO2 slope, VD/VT and PaCO2 at peak exercise was evaluated by Kaplan-
Meier approach with log-rank testing and by multivariate Cox regression analysis.
Results. During a mean follow-up of 31.3± 20 months, 24 patients died for cardiac 
reasons. Non-survivors vs survivors, showed a smaller peak VO2 (14.3± 4.0 vs 17.0± 4.0 
mL.min-1.kg-1; p<0.01) a steeper VE/VCO2 slope (42± 10 vs 32± 6; p<0.01), a lower PaCO2 
(33± 5 vs 37± 5; p<0.01), and a higher VD/VT (0.24± 0.04 vs 0.22± 0.04; p<0.05), at 
peak exercise. Multivariate analysis identiﬁed a low PaCO2 as the strongest independent 
prognostic indicator (HR 4.65, 95% CI 1.695 to 12.751, P=0.003) that primarily accounts 
for the VE/VCO2 slope prognostic power.
Conclusions. Findings imply that regulatory mechanisms involved in the tight control 
between blood gas tension and ventilatory command, rather than lung abnormalities, play 
a critical pathophysiological role in the exercise ventilation inefﬁciency of CHF patients. 
1161-169 Direct Bilirubin and Red Cell Distribution Width (RDW) 
are Powerful Independent Predictors of Outcome 
in Chronic Heart Failure: Results from the CHARM 
Program
Christopher Granger, John McMurray, Marc Pfeffer, Karl Swedberg, Duolao Wang, Salim 
Yusuf, Eric Michelson, Stuart Pocock, Duke University Medical Center, Durham, NC
Background: While clinical factors predicting outcome in chronic heart failure (CHF) 
have been deﬁned, less is known about how standard laboratory tests relate to outcome 
in CHF.
Methods: We evaluated data from 2679 patients in the CHARM program (from the US 
and Canada with baseline blood laboratory values) with symptomatic chronic heart failure 
randomized to candesartan or placebo for 38 months. A multivariable Cox regression 
model was developed using baseline variables to predict the composite of cardiovascular 
(CV) death and heart failure hospitalization (952 events).
Results: In order of amount of prognostic information (based on chi-square), the most 
important clinical predictors were age, NYHA class, diabetes, cardiomegaly on chest x-ray, 
ejection fraction, previous hospitalization for heart failure, and treatment with candesartan 
(all p<0.001). The most predictive laboratory values were higher direct bilirubin (HR 1.24 
per 10 umol/L, p<0.001), red cell distribution width (RDW) (HR 1.5 per 5%, p<0.001)), uric 
acid and lymphocyte count (p=0.001). Hazard ratios for quintiles of bilibubin (square for 
unadjusted, circle and 95% CI for adjusted) are shown in ﬁgure. Hemoglobin, creatinine, 
and glycosylated hemoglobin were also independent predictors. RDW was only modestly 
correlated with hemoglobin (correlation coefﬁcient -0.27).
Conclusions: In a large contemporary CHF population, bilirubin and RDW were found to 
be surprisingly strong independent predictors of morbidity and mortality.
 
1161-170 Dobutamine Related Eosinophilia Leads To Cardiac 
Decompensation By TNF-Alpha Deployment
Gustavo A. Cardenas, Patricia A. Uber, Mandeep R. Mehra, Ochsner Clinic Foundation, 
New Orleans, LA
Background: Dobutamine may lead to the development of idiosyncratic eosinophilia 
associated with clinical decompensation. We sought to evaluate whether eosinophilia was 
accompanied by the upregulation of the pro-inﬂammatory cytokine, Tumor necrosis alpha 
(TNF-alpha).
Methods: We examined 77 inotropic therapy-bound patients awaiting transplantation. Peripheral 
eosinophil counts were measured at baseline and weekly until transplantation. TNF-alpha was 
measured serially at baseline and at the time of heart explant. Explanted hearts were examined 
histologically to determine eosinophilic inﬁltration (n=54 evaluable patients).
Results: The patients were 53 ± 13 years, 78% men, 53% ischemic, LVEF 16.3 ± 5%. 
Absolute Eosinophilia (>440 mm3) was diagnosed in 33 patients (43%) but eosinophilic 
myocardial inﬁltration was documented in only 3 of 54 patients (6%). A signiﬁcant increase 
in TNF alpha levels (50%) was noted among those with eosinophilia who developed 
cardiac decompensation(table). Stepwise logistic regression found eosinophilia to be the 
most signiﬁcant predictor of cardiac decompensation while type, dose and duration of 
inotropic therapy were not.
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Conclusions: Peripheral eosinophilia, without eosinophilic cardiac inﬁltration is frequently 
found in inotropic therapy-bound patients and predicts impending cardiac decompensation. 
We suggest that this eosinophilia is associated with deployment of TNF-alpha, which may 
mediate the syndrome of cardiac decompensation.
Eosinophilia (n=33) No eosinophilia (n=44) p value
Abs Eosinophilia 243 + 131 1202 + 918 <.0001
Δ Eosinophilia 168 + 111 999 + 790 <.0001
Δ TNFα (%) 49 1 0.0016
1161-171 Incidence, Prevalence and Recovery of Anaemia in 
Heart failure
Lwin Tin, Periaswamy Velavan, Ramesh de Silva, Alan S. Rigby, Andrew L. Clark, John 
G F Cleland, University of Hull, Hull, United Kingdom
Background: A high prevalence of anaemia has been reported amongst patients with 
chronic heart failure (CHF) but few data exist on its incidence and persistence.
Methods: We assessed 254 consecutive patients attending a community heart failure 
clinic who were diagnosed with left ventricular systolic dysfunction and survived one year. 
Each patient underwent a full assessment including symptom scores, ECG, blood tests 
for electrolytes and creatinine and echocardiographic assessment of cardiac function. 
Haemoglobin (Hb) and haematinic indices were also measured at baseline and after 1 year 
of optimal medical therapy for heart failure with ACE inhibitors and beta-blockers. Anaemia 
was deﬁned as a Hb <13g/dl in men and 127umol/l in men and >107umol/l in women.
Results: The mean age of the patients was 70 years, 30% were women and the mean 
left ventricular ejection fraction was 31+9%. 69 (27%) patients were anaemic at baseline; 
14 (20%) cases resolved by one year. Of the 185 patients who were not anaemic, 45 
(24%) became anaemic by one year, with the prevalence of anaemia increasing from 27% 
at baseline to 39% at 1 year. The prevalence of renal dysfunction at baseline was 34% 
rising to 39% at one year. At baseline, 31(12%) patients had a low serum iron of which 5 
also had low serum ferritin concentrations. 32 (13%) patients had low B12 and 12 patients 
(5%) had low red cell folate levels. Hb level correlated with serum iron (r=0.6; p < 0.0001) 
and ferritin (r=0.2; p = 0.001), but did not correlate with B12 or red cell folate levels. Few 
patients were prescribed speciﬁc haematinic therapy. On multivariate analysis by logistic 
regression, only serum iron (p < 0.0001) and creatinine (p < 0.0001) were independent 
predictors of anaemia at baseline and only baseline serum iron of anaemia at 1 year 
(p<0.05) with an odds ratio of 6 comparing the upper and lower terciles.
Conclusions: Anaemia is common in patients with heart failure and its prevalence rises 
with longer duration of disease. It does not commonly resolve without speciﬁc therapy. Renal 
impairment and low serum iron are independent predictors of anaemia in heart failure.
1161-172 Diminished T Helper and B Cell Numbers and 
Attenuated Antigen Presentation Capacity in Chronic 
Heart Failure
Stephan von Haehling, Ewa A. Jankowska, Darlington O. Okonko, Kristin Strohschein, 
Wolfram Doehner, Stefan D. Anker, National Heart and Lung Institute, London, United 
Kingdom
BACKGROUND: Chronic heart failure (CHF) is a state of chronic immune activation. 
Although the role of pro-inﬂammatory cytokines has been studied in detail, the role of 
leukocyte subsets and their antigen presenting capacity remains unclear.
METHODS:  We prosepectively enrolled 32 CHF patients (age 69.3±1.8 y [mean±SEM], 
NYHA 2.5±0.1, left ventricular ejection fraction 33±4%, white blood cell count [WBC] 
7±0.4 x 109/L, CRP 13.2±2.2 mg/L, creatinine 128±8 µmol/L) and 8 healthy control 
subjects (age 65.8±3.4, WBC 7.3±0.5, CRP 8.2±1.2, creatinine 77±6). Flow cytometry 
was performed using EDTA anticoagulated whole blood after staining with CD4/CD8/CD3, 
CD14/CD19, and CD95/human leukocyte antigen (HLA)-DR. Data were analysed using 
scatter plot gating.
RESULTS: Lymphocytes from CHF patients were enlarged in size (mean ﬂuorescence 
intensity [MFI], CHF vs. control: 274±4 vs. 254±5, p=0.04). Lymphocyte distribution 
differed between CHF patients and controls: CD3 positive T cells 14±1 vs. 21±3%, 
p=0.004, CD4 positive T helper cells 9±0.7 vs. 14±2%, p=0.004, CD8 positive cytotoxic 
T cells 5.9±1.5 vs. 4.2±0.5%, p=NS, CD19 positive B-lymphocytes 2.8±0.4 vs.5.6±1%, 
p=0.01. The relative number of CD95 positive lymphocytes in CHF patients was reduced 
compared to controls (21±1 vs. 31±5%, p=0.007). The relative number of HLA-DR positive 
lymphocytes was reduced in CHF patients as compared to controls (21±1 vs. 31±5%, 
p=0.01). In monocytes, there was no difference in absolute number, cell size, CD95 or 
HLA-DR expression.
CONCLUSION: CHF is associated with attenuated speciﬁc immunity as characterized by 
reduced T helper and B cell numbers and diminished T cell antigen presenting capacity. 
The latter is reﬂected by reduced HLA-DR expression. Innate responses, which have 
been shown in CHF, may be a compensation for this phenomenon.
1161-173 Plasma Concentrations of the Novel Peptide Apelin are 
Decreased in Patients With Chronic Heart Failure
Kwok S. Chong, Roy S. Gardner, James J. Morton, Theresa A. McDonagh, The Scottish 
Cardiopulmonary Transplant Unit, Glasgow Royal Inﬁrmary, Glasgow, United Kingdom, 
Royal Brompton Hospital, London, United Kingdom
Background: Apelin, the novel endogenous ligand for the G-protein-coupled receptor 
APJ, has positive inotropic, vasodilatory and diuretic properties. Differential expression 
and synthesis of apelin and APJ receptor were also observed in normal and failing hearts, 
suggesting an important role in cardiovascular homeostasis. Changes in plasma apelin 
concentrations in relation to chronic heart failure (CHF) have been described in small 
studies with conﬂicting results. We studied plasma apelin concentrations in a large cohort 
of patients with CHF across a broad spectrum of disease severity.
Methods: We studied 200 patients with CHF secondary to left ventricular systolic 
dysfunction and 22 normal controls. We report on the characteristics of this novel peptide 
in patients with CHF compared to normal controls.
Results: Plasma apelin concentrations were signiﬁcantly lower in patients with left 
ventricular systolic dysfunction, irrespective of NYHA class(0.85 [0.53-2.04] versus 3.33 
[0.85-6.60] ng/ml, p<0.01), ejection fraction or aetiology when compared to age-matched 
controls. Apelin concentrations were seen to correlate with peak VO2 and right ventricular 
ejection fraction, but not with age, sex, body mass index, renal function or NT-proBNP 
concentrations.
Conclusions: Plasma concentrations of apelin are decreased in patients with chronic 
heart failure. Apelin might play an important role in the pathophysiological processes of 
heart failure and has potential therapeutic implications. 
1161-174 Increased Activity of Secreted Sphingomyelinase in 
Chronic Heart Failure - Marker of Immune and Metabolic 
Imbalance.
Wolfram Doehner, Ralf A. Claus, Stephan von Haehling, Alexander Bunck, 
Mariantonietta Cicoira, Mathias Rauchhaus, Piotr P. Ponikowski, Frank M. Brunkhorst, 
Stefan D. Anker, Applied Cachexia Research, Charite, Campus Virchow Klinikum, Berlin, 
Germany, NHLI, Imperial College, London, United Kingdom
The sphingomyelin degrading enzyme sphingomyelinase (SMase) is crucially important for 
ceramide-mediated signalling processes. Vascular endothelium is a rich source of secreted 
SMase and a contribution to processes of immune activation and metabolic balance has 
been reported. In chronic heart failure (CHF) immune activation is a common ﬁnding as is 
anabolic failure leading to cachexia. The signiﬁcance of SMase in in CHF is unknown.
SMase activity was measured by a ﬂuorimetric method in 112 patients with CHF (age 
63±1y, NYHA mean 2.5±0.1, I/II/III/IV 9/48/46/9; LVEF 30±2%; peak VO2 18.6±0.7 ml/
kg/min, mean RR 85±1 mmHg) and in 13 healthy control subjects aged 54±4. Body 
composition was assessed by DEXA scan and resting and postischaemic peak limb blood 
ﬂow was assessed by venous occlusion plethysmography.
Results: SMase activity was higher in CHF than in healthy controls (299.3±26.8 vs 
150.3±33.7 pmol/ml/h, p<0.5). SMase increased stepwise according to NYHA class (I: 
205.9±67.4, II: 284.4±35.0, III: 305.6±31.2, IV: 439.9±221.6 pmol/ml/h; ANOVA p<0.05). 
Patients with cardiac cachexia had further increased SMase activity compared to non-
cachectic patients (405.2±54 vs 233.2±24.3 pmol/ml/h, p<0.001). In univariate regression 
analyses SMase was signiﬁcantly predicted by age (r=0.29, p<0.01), BMI (r=-0.25, 
p<0.01), peak VO2 (r=-0.33, p<0.001), but not by LVEF. SMase correlated inversely with 
total and regional leg and arm lean tissue (all p<0.01) but not with parameters of fat mass 
or distribution. Maximum isometric muscle strength was inversely related to SMase (r=-
0.46, p<0.0001). Postischeamic peak blood ﬂow (r=-34), and the ratio peak/resting blood 
ﬂow (r=-0.32) both were inversely related to SMase (both p<0.05).
Conclusion: We show for the ﬁrst time that plasma SMase activity is up-regulated 
in CHF patients, independently of the underlying aetiology. SMase activity increases 
in parallel to CHF severity and is inversely related to skeletal muscle tissue mass and 
muscle functional capacity and to vasodilator capacity. The association of elevated SMase 
with clinical status and symptoms of CHF suggest that SMase may be part of regulatory 
processes of CHF pathophysiology.
1161-175 Circulating Adiponectin Levels Predict Outcome in 
Patients with Congestive Heart Failure
Jacob George, Dov Wexler, Yehonatan Sharabi, David Sheps, Gad Keren, Tel Aviv 
Sourasky Medical Center, Tel Aviv, Israel
Patients with congestive heart failure (CHF) still suffer considerable morbidity and mortality 
despite advancing treatment modalities and there is a need to elucidate additional 
determinants in the pathogenesis of this syndrome. Adiponectin is an adipocyte-derived 
cytokine that exhibits anti-inﬂammatory and anti-atherogenic properties and its levels are 
reduced in obesity, diabetes and coronary atherosclerosis. We determined adiponectin 
levels and its predictive value on outcome in a cohort of CHF patients.
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Serum and clinical data was obtained for clinically controlled CHF outpatients (n=175). Serum 
levels of adiponectin, C-reactive protein, N-terminal pro-brain natriuretic peptide, IL-1beta, 
IL-6, IL-8, IL-10, IL-12 TNF-alpha and CD-40 ligand were determined. The association of 
adiponectin with the clinical severity of CHF was sought as well as the predictive value of this 
adipokine on mortality, CHF hospitalizations or the occurrence of each of these end points.
Levels of adiponectin were signiﬁcantly increased in patients with CHF. Patients with higher 
New-York Heart Association class had signiﬁcantly higher serum levels of adiponectin. 
Adiponectin serum levels were lower in diabetic CHF patients as well as in patients with 
ischemic cardiomyopathy and positively associated with age. A positive association was 
found between serum adiponectin and NT-ProBNP whereas a negative correlation was 
found with regard to CRP levels. Serum adiponectin above the 75th percentile was found 
to be an independent predictor of total mortality, CHF hospitalizations or either of these 
composite endpoints over a 2-year prospective follow-up.
Adiponectin is increased in CHF patients and predicts mortality and morbidity.
1161-176 Serum Uric Acid, Left Ventricular Mass Index, and 
Creatinine Clearance as Predictors for Congestive Heart 
Failure in Essential Hypertension
Yoshio Iwashima, Takeshi Horio, Hiromi Rakugi, Toshio Ogihara, Yuhei Kawano, 
Osaka University Graduate School of Medicine, Suita City, Osaka, Japan, National 
Cardiovascular Center, Suita City, Osaka, Japan
Background: Hypertension and left ventricular hypertrophy (LVH) are principal precursor 
of congestive heart failure (CHF), and elevated serum uric acid (UA) and decreased 
creatinine clearance (Ccr) are associated with worse functional status and adverse 
prognosis in CHF. In this study, we examined the association between serum UA and 
LVH, and investigated prospectively whether UA and left ventricular mass index (LVMI) 
assessed by echocardiogram can predict the incidence of CHF in asymptomatic essential 
hypertensive subjects.
Methods and Results: A total of 713 subjects (mean age 62 years, 50 % female) free 
of prior myocardial infarction and CHF were included in this study. After adjustment for 
confounding factors, UA was signiﬁcantly elevated in subjects with LVH (non-LVH: 369±7 
vs LVH: 382±6 µmol/l, p<0.04). Furthermore, multiple linear regression analysis indicated 
that UA (F=6.89, p<0.01) and Ccr (F=23.89, p<0.01) were independently associated 
with LVMI. During follow-up (mean 32 months), 32 subjects (13 female) developed CHF. 
Kaplan-Meier curves showed a signiﬁcantly lower event-free survival rate in subjects with 
lowest tertile of UA (male: <358, female: < 274 µmol/l) and LVMI (male: <117.6, female: 
<102.2 g/m2) (p<0.001, respectively). Cox regression analysis showed that the incidence 
of CHF increased when UA (male: >421, female: >350 µmol/l) and LVMI (male: >143.4, 
female: > 128.3 g/ m2) were in the highest tertile compared with the lowest tertile (UA: OR 
2.11, p<0.05; LVMI: OR 2.74, p<0.01), after adjustment for age, pulse pressure, diabetes, 
Ccr, and left atrial diameter. In addition, Ccr was also independent predictictor for CHF 
(OR 0.96, p<0.01).
Conclusion: UA was signiﬁcantly increased in patients with LVH, and independently 
associated with LVMI. Increased UA and LVMI, and decreased Ccr are independent 
predictors for CHF.
1161-177 Serum Serum Matrix Metalloproteinases Proﬁle in 
Patients With Heart Failure: Relating to Beta-Blocker 
Therapy
Hiroyasu Uzui, Jong-Dae Lee, Akira Nakano, Toru Geshi, Kiyohiro Toyoda, Haruhisa Shirasaki, 
Naoki Amaya, Toshihiro Mizuguchi, Takanori Ueda, University of Fukui, Fukui, Japan
Background: Although several matrix metalloproteinases (MMPs) activation in dilated 
failing heart are identiﬁed, it remains unclear whether activation of MMPs species is also 
evident in dilated failing heart. If so, a speciﬁc proﬁle of MMPs may provide a potential 
therapeutic strategy.
Methods: Serum levels of MMP-2,-9, TIMP-1,-2, IL-6 and BNP were measured using 
ELISA in 81 patients (47: ischemic (ICM), 34: idiopathic dilated cardiomyopathy (DCM)) 
with congestive heart failure (CHF) less than 50% of left ventricular ejection fraction 
(LVEF) in the left ventricle imaging. Response to beta-blocker therapy was assessed at 6 
months comparing with baseline data using the change in LVEF from echocardiography.
Results: Serum MMP-2 level was higher in both ICM and DCM groups than age matched 
control subjects (C), but there was no signiﬁcant difference between ICM and DCM (1132 
± 384 vs. 976 ± 166 ng/ml, p=0.26). Serum level of MMP-9 was increased in DCM (66.7 
± 12 ng/ml, p=0.0048 vs. ICM), whereas there was no signiﬁcant difference between ICM 
(24.3 ± 3 ng/ml) and C. Levels of TIMP-1,-2 and IL-6 and BNP were also higher in both ICM 
and DCM groups than C group (TIMP-1:124±12 vs. 113±11 ng/ml, p=0.49, TIMP-2:33±10 
vs. 43±21 ng/ml, p=0.35, IL-6:7.9±1.8 vs. 8.2±1.7 pg/ml, p=0.46, BNP: 106±32 vs. 126±36 
pg/ml, p=0.24). Of the 11 patients with high levels of MMP-9 (over 70 ng/ml), only 3 patients 
(27%) responded to beta-blocker therapy. Eighteen of the other 23 patient with low-level 
MMP-9 responded to beta-blocker therapy (67%, p=0.0078 vs. high-level MMP-9 group).
Conclusion: The serum MMP-9 level is differed by the etiologies of the congestive heart 
failure, and it is useful to assess the level for the selection of the treatment strategy. Data 
suggested that responder or non-responder to beta-blocker may be distinguished by the 
level of serum MMP-9 in CHF patients.
1161-178 Anemia in Chronic Heart Failure: an Inadequate 
Erythropoietic Response?
Peter Van der Meer, Pieta W. Bruggink-Andre de la Porte, Erik Lipsic, Dirk J. Lok, 
Adriaan A. Voors, Dirk J. Van Veldhuisen, University Hospital Groningen, Groningen, The 
Netherlands, Deventer Ziekenhuis, Deventer, The Netherlands
Background: Anemia is frequently observed in patients with Chronic Heart Failure (CHF) 
and associated with an impaired prognosis. However, the origin of anemia and the role of 
erythropoietin (EPO) in CHF remains unclear. Therefore, we assessed the prevalence and 
origin of anemia and studied the erythropoietic response in CHF patients.
Methods: In 240 consecutive patients with CHF (NYHA III or IV) due to left ventricular 
systolic dysfunction (EF < 45%) or diastolic dysfunction (according to ACC-criteria), we 
measured renal function, brain natriuretic peptide (BNP), hemoglobin levels, erythropoietin 
(EPO) levels and hematinic levels (folate, vitamine B12 and ferritin). Anemia was deﬁned 
as hemoglobin levels < 12.0 g/dL.
Results: Mean age of patients was 70 years and 76% were male. Anemia was present 
in 37 patients (15.4%). Patients with anemia showed signiﬁcant higher BNP levels, 
compared to non-anemic CHF patients (p=0.01). Of all anemic patients, 18.9% were 
ferritin deﬁcient, 8.1% were vitamin B12 deﬁcient and no folate deﬁciencies were 
observed. Renal impairment (creatinine > 160 µmol/L) was present in 24.3% of all anemic 
patients. To study the erythropoietic response, we correlated EPO levels to hemoglobin 
levels. We observed only a mild, inverse correlation between EPO and hemoglobin levels 
in anemic CHF patients with normal renal function and no hematinic deﬁciencies(r2=0.15, 
p=NS). Interestingly, hematinic deﬁcient CHF patients, showed a clear inverse correlation 
between EPO and hemoglobin levels (r2=0.72, p=0.03).
Conclusion: Anemia is common in CHF patients and associated with higher BNP levels. 
In 55% of the anemic CHF patients, no hematinic deﬁciencies or impaired renal function 
were observed. In these patients EPO levels poorly correlate with the hemoglobin levels, 
indicating a blunted EPO response. In contrast, hematinic deﬁcient patients show a 
clear correlation between EPO and hemoglobin levels, indicative of an adequate EPO 
response.
1161-179 Association of the Metalloproteinase 1 (1G/2G) 
Functional Promoter Variant with Ischemic 
Cardiomyopathy
J. Eduardo Rame, Sameer Mehta, Surai Thaneemit-Chen, Philip Lavori, Daniel L. 
Dries, Johns Hopkins University School of Medicine, Baltimore, MD, University of Texas 
Southwestern Medical Center, Dallas, TX
Background: Metalloproteinase 1 (MMP1) is a major collagenase that is up-regulated 
in the early post-infarct period and moderates the extracellular matrix dynamics that 
contribute to post-infarct ventricular remodeling. Metalloproteinase gene regulation is 
heavily inﬂuenced by transcriptional control. A common single nucleotide polymorphism 
in the promoter region of the MMP1 gene (the 1G/2G) creates a transcriptional factor 
binding site rendering the 2G allele to be more transcriptionally active than the 1G allele. 
We hypothesized that the MMP1-2G allele would increase the susceptibility to adverse 
post-infarct ventricular remodeling and thereby increase the risk for the development of 
ischemic cardiomyopathy. 
Methods: We utilized a case-control design to determine the association of this 
1G/2G promoter variant with ischemic cardiomyopathy. Cases (N=570) of ischemic 
cardiomyopathy were identiﬁed from the Beta-Blocker Evaluation Survival Trial (BEST) 
DNA-Substudy. Controls (N=2742) consisted of participants in the Dallas Heart Study, a 
population-based sample from Dallas County. A TaqMan allelic discrimination assay was 
used to genotype cases and controls. 
Results: There were no signiﬁcant differences in the population prevalence of the 1G/2G 
genotypes between self-reported African-American or Caucasian subjects. The prevalence 
of the MMP1-2G2G genotype relative to the combined group of the 1G/2G or 1G/1G was 
greater in subjects with ischemic cardiomyopathy compared to the control population 
(27.4 vs. 22.6%) (OR ;1.30; 1.05-1.60; P=0.015). In stratiﬁed analysis, the MMP1 2G2G 
genotype remained signiﬁcantly associated with prevalent ischemic cardiomyopathy in 
Caucasians (N=460) (OR 1.41; 95% CI 1.10-1.82; P=0.007), but not in African-Americans 
(N=87) (OR 0.89; 95% CI 0.52-1.50; P=0.586). 
Conclusions: The MMP1-2G2G genotype is associated with prevalent ischemic 
cardiomyopathy suggesting that increased transcriptional activation of the 2G allelic 
variant may contribute to adverse ventricular remodeling in the post-infarct period.
1161-180 Lack of Improvement in Quality of Life Post-
Hospitalization Predicts Mortality in Patients With 
Advanced Heart Failure
Debra Moser, Karen Chiswell, Laura Yamokoski, Ginger Conway, Karen A. Hartman, 
Cynthia Binanay, Lynne W. Stevenson, University of Kentucky, Lexington, KY
Background: Health-related quality of life (HRQL) is a major clinical outcome for heart 
failure (HF) patients. Our aims were to determine whether a lack of improvement in HRQL 
predicts mortality and to deﬁne the time course of HRQL in patients surviving 6 mos. 
Methods: We analyzed HRQL data, as measured by the Minnesota Living with Heart 
Failure® Questionnaire (MLHFQ), for 433 pts (74% male; mean age 56 years; LVEF 19%) 
in the NHLBI-sponsored multicenter ESCAPE trial. All pts had prior HF hospitalization or 
chronic high diuretic doses and ≥1 symptom and 1 sign of ﬂuid overload at admission. 
MLHFQ scores at baseline, 1 mo, and 3 mos were used; 1-mo improvement was deﬁned 
as a decrease of >5 points. 
Results: MLHFQ scores improved (decreased) by 1 mo and stabilized, but the degree 
of improvement differed (p<.0001, group X time interaction) between survivors and non-
survivors at 6 mos. In a Cox regression model, after adjustment for traditional risk factors 
for HF mortality, failure to improve by 1 mo predicted subsequent mortality (p=.013). 
Conclusion: In patients hospitalized with severe HF exacerbation, HRQL is seriously 
impaired but improves substantially within 1 mo of discharge for many pts. Patients for 
whom HRQL does not improve merit speciﬁc focus because of high risk for early mortality.
MLHFQ Scores for Patients Who Did and Did Not Survive to 6-Month Follow-up in the 
ESCAPE Trial 
Baseline Score 1-Month 3-Months
Survived 6 months 74±18 55±23 54±26
Did not survive 6 months 74±16 65±19 67±16
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1162-157 Asymmetry of Systolic Anterior Motion of Mitral 
Valve in Patients with Hypertrophic Obstructive 
Cardiomyopathy: A Real-Time Three-Dimensional 
Echocardiographic Study
Jong-Min Song, Jian Xin Qin, Vorachai Kongsaerepong, Masao Daimon, Shota Fukuda, 
Deborah A. Agler, Jeanne K. Drinko, Maureen Martin, Harry M. Lever, Takahiro Shiota, 
The Cleveland Clinic Foundation, Cleveland, OH
Background: To investigate 3-dimensional geometric features of systolic anterior motion 
of mitral valve (SAM) in patients with hypertrophic obstructive cardiomyopathy (HOCM).
Methods: A real-time 3D echocardiography (RT3DE) was performed in 16 HOCM patients 
with signiﬁcant SAM. Three equidistance antero-posterior planes (medial, central, lateral) 
that were perpendicular to mitral valvular commissure-commissure plane were generated 
to measure the angle between mitral annulus plane and basal portion of the anterior 
mitral leaﬂet (Aα), the angle between the basal portion of the leaﬂet and its tip showing 
SAM (Bα), and the distance between interventricular septum and mitral valve tip (D) in the 
mid-systole. The left-ventricular outﬂow tract (LVOT) pressure gradient was measured with 
Doppler study performed at the same day as RT3DE.
Results: Bα in the medial plane (66±14°) was signiﬁcantly smaller than that in the central 
plane (84±10°, p<0.001) or lateral plane (114±19°, p<0.001). D in the medial plane was 
signiﬁcantly smaller than that in the lateral plane (0.4±1.0 mm vs. 1.9±1.7 mm, p<0.005). 
Aα in the medial plane was smaller than that in the lateral plane with marginal signiﬁcance 
(43±8° vs. 47±7°, p=0.05). Medial D showed signiﬁcant negative correlation with LVOT 
pressure gradient (Spearman rho=-0.53, p<0.05).
Conclusions: Our RT3DE study demonstrated an asymmetry of SAM; SAM develops 
predominantly in the medial side, resulting in laterally located narrow LVOT opening in 
HOCM patients.
1162-158 Contribution of Coronary Hemodynamics to Myocardial 
Ischemia: Comparison With Hypertensive Heart Disease 
and Hypertrophic Cardiomyopathy
Tetsuro Kataoka, Shuichi Hamasaki, Sanemasa Ishida, Keishi Saihara, Hideki Okui, 
Koji Orihara, Tsuyoshi Fukudome, Takuro Shinsato, Etsuko Mizoguchi, Yuichi Ninomiya, 
Yutaka Otsuji, Shinichi Minagoe, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: The present study investigated the difference of coronary hemodynamics 
on myocardial ischemia between the patients with hypertensive heart disease (HHD) and 
hypertrophic cardiomyopathy (HCM). 
Methods and Results: We studied 15 patients with HHD and 10 patients with HCM 
who all showed positive results on exercise thallium-scintigraphy. All patients underwent 
Doppler ﬂow study of the left anterior descending coronary artery. Vascular reactivity was 
examined by intra-coronary administration of papaverine (12.5 mg / 20 sec), acetylcholine 
(Ach) (3 and 30 µg / 2min), and nitroglycerin (200 µg / 20 sec) using a Doppler guidewire. 
The percent increase in coronary blood ﬂow (CBF) and coronary artery diameter induced 
by Ach in the HHD group were signiﬁcantly reduced when compared with those in the 
HCM group (17±49% vs. 95±120%, p<0.05; -8±23% vs. 9±16%, p<0.05, respectively), 
whereas papaverine-induced increase in CBF was similar when comparing the two 
groups (increase ratio: 2.1±0.4 vs. 2.2±1.5, p=NS). Basal and maximum CBF per 100g LV 
mass in the HCM group was signiﬁcantly reduced when compared to those in the HHD 
group (21±18 vs. 31±13 ml/min/100g, p<0.01; 47±58 vs. 65±31, p<0.05, respectively), 
whereas CBF and LV mass did not differ signiﬁcantly. 
Conclusion: These data suggest that myocardial ischemia is more strongly associated 
with impaired coronary endothelial function in patients with hypertensive heart disease 
and reduced basal and maximum coronary blood ﬂow per unit LV mass in patients with 
hypertrophic cardiomyopathy.
1162-159 Percutaneous Septal Ablation for Hypertrophic 
Obstructive Cardiomyopathy: How Much CK is 
Necessary for Signiﬁcant Reduction of the Outﬂow 
Gradient?
Dirk Welge, Dieter Fassbender, Henning K. Schmidt, Dieter Horstkotte, Lothar Faber, 
Heart Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, 
Germany
Background: A less agressive approach to outﬂow obstruction (LVOTO) using smaller 
doses of ethanol is increasingly used in percutaneous septal ablation (PTSMA).
Methods: In a cohort of 244 patients (pts.) who had a complete follow-up over 12 months 
after PTSMA we studied whether the hemodynamic effect differed between pts. groups 
with different CK peaks (group A: <300 U/l; group B: 300-800 U/l years, group C: >800U/l, 
normal: <80 U/l).
Results: Mean NYHA functional class improved from 2.9±0.4 to 1.5±0.7, accompanied 
by a LVOTO reduction from 58±34 to 9±16 mm Hg at rest, and 122±45 to 27±32 mm 
Hg with provocation. The effect of PTSMA in the three different groups according to CK 
release is shown in the table:
Conclusions: A higher CK peak resulting from a higher ethanol dose leads to a more 
pronounced septal thinning 12 months after percutaneous septal ablation. The clinical 
effect and the complication rates were comparable in our cohort of exclusively echo-
guided procedures using ethanol doses in the range of 2-5 ml. Our results do not support 
a “bigger is better” approach with respect to the post-interventional CK rise but suggest 
adjustment of the ethanol dose to baseline septal thickness. 
A (n=31) B (n=187) C (n=26) p value
Baseline NYHA class 2.9±0.3 2.9±0.4 2.9±0.5 0.9
Baseline septum (mm) 19±3 21±4 22±4 <0.05
Baseline watts 97±42 90±50 94±65 0.7
Ethanol dose (ml) 2.3±0.8 2.7±0.9 4.3±2.3 <0.02
Pacemaker rate (%) 7 8 9 0.8
NYHA class improvement 1.3±0.7 1.4±0.7 1.3±0.5 0.5
Septum thinning (mm) 5±3 5±4 9±6 <0.02
LVOTO reduction (%) 70±46 84±29 88±18 0.03
Watts improvement 20±31 19±42 30±52 0.3
1162-160 Evidence Against Myocardial Bridging As A 
Determinant Of Sudden Death In Hypertrophic 
Cardiomyopathy
Cristina Basso, Barry Maron, Domenico Corrado, Jack Titus, Gaetano Thiene, 
Pathology, University of Padua Medical School, Padova, Italy, Minneapolis Heart Institute 
Foundation, Minneapolis, MN
Background. Although myocardial bridging (MB) of the left anterior descending (LAD) 
coronary artery has been associated with myocardial ischemia and sudden death (SD) in 
young patients with hypertrophic cardiomyopathy (HCM), its prevalence in different age 
groups is unresolved and its overall signiﬁcance remains controversial.
Methods. The ﬁles of two pathology cardiac registries were searched for diagnosed 
cases of HCM. A total of 105 hearts were enrolled (32 female and 73 male, ages ranging 
1 day-90 yrs, mean 30 +/- 21). Hearth weight and septal thickness were 465+/-208 g and 
19+/-6 mm, respectively. Mode of death/failure was SD in 67 (64%), heart failure (HF) 
in 27 (27%) (14 with heart transplantation), early postsurgical death in 2 (myectomy), 
infective endocarditis in 1 and extracardiac causes in 6.
Results. A MB of LAD was present in 40 (38%) HCM pts, compared to 21 (21%) of 100 
consecutive controls who died of causes unrelated to HCM (p= 0.01). MB was present 
in 39% of SD, 41% of HF, and 33% of pts who died of extracardiac causes p=NS). The 
prevalence of MB in different age groups ranged from 20% in pts aged <10 yrs to 57% 
in pts aged 20-30 yrs. A higher prevalence was found in pts aged >20 yrs (46%) than 
pts <20 yrs (26%, p=.05), whereas no difference was found speciﬁcally among SD pts 
aged >20 (41%) as compared to those <20 yrs (38%,p=NS). No correlation was found 
between the presence of MB and either septal thickness or heart weight. MB had a 
mean length of 14.8±6.6 mm and a mean thickness of 2.0±1.5 mm. No correlation was 
found between MB thickness and heart weight and septal thickness, whereas the longer 
the MB the greater the MB thickness. At histology, MB more frequently consisted of a 
sheath of myocardial ﬁbers totally encircling the LAD (71%) than of a few superﬁcial ﬁbers 
transversally oriented (29%).
Conclusions. In HCM, MB was present at postmortem in a sizeable minority of pts (i.e., 
more than one-third). However, MB prevalence in HCM was only modestly greater than 
in controls with other heart diseases and did not differ between HCM pts with sudden or 
other modes of death, nor with respect to age and gender. Our ﬁndings do not support the 
hypothesis that MB represent a prognostic marker for sudden death in young HCM pts.
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1162-161 Malignant Clinical Proﬁles and Heterogeneous 
Morphological Pattern Associated With Two Mutations 
of Myosin Binding Protein C Gene in Hypertrophic 
Cardiomyopathy
Chiara Pedone, Lotte E. de Laat, Dennis Dooijes, Marcel J. Kofﬂard, Folkert J. ten 
Cate, Bellaria Hospital, Bologna, Italy, Thoraxcenter Erasmus MC, Rotterdam, The 
Netherlands
Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized 
by cardiac hypertrophy caused by mutations of genes encoding for sarcomeric proteins. 
More than 50 myosin binding protein C (MYBPC) mutations have been identiﬁed, most 
of them related to late onset and benign or intermediate prognosis. We analysed clinical 
features of two MYBPC mutations to enrich the spectrum of known genotype-phenotype 
correlations.
Methods: R943X and 2864delCT mutations, involving C-terminus of the protein, have 
been identiﬁed respectively in 4 and 6 not related HCM patients out of 50 screened for 
MYBPC mutations. Detailed phenotype analysis was obtained from clinical data, rest and 
24 hours electrocardiography, stress test and two-dimensional echocardiography.
Results: Among the 4 patients (men) carrying 2864delCT mutation 2 different clinical 
proﬁles could be identiﬁed. Three patients had an obstructive form, with moderate 
hypertrophy (maximal wall thickness [MWT] 19±7mm), severe symptoms (NYHA class 
≥ III and angina) refractory to maximal medical therapy and requiring myectomy or non 
surgical septal reduction therapy. None had major risk factors for sudden death (SD). 
Differently one patient had severe non obstructive form (MWT=32 mm), no symptoms 
and a family history for SD.
The 6 patients carrying R943X had also an heterogeneous clinical phenotype. Three 
males had non obstructive form, massive hypertrophy (MWT 32±4 mm) and moderate 
symptoms. Three patients (1 male and 2 females) had mild-moderate hypertrophy and 
different degree of dyspnoea (NYHA class from I to III). Five out six patients had an high 
risk proﬁle for SD. In all the 10 cases the diagnosis was made in adulthood (mean age 
45±12 and 43±9 in patients carrying 2864delCT and R943X respectively, p=0.469).
Conclusion: These preliminary data show that MYBP C mutations may carry severe 
clinical features associated with a broad range of hypertrophy degree. In patients sharing 
the same mutation adverse clinical course can proceed along different pathways: high risk 
for SD and severe heart failure due to obstruction or diastolic dysfunction.
1162-162 Left Ventricular Outﬂow Tract Planimetry By 
Cardiovascular Magnetic Resonance Correlates With 
Doppler Pressure Gradient and predicts the obstruction 
In Patients With Hypertrophic Cardiomyopathy
Hassan Abdel-Aty, Matthias G. Friedrich, Rainer Dietz, Jeanette Schulz-Menger, 
Franz-Volhard-Klinik, Helios-Klinikum Berlin, Kardiologie, Charité Campus Berlin-Buch, 
Humboldt-Univ, Berlin, Germany
Background: Measurement of the left ventricular outﬂow tract (LVOT) using 
cardiovascular magnetic resonance (CMR) in hypertrophic cardiomyopathy (HCM) is 
feasible and correlates with disease severity. Data relating this measurement to Doppler-
derived pressure gradient (PG) applying echocardiography (Echo) are lacking. Whether 
rest LVOT measurement can differentiate between the obstructive and non-obstructive 
HCM remains illusive.
Methods: We studied 37 HCM patients (22 males, 56±15 y) and 14 healthy subjects (7 
males, 28±10 y) using CMR and Echo (median inter-study duration= 2 days). Minimal 
systolic LVOT area was quantiﬁed by steady state free precession sequence. PG was 
quantiﬁed at rest and after Valsalva maneuver. Patients were divided into 3 groups 
based on their PG: a) non-obstructive HCM (PG<30 at rest and after provocation, n= 
11) b) Latent obstructive HCM (PG<30 at rest and >30 after provocation, n= 10) and c) 
Obstructive HCM (PG>30 at rest, n= 16).
Results: LVOT measurements in patients showed a signiﬁcant inverse correlation with 
the Doppler-derived PG both at rest (Spearman correlation coefﬁcient= -0.64, p<0.0001) 
and after provocation (-0.71, p<0.0001). Compared to volunteers with a mean LVOT area 
of 4.8±0.8 cm2, the area was smaller in patients with non-obstructive HCM (3.5±1.1 cm2, 
p<0.002), latent obstructive (2.2±1.5 cm2, p<0.002.) and obstructive HCM (1.6±0.6 cm2, 
p<0.0001). Patients with non-obstructive HCM had larger LVOT than latent (3.5±1.1 cm2 vs. 
2.2±1.5 cm2, p<0.013) or obstructive HCM (3.5±1.1 cm2 vs. 1.6±0.6 cm2, p <0.0001). When 
the latent obstructive and obstructive forms were considered together as obstructive HCM, 
signiﬁcant differences in LVOT still existed between obstructive and non-obstructive HCM 
(1.8 cm2±1.0 vs. 3.5±1.1 cm2, p<0.0001). No signiﬁcant difference was found between the 
LVOT in latent and obstructive HCM (2.2±1.5 cm2 vs. 1.6±0.6 cm2, p = 0.478)
Conclusion: CMR-derived LVOT area measurements correlate with pressure gradient 
as assessed by Echo. Measuring the LVOT area by CMR has the potential to differentiate 
between obstructive and non-obstructive HCM and to identify latent LVOT obstruction 
without the need for provocation.
1162-163 Electrophysiologic Evaluation Does not Predict 
Adequate ICD Interventions in Patients With 
Hypertrophic Cardiomyopathy Implanted for Primary 
Prevention
Helga Buschler, Lothar Faber, Juergen Vogt, Johannes Heintze, Cornelia Hoppe, 
Barbara Lamp, Dieter Horstkotte, Heart Center North Rhine-Westphalia, Ruhr University 
Bochum, Bad Oeynhausen, Germany
Background: Sudden cardiac death ( SCD) is a feared complication of hypertrophic 
cardiomyopathy (HCM). Due to the fact that nearly all patients (pts.) fail to survive 
their ﬁrst episode of ventricular ﬁbrillation (VF), risk stratiﬁcation is important. A family 
history of SCD, recurrent syncopes, nonsustained ventricular tachycardia (VT) on Holter 
monitoring, severe left ventricular hypertrophy, and abnormal blood pressure response to 
exercise have been identiﬁed as main risk factors (RFs). The purpose of this study was to 
investigate the impact of VT/VF inducibility during EPS on the frequency of adequate ICD 
interventions in HCM pts. implanted for primary prevention.
Methods: Since 2001, 27 pts with at least two main RFs received an implantable 
cardioverter-deﬁbrillator for primary prevention. Before implantation EPS was performed 
with a cycle length of 500 ms with up to 3 extrastimuli at the right ventricular apex and 
outﬂow tract. The decision to implant the ICD was independent from the EPS result. After 
implantation the ICDs were interrogated at 3 to 6 months intervals.
Results: Sustained polymorphic VT or VF was induced in 14 pts. (group A). Group B 
consists of 13 pts. with negative EPS. Clinical characteristics are shown in the table. The 
distribution of RFs was comparable in both groups.
Conclusions: In our cohort of pts. with HCM and ICD implantation for primary prevention 
the inducibility of VT or VF during EPS did not correlate with the frequency of adequate 
ICD intervention during follow-up.
Group A Group B p value
Age (years) 40.7±14.5 42.4±15.9 n.s.
NYHA class 1.5±0.6 1.5±0.5 n.s.
Number of RFs 2.3±0.5 2.3±0.6 n.s.
LVEF (%) 78.6±12.5 78.2±10.3 n.s.
Duration of follow-up (months) 16.1±10.1 17.3±11.5 n.s.
Adequate ICD interventions (number/pts) 1 / 1 7 / 4 <0.05
1162-164 Cardiovascular Screening Practices of Major North 
American Professional Sports Teams
Kevin M. Harris, Austin Sponsel, Adoiph M. Hutter, Jr., Barry J. Maron, Minneapolis Heart 
Institute Foundation, Minneapolis, MN, Massachusetts General Hospital, Boston, MA
Background. Professional athletes represent the pinnacle of sports achievement and 
excellence in society; sudden unexpected death of such individuals due to cardiovascular 
disease, albeit rare, is particularly tragic and counterintuitive. Therefore, detecting the 
responsible diseases in such athletes is a priority. While preparticipation screening 
strategies are detailed for high school and college competitive sports, customary practice 
in professional sports has not been examined systematically.
Methods. Each of 122 teams comprising the Major League Baseball (MLB), National 
Basketball Association (NBA), National Football League (NFL) and National Hockey 
League (NHL) were contacted to complete a standard questionnaire summarizing 
their screening practices. History and physical examination items were compared to 
recommendations of the AHA consensus panel (12 items).
Results. Of the 122 teams, 101 (83%) returned the questionnaire, allowing a detailed 
proﬁle to be developed: personal and family history (100%); complete physical 
examination (91%); speciﬁc focus on tobacco (96%) and drug/nutritional supplement 
use (88%). Diagnostic testing with ECG was common (90%). An emphasis on screening 
for atherosclerotic coronary disease was evident by lipid panels (88%). Routine use 
of echocardiography (20%) and stress ECG was uncommon (16%). Uniform medical 
screening history and physical forms were available for MLB (10/12 AHA items); NHL 
(8/12 AHA items); and NFL (3/12 AHA items). Of the 101 teams, 33% reported previous 
disqualiﬁcation of ≥ 1 athlete for cardiovascular disease; 5% reported a sudden death.
Conclusions. Preparticipation screening for cardiovascular disease is widespread 
customary practice among U.S. professional sports teams. Strategies vary considerably, 
but are generally superior in MLB and NHL. While screening practices for athletes take 
into account coronary disease and structural abnormalities, current practices would 
appear to have the potential to under diagnose heart disease capable of causing sudden 
death in young athletes. Closer adherence to AHA screening recommendations for history 
and physical would be advantageous.
ORAL CONTRIBUTIONS
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849-3 Identiﬁcation of a Metavinculin Missense Mutation, 
R975W, Associated with Both Hypertrophic and Dilated 
Cardiomyopathy
Vlad C. Vasile, Melissa L. Will, Steve R. Ommen, Timothy M. Olson, Michael J. 
Ackerman, Mayo Clinic College of Medicine, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) 
are partially allelic disorders (identical genes implicated in the pathogenesis of both 
cardiomyopathies). Mutations in metavinculin, a muscle-speciﬁc isoform of vinculin and a 
key component of intercalated discs, were identiﬁed previously in DCM and shown to alter 
in vitro organization of actin ﬁlaments. Here, we tested the hypothesis that perturbations 
in metavinculin may also provide a pathogenic substrate for HCM.
Methods: Using DHPLC and direct DNA sequencing, mutational analysis of the 
metavinculin-speciﬁc exon of vinculin (exon 19) was performed in a cohort of 389 
unrelated patients with clinical HCM, previously genotyped for the 8 most common HCM-
associated sarcomere genes.
Results: Overall, 5 patients were found to host a non-synonymous single nucleotide 
polymorphism (amino acid variant). Among the subset of 147 sarcomere gene-positive 
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patients, 1 patient with L185R-tropomyosin mutation had a P943A-metavinculin mutation. 
However, this variant failed to co-segregate in the familial HCM pedigree. Among the 242 
sarcomere gene-negative patients, 3 patients had the rare, conservative polymorphism, 
A934V. One patient had the missense metavinculin mutation, R975W. Although mildly 
hypertensive for 15 years, she was diagnosed with HCM at the age of 42 characterized 
by severe, obstructive mid-ventricular and apical hypertrophy. R975 is a highly conserved 
residue and W975 was absent in over 1400 reference alleles. Intriguingly, this identical 
missense mutation was demonstrated previously in familial DCM.
Conclusions: Vinculin mutations are a pathogenic substrate for both HCM and DCM, 
further highlighting the allelic nature of these disorders. Mutations in functionally distinct 
regions of certain cardiomyopathy genes may have a dominant effect in determining a 
remodeling pathway of either maladaptive hypertrophy or dilation. This study provides the 
ﬁrst “proof-of-principle” that the same fundamental mutation in humans can yield either 
cardiomyopathic phenotype, establishing that other genetic and/or environmental factors 
may have signiﬁcant disease-modifying effects.
2:15 p.m.
849-4 Chronic Exposure to Cocaine Binging Predisposes to 
an Accelerated Course of Dilated Cardiomyopathy in 
Conscious Dogs Undergoing Rapid Ventricular Pacing
Pratik Parikh, Lazaros A. Nikolaidis, Carol Stolarski, Richard P. Shannon, Allegheny 
General Hospital, Pittsburgh, PA
Background: Despite extensive study, the extent to which cocaine use predisposes to 
cardiac injury remains unknown. We hypothesized that chronic cocaine binging would 
increase susceptibility to a subsequent cardiac insult, even in the absence of demonstrable 
effects on baseline hemodynamics.
Methods: We studied progression of dilated cardiomyopathy (DCM) induced by rapid 
RV-pacing (240 bpm) in 5 conscious, chronically instrumented dogs, after exposure to 
repetitive cocaine binging (COC) in the form of 4 consecutive 1 mg/kg iv boluses daily 
for 8 days, to simulate human cocaine abuse. We compared the results to 9 control dogs 
(CON) undergoing the exact pacing protocol, without prior cocaine exposure.
Results: Baseline hemodynamics were not signiﬁcantly altered by cocaine exposure. 
Following 2 weeks of pacing, COC dogs exhibited accelerated progression to DCM 
(TABLE), depressed plasma NO levels (CON: 17± 2, COC: 10± 2 µM, p< 0.05) and a trend 
for greater increases in plasma epinephrine (CON: 33±6, COC: 104±24 pg/ml). After 2 
weeks of pacing, COC dogs demonstrated progressive DCM of a magnitude comparable 
to end stage pacing induced DCM.
Conclusions: Chronic cocaine binging increases vulnerability to a subsequent myocardial 
insult and accelerates progression of DCM in conscious dogs following rapid pacing. 
These data suggest that while chronic cocaine use alone may not affect myocardial 
function, it predisposes to greater susceptibility to a superimposed insult. 
CONTROLS (n=9) COCAINE (n=5)
BASELINE 2 weeks RVP BASELINE 2 weeks RVP
LVP (mmHg) 117±4 110±5 131±6 100±3**
LVEDP (mmHg) 14±1 26±2 13±2 37±3**
LV dP/dt
(mmHg/s) 2583±123 1544±74 2922±73 1147±98**
MAP (mmHg) 89±4 89±5 98±5 80±3*
HR (bpm) 85±4 99±6 91±6 131±6*
CO (l/min) 2.2±0.3 1.9±0.2 2.6±0.3 2.2±0.3
SV (ml) 27±4 20±3 29±3 17±2*
WTH (mm) 2.6±0.3 1.8±0.2 2.7±0.3 1.1±0.4**
CBF (ml) 26±2 28±2 29±3 30±3
*p<0.05, **p<0.01 change from baseline when compared to controls
2:30 p.m.
849-5 Assessment of Coronary Microvascular Function 
in Patients With Tako-Tsubo-Like Left Ventricular 
Dysfunction (Transient Left Ventricular Apical 
Ballooning syndrome)
Teruyoshi Kume, Takashi Akasaka, Takahiro Kawamoto, Nozomi Watanabe, Eiji Toyoda, 
Yoji Neishi, Nozomi Wada, Kiyoshi Yoshida, Kawasaki Medical School, Kurashiki, Japan
Background: Tako-tsubo-like left ventricular (LV) dysfunction is characterized by acute 
onset and reversible LV wall motion abnormalities without signiﬁcant stenosis on coronary 
angiography. The precise mechanism of this syndrome is still unclear, but coronary 
microvascular dysfunction has been reported to be one of the possible mechanisms of 
this syndrome. The purpose of this study was to evaluate coronary microvascular function 
by measuring coronary ﬂow velocity (CFV) pattern and CFV reserve (CFVR), using 
Doppler guidewire, in patients with tako-tsubo-like LV dysfunction.
Methods: We examined 11 consecutive patients (10 women and 1 man; mean age, 71 ± 
11 years old) who were diagnosed to be tako-tsubo-like LV dysfunction according to the 
following criteria: 1) LV wall motion abnormality at the apex on left ventriculography; 2) ST-
segment elevation or T-wave abnormality at least 2 leads on the ECG; 3) no prior history 
of myocardial infarction; 4) normal coronary angiogram. Immediately after admission and 
3 weeks later, left ventriculography and coronary angiography were performed. After LV 
apical wall motion abnormality and normal coronary angiogram were conﬁrmed, CFV was 
recorded at the middle portion of the coronary artery with a 0.014-inch Doppler guidewire 
at rest and during hyperemia induced by an intravenous injection of 0.15mg/kg/min 
adenosine 5’-triphosphate.
Result: LV ejection fraction improved dramatically during follow-up period (47±9 versus 
65±11 %, p<0.001) mainly due to reduction of LV end-systolic volume (36±9 versus 23±11 
ml, p<0.05). Deceleration time of diastolic CFV (DDT) and CFVR increased in all cases 
during follow-up period (457±178 versus 882±211 msec, p<0.0001 and 1.7±0.5 versus 
2.6±0.6, p<0.0001, respectively). DDT in the acute phase was correlated with the LV 
ejection fraction and LV end-systolic volume index at 3 weeks later (r=0.82, p=0.01 and 
r=0.85, p<0.01, respectively).
Conclusion: Transient coronary microvascular dysfunction demonstrated by rapid DDT 
and restricted CFVR might be considered to be a main mechanism of tako-tsubo-like LV 
dysfunction. DDT in the acute phase can predict the recovery of LV function.
2:45 p.m.
849-6 Statin Therapy Improves Indices of Left Ventricular 
Function and Serum Markers of Inﬂammation in 
Normolipidemic Patients with Chronic Heart Failure
Muhammad Mir, Srikanth Sola, Stamatios Lerakis, Amar Patel, Tarek Helmy, Bobby V. 
Khan, Emory University School of Medicine, Atlanta, GA
Background: In addition to cholesterol lowering, statins have signiﬁcant effects on cellular 
and molecular mechanisms in vascular and myocardial tissue. We hypothesized that the 
use of statins in patients with heart failure (HF) and normal serum lipids would improve 
left ventricular function and serum markers of inﬂammation.
Methods: We followed 446 patients with NYHA class II-III HF, left ventricular ejection 
fraction (EF) ≤ 35%, and an LDL cholesterol ≤ 100mg/dL in a prospective, non-randomized 
fashion for 24 ± 3 months. Patients were classiﬁed according to treatment with a statin, 
which was prescribed at the discretion of their treating physician. Left ventricular EF, 
left ventricle end diastolic diameter (LVEDD) and end systolic diameter (LVESD) were 
determined by echocardiography. Serum markers of inﬂammation were also determined.
Results: Statin therapy was associated with an increase in EF from 0.33 ± 0.05 to 0.37 
± 0.05 (p=0.01), whereas those patients not treated with a statin experienced a decrease 
in EF from 0.34 to 0.31 (p=0.04). In addition, LVEDD was reduced from 57.1 ± 5.9 to 53.4 
± 5.1 mm (p=0.007) and LVESD was reduced from 42.4 ± 3.8 to 39.1 ± 3.8 mm (p=0.02) 
in the cohort of patients treated with statins. There was no change in these dimensions in 
the non-statin cohort. Statin therapy was also associated with a decrease in serum levels 
of interleukin-6 (13.3±0.8 vs. 17.3±1.4 ng/dL, p=0.001) and tumor necrosis factor-alpha 
receptor II (24.3±1.0 vs. 34.5±3.0 ng/dL, p=0.001) compared with the non-statin cohort.
Conclusions: The use of statin therapy in normolipidemic patients with HF due to left 
ventricular systolic dysfunction in this non-randomized trial was associated with a signiﬁcant 
reduction in left ventricular EF and an improvement in left ventricular dimensions. The 
improvement in levels of several serum inﬂammatory markers with statin therapy suggests 
in part mechanisms by which these agents may exert their beneﬁcial effects.
3:00 p.m.
849-7 Acute Hypertension Results in an Exaggerated 
Elevation of Left Ventricular Diastolic Pressures in a 
Canine Model of Diastolic Heart Failure
Steven J. Lavine, University of Florida, Jacksonville, FL
Background: Decompensation of diastolic heart failure (DHF) is often accompanied by 
hypertensive episodes. We hypothesized that markedly elevated LV systolic pressures 
result in both elevated early and late diastolic LV pressures due to further impairment of 
LV relaxation from pressure loading.
Methods: To test this hypothesis, we created a model of chronic DHF with preserved 
ejection fraction (EF) (>50%) in 8 dogs with increased LV mass and interstitial ﬁbrosis 
using coronary microsphere embolization. Prior to embolization and with chronic DHF, 
each dog was paced 10 beats above baseline and high ﬁdelity LV pressures, echo LV 
volumes, and transmitral Doppler were obtained. The dogs were then pressure loaded 
>40 mm Hg with methoxamine, and the above parameters were obtained.
Results: At baseline, LV pressures (mm Hg) at peak - dP/dT (+17), LV pressure minimum 
(+3.6), and at the end of the rapid ﬁlling period (+5) increased (all p<0.05). The timing 
of these events from the R wave were unchanged. LV end diastolic pressure (LVEDP) 
increased (5+3 vs 13+4 mmHg (P=0.006). Tau increased from 26+3 msec to 32+4 msec 
(P<0.05). EF was unchanged though LV size increased 21% (p=0.003). Pressure loading 
with DHF resulted in greater increases in LV pressures (mm Hg) at peak -dp/dT (+44), LV 
pressure at mitral opening (+17), LV minimal pressure (+8), and at the end of rapid ﬁlling 
(+10) as compared to baseline pressure loading (all p< 0.05). The timing of each of these 
pressure events were delayed from 32-78 msec (all p<0.0001). LVEDP increased from 
9+2 to 23+5 mmHg (p<0.0001). The diastolic ﬁlling period shortened (288+51 to 204+54 
msec, p=0.004), and Tau increased (38+5 msec to 74+6 msec (P<0.0001). EF declined 
from 54+9% to 43+9% ( p<0.05) and LV size increased 22% (p<0.05).
Conclusions: We conclude that pressure loading with normal LV function and with DHF result 
in increases in LV diastolic pressures that are further exaggerated with DHF. This exaggeration 
is associated with prolonged relaxation, delay in the onset and shortening of the diastolic 
ﬁlling period resulting in the LV ﬁlling volume entering a poorly relaxed left ventricle. Acute 
hypertension is an important pathophysiologic factor in decompensation in DHF.
2005_4_CardiacFuncHeartFail.indd   181 12/23/04   10:03:49 AM
182A ABSTRACTS - Cardiac Function and Heart Failure JACC February 1, 2005
C
ar
di
ac
 F
un
ct
io
n 
an
d 
H
ea
rt
 F
ai
lu
re
3:15 p.m.
849-8 Potentiation of Doxorubicin Cardiotoxicity by Iron 
Loading in a Rodent Model
Gurusher S. Panjrath, Virender Patel, Navneet Narula, Carolina I. Valdiviezo, Jagat 
Narula, Diwakar Jain, Drexel University College of Medicine, Philadelphia, PA, University 
of Pennsylvania, Philadelphia, PA
Background: Doxorubicin, a commonly used anticancer chemotherapeutic drug causes 
serious and potentially life threatening cardiotoxicity. Free radical injury mediated 
mechanism contribute towards DOX cardiotoxicity. While iron forms a complex with the 
drug resulting in generation of free radical injury, contribution of body iron stores to DOX 
cardiotoxicity is not clear. We hypothesized that higher body iron stores may potentiate 
DOX cardiotoxicity.
Methods: Male Sprague Dawley rats fed 1 % carbonyl iron containing rat chow for 10-
12 weeks (n=24) and control animals fed regular chow (n=22) were treated with DOX 
or saline in varying doses(6mg/kg i/v single dose or 2.5 mg/kg/ip biweekly x 4 weeks). 
Cardiotoxicity was evaluated using mortality, weight changes, Tc-99m-Annexin V imaging 
and histopathology and immunohistochemistry.
Results: Animals fed iron-rich chow showed signiﬁcantly higher DOX cardiotoxicity at 
a lower cumulative dose as evident from greater weight loss (66 ± 29 gm loss versus 
29 ± 36 gm gain, P<0.05), higher mortality ( 5 out of 11 versus 1 out of 8) and higher 
myocardial Annexin uptake (0.13 ± .01 vs 0.09 ± .00 injected dose per gram, P < 0.05). 
Electron microscopy showed most severe myocyte injury in the iron-rich chow fed 
animals with more frequent areas of myocyte loss and sarcoplasmic swelling compared 
to regular chow fed animals. Caspase-3 (cleaved) staining was markedly increased in 
iron-rich chow animals on DOX treatment. Feeding iron-rich chow alone did not result in 
any cardiotoxicity.
Conclusion: Dietary iron loading resulted in a substantial increase in DOX cardiotoxicity 
in rats. Body iron stores as well as bioavailability in tissue may be important predictors of 
susceptibility to DOX cardiotoxicity. Clinical studies are warranted to study the relationship 
between body iron stores and susceptibility to DOX cardiotoxicity in man.
ORAL CONTRIBUTIONS
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851-3 Statins Shorten QTc Interval Without Affecting Plasma 
BNP Levels in Patients With Advanced Heart Failure
Bojan Vrtovec, Renata Okrajsek, Alenka Golicnik, Mateja Ferjan, Paula V. Juarez, 
Branislav Radovancevic, Ljubljana University Medical Center, Ljubljana, Slovenia, Texas 
Heart Institute, Houston, TX
Background. QTc interval duration and plasma BNP levels predict outcomes of patients 
with advanced heart failure (HF). Since statin therapy appears to be related to improved 
survival of such patients, we analyzed the effect of statins on QTc interval duration and 
plasma BNP levels in these patients.
Methods. A prospective randomized trial included 80 patients with advanced HF (NYHA 
3 or 4), low LVEF (<30%), elevated plasma cholesterol (>5 mmol/l), and no evidence of 
arrythmias and pacemaker rhythms on a standard ECG. Forty patients underwent statin 
therapy (atorvastatin 10 mg/day) (statin group); the remaining 40 patients served as 
controls. We measured QTc interval and plasma BNP levels at baseline and at 3 months. 
QT interval duration was determined by averaging 3 consecutive beats through leads II 
and V4 on a standard ECG, then correcting the resulting value using the Bazett formula.
Results. Overall 3-month mortality was 5% (3% in the statin group vs. 8% in the control 
group, P=0.30). The two groups did not differ signiﬁcantly in age (66±16 years in the statin 
group vs. 68±8 years in the control group, P=0.52), male gender (56% vs. 51%, P=0.66), 
ischemic etiology (56% vs. 68%, P=0.32), or LVEF (24.0±4.9% vs. 24.2±3.9%, P=0.88). At 
baseline, QTc interval duration was similar in both groups (450±30 msec in the statin group 
vs. 446 ± 27 msec in controls, P=0.59). After 3 months, QTc interval had decreased in the 
statin group (436±29 msec, P=0.0003), but not in controls (450±25 msec). QTc interval 
shortening with statin therapy was more pronounced in patients with a baseline QTc interval 
>440 msec (from 470±21 msec at baseline to 450±26 msec at 3 months, P=0.0001), and 
in patients with non-ischemic HF (from 452±32 msec at baseline to 435±28 at 3 months, 
P=0.004). Plasma BNP levels at baseline were comparable in both groups (713±303 pg/ml 
in statin group vs. 791±271 pg/ml in controls, P=0.25) and remained relatively unchanged 
after 3 months (695±340 pg/ml vs. 809±331 pg/ml, P=0.13).
Conclusions. Statins shorten QTc interval, but do not change plasma BNP levels in 
advanced HF. Statin therapy may be of particular beneﬁt to patients with non-ischemic HF 
and a prolonged QTc interval, thereby the HF morbidity can be improved.
 
2:15 p.m.
851-4 Statins And Mortality In Congestive Heart Failure: 
Beneﬁt Beyond Cholesterol Reduction?
Daniel Nul, Alberto Fernandez, Carola Zambrano, Daniel Ferrante, Saul Soifer, Sergio 
Varini, Hugo Grancelli, Hernan Doval, GESICA Foundation, Buenos Aires, Argentina
Background: Statins have shown to be effective in reducing events in coronary heart 
disease, but their effect in the prognosis of heart failure (HF) is unknown.
Methods: A cohort of 2331 ambulatory patients was analyzed. Statin therapy status was 
established at baseline. Clinical characteristics between treated and no treated patients 
were compared. The incidence of events (mortality and HF admission) was compared 
between groups using log-rank test and the effect estimates were adjusted for potential 
confounders by the use of Cox regression
Results: Mean follow up was 957 days. Statin use at baseline was 8.7%. The group treated 
with statins showed higher prevalence of male sex (78.4% vs. 70.9%, p=0.02), ischaemic 
miocardiopathy (72.2% vs. 37.6% p<0.0001), dislypemia (85.1% vs. 9.4% p<0.001), 
systolic dysfunction (87.5% vs. 81.6% p=0.03),and lower prevalence of COPD (5.2% vs. 
9.8% p=0.03), admissions for HF in previous year (33% vs. 41.5% p=0.02), NYHA FC 
III-IV (38.7% vs. 53.4% p<0.0001), respectively.
Mortality was lower in statin group: 16.1% vs. 26.8%, RR 0.55, 95%CI 0.38-0.77, p=0.001. 
Adjusting for age, sex, ischaemic myocardiopathy, LVEF, COPD, NYHA FC, previous 
admissions and body mass index the adjusted HR obtained was 0.62, 95%CI 0.43-0.89, 
p=0.009.
The beneﬁt was observed both in patients with ischaemic myocardiopathy (HR 0.61, 
95%CI 0.45-0.82, p=0.001) and in patients without ischaemic myocardiopathy (HR 0.65 
95%CI 0.41-1.0, p=0.05, p for interaction=0.85). There were no differences regarding 
mechanisms of death between groups. Patients treated with statins showed a lower risk 
of being admitted because of HF, not reaching statistical signiﬁcance: 22.4% vs. 25.7% 
(HR = 0.78, 95%CI 0.57-1.05, p=0.07).
Conclusions: Although the available evidence of effectiveness of statins in heart failure 
arises from observational studies, statins could be beneﬁcial in HF through diverse 
mechanisms. Our results and those from other observational studies generate the 
hypothesis that statins could reduce morbimortality in heart failure that would need to be 
answered through well designed randomized controlled clinical trials.
2:30 p.m.
851-5 A Cholesterol Paradox in Congestive Heart Failure 
Survival?
Heidi Thomas, Joseph B. Muhlestein, John F. Carlquist, Benjamin D. Horne, Tami L. Bair, 
Beverly A. Campbell, Dale G. Renlund, LDS Hospital, Salt Lake City, UT, University of 
Utah, Salt Lake City, UT
Background: Hypercholesterolemia is a risk factor for the development of coronary artery 
disease (CAD). While increased levels of cholesterol predict mortality in patients with 
CAD, whether hypercholesterolemia adversely affects survival in patients with congestive 
heart failure (CHF) has not been completely elucidated. We assessed the inﬂuence of lipid 
levels on mortality in patients with CHF.
Methods: The study cohort derived from the Intermountain Heart Collaborative Study 
Registry (1993-2003) who had angiographic assessment of CAD, an ejection fraction 
<40% or a clinical diagnosis of CHF, and long-term follow up for death were studied 
(N=1585). Multivariable Cox regression models were used to evaluate the association of 
cholesterol to mortality. Total cholesterol (TChol) and other lipid parameters (LDL, HDL, 
and triglycerides) were divided into quartiles and sub-analyses performed based on statin 
use/non-use.
Results: Mean age was 65.5 (±13 years); 65% were male; 65% CAD. While 53% were 
using statins, statin use was not different across quartiles of TChol. Average time to 
death was 2.4 (±1.9) years (maximum 10 years). The model chi-square after adjustment 
for covariables was 171.5, p<0.001. TChol was divided into the following quartiles: Q1 
<141.3 mg/dL, Q2 141.3-167.9 mg/dL, Q3 168.0-200.9 mg/dL, and Q4 >201.0 mg/dL. 
Mortaliy for Q4 vs. Q1 was not different (HR=1.12, p=0.52), was reduced for Q3 vs. Q1 
(HR=0.66, p=0.027) and tended to be reduced for Q2 vs. Q1 (HR=0.77, p=0.14). LDL 
and triglycerides were not predictive of mortality, but HDL was (as expected) protective 
at higher levels. Sub-analysis of patients not using statins (N=737, D=20.2%) found no 
association between TChol and survival (for Q3 vs. Q1, HR=0.97, p=0.89), but for patients 
using statins (N=848, D=16.3%) the effect was even greater for Q3 vs. Q1 (HR=0.40, 
p=0.002) than in the overall population.
Conclusion: In CHF, elevated TChol appears to be associated with improved survival. 
The effect was stronger in patients on statin therapy, but the cause of this differential effect 
is uncertain and requires further investigation.
2:45 p.m.
851-6 Effects of Atorvastatin on Vascular Endothelium and 
Proinﬂammatory Cytokines and Adhesion Molecules in 
Patients With Heart Failure
Dimitris Tousoulis, Charalambos Antoniades, Erini Bosinakou, Maria Kotsopoulou, 
Costas Tentolouris, Kyriakoula Marinou, Marieta Harakida, Christos Pitsavos, 
Christodoulos Stefanadis, Athens University Medical School, Athens, Greece
Background: Heart failure is characterized by endothelial dysfunction, while inﬂammatory 
molecules such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-a), monocyte 
chemoattractant protein-1 (MCP-1) and soluble vascular cell adhesion molecule (sVCAM-
1) are implicated in the pathogenesis of heart failure. We evaluated the effect of atorvastatin 
on endothelial function and inﬂammatory process in patients with heart failure.
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Methods: Thirty-seven patients with heart failure (aged 69+/-2.3 yrs, NYHA II-IV with 
ejection fraction<35%) were enrolled. Nineteen pts received atorvastatin 10mg/day 
while 18 (controls) received no statin for 4 weeks. Forearm blood ﬂow was measured by 
strain-gauge plethysmography. Endothelium dependent dilation (EDD) and endothelium 
independent dilation (EID) were expressed as the % change of ﬂow from baseline to the 
maximum ﬂow during reactive hyperemia or after sublingual nitroglycerin administration 
respectively. Serum sVCAM-1, IL-6, MCP-1 and TNF-a were determined by ELISA.
Results: Basal forearm blood ﬂow remained unchanged in both groups after treatment. 
EDD was signiﬁcantly increased in atorvastatin group (from 44.2±4.5 to 89.5±12.0% 
p<0.01) but not in controls (from 47.2±4.7 to 43.1±5.4%, p=NS). Levels of sVCAM-1, IL-6 
and TNF-a were signiﬁcantly decreased in atorvastatin group (from 650.7±61.7, 7.69±0.69 
and 3.8±0.35 to 471.6±44.5 ng/ml, 6.02±0.81 pg/ml and 2.8±0.22 pg/ml respectively, 
p<0.05 for all) but not in controls (from 656.2±70.0, 7.30±0.72 and 4.5±0.62 to 643.9±71.1 
ng/ml, 6.31±0.81 pg/ml and 4.53±0.61 pg/ml respectively, p=NS for all). EID and levels of 
MCP-1 remained unchanged in both atorvastatin-treated (from 66±8 and 305.9±29.7 to 
65±6% and 291.4±26.1 ng/ml respectively, p=NS for both) and control group (from 66±8 
and 311.0±26.0 to 60±7% and 321.5±19.6 ng/ml respectively, p=NS for both).
Conclusions: Atorvastatin improves endothelial function and decreases the expression 
of IL-6, TNF-a and sVCAM-1 in patients with heart failure. These ﬁndings indicate that 
statins may have further antiinﬂammatory effects in patients with heart failure, beyond 
their lipid-lowering effects.
3:00 p.m.
851-7 Statins Improve Survival in Patients with Congestive 
Heart Failure: A study on 32,000 U.S Veterans
Sathya Jaganmohan, Vikas Khurana, LSU Health Sciences Center, Shreveport, LA, 
Overton Brooks VA medical Center, Shreveport, LA
BACKGROUND: Though HMG CoA reductase inhibitors (Statins) have been proven to 
be beneﬁcial in reducing coronary events, their effect on patients with congestive heart 
failure is inconclusive.
METHODS: Using patient data from the VA’s VISN 16 database from 4 states(LA, MS, 
TX, AK), we performed a retrospective case-control study on 32,463 people with a 
diagnosis of congestive heart failure. The use of statins was correlated with the primary 
outcome of all cause mortality.
RESULTS: The mean age of the cohort was 62.72(+/- 0.04). 19,838(61.1%) patients 
were on statin therapy and 10,137(31.2 %) patients had a diagnosis of ischemic heart 
disease (IHD). A total of 9,028 deaths were recorded in the cohort, of which 4,186(46%) 
patients were on statins. Cox proportional hazards model was used to adjust for covariates 
including age, sex, smoking, IHD, diabetes, beta blocker use, ACE Inhibitor use and 
aspirin use. The unadjusted hazards ratio (HR) for statin use was 0.85 (95% C.I 0.83- 
0.86)and the adjusted HR for statin use was 0.90 (95% C.I 0.88- 0.92).The mean length 
of survival of the statin group was 22.8 months (+/- 0.2) and 17.2 (+/- 0.2) for the controls. 
Twenty month survival in the control group vs statin group was 44% vs 58% respectively 
(See Fig). The data however needs to be interpreted with caution due to the limitations of 
the population and the database.
CONCLUSIONS: Statin therapy improves survival in patients with congestive heart 
failure after adjusting for various covariates in the veteran population. 
3:15 p.m.
851-8 Statin Use Is Associated with a Marked Improvement in 
Survival in an Advanced Heart Failure Population from 
the COMPANION Trial
Andrew D. Sumner, John Boehmer, Leslie A. Saxon, Arthur M. Feldman, Michael R. 
Bristow, Penn State College of Medicine, Hershey, PA
Background: Statin use reduces mortality in patients with ischemic heart disease. The 
beneﬁcial effect of statins in advanced heart failure (HF) patients of various etiologies 
receiving cardiac resynchronization therapy (CRT) is unknown. The objective of this study 
was to assess the effect of statin use on survival in patients with advanced HF of various 
etiologies receiving CRT.
Methods: A retrospective analysis of the effect of statin use on survival was performed 
with the COMPANION Trial database using a COX proportional hazard model. Variables 
included in the model were statin use, CRT, CRT-D (CRT-deﬁbrillator) , NYHA Class, QRS 
duration, LVEF, HR, conduction disorder, blood pressure, gender, age, history of diabetes, 
duration of HF, and HF medications. Patients were considered to be on statin therapy if the 
medicine was taken at the time of enrollment.
Results: 1520 patients were included and were characterized as male (68%), age 66 ± 11 
years, LVEF 22 ± 7, QRS duration 158 ± 24 msec, ischemic (55%), and NYHA III/IV (86%, 
14%). 603 patients (40%) were taking statins and 917 patients (60%) were not. All-cause 
mortality was 18% in the statin group and 22% in the no statin group (HR 0.85, p=0.15). 
In a multivariable analysis controlling for baseline characteristics and use of CRT/CRT-D 
devices, statin use was associated with a 28% relative risk reduction in mortality (HR 
0.72, CI 0.56-0.92, p=0.008). There was no interaction for mortality demonstrable between 
statin use and either etiology of heart failure or CRT/CRT-D therapy.
Conclusions: Statin use is associated with a marked improvement in survival in patients 
with advanced heart failure. The mortality beneﬁt persists after adjusting for use of CRT/
CRT-D and etiology of heart failure.
ORAL CONTRIBUTIONS
860  Molecular Studies of Myocardial 
Function
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 230B
4:00 p.m.
860-3 Erythropoietin Increases Capillary Density and 
Improves Cardiac Function in Rats with Heart Failure 
After Myocardial Infarction
Peter Van der Meer, Erik Lipsic, Rob H. Henning, Kristien Boddeus, Adriaan A. Voors, 
Dirk J. Van Veldhuisen, Wiek H. Van Gilst, Regien G. Schoemaker, University Hospital 
Groningen, Groningen, The Netherlands
Introduction: Erythropoietin (EPO), traditionally known as a hematopoietic growth factor, 
has been linked to angiogenesis in vitro and in vivo. After myocardial infarction (MI), acute 
administration of EPO, has been shown to reduce infarct size and to improve cardiac 
function. However, its role in the failing heart is unknown. Therefore, we assessed the 
effects of EPO treatment in a rat model of post-MI heart failure.
Methods and Results: Male Sprague Dawley rats underwent coronary ligation (n=50) or 
sham surgery (SH) (n=8). Rats with MI were randomly assigned to one of four treatments: 
untreated (MI), a single bolus of EPO immediately after MI induction (MI-EPO-early), 
EPO treatment immediately after MI and once every three weeks (MI-EPO-early+late) 
and EPO treatment starting three weeks after induction of MI, once every three weeks 
(MI-EPO-late). After nine weeks, hemodynamic parameters, infarct size and capillary 
density were measured. Treatment with EPO immediately after myocardial infarction (MI-
EPO-early and MI-EPO-early+late) resulted in a 23-30% reduction in infarct size and 
improved hemodynamic parameters, compared to MI (p<0.01). EPO treatment, started 
three weeks after MI (MI-EPO-late), did not affect infarct size, but resulted in an improved 
cardiac contractility (systolic dp/dt) and relaxation (diastolic dp/dt) (p<0.05). Furthermore, 
we observed a 34% reduction in left ventricular end-diastolic pressure (p<0.01), and 46% 
decrease in ANP levels (p<0.05) in MI-EPO-late compared to MI. The improved cardiac 
function, was accompanied by an increased capillary density (p<0.01 vs. MI) and an 
increased capillary to myocyte ratio (p<0.05 vs. MI) in all treated groups, indicating newly 
formed capillaries.
Conclusion: EPO treatment improves cardiac function in a rat model of post-MI heart 
failure. This observation could be explained by the increased capillary density and 
capillary to myocyte ratio, indicating actual capillary growth.
4:15 p.m.
860-4 Cardiac Myocyte Apoptosis is Associated with Left 
Ventricular Hypertrophy in Murine Models of Obesity
Lili A. Barouch, Daquing Gao, Lei Chen, Shakil A. Khan, Shubha V. Y. Raju, Koenraad 
Vandegaer, Christopher P. O’Donnell, Dan E. Berkowitz, Chiming Wei, Joshua M. 
Hare, The Johns Hopkins University School of Medicine, Baltimore, MD, University of 
Pittsburgh School of Medicine, Pittsburgh, PA
Background: Cardiac myocyte apoptosis increases in heart failure and normal aging. 
Disruption of leptin signaling is associated with obesity, heart failure and cardiac 
hypertrophy, but the role of leptin in cardiac myocyte apoptosis is unknown. We tested the 
hypothesis that apoptosis increases in leptin-deﬁcient ob/ob and leptin-resistant db/db 
mice, and is associated with aging and LV hypertrophy. 
Methods and Results: We performed echocardiography on young (2-3 month) and old 
(13-15 month) ob/ob, db/db, and WT mice (n=2-4). Septal wall thickness was similar 
among young mice of all strains, but increased in old ob/ob (1.12±0.01mm) and db/db 
(1.09±0.04mm) vs. old WT (0.76±0.03mm, P<0.0001 for both). Fractional shortening and 
chamber dimensions were similar among all groups. An additional group of 6-month-old 
ob/ob mice received leptin (0.3mg/kg/day SC) for 4 weeks. Heart weights were higher in 
old ob/ob (177±11mg) and db/db (231±57mg) hearts vs. old WT (99±7mg, P<0.0005 for 
both). We assessed apoptosis by TUNEL staining (% positive nuclei per 10 high-powered 
ﬁelds) and apoptosis inducing factor (AIF; 0-4 scale: 0=no staining, 4=50-80% positive). 
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TUNEL staining showed low levels of apoptosis in young WT (0.5±0.1%), which increased 
with age (3±1%, P<0.05). Young ob/ob (13±2%) and db/db (11±2%, P<0.05 vs. WT for 
both) showed markedly elevated apoptosis that rose even further with age (old ob/ob 
26±3%, old db/db 18±3%, P<0.05 for both). AIF scores correlated closely with TUNEL 
staining in all groups. Leptin treatment signiﬁcantly reduced the rate of apoptosis in ob/ob 
mice by both TUNEL staining (5±2%, P<0.05 vs. young ob/ob) and AIF score. 
Conclusion: Normal receptor-mediated leptin signaling activates an anti-apoptotic 
pathway in the heart. These data offer novel insights into potential mechanisms of 
myocardial dysfunction in obesity.
4:30 p.m.
860-5 Calpain Inhibition Prevents Acute Myocardial 
Dysfunction and Apoptosis Associated With 
Reperfusion Injury
Jeffrey M. Pearl, Jefferson M. Lyons, Connie J. Wagner, Jodie Y. Duffy, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH, University of Cincinnati College of 
Medicine, Cincinnati, OH
Background: Myocardial ischemia-reperfusion stimulates cysteine proteases called 
calpains. Calpain activation is associated with interruption of calcium-regulated contraction 
by degrading contractile proteins and initiating cell death. Immature myocardium 
has elevated levels of calpain suggesting an enhanced role in neonatal tissues. We 
hypothesized that calpain inhibition could reduce myocardial injury from reperfusion of 
ischemic neonatal piglets.
Methods: Neonatal piglets (n=8, controls) were cooled to 18oC on cardiopulmonary 
bypass, underwent 2 hr of deep hypothermic circulatory arrest, then were re-warmed and 
recovered for 2 hr. Another 6 animals received 1 mg/kg of the peptide calpain inhibitor 
(Z-Leu-Leu-Tyr-FMK) 1 hr before circulatory arrest. Hemodynamics were continuously 
monitored and myocardial tissue collected at 2 hr of recovery for analyses of NF-�B 
activation and pro-apoptotic pathways.
Results: Oxygen delivery was signiﬁcantly depressed in controls at the end of recovery 
(260 ± 5 ml/min), but was maintained in calpain inhibitor-treated animals (955 ± 17 ml/
min, p<.05). Myocardial calpain activity was decreased in treated animals compared with 
controls (102 ± 22 vs 185 ± 27 ﬂuorescent units, p<.05) Calpain inhibitor-treated animals 
had higher cytosolic IκBα protein levels compare with controls (0.61 ± 0.2 vs 0.18 ± 0.16 
IκBα/GAPDH protein ratio, p<.01), and decreased NF-κB DNA binding activity (80 ± 22 vs 
137 ± 27 densitometry units, p <.05) at end-recovery. Treated animals also demonstrated 
reduced cleavage of Bid, an early initiator of the apoptosis cascade, 37 ± 10 vs 59 ± 
3.5 % (expressed as percent 15 kDa of total Bid protein, p<.05). Caspase-3 activity was 
reduced after calpain inhibitor (0.47 ± 0.33 vs 0.8 ± 0.48 pmol/min/µg protein DEVDase 
activity, p<.05).
Conclusions: Calpain inhibition decreased cardiac dysfunction associated with reperfusion 
and prevented activation of NF-�B pathways. Decreased Bid cleavage and caspase-3 activity 
were evident with calpain inhibition, which along with decreased NF-κB activity, indicated 
less cell death and possible prevention of permanent cardiac myocyte loss.
4:45 p.m.
860-6 Correlation Between Cell-to-cell Uncoupling And 
Remodeling In An Ovine Model Of Ischemic Heart 
Failure
Carlos L. del Rio, Patrick I. McConnell, Roger Dzwonczyk, Pawel Kwiatkowski, Bradley 
D. Clymer, Michael B. Howie, Robert E. Michler, The Ohio State University, Columbus, OH
Introduction: Heart Failure (HF) is associated with sudden death due to VF. Electric 
uncoupling is suggested as a mechanism for these arrhythmias. However, despite the altered 
expression of Connexin43 in HF, studies linking remodeling and uncoupling are lacking.
Myocardial electrical impedance (MEI) detects uncoupling, as induced by ischemia. 
Hence, we studied the relationship between uncoupling and remodeling during HF.
Methods: Adult sheep were instrumented with sonomicrometry crystals and bipolar 
pacing electrodes for left ventricular (LV) geometry and MEI measurements. The pacing 
wires were stitched in the LAD and LCX distributions. Ischemic HF (EF<35% and 
ESV>80ml) was created by serial LCX microembolizations.
We report on the LV volume (end-systolic, ESV, and end-diastolic, EDV), pressure (end-
diastolic, EDP) and MEI of 5 sheep at baseline, and weeks 1, 3, and 5 after HF.
Results: Data are presented in Table (mean±SEM).
Myocardial LV dilatation was accompanied by uncoupling, as indicated by MEI. A 
linear relationship (P<0.001) was observed between LV volume and the MEI of 
remote myocardium (REDV=0.798 and RESV=0.753, respectively) (ﬁgure). However, no 
linear relationship was observed with the MEI of infracted myocardium (REDV=0.231, 
RESV=0.157).
Discussion: The MEI, a property sensitive to cell-to-cell uncoupling, has been shown 
to increase progressively in the failing heart. Thus, suggesting uncoupling as a potential 
mechanism linking remodeling and the arrhythmic substrate in HF.
ORAL CONTRIBUTIONS
864  Heart Failure Treatment
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Hall F5
8:30 a.m.
864-3 Spironolactone, Diuretics or None in Ischemic Heart 
Failure: Use and Outcomes from the Duke Databank
Adrian F. Hernandez, Olcay Aksoy, Robert H. Tuttle, Linda Shaw, Christopher M. 
O’Connor, Duke Clinical Research Institute, Durham, NC
Background: Spironolactone use is controversial outside patients studied in clinical 
trials and some have argued other diuretics may be harmful. Therefore, we evaluated the 
use of spironolactone and diuretics in patients with ischemic heart failure (HF).
Methods: HF patients with CAD on catheterization between 1998 and 2002 were 
identiﬁed from the Duke Databank. We divided the cohort into 3 groups based on diuretic 
use: a) spironolactone b) other diuretics c) no diuretics. Using a Cox proportional hazards 
model (covariates: age, HF class, ejection fraction, Charlson index, mitral insufﬁciency), 
we examined long-term survival in each group.
Results: Of 2136 HF patients who consistently reported medication use, 20.3% were on 
spironolactone, 57.8% were on other diuretics and 21.9% were on none. The median EF 
was 32% in spironolactone users, 48% in other diuretic users and 51% in those on none 
(p <0.001). An EF > 40% was present in 36.2% of spironolactone users, 47.5% in other 
diuretic users and 51.1% in no diuretic users (p <0.001). With a median follow-up of 2.9 
yrs, spironolactone was associated with lower mortality (HR, 0.512; 95% CI, 0.408-0.642) 
compared to no diuretic use. Similarly, other diuretics had a lower mortality (HR, 0.521; 
95% CI, 0.435-0.624). Cox Model: Chi sq=254.5, p <0.0001. (Figure)
Conclusions: Spironolactone is used commonly in ischemic HF including patients with 
EF >40%. Spironolactone and other diuretics are associated with similar survival and 
better than none.
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8:45 a.m.
864-4 Acute Tumor Necrosis Factor Antagonism Improves 
Left Ventricular Function and Exercise Performance in 
Heart Failure: Assessment by Left Ventricular Pressure-
Volume Analysis
Hiroshi Hasegawa, Hideo Tachibana, Atsushi Morimoto, Heng-Jie Cheng, Akihiko Igawa, 
William C. Little, Che-Ping Cheng, Wake Forest University School of Medicine, Winston-
Salem, NC
Background. Abnormal cardiac response to β-adrenergic stimulation contributes to 
exercise (Ex) intolerance in heart failure (HF). Previous studies indicate that elevated 
levels of tumor necrosis factor-α (TNF-α) in HF patients diminish cardiac positive inotropic 
response to β-adrenergic stimulation. Thus, antagonizing TNF-α with Etanercept (ETA) 
may improve Ex performance in HF.
Methods. We compared left ventricular (LV) systolic and diastolic responses and plasma 
TNF-α levels at rest and during Ex before and after receiving ETA (0.3 mg/kg iv) at 1, 7, 
and 24 hours (H) in 9 dogs with pacing-induced HF.
Results. After HF, ETA caused a 40% reduction of plasma TNF-α (control: 24 pg/ml; ETA: 
1H, 15 pg/ml; 24H, 14 pg/ml), which was correlated with sustained augmentation of LV 
contraction and relaxation. Compared with control, 24 H after ETA, heart rate, LV end-
systolic P, and arterial elastance were unchanged. Stroke volume (V) (15.6 vs 13.9 ml) 
and LV contractility, measured as the slopes of LV P-V relations, signiﬁcantly increased 
(EES: 7.1 vs 4.3 mmHg/ml; Msw: 70.5 vs 62.4 mmHg). The time constant of LV relaxation 
(τ) decreased (31.7 vs 38.5 ms). LV mechanical efﬁciency, determined as the ratio of 
stroke work to total P-V area, improved (0.59 vs 0.43) (p<0.05). These beneﬁcial actions 
persisted during Ex. After HF, without ETA, Ex increased τ (48.2 vs 38.5 ms) and LVPmin. 
The peak mitral ﬂow (dV/dtmax, 231 vs 173 ml/s) increased due entirely to elevated mean 
LA P (30.7 vs 21.9 mmHg). In contrast, with ETA, Ex signiﬁcantly decreased τ (33.9 vs 
38.5 ms) and LVPmin (9.9 vs 15.8 mmHg) with a leftward and downward shift of LV P-V 
loop; thus, dV/dtmax was further augmented (278 ml/s) without change in mean LA P. Ex 
duration also increased (5.9 vs 4.6 min) after ETA.
Conclusion. After HF, a clinically relevant dose of ETA infusion causes sustained reduction 
of plasma TNF-α; increases LV relaxation, contractility, and mechanical efﬁciency; and 
improves Ex performance.
9:00 a.m.
864-5 Digoxin Therapy Increases Mortality Only in Female 
Heart Failure Patients With a Prolonged QTc Interval
Bojan Vrtovec, Reynolds M. Delgado, III, Igor D. Gregoric, Rajko Radovancevic, 
Branislav Radovancevic, Texas Heart Institute, Houston, TX
Background. Although digoxin appears to increase mortality in female heart failure (HF) 
patients, the underlying mechanisms remain undeﬁned. Since QTc interval prolongation 
is related both to female gender and increased mortality in HF, we evaluated the role of 
QTc interval prolongation in female HF patients who received digoxin therapy.
Methods. Of 145 female NYHA class III or IV HF patients who presented with BNP levels 
>400 pg/ml, 97 (67%) were treated with digoxin (DIG group), and 48 (33%) received 
no digoxin therapy (Controls). QT interval duration was determined by averaging 3 
consecutive beats through leads II and V4 on a standard 12-lead ECG and corrected 
using the Bazett formula. Patients were followed for 6 months. Cardiac causes of death 
included death due to pump failure and sudden cardiac death.
Results. At baseline, the two groups did not differ in age (67±13 years in DIG group 
vs. 68±14 years in Controls, P=0.88), HF etiology (ischemic: 43% in DIG group vs. 41% 
in Controls, P=0.85), plasma BNP levels (773±282 pg/ml in DIG group vs. 761±321 pg/
ml in Controls, P=0.41), and mean QTc interval duration (475±55 ms in DIG group vs. 
451±42 ms, P=0.44). In the DIG group, QTc interval was prolonged (>440 ms) in 55 (57%) 
patients and normal in 42 (43%). During follow-up, 24 (25%) of patients died. Cardiac 
mortality in DIG group was signiﬁcantly higher in patients with prolonged QTc (17/55; 
31%) than in patients with normal QTc (3/42; 7%) (P=0.004). In Controls, the mortality 
rates were comparable to mortality of digoxin-treated patients with normal QTc (4/48; 
8%) (P=0.83). Prolonged QTc interval was the only independent predictor of cardiac 
mortality (P=0.002), sudden cardiac death (P=0.004), and pump failure death (P=0.006) 
on multivariate analysis.
Conclusions. In women with advanced HF, digoxin treatment increases cardiac mortality 
only in patients who have a prolonged QTc interval. Since QTc interval prolongation is 
more frequent in women than in men, the previously described gender-based differences 
in the effect of digoxin for the treatment of HF may merely reﬂect the gender differences 
in the duration of QTc interval, which is a marker of HF mortality.
9:15 a.m.
864-6 Does Spironolactone Reduce Heart Failure Mortality in 
a Real-World Population?
Maral Ouzounian, Jafna L. Cox, David E. Johnstone, Jonathan G. Howlett, Dalhousie 
University, Halifax, NS, Canada
Background: Spironolactone use in heart failure (HF) has increased dramatically 
following the publication of the Randomized Spironolactone Evaluation Study (RALES) 
trial. Outcomes with respect to mortality and appropriateness of spironolactone use are 
limited. We wished to determine the effect of spironolactone use on long-term mortality in 
a population of patients discharged from hospital with HF.
Methods: All patients discharged alive from October 1997 to December 2001, with a primary 
diagnosis of HF were identiﬁed in the prospectively collected Improving Cardiovascular 
Outcomes in Nova Scotia (ICONS) Program, which included 100% of Nova Scotia Hospital 
admissions. Data was censored at 2-year follow up for total mortality. Those discharged 
with a prescription for spironolactone were compared to those who were not. Comparisons 
were made using ANOVA for continuous and �2 for categorical variables. Adjustment for 33 
baseline characteristics was made using a multivariate regression model.
Results: A total of 7816 patients were identiﬁed. Average age was 76 years, 52% were 
female and the median ejection fraction was 40%. Of these, 644 (8%) were discharged 
on spironolactone. Patients discharged on spironolactone were more likely to be younger, 
male, and diabetic. Furthermore, 6% had a creatinine >2.5 mg/dL, 9% had K+> 5.0, 
and 5% were given concomitant therapy with non-steroidal anti-inﬂammatory drugs 
(NSAIDs). After adjusting for clinical covariates, spironolactone use did not emerge as an 
independent predictor of long-term survival (Odds Ratio (OR) 0.97, p=0.80). When only 
patients enrolled in a HF clinic were included (n=981), spironolactone was associated with 
improved survival (OR 0.52, p=0.003).
Conclusion: In the HF population, spironolactone was not associated with improved 
survival, in contrast to those followed in HF clinics. These data suggest spironolactone 
should be prescribed to HF patients in a disease management setting.
9:30 a.m.
864-7 d-Ribose Supplementation Improves Peak Exercise 
Capacity and Ventilatory Efﬁciency in Heart Failure 
Patients
Orly Carter, Dean MacCarter, Steve Mannebach, Joseph Biskupiak, Greg Stoddard, 
Edward M. Gilbert, Mark A. Munger, University of Utah, Salt Lake City, UT
Background: Many clinicians and scientists concur that the failing heart is energy starved. 
d-Ribose (dR), a naturally occurring monosaccharide, has been shown to increase 
myocardial high-energy phosphate stores and improve post-ischemic myocardial function 
in humans. This study was designed to determine whether dR could improve maximal 
exercise capacity and ventilatory efﬁciency, a powerful independent predictor of heart 
failure (HF) survival, in subjects with NYHA II-III HF.
Methods: Fourteen subjects with HF of ischemic etiology (LVEF: 32.4±8.1) completed a 
single-center study, using a randomized, double-blind, placebo-controlled (PL), cross-over 
design. Each subject underwent maximal cycle ergometry with gas exchange monitoring, 
quality of life (QOL, DASI questionnaire), and BNP levels at baseline and the end of 
each 8-week cross-over phase with a 2-week washout phase. Ventilatory efﬁciency was 
assessed using the linear VE to VC02 slope. dR or PL was administered on a 5 gram TID 
schedule in addition to standard systolic HF drug regimens.
Results: dR signiﬁcantly maintained VO2max vs. PL, while improving the VE/VCO2 
relationship, up to the respiratory compensation point (RCP), and the RCP. (Table 1) 
There was no signiﬁcant difference in QOL scores or BNP levels.
Conclusions: dR maintains maximal exercise capacity while improving ventilation 
efﬁciency, a strong predictor of HF survival, in NYHA II-III HF. dR may offer adjunctive, 
metabolic therapy for HF.
VO2max (%change) [mean±SD] VE/VCO2@AT (%change) [mean±SD]
RCP (%change) 
[mean±SD]
d-Ribose -1.4±8.5 (p=0.02 vs. PL) 4.9±-6.4 (p=0.08 vs. PL) 5.8±9.8 (p=0.03 vs. PL)
Placebo -7.8±7.3 -6.9±9.1 -1.4±8.5
9:45 a.m.
864-8 Continuous Aortic Flow Augmentation Using Orqis® 
Cancion® Cardiac Recovery System in Patients 
with Severe Heart Failure: Determinants of the 
Hemodynamic Response
Michael R. Zile, Ron M. Oren, Michael Bohm, Jerzy Sadowski, Adrian B. Van Bakel, Barbara 
Czerska, William T. Abraham, Andrae Wasler, Sanjaya Khanal, Barry Cabuay, Krzysztof 
Bartus, Marvin A. Konstam, Medical University of South Carolina, Charleston, SC
Background: Continuous aortic ﬂow augmentation using the Cancion® Cardiac Recovery 
System (CRS) has been shown to improve both cardiac index (CI) and pulmonary 
capillary wedge pressure (PCWP) in patients with decompensated chronic heart failure 
(CHF). We hypothesized that the magnitude of this hemodynamic response is determined 
by pretreatment cardiac index and creatinine.
Methods: Entry criteria included: 1) recently exacerbated CHF; 2) sustained (>24hr) 
elevated PCWP despite IV inotropes; 3) reduced creatinine clearance and/or diuretic 
resistance. CRS was placed in 23 patients for an average of 73 (24-112) hrs. Pump ﬂows 
averaged 1.33 (1.2-1.5) l/min.
Results: PCWP decreased from 28 ± 5 to 20 ± 7 mmHg and CI increased from 1.97 ± 
0.46 to 2.24 ± 0.45 l/min/m2 72 hrs post implant (p<0.05). Hemodynamic beneﬁts were 
sustained after removal of CRS. Cumulative volume loss averaged -3.5L and weight loss 
averaged -2.2 Kg. There was a signiﬁcant correlation between the average change in 
PCWP over 72 hrs and the baseline CI and creatinine (ﬁgure), i.e., the lower the baseline 
CI and the higher the baseline creatinine, the greater was the fall in PCWP.
Conclusion: Continuous aortic ﬂow augmentation using CRS resulted in progressive 
improvement in cardiac hemodyanamics in patients with exacerbated CHF. Both lower 
baseline cardiac index and higher serum creatinine identiﬁed patients with greater 
hemodynamic response to CRS. These ﬁndings help to identify patients likely to beneﬁt 
from CRS treatment.
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10:30 a.m.
874-3 Rosiglitazone Does Not Adversely Affect Cardiac 
Structure and Function as Determined by 
Echocardiography in Patients With Type 2 Diabetes and 
Class I/II Heart Failure
Henry Dargie, Per R. Hildebrandt, Gunter Riegger, John PH Wilding, John McMurray, 
Steve McMorn, Jeremy N. Roberts, Andrew Zambanini, Murray W. Stewart, Western 
Inﬁrmary, Glasgow, United Kingdom
Background: Although thiazolidinediones have been shown to have potentially 
beneﬁcial effects on some markers of cardiovascular risk in patients with type 2 diabetes 
(T2D), an important consideration in patients with established congestive heart failure 
(CHF) is a possible manifestation of ﬂuid retention which may precipitate or exacerbate 
symptomatic CHF.
Methods: Patients with T2D and New York Heart Association (NYHA) I/II CHF were 
randomized to receive rosiglitazone (RSG 4-8 mg daily) or placebo (PLB) in addition 
to background anti-diabetic agents for 52 weeks. Background anti-diabetic medications 
were uptitrated as required to achieve the glycemic target of fasting plasma glucose <126 
mg/dL and CHF medications were changed as appropriate. Endpoints were adjudicated 
by an independent committee.
Results: 224 patients were randomized in the study (110 RSG, 114 PLB). Ejection 
fraction was similar in both groups at baseline (RSG 35.3 ± 6.2%, PLB 35.7 ± 7.8%) 
and was not signiﬁcantly different following 52 weeks of treatment (RSG 37.8 ± 6.5%, 
PLB 36.8 ± 8.4%, 95% conﬁdence interval -0.32% to 3.30%, p = 0.1). In addition, there 
were no differences between the groups in cardiac structure at 52 weeks. There were few 
adjudicated events of worsening or possible worsening of CHF (RSG n = 7 [6%]; PLB n 
= 4 [4%]), but more adjudicated events in the RSG group of worsening edema (RSG n = 
28 [26%]; PLB n = 10 [9%]) and dyspnea (RSG n = 29 [26%]; PLB n = 19 [17%]). More 
patients in the RSG group required an increase in diuretics (RSG n = 28 [26%]; PLB n = 
16 [14%]). A similar proportion of patients withdrew from the study due to adverse events. 
Conclusions: Following 52 weeks of treatment, RSG does not adversely affect cardiac 
structure and function in patients with T2D and NYHA I/II CHF. However more ﬂuid related 
events occurred with RSG particularly in patients with NYHA II CHF, but these generally 
did not lead to withdrawal from the study or hospitalisation.
10:45 a.m.
874-4 A Comparison of Edema and Weight Gain Effects of 
Pioglitazone and Rosiglitazone in Patients With Type 2 
Diabetes and Dyslipidemia
David M. Kendall, John B. Buse, Ronald B. Goldberg, Mark A. Deeg, Anthony J. Zagar, 
Jane A. Pinaire, Meng H. Tan, Mehmood Khan, Alfonso Perez, Scott J. Jacober, Eli Lilly 
and Company, Indianapolis, IN, Takeda Pharmaceutical Company Ltd, Osaka, Japan
Background: A recent consensus position was developed conjointly by the AHA and the 
ADA on the impact of thiazolidinediones on CHF and edema. We report the effects on 
edema and weight gain of two thiazolidinediones, pioglitazone HCl (PIO) and rosiglitazone 
maleate (ROSI), compared in a prospective, multicenter (78), randomized, double-blind 
trial with the primary objective to compare maximal monotherapy doses of these agents 
on lipid and glycemic parameters.
Methods: Subjects had a diagnosis of type 2 diabetes with fasting triglyceride (TG) levels 
≥150 mg/dL and <600 mg/dL, and fasting LDL-C levels <130 mg/dL. Subjects with NYHA 
Class III or IV cardiac disease were excluded. Previous therapy included either diet alone 
(25%) or oral monotherapy. After 4 weeks of placebo treatment, subjects were treated with 
PIO (n=400; 30 mg QD for 12 weeks followed by 45 mg QD for an additional 12 weeks) or 
ROSI therapy (n=402; 4 mg QD followed by 4 mg BID for the same intervals). Peripheral 
edema was clinically categorized as 0 (none) through 4 (deep pitting) at each visit.
Results: At baseline, mean weight (± SE) for PIO vs ROSI was 93.7 ± 1.1 kg and 92.5 
± 1.1 kg and prevalence of edema was 37.0% and 34.8%. Mean maximum weight 
increase was similar for PIO vs ROSI (3.0 ± 0.2 kg vs 2.7 ± 0.2 kg, p=0.157) as was mean 
categorical edema at endpoint (0.34 ± 0.04 vs 0.29 ± 0.03, p=0.386). 
Changes in edema from baseline to endpoint (LOCF) 
No Change Improving Edema Worsening Edema p-value
PIO, n (%) 295 (80.8) 21 (5.8) 49 (13.4)
NS
ROSI, n (%) 287 (80.2) 25 (7.0) 46 (12.8)
Only one episode of CHF was reported (occurring in a ROSI treated subject).
Conclusions: With monotherapy, weight gain and edema are similar for both 
thiazolidinediones.
11:00 a.m.
874-5 Diabetes is a Predictor of Lower Peak Exercise Capacity 
in Patients with Left Ventricular Systolic Dysfunction
Amit S. Tibb, Ashok Talreja, Susheel Gundewar, Ali Haider, Jennifer Ann Chen, Vimla S. 
Aggarwal, Anita Banerjee, Bette Kim, Thierry H. Le Jemtel, Albert Einstein College of 
Medicine- Jacobi Medical Center, Bronx, NY
Background: Age, gender and level of physical conditioning are important determinants 
of peak aerobic capacity (peak VO2). We hypothesize that diabetes with its skeletal muscle 
metabolic and vascular abnormalities may affect peak VO2 in patients with chronic heart 
failure (CHF) due to left ventricular (LV) systolic dysfunction.
Methods: Peak VO2 was measured in 204 ambulatory patients (78 diabetics and 126 
non-diabetics) with stable CHF during symptom-limited treadmill exercise using breath-
by-breath analysis of expired gases. Levels of B-type natriuretic peptide (BNP) were 
measured before exercise testing in all patients using a ﬂuorescent immunoassay. None 
of the patients were involved in a training program.
Results: The diabetic (DM) group consisted of 58 males and 20 females (mean age 61.7 
and 60.2 years) while there were 87 males and 39 females (mean age 58.3 and 59.5 
years) in the non-diabetic (NDM) group. The level of activity was similar as ascertained 
by the proportion of patients who were sedentary retirees (55.1 % vs. 53.9%), involved 
in physical labor (23.7% vs. 24.6%) and desk job (22.4% vs. 22.2%) in the DM and NDM 
groups respectively. The DM and NDM patient groups were matched with respect to age, 
sex, LV Ejection Fraction (28.7 ± 4.2 % vs. 29.2 ± 3.9 %), proportion of smokers, presence 
of chronic kidney disease (68.6% vs. 64.9 %) ,use of beta-blockers (92.3 % vs. 86.5 %) 
and ACE inhibitors (92.3 % vs.88.1%). The mean BNP level in the DM group was 319 
± 343 pg/ml and NDM group was 275 ± 342 pg/ml (p= 0.368). DM patients had lower 
peak VO2 than NDM patients: 13.02 ± 3.5 ml/kg/min vs.15.5 ± 3.84 ml/kg/min attained at 
similar respiratory exchange ratios (> 1.10). There was a higher prevalence of coronary 
artery disease (CAD) and hypertension (HTN) in the diabetic group. Multivariate analysis 
determined diabetes to be an independent predictor for peak VO2 after adjusting for the 
effect of age, sex, CAD and HTN (p=0.027).
Conclusion: DM patients with CHF due to LV systolic dysfunction attained a lower peak 
VO2 than age, gender and activity matched NDM patients. Whether abnormal skeletal 
muscle metabolism, limited oxygen delivery to exercising muscles or both limit peak VO2 
in DM patients remains to be investigated.
11:15 a.m.
874-6 Role Of Activated Renin-angiotensin System In 
Myocardial Fibrosis And Left Ventricular Diastolic 
Dysfunction In Diabetic Patients: Reversal By Long-
term Angiotensin II Blockade
Daizo Kawasaki, Keisuke Kosugi, Hidehiko Waki, Kazuhiro Yamamoto, Takeshi Tsujino, 
Tohru Masuyama, Hyogo College of Medicine, Nishinomiya, Japan, Osaka Police 
Hospital, Osaka, Japan
Background: LV diastolic dysfunction is a commonly observed cardiovascular 
manifestation even in the absence of coronary artery disease in diabetic patients. 
Myocardial ﬁbrosis is one of the most important mechanisms for the diastolic dysfunction, 
and activation of local renin-angiotensin system has been shown to contribute to 
myocardial ﬁbrosis in animal models of LV diastolic dysfunction. We attempted to test the 
hypothesis that long-term angiotensin-II receptor blockade alters collagen turnover in the 
myocardium leading to an improvement of diastolic dysfunction in diabetic patients.
Methods: We assessed pulsed Doppler LV diastolic ﬁlling, plasma B-type natriuretic 
peptide (BNP) level and biomarkers of collagen type I synthesis and degradation in 38 
diabetic patients (mean age, 68 years) before and after administration of candesartan 
for 6 months.
Results: (1) Mitral E/A ratio increased from 0.64±0.10 to 0.76±0.18 (p<0.01) without a 
change in LV diastolic diameter, indicating an improvement of LV diastolic dysfunction. (2) 
Plasma BNP level tended to decrease from 27.7±27.5 to 23.6±20.2 pg/ml). (3) Carboxy-
terminal propeptide of procollagen type I (PICP), an index of collagen type I synthesis, 
tended to decrease from 99±29 to 94±39 ng/ml and carboxy-terminal telopeptide of 
collagen type I (CITP), an index of collagen type I degradation, increased from 3.3±1.0 to 
3.8±1.2 ng/ml (p<0.01) following chronic angiotensin-II receptor blockade. Consequently, 
the PICP/CITP ratio, an index of coupling between the synthesis and degradation of 
collagen type I., decreased from 32.2±15.2 to 26.8±11.3 (p<0.01). 
Conclusion: Chronic blockade of angiotensin-II-mediated signaling pathway improves 
LV diastolic dysfunction in diabetic patients, at least partially through the attenuation of 
myocardial ﬁbrosis by regulating both collagen production and degradation.
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874-7 Carvedilol Reduces the Risk for New Onset of Diabetes-
Related Adverse Events in Heart Failure Compared to 
Metoprolol: Results of the COMET Study
Christian Torp-Pederson, John Cleland, Andrea Di Lenarda, Peter Hanrath, Beatrix 
Lutiger, Michel Komajda, Philip A. Poole-Wilson, Willem J. Remme, Marco Metra, 
Armin Scherhag, Andrew Charlesworth, Karl Swedberg, Bispebjerg University Hospital, 
Copenhagen, Denmark
Carvedilol has reported beneﬁcial effects on insulin sensitivity compared with other 
betablockers. In COMET (Carvedilol or Metoprolol European Trial) patients without 
diabetes at baseline were assessed for the predeﬁned endpoint of new onset of 
diabetes-related adverse events (NDMAE) to further evaluate whether beta-blockers may 
predispose patients to developing diabetes. Of the total patients randomized to target 
doses of 25 mg BID carvedilol (C: n=1511) or 50 mg BID metoprolol (M: n=1518), 76.1% 
and 75.3% did not have diabetes at baseline, respectively. 
METHODS: NDMAE was evaluated by time to event analysis of coded diabetes-related 
adverse events (diabetes, diabetic coma, peripheral gangrene/diabetic foot, decreased 
glucose tolerance or hyperglycemia).
RESULTS: Among patients without diabetes at baseline, fewer C patients (10.5%) than 
M patients (13%) met the deﬁnition of NDMAE, representing a reduction in risk with of 
23% (95% CI: 2%-39%; p = 0.0334). Patients who developed NDMAE were generally 
similar in age (60.4 vs 61.5 years) and gender (female 25% vs 18%) to those who did 
not, but were heavier (84 kg vs 77 kg), had more co-morbidities (hypertension; 38% vs 
32%), were more often classiﬁed as NYHA II (55% vs. 51%) and used digitalis more 
frequently (72% vs 57%). In patients with NDMAE, C and M were well balanced for these 
characteristics.
Median time to NDMAE was 667 days and mean was 740. In NDMAE patients, there were 
19 deaths (15.6%) on C and 35 (23.5%) on M, a risk reduction of 34% (95% CI -16%, 
62%, p = 0.149). Death or hospitalization for any cause occurred in 61.5% of new onset 
diabetics on C compared to 71.1% on M (risk reduction 22%, 95% CI -5%, 42%, p = 
0.107). Overall, premature study withdrawals occurred in 25% of the new onset diabetics 
on C and 36% of those on M (p = 0.09), with 32% vs 43% withdrawn due to an adverse 
event, respectively.
CONCLUSIONS: Heart failure patients treated with carvedilol were signiﬁcantly less 
likely to develop NDMAE during long-term treatment.. Among those with diabetic events, 
the carvedilol patients had better outcomes (fewer deaths or hospitalizations) and 
tolerability (fewer withdrawals).
11:45 a.m.
874-8 Impact of Heart Failure on Survival Among Diabetics 
with Coronary Artery Disease
Jeffrey S. Berger, David L. Brown, Beth Israel Medical Center, New York City, NY
Background: The impact of heart failure (HF) on survival of patients with coronary artery 
disease (CAD) is not well understood. We sought to evaluate the effect of HF on survival 
of patients with diabetes and CAD following percutaneous coronary intervention (PCI). 
Methods: Three hospitals in New York City contributed prospectively deﬁned data on 1142 
consecutive diabetic patients undergoing PCI in 1998-9. HF was deﬁned by treatment for 
HF prior to the admission for PCI. All cause mortality at a mean follow-up of 3 years was 
the primary end point. 
Results: Among diabetics, HF was present in 187 patients (16%). Diabetics with HF were 
older and more likely to be female. Diabetic patients with HF had a greater prevalence of 
vascular disease (18% vs. 9.4%, P=0.001), renal insufﬁciency (11.2% vs. 2.4%, P<0.001) 
and end-stage renal disease (10.7% vs. 2.6%, P<0.001). Diabetics with HF were more 
likely to have a previous MI (47% vs. 34%, P=0.001) and prior cardiac surgery (32% vs. 
21%, P=0.001). At clinical presentation, diabetics with heart failure were more likely to be 
hemodynamically unstable than those without heart failure. Diabetics with HF presented 
more often with 3-vessel disease (36% vs. 21%, P<0.001). Mean ejection fraction was 
lower in diabetics with HF (44% vs. 51%, P<0.001). Stent placement and glycoprotein 
IIb/IIIa inhibitor use were similar between groups. Angiographic success was 97% in 
both groups. In-hospital mortality was more than 20 times greater among diabetics with 
HF (4.8% vs. 0.2%, P<0.001). Other adverse in-hospital outcomes including post-PCI 
myocardial infarction, emergency bypass surgery and stent thrombosis were not different 
between groups. At 3-year follow-up, mortality for diabetics with HF was 29.4% vs. 9.5% 
in diabetics without HF (log-rank P<0.0001). On Cox proportional hazards analysis, 
HF in diabetics was an independent predictor of mortality (Hazard Ratio, 1.978, 95% 
Conﬁdence Interval, 1.358-2.881, P<0.001). 
Conclusion: Diabetes with HF at the time of PCI is independently associated with a 
doubling in the hazard of death. The increased mortality of CAD among diabetics with HF 
should stimulate research concerning appropriate treatment and surveillance regimens.
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879-4 Do Improvements in Functional Capacity and Heart 
Rate Recovery after Phase II Cardiac Rehabilitation 
Predict Better Long-term Survival?
Claire Pothier, Gordon Blackburn, Michael Lauer, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Impaired functional capacity (FC) abnormal heart rate recovery (HRR) 
have shown to predict mortality. Whether improvements in FC or HRR are associated with 
reduced long-term mortality is unclear.
Methods: Consecutive adults (n=692, 62 + 10 years, 82% male, 81% Caucasian) who 
completed Phase II cardiac rehabilitation had an exercise test before and after the 
program as part of a routine protocol. Functional capacity was categorized by age and 
gender as impaired or not. Heart rate recovery was the difference of heart rate at peak 
exercise and one minute recovery with < 12 bpm considered abnormal.
Results: There were 100 deaths during a mean of 6.7 years of follow-up. Of 316 patients 
(46%) with impaired FC at baseline, 189 improved (60%). Failure to improve predicted 
higher mortality, compared to those who improved and those without FC at baseline (28% 
vs. 18% vs. 8%, p<0.0001) (Figure 1). 
Patients with a normal HRR at baseline and an abnormal HRR at exit had the highest 
mortality when compared to patients whose HRR stayed abnormal, patients who improved 
and those who remained normal (29% vs. 22% vs. 17% vs 6%, p<0.0001). Cox analyses 
that accounted for clinical and socioeconomic confounders showed that preserved FC 
and normal HRR on the exit stress test were predictive of lower mortality (HR 0.77, 95% 
CI 0.69 - 0.87; HR 0.95, 95% CI 0.92 - 0.99, respectively).
Conclusions: Improvement of functional capacity and heart rate recovery during a 
cardiac rehabilitation program predicts improved long-term survival.
11:00 a.m.
879-5 Multicenter Study of the Clinical Effectiveness of a 
Contemporary Cardiac Rehabilitation Program in 
Elderly Versus Younger Patients
Neil F. Gordon, Richard D. Salmon, Ivan Levinrad, George C. Faircloth, Richard F. 
Leighton, Martin R. Berk, Linda K. Hall, Laurence S. Sperling, William A. Dafoe, Melvyn 
Rubenﬁre, Diane Vogel, C. Noel Bairey Merz, William L. Haskell, Barry A. Franklin, St. 
Joseph’s/Candler Health System, Savannah, GA, INTERVENT Coordinating Center, 
Savannah, GA
Background: The aging of the American population and improving survival of patients 
with cardiovascular disease (CVD) has created a large population of elderly patients (>65 
years of age) eligible for cardiac rehabilitation. However, no comprehensive data are 
currently available on the effect of a contemporary phase 2 cardiac rehabilitation program 
on multiple CVD risk factors in elderly versus younger patients.
Methods: In this multicenter study, we investigated the effect of a contemporary phase 2 
cardiac rehabilitation program on multiple CVD risk factors in 5,418 consecutive patients 
>65 years of age (Group A; n=2,526; age=74+/-6 years) and <65 years of age (Group B; 
n=2,892; age=52+/-10 years). Outcome measures were evaluated at baseline and after 
approximately 12 weeks of participation in a phase 2 cardiac rehabilitation program at 30 
centers in the U.S.
Results: On program exit, improvements (p <0.05) in multiple CVD risk factors were 
observed for both elderly and younger patients who had abnormal baseline risk factor 
values (based on national clinical guidelines), as follows: systolic blood pressure (Group 
A, -19 mmHg; Group B, -22 mmHg; p <0.05 for Group A versus Group B); diastolic blood 
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pressure (Group A, -17 mmHg; Group B, -14 mmHg; p <0.05 for Group A versus Group 
B); LDL cholesterol (Group A, -28 mg/dl; Group B, -18 mg/dl; p <0.05 for Group A versus 
Group B); HDL cholesterol (Group A, 4 mg/dl; Group B, 4 mg/dl; p=NS for Group A versus 
Group B); triglycerides (Group A, -41 mg/dl; Group B, -43 mg/dl; p=NS for Group A versus 
Group B); fasting glucose (Group A, -14 mg/dl; Group B, -17 mg/dl; p=NS for Group A 
versus Group B); and weight (Group A, -4 lbs; Group B, -4 lbs; p=NS for Group A versus 
Group B).
Conclusion: To our knowledge, these are the ﬁrst multicenter clinical trial data to 
demonstrate that elderly patients derive similar improvements in multiple CVD risk factors 
as compared to younger patients during participation in a contemporary phase 2 cardiac 
rehabilitation program. Increased efforts should be devoted to providing these important 
services to elderly patients.
11:15 a.m.
879-6 Plasma Lipoprotein Lipids Do Not Regulate Exercise 
Training-Induced Changes in Coagulation Factor VIII 
Antigen and Prothrombin Fragment 1+2 Levels in 
Sedentary, Dyslipidemic Individuals
Rakesh Gopinathannair, Michael M. Lockard, Chad Paton, Joon Y. Park, Dana A. 
Phares, James M. Hagberg, Drexel University College of Medicine, Philadelphia, PA, 
University of Maryland, College Park, MD
Background: Elevated plasma factor VIII antigen (FVIII:Ag) and prothrombin fragment 
1+2 (F1+2) levels have been shown to result in a hypercoagulable state, thus increasing 
the risk for thrombotic events. Aerobic training may decrease thrombotic risk by reducing 
the activity of the coagulation cascade at rest. We analyzed the effect of 6 months of 
standardized exercise training on resting levels of FVIII:Ag and F1+2 in dyslipidemic 
men and women. A second objective was to assess whether training-induced changes 
in plasma lipoprotein-lipid levels were associated with training-induced changes in FVIII:
Ag and F1+2.
Methods: Forty-four sedentary men (n=16, 58±2 yrs) and post-menopausal women 
(n=28, 59±1 yrs), with at least one lipid abnormality (total cholesterol > 200 mg/dl, LDL 
>130 mg/dl, HDL< 40 mg/dl, or triglycerides > 200 mg/dl), underwent supervised aerobic 
training 3d/wk for 6 months, while maintaining a low-fat diet. All subjects had FVIII:Ag, 
F1+2, lipoprotein-lipid levels, and maximal oxygen consumption measured at baseline 
and after the training period.
Results: At baseline, there were no signiﬁcant differences in FVIII:Ag and F1+2 levels 
between genders. Mean F1+2 (1.49±0.1 nmol/l to 1.42±0.1 nmol/l, n=41, p=0.83) and 
FVIII:Ag (152.5±6.7% to 156.0±6.1%, n=44, p=ns) levels did not change signiﬁcantly 
with 6 mo of training. There was a signiﬁcant decrease in F1+2 levels with training when 
adjusted for baseline levels (p=0.035). There were signiﬁcant improvements in plasma 
triglyceride and HDL levels (161±11.6 to 142.7±9.6 mg/dl, p< 0.0001 and 45.1±2.3 to 
49.5±2.4 mg/dl, p=0.01 respectively) with training. F1+2 and FVIII:Ag changes with 
training showed no signiﬁcant association with training-induced changes in plasma 
lipoprotein-lipid levels.
Conclusions: Long-term aerobic training has a signiﬁcant impact on the common pathway 
of coagulation, reducing thrombin formation and hypercoagulability at rest. This suggests 
a reduced risk for atherosclerotic disease progression. Aerobic training induces favorable 
changes in the coagulation cascade, independent of changes in plasma lipoprotein-lipids, 
in elderly dyslipidemic individuals.
11:30 a.m.
879-7 Even Short-Duration Exercise Training Improves Brain 
Natiuretic Peptide and C-Reactive Protein Levels in 
Severely Deconditioned Patients With Coronary Disease
Richard A. Krasuski, Sandra A. Black, Ara M. Maranian, Wilford Hall Medical Center, 
San Antonio, TX
Background: Serum levels of brain natiuretic peptide (BNP) and C-reactive protein 
(CRP) predict future cardiovascular events and mortality in patients with coronary artery 
disease (CAD). Similarly, lack of exercise has been associated with a shorter lifespan. We 
sought to examine if short-duration exercise training could reduce BNP and CRP levels 
in deconditioned CAD patients.
Methods: Forty-two consecutive patients with chronic CAD and signiﬁcant deconditioning 
were recruited into a six-week graded-exercise program. Fasting bloodwork were collected 
at study entry and within 1 week of completion.
Results: Baseline characteristics included age 69 ± 10 years, echo ejection fraction 52 
± 16%, 32% women, 76% hypertensives, 88% dyslipidemics, 31% diabetics, and 14% 
active smokers. Medication use included aspirin 83%, beta-blockers 90%, angiotensin 
converting enzyme inhibitors 81%, and statins 76%. Tolerated exercise levels increased 
by 2.2 ± 1.9 metabolic equivalents over the 6-week period (p<0.001). There was no 
appreciable difference in body mass or any lipid panel component after 6 weeks. Percent 
body fat dropped from 32.8 ± 10.2 to 31.4 ± 10.2 (p=0.04). Levels of BNP and CRP 
signiﬁcantly decreased from baseline values (see below).
Conclusions: Short term exercise leads to signiﬁcant reductions in serum BNP and 
CRP in deconditioned patients with coronary disease. These changes appear to be 
independent of changes in body mass or any individual lipid panel component.
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879-8 Association of Metabolic Syndrome With Poor Exercise 
Capacity and Heart Rate Recovery in Patients With 
Coronary Disease: the Heart and Soul Study
Christian Spies, Christian Otte, Alka Kanaya, Sharon S. Pipkin, Nelson B. Schiller, Mary 
A. Whooley, University of California San Francisco, San Francisco, CA, Rush University 
Medical Center, Chicago, IL
Background: Metabolic syndrome (MS) is associated with incident cardiovascular 
disease. However, it is unknown whether MS is associated with poor cardiac function 
among patients with established coronary heart disease (CHD). We evaluated the 
association of MS with treadmill exercise capacity and heart rate recovery among patients 
with CHD using data from the Heart and Soul Study. 
Methods: We measured treadmill exercise capacity (metabolic equivalent tasks) and 
heart rate recovery at one minute (beats per minute) in 943 subjects with known CHD. 
Of these, 377 (40%) had MS, as deﬁned by the National Cholesterol Education Program 
criteria.
Results: Participants with MS were more likely to have poor exercise capacity (METS 
<5) (33% vs. 18%; p<0.0001), and poor heart rate recovery (≤16 beats/minute) (34% vs. 
21%; p<0.0001), than those without metabolic syndrome. In ordinal logistic regression 
analyses, MS was associated with worse exercise capacity (odds ratio (OR) 2.2; 95% CI, 
1.7-2.8; p<0.0001) and worse heart rate recovery (OR 1.8; 95% CI, 1.4-2.3; p<0.0001). 
These associations remained strong after adjusting for potential confounding variables 
(OR 1.6; 95% CI, 1.2-2.1; p=0.003 for worse exercise capacity; OR 1.4; 95% CI, 1.1-1.9; 
p=0.02 for worse heart rate recovery).
Conclusions: MS is independently associated with poor exercise capacity and poor 
heart rate recovery in patients with established CHD. Poor cardiac function may contribute 
to the adverse outcomes associated with the MS. 
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